BC_Type,Type Count,Rank,Count,NCT Number,ADD_Simple Phase,Count MOAbyType,add moa&BC type,ADD_MOA Bucket,ADD_LOT,ADD_Disease Bucket,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
TNBC,88,1,1,NCT03036488,Ph 3,45,TNBCCPI Combo,CPI Combo,Neo-adj,Breast Only,Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),,"Active, not recruiting",No Results Available,Triple Negative Breast Neoplasms,Biological: Pembrolizumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Placebo|Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim,"Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery|Event-free Survival (EFS) as assessed by Investigator|pCR rate using an alternative definition, ypT0 ypN0 (i.e., no invasive or noninvasive residual in breast or nodes) at the time of definitive surgery|pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery|EFS in participants with tumors expressing PD-L1|pCR rate using an alternative definition, ypT0/Tis (i.e., absence of invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement) at the time of definitive surgery|Overall survival (OS)|Percentage of participants who experience an adverse event (AE)|Percentage of participants who discontinue study treatment due to an AE|European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 Questionnaire (QLQ-C30) score|EORTC Breast Cancer-Specific QoL Questionnaire (QLQ-BR23) score",Merck Sharp & Dohme Corp.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,1174,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3475-522|2016-004740-11|173567|MK-3475-522|KEYNOTE-522,03/07/17,09/30/25,09/30/25,01/30/17,null,29-Jan-19,"Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089), Scottsdale, Arizona, United States|Arizona Oncology Associates PC- HOPE ( Site 8001), Tucson, Arizona, United States|Cedars Sinai Medical Center ( Site 0091), Los Angeles, California, United States|Pacific Cancer Care ( Site 0069), Monterey, California, United States|ICRI ( Site 0072), Whittier, California, United States|University of Colorado Cancer Center ( Site 0021), Aurora, Colorado, United States|Yale University School of Medicine ( Site 0054), New Haven, Connecticut, United States|Christiana Hospital ( Site 0029), Newark, Delaware, United States|Univ of Miami-Sylvester Comprehensive Cancer Center- Kendall satellite ( Site 0079), Miami, Florida, United States|The University of Chicago Medical Center ( Site 0047), Chicago, Illinois, United States|North Shore University Health System ( Site 0081), Evanston, Illinois, United States|Orchard Healthcare Research Inc. ( Site 0049), Skokie, Illinois, United States|Goshen Center for Cancer Care ( Site 0010), Goshen, Indiana, United States|University of Iowa Hospital and Clinics ( Site 0038), Iowa City, Iowa, United States|New England Cancer Specialists ( Site 0005), Scarborough, Maine, United States|Henry Ford Hospital ( Site 0003), Detroit, Michigan, United States|Minnesota Oncology Hematology, PA ( Site 8013), Minneapolis, Minnesota, United States|Rutgers Cancer Institute of New Jersey ( Site 0073), New Brunswick, New Jersey, United States|Broome Oncology, LLC ( Site 8002), Johnson City, New York, United States|Nyack Hospital Infusion Center ( Site 0059), Nyack, New York, United States|TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0044), Cincinnati, Ohio, United States|Oncology Hematology Care, Inc. ( Site 8011), Cincinnati, Ohio, United States|Providence Portland Medical Center ( Site 0052), Portland, Oregon, United States|Northwest Cancer Specialists, P.C. ( Site 8008), Portland, Oregon, United States|Magee - Women's Hospital ( Site 0011), Pittsburgh, Pennsylvania, United States|Rhode Island Hospital ( Site 0060), Providence, Rhode Island, United States|The West Clinic, P.C. ( Site 0078), Germantown, Tennessee, United States|Texas Oncology-Austin Central ( Site 8005), Austin, Texas, United States|Parkland Health and Hospital System ( Site 0093), Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8006), Dallas, Texas, United States|Simmons Cancer Center ( Site 0094), Dallas, Texas, United States|UT Southwestern Medical Center ( Site 0030), Dallas, Texas, United States|Moncrief Cancer Institute ( Site 0092), Fort Worth, Texas, United States|Texas Oncology-Memorial City ( Site 8003), Houston, Texas, United States|Houston Methodist Cancer Center ( Site 0013), Houston, Texas, United States|Texas Oncology- Plano East ( Site 8010), Plano, Texas, United States|Texas Oncology-San Antonio Northeast ( Site 8012), San Antonio, Texas, United States|Texas Oncology-Tyler ( Site 8007), Tyler, Texas, United States|University of Virginia ( Site 0022), Charlottesville, Virginia, United States|Virginia Cancer Specialists, PC ( Site 8009), Fairfax, Virginia, United States|Bon Secours Cancer Institute Medical Oncology at St. Mary's ( Site 0033), Midlothian, Virginia, United States|Peninsula Cancer Institute, LLC ( Site 0041), Newport News, Virginia, United States|Virginia Oncology Associates ( Site 8000), Norfolk, Virginia, United States|Kadlec Clinic Hematology and Oncology ( Site 0087), Kennewick, Washington, United States|Seattle Cancer Care Alliance ( Site 0068), Seattle, Washington, United States|Medical Oncology Associates (Summit Cancer Centers) ( Site 0014), Spokane, Washington, United States|YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 8004), Yakima, Washington, United States|Royal North Shore Hospital ( Site 2000), Sydney, New South Wales, Australia|Westmead Hospital ( Site 2002), Sydney, New South Wales, Australia|Royal Adelaide Hospital ( Site 2008), Adelaide, South Australia, Australia|Cabrini Health ( Site 2009), East Malvern, Victoria, Australia|Frankston Hospital ( Site 2010), Franskton, Australia|Royal Brisbane and Women s Hospital ( Site 2003), Herston, Australia|St John of God Subiaco Hospital ( Site 2006), Perth, Australia|Hospital Nossa Senhora da Conceicao ( Site 0203), Porto Alegre, Rio Grande Do Sul, Brazil|UOPECCAN - Uniao Oeste Paranaense de Estudos e Combate ao Cancer ( Site 0206), Cascavel, Brazil|Universidade de Caxias do Sul ( Site 0201), Caxias do Sul, Brazil|Hospital Erasto Gaertner ( Site 0207), Curitiba, Brazil|Instituto do Cancer do Ceara ( Site 0205), Fortaleza, Brazil|Hospital Araujo Jorge ( Site 0204), Goiania, Brazil|Hospital Sao Lucas da PUCRS ( Site 0200), Porto Alegre, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0208), Sao Jose do Rio Preto, Brazil|Instituto do Cancer de Sao Paulo - ICESP ( Site 0211), Sao Paulo, Brazil|Tom Baker Cancer Centre ( Site 0105), Calgary, Alberta, Canada|The Ottawa Hospital - Cancer Care ( Site 0100), Ottawa, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0103), Toronto, Ontario, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106), Montreal, Quebec, Canada|Jewish General Hospital ( Site 0101), Montreal, Quebec, Canada|CIUSSS de l'Estrie-CHUS ( Site 0102), Sherbrooke, Quebec, Canada|CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0104), Quebec, Canada|Oncomedica S.A. ( Site 0404), Monteria, Cordoba, Colombia|Oncologos del Occidente S.A. ( Site 0405), Pereira, Risaralda, Colombia|Hospital Universitario San Ignacio ( Site 0401), Bogota, Colombia|Instituto Nacional de Cancerologia [Bogota-Colombia] ( Site 0403), Bogota, Colombia|Hemato Oncologos S.A. ( Site 0400), Cali, Colombia|Instituto De Cancerologia S.A. ( Site 0406), Medellin, Colombia|CHU Jean Minjoz ( Site 0917), Besancon, France|Polyclinique Bordeaux Nord Aquitaine ( Site 0911), Bordeaux, France|Centre Francois Baclesse ( Site 0907), Caen, France|Centre Jean Perrin ( Site 0903), Clermont-Ferrand Cedex 01, France|Clinique Victor Hugo ( Site 0901), Le Mans, France|Hopital prive du Confluent ( Site 0902), Nantes, France|Institut Curie ( Site 0909), Paris, France|Hopital Saint Louis ( Site 0908), Paris, France|Hopital Diaconesses Croix Saint Simon ( Site 0905), Paris, France|CHU de la Miletrie Poitiers ( Site 0913), Poitiers, France|Institut Claudius Regaud IUCT Oncopole ( Site 0914), Toulouse Cedex 9, France|HELIOS Klinikum Berlin-Buch ( Site 1005), Berlin, Germany|Gynaekologisches Zentrum ( Site 1004), Bonn, Germany|Universitaetsklinikum Erlangen ( Site 1001), Erlangen, Germany|Kliniken Essen Mitte ( Site 1012), Essen, Germany|Universitaetsklinik und Poliklinik Halle/Saale ( Site 1008), Halle, Germany|Universitaetsklinikum Hamburg-Eppendorf ( Site 1007), Hamburg, Germany|Klinikum der Universit. Muenchen ( Site 1002), Muenchen, Germany|Caritasklinik St. Theresia ( Site 1011), Saarbruecken, Germany|Universitaets-Frauenklinik Tuebingen ( Site 1003), Tubingen, Germany|Bon Secours Hospital ( Site 1551), Cork, Ireland|St Vincents University Hospital ( Site 1550), Dublin, Ireland|Oncology institute ( Site 1601), Beer Sheva, Israel|Assaf Harofeh MC ( Site 1605), Beer Yaakov-Zerifin, Israel|Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1600), Jerusalem, Israel|Rabin-Medical Center ( Site 1604), Petah Tikva, Israel|Sheba Medical Center ( Site 1602), Ramat-Gan, Israel|Sourasky Medical Center ( Site 1603), Tel Aviv, Israel|Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1101), Meldola, FC, Italy|Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 1103), Brescia, Italy|Ospedale San Luca, AZIENDA USL2 TOSCANA NORD OVEST ( Site 1105), Lucca, Italy|Ospedale Civile di Macerata ( Site 1104), Macerata, Italy|Istituto Europeo di Oncologia ( Site 1106), Milano, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1102), Napoli, Italy|Aichi Cancer Center Hospital ( Site 2502), Nagoya, Aichi, Japan|National Cancer Center Hospital East ( Site 2518), Kashiwa, Chiba, Japan|National Hospital Organization Hokkaido Cancer Center ( Site 2512), Sapporo, Hokkaido, Japan|Hyogo College of Medicine Hospital ( Site 2506), Nishinomiya, Hyogo, Japan|Tokai University Hospital ( Site 2517), Isehara, Kanagawa, Japan|St. Marianna University School of Medicine Hospital ( Site 2516), Kawasaki, Kanagawa, Japan|Kindai University Hospital ( Site 2507), Osakasayama, Osaka, Japan|Saitama Medical University International Medical Center ( Site 2513), Hidaka, Saitama, Japan|Saitama Cancer Center ( Site 2510), Kitaadachi-gun, Saitama, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 2514), Sunto-gun, Shizuoka, Japan|Chiba Cancer Center ( Site 2519), Chiba, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2501), Hiroshima, Japan|Social medical corporation Hakuaikai Sagara Hospital ( Site 2508), Kagoshima, Japan|Kumamoto University Hospital ( Site 2515), Kumamoto, Japan|National Hospital Organization Osaka National Hospital ( Site 2505), Osaka, Japan|National Cancer Center Hospital ( Site 2500), Tokyo, Japan|St.Luke's International Hospital ( Site 2511), Tokyo, Japan|Toranomon Hospital ( Site 2503), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 2509), Tokyo, Japan|Seoul National University Hospital ( Site 2101), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2100), Seoul, Korea, Republic of|Asan Medical Center ( Site 2102), Seoul, Korea, Republic of|Samsung Medical Center ( Site 2103), Seoul, Korea, Republic of|Mazowiecki Szpital Onkologiczny ( Site 1713), Wieliszew, Mazowieckie, Poland|Centrum Onkologii Instytut im. Marii Sk≈Çodowskiej Curie ( Site 1717), Gliwice, Slaskie, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1708), Bydgoszcz, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1712), Bydgoszcz, Poland|Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1701), Gdynia, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej Curie ( Site 1719), Krakow, Poland|Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli ( Site 1700), Lublin, Poland|Dolnoslaskie Centrum Onkologii. ( Site 1702), Wroclaw, Poland|Fundacao Champalimaud ( Site 2444), Lisboa, Portugal|Hospital de Santa Maria, E.P.E. ( Site 2445), Lisboa, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2446), Porto, Portugal|Arkhangelsk Clinical Oncological Dispensary ( Site 1810), Arkhangelsk, Russian Federation|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1805), Chelyabinsk, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1806), Kazan, Russian Federation|Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1801), Moscow, Russian Federation|GBU RO Regional Clinical Oncological Dispensary ( Site 1808), Ryazan, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1803), Saint Petersburg, Russian Federation|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1804), Ufa, Russian Federation|National Cancer Centre Singapore ( Site 2600), Singapore, Singapore|ICO L Hospitalet ( Site 1305), Hospitalet de Llobregat, Barcelona, Spain|Hospital Quiron de Madrid ( Site 1303), Pozuelo de Alarcon, Madrid, Spain|Hospital del Mar ( Site 1306), Barcelona, Spain|Instituto Oncologico Baselga.Hospital Quiron. ( Site 1312), Barcelona, Spain|Hospital General Universitari Vall d Hebron ( Site 1301), Barcelona, Spain|Hospital Universitario Reina Sofia ( Site 1304), Cordoba, Spain|Hospital Universitario Ramon y Cajal ( Site 1300), Madrid, Spain|Complejo Hospitalario Universitario de Santiago ( Site 1308), Santiago de Compostela, Spain|Hospital Universitario Virgen del Rocio ( Site 1314), Sevilla, Spain|Hospital Clinico Univ de Valencia ( Site 1313), Valencia, Spain|Linkopings Universitetssjukhus ( Site 1402), Linkoping, Sweden|Karolinska Universitetssjukhuset Solna ( Site 1404), Solna, Sweden|Norrlands Universitetssjukhus ( Site 1401), Umea, Sweden|Akademiska Sjukhuset ( Site 1403), Uppsala, Sweden|Taipei Veterans General Hospital ( Site 2302), Taipei, Beitou, Taiwan|National Cheng Kung University Hospital ( Site 2305), Tainan, Taiwan|National Taiwan University Hospital ( Site 2301), Taipei, Taiwan|MacKay Memorial Hospital ( Site 2303), Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 2304), Taipei, Taiwan|Linkou Chang Gung Memorial Hospital ( Site 2300), Taoyuan, Taiwan|Samsun Ondokuz Mayƒ±s Universitesi Tƒ±p Fakultesi Hastanesi ( Site 1910), Samsun, Atakum, Turkey|Adana Acƒ±badem Hospital Department of Medical Oncology ( Site 1906), Adana, Turkey|Baskent Unƒ±versity Adana Kƒ±sla Hospital ( Site 1903), Adana, Turkey|Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1912), Ankara, Turkey|Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 1909), Ankara, Turkey|Ozel Medicana International Ankara Hastanesi ( Site 1915), Ankara, Turkey|Antalya Memorial Hospital Department of Medical Oncology ( Site 1908), Antalya, Turkey|Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1901), Edirne, Turkey|Acibadem Altunizade Hastanesi ( Site 1900), Istambul, Turkey|ƒ∞stanbul University Cerrahpa≈üa Medical Faculty ( Site 1904), Istanbul, Turkey|Amerikan Hospital Medical ( Site 1902), Istanbul, Turkey|Memorial Sisli Hastanesi ( Site 1913), Istanbul, Turkey|Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 1905), Izmir, Turkey|Izmir Medical Park Hospital Department of Medical Oncology ( Site 1907), Izmir, Turkey|Colchester General Hospital ( Site 1508), Colchester, Essex, United Kingdom|Barts Cancer Institute ( Site 1500), London, United Kingdom|St George s Hospital ( Site 1516), London, United Kingdom|Maidstone Hospital ( Site 1511), Maidstone, United Kingdom|The James Cook University Hospital ( Site 1515), Middlesbrough, United Kingdom|Nottingham University Hospitals NHS Trust ( Site 1505), Nottingham, United Kingdom|Royal Cornwall Hospitals NHS Trust ( Site 1504), Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT03036488
TNBC,88,2,1,NCT03281954,Ph 3,45,TNBCCPI Combo,CPI Combo,Neo-adj,Breast Only,Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo,,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Placebo|Drug: Atezolizumab,Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0)|Event-free survival (EFS)|Pathologic complete response in the breast (ypT0/Tis)|Pathologic complete response in the breast and lymph nodes (ypT0 ypN0)|Positive nodal status conversion rate|Overall survival (OS)|Recurrence-free interval (RFI)|Distant disease-free survival (DDFS)|Brain metastases free survival|Frequency of Adverse Events|Frequency of immune Adverse Events of Special Interest|Cardiac safety lead-in (Troponin-T)|Cardiac safety lead-in (Left ventricular ejection fraction; LVEF),"NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,1520,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NSABP B-59/GBG 96-GeparDouze|2017-002771-25|MO39875,12/19/17,12/31/23,06/30/24,09/13/17,null,11-Mar-19,"University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Kaiser Permanente-Fontana, Fontana, California, United States|Kaiser Permanente-Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|Kaiser Permanente-Sunset, Los Angeles, California, United States|Kaiser Permanente-West Los Angeles, Los Angeles, California, United States|Kaiser Permanente-Panorama City, Panorama City, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente Medical Group, San Diego, California, United States|Kaiser Permanente-Zion, San Diego, California, United States|Kaiser Permanente- San Marcos, San Marcos, California, United States|Kaiser Permanente-Woodland Hills, Woodland Hills, California, United States|Mount Sinai Comprehensive Cancer Center Aventura, Aventura, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Illinois Cancer Care-Bloomington, Bloomington, Illinois, United States|John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Emhurst Memorial Nancy W. Knowles Cancer Center, Elmhurst, Illinois, United States|Illinois Cancer Care-Galesburg, Galesburg, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Illinois Cancer Care-Ottawa, Ottawa, Illinois, United States|Illinois Cancer Care PC, Peoria, Illinois, United States|Illinois Cancer Care-Peru, Peru, Illinois, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, United States|Cancer Care Specialists of Central Illinois-Swansea, Swansea, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc (W. Jefferson Blvd), Fort Wayne, Indiana, United States|Fort Wayne Medical Oncology and Hematology Inc (Parkview Plaza), Fort Wayne, Indiana, United States|Norton Cancer Institute-Downtown, Louisville, Kentucky, United States|Norton Cancer Institute-Norton Healthcare Pavilion, Louisville, Kentucky, United States|University of Louisville-James Graham Brown Cancer Center, Louisville, Kentucky, United States|Baptist Health Louisville; Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Norton Cancer Institute-St Matthews, Louisville, Kentucky, United States|Norton Cancer Institute-Brownsboro, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Medstar Union Memorial Hospital, Baltimore, Maryland, United States|Harry and Jeanette Weinberg Cancer Center at Franklin Square, Baltimore, Maryland, United States|Maryland Oncology Hematology, Bethesda, Maryland, United States|Maryland Oncology Hematology, Rockville, Maryland, United States|Capital Hematology Oncology Associates, Silver Spring, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Maryland Oncology Hematology, Wheaton, Maryland, United States|Berkshire Hematology Oncology Services at Berkshire Medical Center Cancer and Infusion Center, Pittsfield, Massachusetts, United States|Michigan State University, East Lansing, Michigan, United States|Michigan State University-Breslin Cancer Center, Lansing, Michigan, United States|University of Missouri-Ellis Fischel Cancer Center, Columbia, Missouri, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|MD Anderson Cancer Center at Cooper, Voorhees, New Jersey, United States|Health Quest Medical Practice, Poughkeepsie, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|RHOA of Cary, Cary, North Carolina, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|Carolinas Medical Center-Levine Cancer Insitute, Charlotte, North Carolina, United States|Levine Cancer Center Institute Pineville, Charlotte, North Carolina, United States|RHOA of Garner, Garner, North Carolina, United States|UNC Regional Physicians Hematology and Oncolgoy, High Point, North Carolina, United States|FirstHealth of the Carolinas FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|RHOA of Blue Ridge, Raleigh, North Carolina, United States|RCC of Wakefield, Raleigh, North Carolina, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Aultman Alliance Cancer Center, Alliance, Ohio, United States|Aultman Hospital, Canton, Ohio, United States|Aultman Medical Group Hematology and Oncology, Canton, Ohio, United States|Kaiser Permanente Northwest-Oncology/Hematology, Portland, Oregon, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|St. Vincent Hospital, Erie, Pennsylvania, United States|Wellspan Medical Oncology, Gettysburg, Pennsylvania, United States|AHN Cancer Institute at Jefferson, Jefferson Hills, Pennsylvania, United States|Seechler Family Cancer Center, Lebanon, Pennsylvania, United States|Forbes Regional Hospital, Monroeville, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|WPAON at AGH, Pittsburgh, Pennsylvania, United States|WPAON at WPH, Pittsburgh, Pennsylvania, United States|Magee-Women's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|UPCI Investigational Drug Services, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center @ Passavant - HOA, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center @ Passavant - OHA, Pittsburgh, Pennsylvania, United States|Wexford Health & Wellness Pavilion, Wexford, Pennsylvania, United States|Cancer Care Associates of York, York, Pennsylvania, United States|Wellspan Health-York Cancer Center Oncology Research, York, Pennsylvania, United States|Women's and Infants Hospital, Providence, Rhode Island, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute-Sioux Falls, Sioux Falls, South Dakota, United States|Wellmont Cancer Institute, Johnson City, Tennessee, United States|Wellmont Cancer Institute, Kingsport, Tennessee, United States|Dell Seton Medical Center at the University of Texas-Seton Infusion Center, Austin, Texas, United States|Wellmont Medical Associates-Oncology and Hematology, Bristol, Virginia, United States|Bon Secours Richmond Community Hospital Medical Oncology Associates at Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours St Francis Medical Center, Midlothian, Virginia, United States|Southwest Virginia Regional Cancer Center, Norton, Virginia, United States|Bon Secours Richmond Community Hospital Oncology Associates at St. Mary's Hospital, Richmond, Virginia, United States|MRCC Auburn, Auburn, Washington, United States|MRCC Gig Harbor, Gig Harbor, Washington, United States|MRCC Puyallup, Puyallup, Washington, United States|MultiCare Health System, Tacoma, Washington, United States|MultiCare Institute for Research & Innovation, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Aurora Cancer Care-Southern Lakes, Burlington, Wisconsin, United States|Aurora Health Center Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Cancer Care-Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Aurora Cancer Care, Milwaukee, Wisconsin, United States|Aurora Cancer Care-Milwaukee South, Milwaukee, Wisconsin, United States|Aurora St. Lukes Medical Center-Pharmacy Only, Milwaukee, Wisconsin, United States|Aurora West Allis Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Vince Lombardi Cancer Clinic Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Vince Lombardi Cancer Clinic Sheboygan, Sheboygan, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aurora Cancer Care, Wauwatosa, Wisconsin, United States|Centre Hospitalier d'Universite de Montreal CHUM-Hotel Dieu, Montr√©al, Quebec, Canada|SMBD-Jewish General Hospital (MPSG), Montr√©al, Quebec, Canada|McGill University Health Centre-Cedars Cancer Centre, Montr√©al, Quebec, Canada|CHU de Quebec-Hospital du Saint-Sacrement, Quebec City, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03281954
TNBC,88,3,1,NCT03498716,Ph 3,45,TNBCCPI Combo,CPI Combo,Adj,Breast Only,A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer,IMpassion030,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Atezolizumab|Drug: Paclitaxel|Drug: Dose-dense Doxorubicin or dose-dense Epirubicin|Drug: Cyclophosphamide,"Invasive Disease-Free Survival (iDFS)|Overall Survival (OS)|Disease-Free Survival (DFS)|Recurrence-Free Interval (RFI)|Distant RFI|Percentage of participants with adverse events|Serum concentration of Atezolizumab|Invasive Disease-Free Survival (iDFS) in PDL1- Selected Patients|Invasive Disease-Free Survival (iDFS) in Node- Positive Disease|Invasive Disease Free Survival (iDFS) including second primary non-breast invasive cancer|Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab|Mean changes from baseline in patient-reported function (role, physical)|Mean changes from baseline in patient-reported health-related quality of life (HRQoL)",Hoffmann-La Roche|Breast International Group|Alliance Foundation Trials (AFT)|Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)|Frontier Science and Technology Research Foundation Inc (FS),All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,2300,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WO39391|2016-003695-47|BIG 16-05|AFT-27|ALEXANDRA,08/02/18,01/15/22,12/29/24,04/17/18,null,23-Apr-19,"John Muir Health Clinical Research Center, Concord, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Martin-O'Neil Cancer Center, Saint Helena, California, United States|Baptist - MD Anderson Cancer Center, Jacksonville, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Advocate Illinois Masonic Outpatient Center for Advanced Care, Chicago, Illinois, United States|Des Moines Oncology Research Association, Des Moines, Iowa, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Christus Cabrini Cancer Center, Alexandria, Louisiana, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|University of Maryland; St. Joseph Medical Center, Towson, Maryland, United States|Fairview Southdale Medical Oncology Clinic, Edina, Minnesota, United States|Mercy Cancer Center - Joplin, Joplin, Missouri, United States|HCA Midwest Division, Kansas City, Missouri, United States|MT Cancer Consortium, Billings, Montana, United States|New Hampshire Hematology Oncology, Hooksett, New Hampshire, United States|The Valley Hospital, Paramus, New Jersey, United States|Monter Cancer Center, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rochester General Hospital; Lipson Cancer and Blood Center, Rochester, New York, United States|Southeastern Medical Oncology Center - Goldsboro, Goldsboro, North Carolina, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Rapid City Regional Hospital/Regional Cancer Care Institute, Rapid City, South Dakota, United States|SCRI, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Intermountain Precision Genomics Cancer Research Clinic-Dixie, Saint George, Utah, United States|St. Mary's Medical Center, Huntington, West Virginia, United States|COIBA; Centro de Oncologia e; Investigacion Buenos Aires, Berazategui, Argentina|Hospital Aleman, Caba, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Clinica Universitaria Reina Fabiola, Cordoba, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Instituto de Oncolog√≠a de Rosario, Rosario, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Argentina|Centro de Investigacion Clinica - Clinica Viedma S.A.; Oncology Department, Viedma, Argentina|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Lismore Base Hospital, Lismore, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Tweed Hospital, Tweed Heads, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|Icon Cancer Foundation; Icon Cancer Care Chermside, Chermside, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Icon Cancer Foundation; Icon Cancer Care Southport, Southport, Queensland, Australia|Princess Alexandra Hospital; Cancer Trials Unit, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital; Cancer Centre, Adelaide, South Australia, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Box Hill Hospital; Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Austin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia|Maroondah Hospital; Breast Clinic, Ringwood East, Victoria, Australia|Medical University Innsbruck; Frauenklinik Innsbruck, Dept Gyn, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Interne 1 - H√§mato-Onkologie, Linz, Austria|AKH - Medizinische Universit√§t Wien; Department of Oncology, Vienna, Austria|Salzkammergut-Klinikum Voecklabruck, V√∂cklabruck, Austria|Klinikum Kreuzschwestern Wels; Iv. Interne Abt., Wels, Austria|AZ KLINA, Brasschaat, Belgium|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Chr de La Citadelle, Li√®ge, Belgium|CHU de Li√®ge, Li√®ge, Belgium|Clinique Saint-Joseph, Li√®ge, Belgium|CHU Ambroise Par√©, Mons, Belgium|Clinique Sainte-Elisabeth; Oncologie, Namur, Belgium|AZ Nikolaas (Sint Niklaas), Sint Niklaas, Belgium|Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia, BA, Brazil|Clinica Amo - Assistencia Medica Em Oncologia, Salvador, BA, Brazil|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|INCA 1- Instituto Nacional de C√¢ncer, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Iju√≠, Iju√≠, RO, Brazil|Hospital Moinhos de Vento; Instituto de Educa√ß√£o e Pesquisa, Porto Alegre, RO, Brazil|Hospital M√£e de Deus; Centro de Pesquisa Cl√≠nica - Instituto do C√¢ncer, Porto Alegre, RS, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Hospital de Cl√≠nicas de Porto Alegre, Porto Alegre, RS, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Funda√ß√£o Pio XII Hospital de C√¢ncer de Barretos, Barretos, SP, Brazil|Hospital Amaral Carvalho; Oncologia Clinica, Jau, SP, Brazil|CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo Andr√©, SP, Brazil|Hospital S√≠rio-Liban√™s, Sao Paulo, SP, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, Brazil|Instituto Do C√¢ncer Do Estado de S√£o Paulo Oct√°vio Frias de Oliveira, S√£o Paulo, SP, Brazil|Instituto Brasileiro De Controle Do C√¢ncer - IBCC; Laborat√≥rio De Patologia, S√£o Paulo, SP, Brazil|The 307th Hospital of Chinese People's Liberation Army, Beijing City, China|Peking University People's Hospital, Beijing, China|Beijing Hospital of Ministry of Health, Beijing, China|Beijing Union Hospital, Beijing, China|Jilin Cancer Hospital, Changchun, China|the First Hospital of Jilin University, Changchun, China|West China Hospital, Sichuan University, Chengdu, China|Chongqing Cancer Hospital, Chongqing, China|Fujian Medical University Union Hospital, Fujian, China|Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, China|Sun Yat-sen Memorial Hospital, Guangzhou, China|Sun yat-sen University Cancer Center; Internal Medicine of Oncology, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|The Second Affiliated Hospital of Zhejiang University College, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China|The Affiliated Hospital of Medical College Qingdao University, Qingdao, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Changhai Hospital of Shanghai, Shanghai, China|The University of Hong Kong-Shenzhen Hospital, Shenzhen City, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, China|The First Affiliated Hospital of Xian Jiao Tong University, Xi'an City, China|Henan Cancer Hospital, Zhengzhou, China|Nemocnice Horovice, NH Hospital a.s.; Oncology Department, Horovice, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni Nemocnice V Motole, S.P., Prague, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Krajska nemocnice T. Bati, a.s., Zlin, Czechia|Herlev Hospital; Onkologisk afdeling, Herlev, Denmark|Sj√¶llands Universitetshospital, N√¶stved; Onkologisk Afdeling, Naestved, Denmark|Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed, Odense C, Denmark|Sygehus Lilleb√¶lt, Vejle, Vejle, Denmark|Centre Hospitalier Regional Metz-Thionville - Hopital de Mercy, Ars-Laquenexy, France|Institut Sainte Catherine, Avignon, France|CH de Beauvais, Beauvais, France|CHU Jean Minjoz, Besan√ßon, France|Centre Hospitalier De Blois, Blois, France|Clinique Tivoli; Sce Radiotherapie, Bordeaux, France|Institut Bergonie, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Hospitalier Fleyriat, Bourg-en- Bresse Cedex, France|CHRU De Brest - Hopital Morvan - Institut De Cancerologie Et D'Hematologie, Brest, France|CRLCC-Francois Baclesse; Oncologie M√©dicale, Caen, France|CH de Cholet; oncologie, Cholet, France|Centre Jean Perrin, Clermont Ferrand, France|Polyclinique Saint Come; Hopital De Jour Oncologie, Compiegne, France|Centre Hospitalier Alpes Leman, Contamine Sur Arve, France|Centre Georges Francois Leclerc, Dijon, France|CHU de Grenoble - H√¥pital Andr√© Michallon, Grenoble Cedex 9, France|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier De Versailles, Le Chesnay, France|Clinique des Ormeaux; Oncologie, Le Havre, France|H√¥pital Priv√© de l'Estuaire, Le Havre, France|Clinique Chenieux; Oncology, Limoges, France|Centre Hospitalier Bretagne Sud, Lorient, France|Centre Leon Berard, Lyon, France|Hopital Prive Jean Mermoz, Lyon, France|Hopital Europeen, Marseille, France|H√¥pital Saint Joseph, Marseille, France|Institut Paoli Calmettes, Marseille, France|Centre Hospitalier de Mont de Marsan - Hopital Layne, Mont De Marsan, France|Clinique Cl√©mentville, Montpellier, France|Institut r√©gional du Cancer Montpellier, Montpellier, France|l'H√¥pital priv√© du Confluent SAS, Nantes, France|Centre Antoine Lacassagne, Nice, France|CHR Orleans, Hopital Madeleine, Orl√©ans, France|Institut Curie, Paris, France|Polyclinique Francheville, Perigueux, France|Centre Armoricain de Radioth√©rapie, d'Imagerie M√©dicale et d'Oncologie (CARIO), Plerin, France|CH Annecy Genevois site Annecy; Oncologie, Pringy, France|Chi De Cornouaille; Oncologie Hospitalisation, Quimper, France|Institut Jean Godinot, Reims, France|Institut du Cancer Coulancy Reims, Reims, France|Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer, Rennes, France|Centre Henri Becquerel, Rouen, France|Institut De Cancerologie Lucien Newrth, St Priest en Jarez CEDEX, France|Centre Paul Strauss, Strasbourg, France|Hopitaux Du Leman - Site Georges Pianta, Thonon Les Bains, France|Institut Claudius R√©gaud, Toulouse, France|Clinique Pasteur, Toulouse, France|Clinique Pasteur; Imagerie Medicale, Toulouse, France|CHU Tours - H√¥pital Bretonneau, Tours, France|Hopital Prive Drome Ardeche; Hopital De Jour, Valence, France|Institut de Canc√©rologie de Lorraine, Vandoeuvre-Les-Nancy, France|Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France|Hopital Prive Villeneuve d Ascq;Chimiotherapie Radiotherapie, Villeneuve D Ascq, France|Praxisklinik Krebsheilkunde f√ºr Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, Germany|Studienzentrum Berlin City, Berlin, Germany|St. Johannes-Hospital, Dortmund, Germany|Onkozentrum Dres. G√∂hler, Dresden, Germany|Praxis f√ºr Hamatologie und Onkologie, Erfurt, Germany|Klinikum Frankfurt H√∂chst GmbH, Frankfurt, Germany|Onkodok GmbH, G√ºtersloh, Germany|√Ñrztehaus am Bahnhofsplatz; Praxis Uleer/Pourfard, Hildesheim, Germany|St. Elisabeth-Krankenhaus, K√∂ln, Germany|Klinikum Ludwigsburg; Studiensekretariat, Ludwigsburg, Germany|St. Vincenz-Elisabeth-Hospital; Katholisches Klinikum Mainz, Mainz, Germany|Uniklinik Mainz; I. Medizinische Klinik, Mainz, Germany|Universitaets Medizin Mannheim, Mannheim, Germany|Dres. Michael Maasberg Marion Schmitz und Maria Theresia Keller, Mayen, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum der Universit√§t M√ºnchen; Frauenklinik - Onkologie II, M√ºnchen, Germany|Klinikum Neumarkt; Frauenklinik, Neumarkt i.d.OPf., Germany|Studienzentrum Onkologie Ravensburg; Onkologie Ravensburg, Ravensburg, Germany|Johanniter Frauenklinik Stendal Germany, Stendal, Germany|Universit√§tsklinik T√ºbingen; Frauenklinik, T√ºbingen, Germany|Marien-Hospital Witten, MVZ Witten, Witten, Germany|Klinikum Worms; Frauenklinik; Klinik f√ºr Gyn√§kologie und Geburtshilfe, Worms, Germany|Pamela Youde Nethersole Eastern Hospital; Clinical Oncology, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong|Szent Margit Hospital; Dept. of Oncology, Budapest, Hungary|National Institute of Oncology, A Dept of Internal Medicine, Budapest, Hungary|Borsod-Aba√∫j-Zempl√©n Megyei K√∂zponti K√≥rh√°z √©s Egyetemi Oktat√≥k√≥rh√°z, Miskolc, Hungary|P√©csi Tudom√°nyegyetem √Åok; Onkoterapias Intezet, Pecs, Hungary|Mater Misecordiae University Hospital, Dublin, Ireland|Beaumont Hospital; Cancer Clinical Trials Unit, Dublin, Ireland|Galway University Hospital; Clinical Trials Department, Galway, Ireland|University Hospital Limerick - PIN, Limerick, Ireland|Rambam Health Care Campus; Hematology, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Med Org Kiryat; Oncology Institute, Jerusalem, Israel|Meir Medical center, Pediatrics, Kfar Sava, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Abruzzo, Italy|Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi; UO Farmacia Clinica, Bologna, Emilia-Romagna, Italy|Ospedale Degli Infermi - Faenza; Oncologia Medica, Faenza, Emilia-Romagna, Italy|Azienda Ospedaliero - Universitaria di Modena Policlinico, Modena, Emilia-Romagna, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Emilia-Romagna, Italy|Ospedale degli Infermi, Rimini, Emilia-Romagna, Italy|Centro Di Riferimento Oncologico; SOC Oncologia Medica C, Aviano, Friuli-Venezia Giulia, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, Italy|Policlinico Universitario Campus Biomedico Di Roma, Roma, Lazio, Italy|Ospedale Belcolle Di Viterbo; Oncologia, Viterbo, Lazio, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Liguria, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|Ospedale Mater Salutis, Legnago (VR), Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Policlinico di Monza; Istituto di Oncologia, Monza, Lombardia, Italy|Fondazione Salvatore Maugeri, Pavia, Lombardia, Italy|Policlinico San Mattea, Pavia, Lombardia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Lombardia, Italy|Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria, Alessandria, Piemonte, Italy|Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica, Ponderano (BI), Piemonte, Italy|Nuovo Ospedale Di Prato, Prato, Toscana, Italy|Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia, Perugia, Umbria, Italy|Azienda Ospedaliero Universitaria di Ferrara - U.O. Di Oncologia, Cona (FE), Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|Chiba Cancer Center, Chiba, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|Sagara Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kyoto University Hospital, Kyoto, Japan|Naha-nishi Clinic, Okinawa, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Medical University International Medical Center, Saitama, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|St. Luke's Internat. Hospital, Breast Surgical Oncology, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital, Dongnam-gu, Cheonan-si, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital; Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Wonju Christian Hospital, Wonju, Korea, Republic of|Oncologico Potosino, San Luis Potos√≠, SAN LUIS Potosi, Mexico|Merida Investigacion Clinica, M√©rida, Yucatan, Mexico|Tecnologico De Monterrey Campus Ciudad De Mexico; Unidad De Investigacion Clinica, D. F., Mexico|Iem-Fucam, D.f., Mexico|Instituto Nacional De Cancerologia; Oncology; Tumores Mamarios, Distrito Federal, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Centro Medico Dalinde, Mexico City, Mexico|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Oncosalud Sac; Oncolog√≠a, Lima, Peru|Clinica San Felipe, Lima, Peru|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdansk, Poland|Szpital Uniwersytecki w Krakowie, Oddzia≈Ç Kliniczny Kliniki Onkologii, Krakow, Poland|Wielkopolskie Centrum Onkologi, Poznan, Poland|Wojskowy Inst.Medyczny Mon; Klinika Onkologii, Warszawa, Poland|Instytut MSF Sp. z o.o., ≈Å√≥d≈∫, Poland|""Filantropia"" Clinical Hospital; Gynecological Oncology, Bucharest, Romania|Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala, Cluj Napoca, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, Romania|Regional Clinical Oncology Hospital, Yaroslavl, Jaroslavl, Russian Federation|Federal State Institution Medical Radiology Research Center, Obninsk, Kaluga, Russian Federation|Evimed, Chelyabinsk, Kurgan, Russian Federation|Moscow Clinical Scientific Center, Moscow, Moskovskaja Oblast, Russian Federation|LLC Strategic Medical Systems, Sankt-peterburg, Sankt Petersburg, Russian Federation|EosMed LLC, Sankt-peterburg, Sankt Petersburg, Russian Federation|LCC Center of Palliative Medicine - Devita, Sankt-peterburg, Sankt Petersburg, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Belgorod Regional Oncology Dispensary; Chemotherapy, Belgorod, Russian Federation|Regional Oncology Hospital, Irkutsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|P.A. Herzen Oncological Inst. ; Oncology, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|Regional Oncology Dispensary; Dept of Chemotherapy, Novgorod Veliky, Russian Federation|BIH at Omsk Region ""Clinical Oncology Dispensary"", Outpatient clinic, Omsk, Russian Federation|Pyatigorsky Oncologic Dispensary, Pyatigorsk, Russian Federation|Rostov Scientific Research Inst. of Oncology; Chemotherapy, Rostov-na-donu, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|FBI ""Scientific Research Institute of Oncology n. a. N. N. Petrov"", Saint-Petersburg, Russian Federation|Multidisciplinary clinic Reaviz, Samara, Russian Federation|Mordovia State University, Saransk, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Oncologica Dispensary #2, Sochi, Russian Federation|Non-state Healthcare Institution ""Road Clinical Hospital of JSC Russian Railways"", St. Petersburg, Russian Federation|National University Hospital; Medical Oncology, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital General De Catalunya; Servicio de Oncologia, Sant Cugat Del Valles, Barcelona, Spain|Hospital Mutua de Terrassa; Servicio de Oncologia, Terrassa, Barcelona, Spain|Consorci Hospitalari de Terrassa, Terrassa, Barcelona, Spain|Hospital de Donostia.; Servicio de Oncolog√≠a Radioter√°pica, San Sebasti√°n, Guipuzcoa, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Centro Oncologico de Galicia COG; Medical Oncology, A Coruna, LA Coru√±a, Spain|Complejo Hospitalario Universitario A Coru√±a (CHUAC); Servicio de Oncologia, La Coruna, LA Coru√±a, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coru√±a, Spain|Hospital Universitario Rey Juan Carlos de M√≥stoles; Servicio de Neurolog√≠a, M√≥stoles, Madrid, Spain|Hospital Infanta Cristina; Servicio de Oncologia, Parla, Madrid, Spain|Hospital Infanta Sofia; Servico de Oncologia, San Sebastian de Los Reyes, Madrid, Spain|Complexo Hospitalario de Vigo. Hospital √Ålvaro Cunqueiro; Servicio de Oncolog√≠a, Vigo, Pontevedra, Spain|Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Universitario de Canarias; Servicio de Digestivo, La Laguna, Tenerife, Spain|Hospital General Univ. de Alicante; Servicio de Oncologia, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Provincial Castell√≥n, Castellon, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Oncologia, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Universitario Ram√≥n y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncol√≥gico Clara Campal Ensayos Cl√≠nicos START, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Madrid, Spain|Hosp Univ Fundacion Alcorcon, Madrid, Spain|Hospital Universitario de Fuenlabrada; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital Quir√≥n Sagrado Coraz√≥n, Sevilla, Spain|Hospital Universitario Virgen de la Macarena;, Sevilla, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova (Valencia), Valencia, Spain|Hospital Universitari i Politecnic La Fe; Oncologia, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia, Zaragoza, Spain|Hirslanden Medical Center, Tumorzentrum, Aarau, Switzerland|Inselspital Bern; Universit√§tsklinik f√ºr medizinische Onkologie, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne, Switzerland|Kantonsspital Olten; Medizinische Klinik, Olten, Switzerland|Brustzentrum, Z√ºrich, Switzerland|Chunghua Christian hospital, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan|Chi Mei Medical Center Liou Ying Campus, Liuying Township, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital - Taipei Branch, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation Linkou Branch, Taoyuan City, Taiwan|Bhumibol Adulyadej Hospital; Medicine, Bangkok, Thailand|National Cancer Institute; Department of Medicine, Bangkok, Thailand|Ramathibodi Hospital; Medicine/Oncology, Bangkok, Thailand|Siriraj Hospital; Medical Oncology Unit, Bangkok, Thailand|Chiang Rai Prachanukroh Hospital; Department Of Medicine, Chiang Rai, Thailand|Songklanagarind Hospital, Hat Yai, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Lampang Cancer Hospital, Muang Lampang, Thailand|Municipal Institution Odesa Regional Oncology Dispensary, Odesa, KIEV Governorate, Ukraine|Vinnytsya Regional Clinical Oncology Dispensary, Vinnytsya, Podolia Governorate, Ukraine|Regional Oncology Center; Department of Mammology, Chernigiv, Ukraine|Chernivtsi Regional Clinical Oncology Dispensary, Chernivtsi, Ukraine|MI""Zapor.Reg.Clin.Hosp."",ZMA of PGE,Ch.of Nerv.Dis., Dnipropetrovsk, Ukraine|City Clinical Hospital #4, Dnipropetrovsk, Ukraine|Municipal Institution Kirovograd Regional Oncology Dispensary, Kirovograd, Ukraine|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|Sumy Reg. Clin. Oncological Dispensary; Thoracall Department, Sumy, Ukraine|CCCH City Oncological Center SHEI Uzhgorod NU, Uzhgorod, Ukraine|Transkarpathian Regional Oncology Clinic; Chemotherapy, Uzhgorod, Ukraine|Zaporizhzhia Regional Clinical Oncology Dispensary; Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine|NHS Lothian - Western General Hospital; NHS Lothian - Western General Hospital, Edinburgh, United Kingdom|NHS Greater Glasgow and Clyde; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom|Leeds Teaching Hosp NHS Trust;St James's Institute of Onc, Leeds, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|North West Anglia NHS Foundation Trust, Peterborough, United Kingdom|University Hospitals of North Midlands NHS Trust-Royal Stoke University Hospital, Stoke-On-Trent, United Kingdom",,https://ClinicalTrials.gov/show/NCT03498716
TNBC,88,4,1,NCT02425891,Ph 3,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130),,"Active, not recruiting",No Results Available,Triple Negative Breast Cancer,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Drug: Nab-Paclitaxel|Drug: Placebo",Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in all Randomized Participants|PFS According to RECIST v1.1 in Participants with Detectable Programmed Death-Ligand 1 (PD-L1)|Overall Survival (OS) in all Randomized Participants|OS in Participants with Detectable PD-L1|Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 in all Randomized Participants|Percentage of Participants With an Objective Response of CR or PR According to RECIST v1.1 in Participants with Detectable PD-L1|Duration of Response (DOR) According to RECIST v1.1 in all Randomized Participants|DOR Acccording to RECIST v1.1 in Participants with Detectable PD-L1|Time to Deterioration (TTD) in Global Health Status/Health Related Quality of Life According to European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) v3.0 in all Randomized Participants|TTD in Global Health Status/Health Related Quality of Life According to EORTC QLQ-C30 v3.0 in Participants with Detectable PD-L1|Percentage of Participants with Adverse Events (AEs) or Serious AEs (SAEs)|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab|Maximum Serum Concentration (Cmax) for Atezolizumab|Minimum Serum Concentration (Cmin) for Atezolizumab|Plasma Concentrations of Total Paclitaxel,Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,900,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WO29522|2014-005490-37,06/23/15,04/30/20,04/30/20,04/24/15,null,26-Feb-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Katmai Oncology, Anchorage, Alaska, United States|HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States|Arizona Oncology Associates, P.C., Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Marin Cancer Care Inc, Greenbrae, California, United States|Kaiser Permanente of Northern California, Oakland, California, United States|Emad Ibrahim, Md, Inc, Redlands, California, United States|Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States|Kaiser Permanente - San Marcos, San Marcos, California, United States|Cancer Research Collaboration, Inc., Santa Ana, California, United States|Stanford Univ School of Med; Oncology, Stanford, California, United States|Kaiser Permanente Of Colorado, Aurora, Colorado, United States|Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Stamford Hospital; BCC, MOHR, Stamford, Connecticut, United States|MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington, District of Columbia, United States|Florida Cancer Specialists - SCRI; Pharmacy, Fort Myers, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|The Mount Siani Comprehensive Cancer Center, Miami Beach, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Rush University Medical Center - Chicago, Chicago, Illinois, United States|University hospitals and clinics, Lafayette, Louisiana, United States|LSU Health Sciences Center, Shreveport, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Maryland Oncology Hematology, Rochville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr; Hem/Onc, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute; Oncology, Detroit, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New Hampshire Hematology Oncology, Hooksett, New Hampshire, United States|Hackensack U Med Ctr, Hackensack, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|ProHEALTH Care Associates LLP, Lake Success, New York, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States|Onc/Hem Care Clin Trials LLC, Cincinnati, Ohio, United States|The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States|Kaiser Perm NW - Rheuma, Portland, Oregon, United States|Providence Cancer Center, Portland, Oregon, United States|St. Luke's Cancer Care Associates, Bethlehem, Pennsylvania, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Greenville Health System (GHS) Cancer Institute, Greenville, South Carolina, United States|Wellmont Bristol Regional Medical Center, Bristol, Tennessee, United States|West Clinic, Germantown, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|Texas Oncology- El Paso Cancer Treatment Center Gateway, El Paso, Texas, United States|The Methodist Cancer Center, Houston, Texas, United States|University of Texas;M.D. Anderson Cancer Center, Houston, Texas, United States|Inova Medical Group, Fairfax, Virginia, United States|Cancer Care Northwest, Spokane, Washington, United States|Northwest Cancer Specialists - Vancouver, Vancouver, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|Centro de Oncologia e Investigacion Buenos Aires (COIBA), Buenos Aires, Argentina|Fundaci√≥n CENIT para la Investigaci√≥n en Neurociencias, Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Nepean Cancer Care Centre, Sydney, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Princess Alexandra Hospital; Division of Cancer Services, Woolloongabba, Queensland, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia|Lkh-Univ. Klinikum Graz; Klinik F√ºr Innere Medizin I, Graz, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|A.√ñ. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gastr√∂nter. & Onkologie, Steyr, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Frauenheilkunde - Klinik f√ºr Gyn√§kologie, Wien, Austria|Medizinische Universit√§t Wien; Univ.Klinik f√ºr Innere Medizin I, Wien, Austria|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Santa Casa de Misericordia de Salvador; Oncologia, Salvador, BA, Brazil|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital de Clinicas de Porto Alegre;Centro de Pesquisa Clinica, Porto Alegre, RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital Sao Jose, S√£o Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Bcca - Cancer Center Southern Interior, Kelowna, British Columbia, Canada|Bcca-Fraser Valley Cancer Centre, Surrey, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hospital Du Saint-Sacrement, Quebec City, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Chile|Centro de Cancer Pontificie Universidad Catolica de Chile, Santiago, Chile|Centro Internacional de Estudios Cl√≠nicos (CIEC), Santiago, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Clinica del Country, Bogota, Colombia|Oncologos De Occidente, Manizales, Manizales, Colombia|Oncomedica S.A., Monteria, Colombia|Clinica CIMCA, San Jose, Costa Rica|ICIMED Instituto de Investigaci√≥n en Ciencias M√©dicas, San Jose, Costa Rica|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Herlev Hospital; Onkologisk afdeling, Herlev, Denmark|Rigshospitalet; Onkologisk Klinik, K√∏benhavn √ò, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|North Estonia Medical Centre Foundation; Oncology Centre, Tallinn, Estonia|Tartu Uni Hospital; Hematology - Oncology Clinic, Tartu, Estonia|KYS S√§desairaala; Sy√∂p√§tautien poliklinikka, Kuopio, Finland|Oulu University Hospital; Oncology, Oulu, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Ico - Paul Papin, Angers, France|Institut Sainte Catherine, Avignon, France|Hopital Jean Minjoz, Besancon, France|Centre Francois Baclesse; Comite Sein, Caen, France|HOPITAL MICHALLON - CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE, Service d'oncologie M√©dicale, Grenoble, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Institut r√©gional du Cancer Montpellier, Montpellier, France|Clinique Catherine de Sienne, Nantes, France|Institut Curie, Paris, France|Hopital La Pitie Salpetriere, Paris, France|Institut De Cancerologie De L'Ouest; Medical Oncology, Saint Herblain, France|Centre Paul Strauss, Strasbourg, France|Onkologische Schwerpunktpraxis Kurf√ºrstendamm, Berlin, Germany|Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany|St. Johannes Hospital; Abt. f√ºr H√§matologie und Onkologie, Dortmund, Germany|Universit√§tsklinikum ""Carl Gustav Carus"" der Technischen Universit√§t Dresden, Dresden, Germany|Universit√§tsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Uniklinik Essen; Gyn√§kologie, Essen, Germany|Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH, Georgsmarienh√ºtte, Germany|Universit√§tsklinikum Halle (Saale); Universit√§tsklinik Und Poliklinik F√ºr Gyn√§kologie, Halle, Germany|Universit√§tsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|Facharztzentrum Eppendorf, Studien GbR, Hamburg, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, Germany|Universitatsklinik Heidelberg; Universit√§tshautklinik und Nationales Centrum f√ºr Tumorerkrankungen, Heidelberg, Germany|Praxis K√∂ppler, Heymann, Weide, Thomalla; F√§ F√ºr Innere Medizin, Koblenz, Germany|St. Elisabeth-Krankenhaus; Brustzentrum, K√∂ln, Germany|Universit√§tsklinikum Schleswig-Holstein; Campus L√ºbeck, L√ºbeck, Germany|Klinikum Magdeburg gemeinn√ºtzige GmbH; Klinik Haematologie und Onkologie, Magdeburg, Germany|Klinikum rechts der Isar der TU M√ºnchen; Frauenklinik & Poliklinik, M√ºnchen, Germany|Gemeinschaftspraxis f√ºr H√§matologie und Onkologie, M√ºnster, Germany|MVZ Nordhausen gGmbH, Praxis Dr. Grafe, Nordhausen, Germany|Oncologianova GmbH - Gesellschaft f√ºr Innovationen in der Onkologie, Recklinghausen, Germany|Universit√§tsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|Mutterhaus der Borrom√§erinnen gGmbH, Abteilung H√§matologie-Onkologie, Trier, Germany|Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis, Troisdorf, Germany|Universit√§tsklinik T√ºbingen; Frauenklinik & Poliklinik, T√ºbingen, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|IASO General Hospital of Athens, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Grupo Angeles, Guatemala City, Guatemala|Queen Elizabeth Hospital; Clinical Oncology, Hong Kong, Hong Kong|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Oncology, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai K√∂zpont, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|F√∂v√°rosi √ñnkorm√°nyzat uzsoki utcai K√≥rh√°z, Budapest, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, Italy|Ospedale Vito Fazzi; Div. Oncoematologia, Lecce, Puglia, Italy|Ospedale Della Misericordia; U.O. Di Medicina Ia - Oncologia Medica, Grosseto, Toscana, Italy|Aichi Cancer Center Hospital, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gunma Prefectural Cancer Center, Gunma, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|Sagara Hospital, Kagoshima, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|Mie University Hospital, Mie, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Naha-nishi Clinic, Okinawa, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Saitama Medical University International Medical Center, Saitama, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka General Hospital, Shizuoka-shi, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|St. Luke's International Hospital, Tokyo, Japan|Toranomon Hospital, Tokyo, Japan|Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|National Cancer Center; Neurology, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System; Pharmacy, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Samsung Medical Center - Neurology, Seoul, Korea, Republic of|Daugavpils Regional Hospital, Daugavpils, Latvia|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Latvia|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Centro M√©dico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Instituto Estatal de Cancerologia Colima, Colima, Mexico|Iem-Fucam, D.f., Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Helse Bergen HF Haukeland universitetssjukehus kreftavdelingen poliklinikk, Bergen, Norway|S√∏rlandet Sykehus Kristiansand, Kristiansand, Norway|Stavanger Universitetssykehus, Helse Stavanger HF, Stavanger, Norway|Centro Oncol√≥gico de Panam√°, Panama, Panama|Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii, Bydgoszcz, Poland|Szpitale Wojewodzkie w Gdyni Sp. z o.o., Gdynia, Poland|Przychodnia Lekarska KOMED, Konin, Poland|Szpital Uniwersytecki w Krakowie, Oddzia≈Ç Kliniczny Kliniki Onkologii, Krakow, Poland|Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii, Lublin, Poland|Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Mazowiecki Szpital Onkologiczny, Wieliszew, Poland|Euroclinic Center of Oncology SRL, Iasi, Romania|Oncomed SRL, Timisoara, Romania|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Main Military Clinical Hospital named after N.N. Burdenko, Moscow, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Institute for Onc/Rad Serbia, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Institute for oncology of Vojvodina, Sremska Kamenica, Serbia|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Hospital Universitario Reina Sofia; Servicio de Oncologia, C√≥rdoba, Cordoba, Spain|Hospital de Donostia; Servicio de Oncologia Medica, San Sebastian, Guipuzcoa, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Sk√•nes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling, Malm√∂, Sweden|Sodersjukhuset; Onkologkliniken, Stockholm, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Universitetssjukhuset √ñrebro, Onkologiska kliniken, √ñrebro, Sweden|Universitaetsspital Basel; Onkologie, Basel, Switzerland|Kantonsspital Graub√ºnden;Onkologie und H√§matologie, Chur, Switzerland|Kantonsspital St. Gallen; Brustzentrum, St. Gallen, Switzerland|OnkoZentrum Zuerich, Z√ºrich, Switzerland|Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung, Taiwan|China Medical University Hospital; Surgery, Taichung, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Prince of Songkla Uni ; Unit of Medical Oncology, Songkhla, Thailand|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, Turkey|Istanbul University Cerrahpasa Medical Faculty; Radiation Oncology Department, Istanbul, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Ege Uni Medical Faculty Hospital; Oncology Dept, Izmir, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sƒ±hhiye, Ankara, Turkey|CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|Treatment and Prevention Institution Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv, Ukraine|Velindre Cancer Centre, Cardiff, United Kingdom|Western General Hospital; Clinical Oncology, Edinburgh, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Guys ST Thomas Hospital, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Preston Hosptial, Preston, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02425891
TNBC,88,5,1,NCT03125902,Ph 3,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC),IMpassion131,Recruiting,No Results Available,Triple-Negative Breast Cancer,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Drug: Atezolizumab Placebo|Drug: Paclitaxel",Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation with Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status|Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population|Overall Survival (OS) in the PD-L1-Positive Subpopulation|Overall Survival (OS) in the ITT Population|Percentage of Participants Who are Alive at 12 and 18 Months|Time to deterioration (TTD) in Global Health Status/ Health Related Quality of Life (HRQoL)|Percentage of Participants Who are Alive Without Progression Event at Month 12 Assessed Using RECIST v1.1|Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Subpopulation|Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the ITT Population|Duration of Objective Response (DOR) Assessed Using RECIST v1.1|Percentage of Participants With Clinical Benefit Assessed Using RECIST v1.1|Minimum Observed Serum Concentration (Cmin) of Atezolizumab|Maximum Observed Serum Concentration (Cmax) of Atezolizumab|Minimum Observed Plasma Concentration (Cmin) of Paclitaxel|Maximum Observed Plasma Concentration (Cmax) of Paclitaxel|Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)|Percentage of Participants With Drug Antibodies (ADAs)|Change From Baseline in PD-L1 Expression by Immunohistochemistry at Approximately 45 Months,Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,600,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MO39196|2016-004024-29,08/25/17,01/30/20,06/30/21,04/24/17,null,11-Apr-19,"Stanford Cancer Center, Stanford, California, United States|Florida Cancer Specialists; Department of Oncology, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|HCA Midwest Health, Kansas City, Missouri, United States|The Valley Hospital, Paramus, New Jersey, United States|Magee-Woman's Hospital, Pittsburgh, Pennsylvania, United States|Tennessee Oncology; Sarah Cannon Research Institute, Nashville, Tennessee, United States|CPMC; Service d'Oncologie M√©dicale, Algiers, Algeria|CHU Blida; Service d'Oncologie M√©dicale, Blida, Algeria|CHU Oran; Service d'Oncologie M√©dicale, Oran, Algeria|Inst. Alexander Fleming; Oncology Dept, Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Santa Casa de Misericordia de Salvador, Salvador, BA, Brazil|Hospital Evangelico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, ES, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Cetus Hospital Dia Oncologia, Belo Horizonte, MG, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|McGill University; Glen Site; Oncology, Montreal, Quebec, Canada|Hospital Du Saint-Sacrement, Quebec City, Quebec, Canada|Cuse - Centre Universitaire De Sante; Site Fleurimont, Sherbrooke, Quebec, Canada|The 307th Hospital of Chinese People's Liberation Army, Beijing City, China|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Union Hospital, Beijing, China|West China Hospital, Sichuan University; Department of Breast, Chengdu, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, China|Sun Yat-sen Memorial Hospital, Guangzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Jiangsu Cancer Hospital, Nanjing, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China|The Second Affiliated Hospital of Xi'an Jiao Tong University, Xian, China|Henan Cancer Hospital, Zhengzhou, China|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni nemocnice Ostrava; Klinika onkologicka FNO a LF OU, Ostrava-Poruba, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|ONKOCENTRUM, Medicon Services s.r.o, Praha 4, Czechia|Clinical Research Center (CRC), Faculty of Medicine, Alexandria University, Alexandria, Egypt|Kasr Eieny Uni Hospital; Oncology (Nemrock), Cairo, Egypt|Clinique Sainte Catherine; Hopital De Semaine, Avignon, France|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital Morvan, Brest, France|CHD Les Oudairies, La Roche Sur Yon, France|Centre Oscar Lambret; Senologie, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|Hopital Caremeau; Hematologie Oncologie, Nimes, France|Hopital Tenon, Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis, Service D Oncologie Medicale, Paris, France|Ch Pitie Salpetriere; Oncologie Medicale, Paris, France|Polyclinique De Courlancy; Centre Radiotherapie Oncologie, Reims, France|Centre Eugene Marquis; Service d'oncologie, Rennes, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France|Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany|Marien-Hospital Klinik f.H√§matologie Onkologie u.Palliativmedizin, D√ºsseldorf, Germany|Universit√§tsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik f√ºr Senologie / Brustzentrum, Essen, Germany|Dres.Jochen Wilke und Harald Wagner, F√ºrth, Germany|HOPA im Struensee-Haus, Dres. Erik Engel, Wiebke Hollburg, Hamburg, Germany|Nationales Centrum f√ºr Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Institut f√ºr Versorgungsforschung in der Onkologie GbR Koblenz, Koblenz, Germany|St. Elisabeth Krankenhaus K√∂ln GmbH; Gyn√§kologie und Geburtshilfe, Koeln, Germany|Universit√§tsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz, Germany|OnkoNet Marburg GmbH, Marburg, Germany|Klinik & Poliklinik f√ºr Frauenheilkunde und Geburtshilfe, Campus Innenstadt, M√ºnchen, Germany|Klinikum rechts der Isar der TU M√ºnchen; Klinik und Poliklinik f√ºr Frauenheilkunde, M√ºnchen, Germany|Gemeinschaftspraxis f√ºr H√§matologie und Onkologie, M√ºnster, Germany|Klinikum Ernst von Bergmann; Frauenklinik, Potsdam, Germany|Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis, Troisdorf, Germany|Universit√§tsklinik T√ºbingen; Frauenklinik, T√ºbingen, Germany|Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece|ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens, Greece|Attikon University General Hospital, Athens, Greece|Attikon University Hospital;2nd Propedeutic Clinic; Oncology Dept., Haidari, Greece|Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept., Kifisia, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Sanjeevan Hospital; Medical Oncology, Pune, Maharashtra, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|Apollo Speciality Hospital, Chennai, India|MAX Balaji Hospital, Delhi, India|Apollo Gleneagles Hospitals, Kolkata, India|Dr. B L Kapur Memorial Hospital; BLK Cancer Centre, New Delhi, India|Ruby Hall Clinic, Pune, India|Christian Med Clg & Hspt, Vellore, India|Shaare Zedek Medical Center; Oncology Dept, Jerusalem, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Rambam Health Corporation; Oncology Institute, Rambam, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Ctr; Oncology, Tel Aviv, Israel|Assaf Harofeh; Oncology, Zerifin, Israel|Fondazione Universit√† G. D'Annunzio; Clinical Research Center (CRC); Centro Studi (CESI), Chieti, Abruzzo, Italy|Presidio Ospedaliero S. Giovanni Di Dio; U.O. Di Oncologia, Frattamaggiore, Campania, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Azienda Ospedaliero - Universitaria di Modena Policlinico, Modena, Emilia-Romagna, Italy|Universita Campus Bio-Medico di Roma (UCBM), Roma, Lazio, Italy|IRCCS Istituto Regina Elena (IFO); Oncologia Medica B, Roma, Lazio, Italy|Azienda Policlinico Umberto I, Roma, Lazio, Italy|A.O. Universitaria S. Martino Di Genova, Genova, Liguria, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Lombardia, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, Italy|Hospital San Raffaele, Milano, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|IEO Istituto Europeo di Oncologia;Divisione Oncologia Medica, Milano, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo, Candiolo, Piemonte, Italy|Ospedale S. Vincenzo; Oncologia Medica, Taormina, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, Italy|Ospedale Civile; Unita Operativa Di Oncologia Medica, Livorno, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Gunma Prefectural Cancer Center, Gunma, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Sagara Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Naha-nishi Clinic, Okinawa, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|American University of Beirut - Medical Center, Beirut, Lebanon|Bellevue Medical Center, El- Metn, Lebanon|Centre Hospitalier Universitaire Mohamed VI; Oncologie-H√©matologie, Marrakech, Morocco|Institut National D'oncologie Sidi Mohammed Ben Abdellah; Anatomopathologie, Rabat, Morocco|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta, Constanta, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, Romania|Russian Oncology Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Petrov Research Inst. of Oncology, St Petersburg, Russian Federation|King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia|International Medical Center (IMC), Jeddah, Saudi Arabia|King Fahad Medical City; Gastroentrology, Riyadh, Saudi Arabia|Mammacentrum sv. Ag√°ty, Bansk√° Bystrica, Slovakia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A, Bratislava, Slovakia|POKO Poprad; Department of Oncology, Poprad, Slovakia|Fakultna nemocnica Trenc√≠n; Onkologicke odd., Trencin, Slovakia|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Wilgers Oncology Centre, Pretoria, South Africa|Private Oncology Centre, Pretoria, South Africa|Sandton Oncology Medical Group, Sandton, South Africa|Hospital Son Llatzer; Servicio de Oncologia, Palma de Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario A Coru√±a (CHUAC); Servicio de Oncologia, La Coruna, LA Coru√±a, Spain|Hospital Cl√≠nic i Provincial; Servicio de Hematolog√≠a y Oncolog√≠a, Barcelona, Spain|Hospital Universitario de Fuenlabrada; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Adana Baskent University Medical Faculty; Oncology, Adana, Turkey|Ankara City Hospital, Ankara, Turkey|Gazi University Medical Faculty, Oncology Hospital, Ankara, Turkey|Uludag University Medical Faculty; Internal Medicine, Bursa, Turkey|Dicle Uni Medical Faculty; Internal Medicine, Diyarbakir, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, Turkey|Istanbul Uni Istanbul Medical Faculty, Istanbul, Turkey|Medeniyet University Goztepe Training and Research Hospital., Istanbul, Turkey|Izmir Ataturk Training and Research Hospital, Izmir, Turkey|Kocaeli University Faculty of Medicine; Medical oncology, Izmit, Turkey|Western General Hospital, Edinburgh, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|K hospital, Hanoi, Vietnam|Hochiminh city oncology hospital, Hochiminh city, Vietnam",,https://ClinicalTrials.gov/show/NCT03125902
TNBC,88,6,1,NCT02819518,Ph 3,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),,"Active, not recruiting",No Results Available,Triple Negative Breast Cancer (TNBC),Biological: Pembrolizumab|Drug: Nab-paclitaxel|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Carboplatin|Drug: Normale Saline Solution,Part 1: Percentage of Participants Who Experience an Adverse Event (AE)|Part 1: Percentage of Participants Who Discontinue Study Drug Due to an AE|Part 2: Progression-Free Survival (PFS) - All Participants|Part 2: PFS - Participants With Programmed Cell Death-Ligand 1 (PD-L1) Positive Tumors|Part 2: Overall Survival (OS) - All Participants|Part 2: OS - Participants With PD-L1 Positive Tumors|Part 2: Objective Response Rate (ORR) - All Participants|Part 2: ORR - Participants With PD-L1 Positive Tumors|Part 2: Duration of Response (DOR) - All Participants|Part 2: DOR - Participants With PD-L1 Positive Tumors|Part 2: Disease Control Rate (DCR) - All Participants|Part 2: DCR - Participants With PD-L1 Positive Tumors|Part 2: Percentage of Participants Who Experience an AE|Part 2: Percentage of Participants Who Discontinue Study Drug Due to an AE|Part 2: Change from Baseline to End of Study in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Total Score - All Participants|Part 2: Change from Baseline to End of Study in EORTC QLQ-C30 Total Score - Participants With PD-L1 Positive Tumors|Part 2: Change from Baseline to End of Study in EORTC Breast Cancer-Specific Quality of Life Questionnaire (QLQ-BR23) Total Score - All Participants|Part 2: Change from Baseline to End of Study in EORTC QLQ-BR23 Total Score - Participants with PD-L1 Positive Tumors,Merck Sharp & Dohme Corp.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,882,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3475-355|2016-001432-35|163422|MK-3475-355|KEYNOTE-355,07/27/16,12/30/19,12/30/19,06/30/16,null,26-Apr-19,,,https://ClinicalTrials.gov/show/NCT02819518
TNBC,88,7,1,NCT03777579,Ph 3,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC (KEYSTONE),,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: JS001Ôºåan engineered anti-PD-1 antibody|Drug: Nab-Paclitaxel|Drug: Placebo,Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by Independent Review Committee (IRC)|Progression-Free Survival (PFS) Assessed Using RECIST v1.1 by investigator|Objective response rate (ORR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by IRC|Duration of response (DoR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by IRC|Disease control rate (DCR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)by IRC|Overall Survival (OS)|OS rate at 12 months|OS rate at 24 months|PFS Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator|ORR Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator|DoR Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator|DCR Assessed Using immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) by investigator|Percentage and severity of Participants With Adverse Events (AEs)|Percentage of Participants With Anti-Drug Antibodies (ATAs),"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|TopAlliance Biosciences, Inc.",Female,"18 Years to 70 Years ¬† (Adult, Older Adult)",Phase 3,375,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NABP201801,12/30/18,12/30/19,07/30/20,12/17/18,null,7-Jan-19,,,https://ClinicalTrials.gov/show/NCT03777579
TNBC,88,8,1,NCT03371017,Ph 3,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer,IMpassion132,Recruiting,No Results Available,Triple Negative Breast Neoplasms,Drug: Atezolizumab|Drug: Placebo|Drug: Gemcitabine|Drug: Capecitabine|Drug: Carboplatin,"Overall survival (OS)|Proportion of patients alive 12 months|Proportion of patients alive 18 months|Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Objective response rate (ORR), defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1|Duration of objective response (DoR) as determined by the investigator according to RECIST 1.1|Clinical benefit rate (CBR), defined as the proportion of patients with a CR or a PR or stable disease as determined by the investigator according to RECIST 1.1",Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,350,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MO39193|2016-005119-42,01/11/18,07/31/19,01/31/21,12/13/17,null,13-Mar-19,"Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|HCA Midwest Division, Kansas City, Missouri, United States|The Valley Hospital, Paramus, New Jersey, United States|Magee-Woman's Hospital; UPMC Pinnacle Cancer Center, Harrisburg, Pennsylvania, United States|Magee-Woman's Hospital, Pittsburgh, Pennsylvania, United States|Tennessee Oncology; Sarah Cannon Research Institute, Nashville, Tennessee, United States|Inova Schar Cancer Institute, Falls Church, Virginia, United States|Centre hospitalo-univerisitaire de Rouiba;Service d'oncologie m√©dicale, Algiers, Algeria|Centre Anti Cancer Beau-fraisier;Service d'oncologie m√©dicale, Algiers, Algeria|CHU Constantine; Service d'Oncologie M√©dicale, Constantine, Algeria|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital do Cancer de Pernambuco - HCP, Recife, PE, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital Hermanos Ameijeiras, La Habana, Cuba|Instituto Nacional de Oncolog√≠a y Radiolog√≠a (INOR), La Habana, Cuba|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Centre Georges-Fran√ßois Lecler; Ctr de Lutte Contre le Canc, Dijon, France|Centre Leon Berard; Oncologie Genetique, Lyon, France|Institut Paoli-Calmettes; Oncologie Medicale 1, Marseille Cedex 09, France|Centre R√©gional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque, Montpellier, France|INSTITUT CURIE_SITE PARIS - Service d'Oncologie M√©dicale., Paris, France|Centre Eugene Marquis; Service d'oncologie, Rennes, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre Les Nancy, France|IGR, Villejuif, France|Praxisklinik Krebsheilkunde f√ºr Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, Germany|Universit√§tsklinikum ""Carl Gustav Carus""; Frauenheilkunde und Geburtshilfe, Dresden, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik f√ºr Senologie / Brustzentrum, Essen, Germany|Klinikum Frankfurt H√∂chst GmbH; Klinik f√ºr Gyn√§kologie und Geburtshilfe, Frankfurt, Germany|Universit√§tsklinikum Halle (Saale); Universit√§tsklinik Und Poliklinik F√ºr Gyn√§kologie, Halle, Germany|Onkologische Schwerpunktpraxis Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Klinik f√ºr Frauenheilkunde und Geburtshilfe, Hannover, Germany|Nationales Centrum f√ºr Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Kliniken der Stadt K√∂ln gGmbH Krankenhaus Holweide; Brustzentrum, K√∂ln, Germany|Gemeinschaftspraxis Prof. Dr.med. Christoph Salat und Dr.med. Oliver J. St√∂tzer, M√ºnchen, Germany|Caritas-Krankenhaus St. Josef; Klinik f√ºr Frauenheilkunde und Geburtshilfe, Regensburg, Germany|Szent Margit Hospital, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz;Sugarterapias Klinikai Onkologiai Intez, Miskolc, Hungary|P√©csi Tudom√°nyegyetem √Åok; Onkoterapias Intezet, Pecs, Hungary|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, Italy|Ospedale San Gerardo, Monza, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department, Almaty, Kazakhstan|Almaty Cancer Hospital; Chemotherapy department, Almaty, Kazakhstan|Oncology centre of Astana; Chemotherapy department, Astana, Kazakhstan|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center - Neurology, Seoul, Korea, Republic of|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Clinical Center of Montenegro; Clinic for Oncology and Radiotherapy, Podgorica, Montenegro|Centre Hospitalier Universitaire Mohamed VI; Oncologie-H√©matologie, Marrakech, Morocco|Clinique specialise Menara; Oncology Medical, Marrakech, Morocco|Institut National D'oncologie Sidi Med Benabdellah, Rabat, Morocco|Centro Hemato Oncologico Panama, Panama, Panama|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|FSBI ""National Medical Research Center of Oncology N.N. Blokhin"", Moscow, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, SPb SBIH CCOD, Saint-Petersburg, Russian Federation|Clinical Hospital Center Bezanijska kosa; Clinic for Oncology, Belgrade, Serbia|Institute of Oncology and Radiology of Serbia, Belgrade, Serbia|Clinical Centre Nis, Clinic for Oncology, Nis, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Cape Town Oncology Trials, Cape Town, South Africa|The Oncology centre,Durban; Clinical Oncology, Durban, South Africa|Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|University of Pretoria Oncology Department; Medical Oncology, Pretoria, South Africa|Private Oncology Centre, Pretoria, South Africa|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Cl√≠nico Universitario de Valencia; Servicio de Oncolog√≠a, Valencia, Spain|Hacettepe University Medical Faculty; Department of Internal Medicine, Ankara, Turkey|Ankara Oncology Hospital; Medical Oncology Department, Ankara, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, ƒ∞ÃázmiÃár, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Marmara University Pendik Training and Research Hospital; Medikal Onkoloji, Istanbul, Turkey|Necmettin Erbakan University Meram Medical Faculty ; Internal Diseases, Konya, Turkey|Velindre Cancer Centre; Oncology Dept, Cardiff, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Western General Hospital; Edinburgh Cancer Center, Edinburgh, United Kingdom|Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust, Lancaster, United Kingdom|Barts, London, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Royal Stoke University Hospital, Stoke on Trent, United Kingdom",,https://ClinicalTrials.gov/show/NCT03371017
TNBC,88,9,1,NCT03197935,Ph 3,45,TNBCCPI Combo,CPI Combo,Neo-adj,Breast Only,A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer,IMpassion031,"Active, not recruiting",No Results Available,Triple-negative Breast Cancer,"Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Drug: Placebo|Drug: Nab-paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Filgrastim|Drug: Pegfilgrastim",Percentage of Participants with Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System|Percentage of Participants with pCR in Subpopulation with PD-L1-Positive Tumor Status (tumor-infiltrating immune cell [IC] 1/2/3) Using AJCC Staging System|Event-Free Survival (EFS) Using AJCC Staging System|Event-Free Survival (EFS) in Subpopulation with PD-L1-Postive Tumor Status Using AJCC Staging System|Disease-Free Survival (DFS) in All Participants Who Undergo Surgery|Disease-Free Survival (DFS) in Subpopulation of Participants with PD-L1-Positive Tumor Status Who Undergo Surgery|Overall survival (OS) in All Participants|Overall survival (OS) in Subpopulation with PD-L1-Positive Tumor Status|Changes From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Score|Percentage of Participants with Adverse Events (AEs)|Serum Concentration of Atezolizumab|Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab,Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,204,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",WO39392|2016-004734-22,07/24/17,09/30/20,01/31/23,06/23/17,null,29-Jan-19,"Stanford University Medical Center, Palo Alto, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Northwest Georgia Oncology Centers P.C., Carrollton, Georgia, United States|Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States|Mercy Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|HCA Midwest Division, Kansas City, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|The Valley Hospital; Valley Medical Group, Westwood, New Jersey, United States|Montefiore Einstein Cancer Center, Bronx, New York, United States|Westchester Hospital Cancer, Mount Kisco, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|Santa Casa de Misericordia de Salvador; Oncologia, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|CETUS Hospital Dia, Belo Horizonte, MG, Brazil|Instituto de Oncologia do Paran√°, Curitiba, PR, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Hopital Sacre-Coeur Research Centre, Montreal, Quebec, Canada|Hospital Du Saint-Sacrement, Quebec City, Quebec, Canada|Hochwaldkrankenhaus, Bad Nauheim, Germany|Praxisklinik Krebsheilkunde f√ºr Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany|Luisenkrankenhaus GmbH, Brustzentrum, D√ºsseldorf, Germany|Evangelische Kliniken Gelsenkirchen GmbH; Brustzentrum, Gelsenkirchen, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, Germany|Dres. Andreas K√∂hler und Roswitha Fuchs, Langen, Germany|St. Elisabeth-Krankenhaus, Senologie/Brustzentrum, Leipzig, Germany|Klinik & Poliklinik f√ºr Frauenheilkunde und Geburtshilfe, Campus Innenstadt, M√ºnchen, Germany|Universit√§tsklinikum M√ºnster; Klinik f√ºr Frauenheilkunde und Geburtshilfe, M√ºnster, Germany|Klinikum Oldenburg A√∂R; Universit√§tsklinik f√ºr Innere Medizin - Onkologie und H√§matologie, Oldenburg, Germany|Aichi Cancer Center Hospital, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital; Breast Surgery, Hiroshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|National Hospital Organization Osaka National Hospital; Breast Surgery, Osaka, Japan|St. Luke's Internat. Hospital, Breast Surgical Oncology, Tokyo, Japan|The Cancer Inst. Hosp. of JFCR; Breast Oncology Center, Tokyo, Japan|National Cancer Center; Neurology, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System; Pharmacy, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Chang Gung Medical Foundation-Taipei, Taoyuan, Taiwan|Leicester Royal Infirmary, Leicester, United Kingdom|Barts & London School of Med; Medical Oncology, London, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT03197935
TNBC,88,10,1,NCT03756298,Ph 2,45,TNBCCPI Combo,CPI Combo,Adj,Breast Only,Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer,,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Atezolizumab|Drug: Capecitabine,5-yr invasive disease-free survival (IDFS) rate,"National Cancer Center, Korea",All,"19 Years and older ¬† (Adult, Older Adult)",Phase 2,284,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ATOX-2018,01/15/19,01/31/24,01/31/27,11/28/18,null,29-Nov-18,"National cancer center, Goyang-si, Gyeonggido, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03756298
TNBC,88,11,1,NCT03797326,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005),,Recruiting,No Results Available,Advanced Solid Tumors|Triple Negative Breast Cancer|Ovarian Cancer|Gastric Cancer|Colorectal Cancer|Glioblastoma|Biliary Tract Cancers,Biological: Pembrolizumab|Drug: Lenvatinib,Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Glioblastoma (GBM) by Investigator Assessment in Initial Cohorts|ORR per RECIST 1.1 or RANO (GBM) by Blinded Independent Central Review (BICR) in Expanded Cohorts (Combined with Initial Cohorts)|Percentage of Participants who Experience an Adverse Event (AE)|Percentage of Participants who Discontinue Study Treatment Due to an Adverse Event (AE)|Disease Control Rate (DCR) per RECIST 1.1 by Investigator Assessment in Initial Cohorts|Duration of Response (DOR) per RECIST 1.1 or RANO (GBM) by Investigator Assessment in Initial Cohorts|Progression Free Survival (PFS) per RECIST 1.1 or RANO (GBM) by Investigator Assessment in Initial Cohorts|Overall Survival (OS) in Initial Cohorts|DCR per RECIST 1.1 by BICR in Expanded Cohorts (Combined with Initial Cohorts)|DOR per RECIST 1.1 or RANO (GBM) by BICR in Expanded Cohorts (Combined with Initial Cohorts)|PFS per RECIST 1.1 or RANO (GBM) by BICR in Expanded Cohorts (Combined with Initial Cohorts)|OS in Expanded Cohorts (Combined with Initial Cohorts)|Plasma Concentration of Lenvatinib,Merck Sharp & Dohme Corp.|Eisai Inc.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,180,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,7902-005|2018-003747-37|MK-7902-005|E7080-G000-224|LEAP-005,02/12/19,04/11/22,04/11/22,01/09/19,null,26-Apr-19,"City of Hope ( Site 0002), Duarte, California, United States|University of California Davis Comprehensive Cancer Center ( Site 0005), Sacramento, California, United States|University of Colorado, Anschutz Cancer Pavilion ( Site 0007), Aurora, Colorado, United States|West Cancer Center - East Campus ( Site 0018), Germantown, Tennessee, United States|University of Wisconsin Carbone Cancer Center ( Site 0017), Madison, Wisconsin, United States|Royal Brisbane and Women s Hospital ( Site 0901), Herston, Queensland, Australia|Alfred Health ( Site 0902), Melbourne, Victoria, Australia|Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario, Canada|CHU de Quebec Universite de Laval ( Site 0206), Quebec, Canada|Fundacion Arturo Lopez Perez ( Site 1201), Santiago, Chile|Hospital Clinico Universidad de Chile ( Site 1200), Santiago, Chile|Instituto Clinico Oncologico del Sur ( Site 1203), Temuco, Chile|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0402), Saint-Herblain, France|Universitaetsklinikum Frankfurt ( Site 0306), Frankfurt am Main, Germany|Universitaetsklinikum Jena ( Site 0302), Jena, Germany|Universitaetsklinikum Regensburg ( Site 0304), Regensburg, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0301), Wiesbaden, Germany|Soroka Medical Center ( Site 0601), Beer Sheva, Israel|Rambam Medical Center ( Site 0602), Haifa, Israel|Chaim Sheba Medical Center ( Site 0600), Ramat Gan, Israel|Sourasky Medical Center ( Site 0603), Tel Aviv, Israel|Seoul National University Hospital ( Site 1000), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 1001), Seoul, Korea, Republic of|Asan Medical Center ( Site 1002), Seoul, Korea, Republic of|Hospital Clinic i Provincial ( Site 0703), Barcelona, Spain|Hospital Universitario Gregorio Maranon ( Site 0701), Madrid, Spain|Clinica Universitaria de Navarra ( Site 0704), Madrid, Spain|Hospital Ramon y Cajal ( Site 0702), Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03797326
TNBC,88,12,1,NCT03424005,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC),Morpheus-TNBC,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Capecitabine|Drug: Atezolizumab|Drug: Ipatasertib|Drug: SGN-LIV1A|Drug: Bevacizumab|Drug: Cobimetinib|Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|Drug: RO6874281|Drug: Selicrelumab,Objective Response Rate (ORR)|Progression Free Survival (PFS)|Disease Control Rate (DCR)|Overall Survival (OS)|Overall Survival (at specific time-points)|Duration of Response (DOR)|Percentage of Participants with Adverse Events|Serum Concentration of Atezolizumab|Plasma Concentration of Ipatasertib|Plasma or Serum Concentration of SGN-LIV1A|Plasma Concentration of Cobimetinib|Plasma Concentration of Capecitabine|Serum Concentration of RO6874281|Serum Concentration of Selicrelumab|Serum Concentration of Bevacizumab,"Hoffmann-La Roche|Seattle Genetics, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,310,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CO40115|2017-002038-21,03/30/18,08/17/21,08/17/21,02/06/18,null,16-Apr-19,"University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States|H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida, United States|Hackensack Univ Medical Center; John Theurer Cancer Ctr, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|NYU Langone Medical Center; NYU Perlmutter Cancer Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The West Clinic; West Cancer Center, Germantown, Tennessee, United States|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|Centre L√©on B√©rard, Lyon, France|Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France|Gustave Roussy, Villejuif CEDEX, France|Universit√§tsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Universit√§tsklinikum Essen, Essen, Germany|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center, Seoul, Korea, Republic of|Vall d¬¥Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Centro Integral Oncol√≥gico Clara Campal Ensayos Cl√≠nicos START, Madrid, Spain|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Barts Health NHS Trust - St Bartholomew's Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03424005
TNBC,88,13,1,NCT03742102,Ph 2,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.,BEGONIA,Recruiting,No Results Available,Triple Negative Breast Neoplasms,Drug: Durvalumab|Drug: Selumetinib|Drug: Capivasertib|Drug: Danvatirsen|Drug: Oleclumab|Drug: Paclitaxel,Incidence of adverse events|Laboratory findings|Objective response rate (ORR)|Progression-free survival (PFS).|Duration of response (DoR)|Overall survival (OS)|Blood concentration of durvalumab and novel oncology therapies|Presence of anti-drug antibodies (ADAs) for durvalumab and applicable novel oncology therapies,AstraZeneca,Female,"18 Years to 130 Years ¬† (Adult, Older Adult)",Phase 1|Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D933LC00001|2018-000764-29,12/21/18,11/01/20,12/31/20,11/15/18,null,25-Apr-19,"Research Site, Goodyear, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Newnan, Georgia, United States|Research Site, Zion, Illinois, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Kelowna, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bialystok, Poland|Research Site, Gda≈Ñsk, Poland|Research Site, Krak√≥w, Poland|Research Site, Lublin, Poland|Research Site, Opole, Poland|Research Site, Radom, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, ≈Å√≥d≈∫, Poland|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT03742102
TNBC,88,14,1,NCT03761914,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers,,Recruiting,No Results Available,Acute Myelogenous Leukemia|Ovarian Cancer|Colorectal Cancer|Triple-negative Breast Cancer|Small-cell Lung Cancer,Biological: galinpepimut-S|Drug: Pembrolizumab,"Number and frequency of TRAEs, including UARs, and SAEs (safety parameters) - for all tumor types|Overall response rate (ORR) by RECIST - for solid tumor arms|Complete Response (CR) rate - for AML arm only|Overall response rate (ORR) by iRECIST - for solid tumor arms|Measurable Residual Disease (MRD) negativity rate - for AML arm only|Time to response (TTR) - for all tumor types|Time to next treatment (TNT) - for all tumor types|Duration of Response (DOR) - for solid tumor arms|Duration of CR - for AML arm only","Sellas Life Sciences Group|Merck Sharp & Dohme Corp.|Cancer Insight, LLC",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,90,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SLS17-201/MK3475-770,04/15/19,10/31/20,04/30/21,12/03/18,null,4-Apr-19,"St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Innovative Clinical Research Institute (ICRI), Whittier, California, United States|Memorial Cancer Institute, Hollywood, Florida, United States",,https://ClinicalTrials.gov/show/NCT03761914
TNBC,88,15,1,NCT03872791,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer,,Not yet recruiting,No Results Available,Triple-negative Breast Cancer,Biological: KN046|Drug: Nab-paclitaxel,IRC assessed objective response|IRC assessed duration of response|PFS rate at 6 and 12 months|Frequency and severity of treatment emergent adverse events|Percentage of subjects with anti-drug antibodies,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,90,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KN046-203,04/15/19,09/15/20,09/15/21,03/13/19,null,13-Mar-19,,,https://ClinicalTrials.gov/show/NCT03872791
TNBC,88,16,1,NCT03098550,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,"A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread",,"Active, not recruiting",No Results Available,Advanced Cancer,Biological: Nivolumab|Biological: Daratumumab,Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Grade of laboratory abnormalities.|Objective Response rate (ORR)|Progression Free Survival (PFS)|Anti-Drug Antibodies (ADA) positivity|Area under the concentration-time curve (AUC)|Minimum observed concentration (Cmin),"Bristol-Myers Squibb|Janssen Biotech, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,120,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA209-9GW|2017-000367-33,06/07/17,08/30/20,08/30/20,03/31/17,null,3-Apr-19,"Pacific Shores Medical Group, Huntington Beach, California, United States|University Of Colorado, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Of Michigan, Ann Arbor, Michigan, United States|Providence Portland Medical Center, Portland, Oregon, United States|Local Institution, St Leonards, Australia|Local Institution, Edmonton, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Strasbourg Cedex, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Fundacion De Investigacion, San Juan, Puerto Rico|Hospital Gral. Univ. Gregorio Maranon, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Klinik Fur Onkologie, Basel, Switzerland|University Hospital of Lausanne, Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT03098550
TNBC,88,17,1,NCT03387085,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.,,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Aldoxorubicin HCl|Biological: N-803|Biological: ETBX-011|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-4000|Biological: GI-6207|Biological: GI-6301|Biological: haNK for Infusion|Biological: avelumab|Biological: bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: nab-Paclitaxel|Procedure: SBRT,"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.|Objective response rate by RECIST|Objective response rate by irRC|Progression-free survival by RECIST during Phase 1b|Progression-free survival by irRC during Phase 1b|Overall survival|Duration of response by RECIST and irRC|Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST and irRC.|Patient-reported outcomes of pancreatic cancer symptoms|Progression-free survival by RECIST during Phase 2|Progression-free survival by irRC during Phase 2","NantKwest, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,79,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QUILT-3.067,03/16/18,12/01/19,01/01/20,12/29/17,null,12-Apr-19,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",,https://ClinicalTrials.gov/show/NCT03387085
TNBC,88,18,1,NCT03499899,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,"A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer",,Recruiting,No Results Available,Triple-negative Breast Cancer,Drug: LAG525|Drug: spartalizumab|Drug: carboplatin,"Overall response rate (ORR) per RECIST v1.1 per investigators' assessment|Duration of response (DOR)|Overall Survival (OS)|Pharmacokinetics (PK) parameter, Ctrough, of LAG525, spartalizumab and carboplatin|Time to response (TTR)|Progression free survival (PFS)|Clinical Benefit Rate (CBR)|PK parameter, Cmax of LAG525, spartalizumab and carboplatin|PK parameter, AUC, of LAG525, spartalizumab and carboplatin|Anti-drug antibodies (ADA) prevalence at baseline for LAG525 and spartalizumab|Anti-drug antibodies (ADA) incidence on treatment for LAG525 and spartalizumab",Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,96,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLAG525B2101,02/12/18,12/19/19,12/01/20,04/17/18,null,26-Mar-19,"Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Sint Niklaas, Belgium|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Saint-Herblain C√©dex, France|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, T√ºbingen, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Minato ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, El Metn, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03499899
TNBC,88,19,1,NCT03277352,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,,"Active, not recruiting",No Results Available,Advanced Malignancies|Metastatic Cancer,Drug: INCAGN01876|Drug: Epacadostat|Drug: Pembrolizumab,"Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]|Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1|Phase 2: Complete response rate (CRR) based on RECIST v1.1|Phase 1: ORR based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Disease control rate based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Duration of response based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Duration of disease control based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Progression-free survival based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Overall survival|Phase 2: Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events (AEs) [Safety and Tolerability]",Incyte Biosciences International S√†rl|Incyte Corporation,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,10,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCAGN 1876-202,11/21/17,03/01/20,05/01/20,09/11/17,null,6-Nov-18,"The Angeles Clinic and Research Institute, Los Angeles, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT03277352
TNBC,88,20,1,NCT03435640,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies,REVEAL,Recruiting,No Results Available,Melanoma|Merkel Cell Carcinoma|Triple Negative Breast Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Cancer|Urothelial Carcinoma|Sarcoma,Drug: NKTR-262|Drug: NKTR-214|Drug: nivolumab,"Safety of NKTR-262 in combination with NKTR-214 / nivolumab as evaluated by incidence of drug-related Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs leading to discontinuation, deaths, and clinical laboratory abnormalities per CTCAE 4.03|Tolerability of NKTR-262 in combination with NKTR-214 / nivolumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, AEs leading to discontinuation, deaths, clinical laboratory abnormalities per CTCAE 4.03|Efficacy of NKTR-262 in combination with NKTR-214 / nivolumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1",Nektar Therapeutics,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,393,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-262-01,03/15/18,12/01/20,12/01/23,02/16/18,null,25-Dec-18,"Local Institution - Scottsdale, Scottsdale, Arizona, United States|Local Institution - New Haven, New Haven, Connecticut, United States|Local Institution - Tampa, Tampa, Florida, United States|Local Institution - Atlanta, Atlanta, Georgia, United States|Local Institution - New York, New York, New York, United States|Local Institution - Durham, Durham, North Carolina, United States|Local Institution - Portland, Portland, Oregon, United States|Local Institution - Dallas, Dallas, Texas, United States|Local Institution - Dallas, Dallas, Texas, United States|Local Institution - Houston, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03435640
TNBC,88,21,1,NCT03567720,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,Intratumoral Tavo and Pembro in Patients With Inoperable Locally Advanced or Metastatic TNBC (KEYNOTE-890),,Recruiting,No Results Available,Triple Negative Breast Cancer,Biological: tavokinogene telseplasmid|Biological: Pembrolizumab|Device: Immunopulse,Objective Response Rate (ORR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Immune Progression Free Survival (iPFS)|Immune Objective Response Rate (iORR)|Overall Survival,OncoSec Medical Incorporated|Merck Sharp & Dohme Corp.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,25,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OMS-I141 (KEYNOTE-890),10/11/18,07/01/19,01/01/20,06/25/18,null,8-Mar-19,"Stanford University Medical Center, Palo Alto, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT03567720
TNBC,88,22,1,NCT03207867,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma,,Recruiting,No Results Available,"NSCLC, Non Small Cell Lung Cancer|RCC, Renal Cell Cancer|Pancreatic Cancer|Urothelial Cancer|Head and Neck Cancer|DLBCL, Diffused Large B Cell Lymphoma|MSS, Microsatellite Stable Colon Cancer|TNBC, Triple Negative Breast Cancer|Melanoma",Drug: NIR178|Drug: PDR001,Determine the overall response rate|Determine the disease control rate (DCR)|Determine the duration of response (DoR)|Determine the overall survival rate (OR)|Progression free survival (PFS)|Safety and tolerability of the NIR178 and PDR001 combination|Characterize changes in the immune infiltrate in tumors|Presence and/or concentration of anti-PDR001 antibodies|Pharmacokinetics: Area under plasma concentration versus time curve (AUC) (NIR178)|Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) (PDR001)|Plasma concentration Vs Time profiles (NIR178)|Plasma concentration Vs Time profiles (PDR001)|Peak plasma concentration- Cmax (NIR178)|Peak plasma concentration- Cmax (PDR001)|Time of maximum concentration observed- Tmax (NIR178)|Time of maximum concentration observed- Tmax (PDR001),Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,260,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CNIR178X2201|2017-000241-49,08/28/17,06/27/19,11/06/20,07/05/17,null,7-Jun-18,"Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Blacktown, New South Wales, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Koto-ku, Tokyo, Japan|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03207867
TNBC,88,23,1,NCT03241173,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,,"Active, not recruiting",No Results Available,Advanced Malignancies,Drug: INCAGN01949|Drug: Nivolumab|Drug: Ipilimumab,Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]|Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1|Phase 1 & Phase 2: ORR based on RECIST v1.1 and modified RECIST (mRECIST)|Phase 1 & Phase 2: Duration of response based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Disease control rate based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Duration of disease control based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Progression-free survival based on RECIST v1.1 and mRECIST|Phase 1 & Phase 2: Overall survival|Phase 1 & Phase 2: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability],Incyte Biosciences International S√†rl|Incyte Corporation,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,52,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCAGN 1949-201,10/02/17,08/01/19,08/01/19,08/07/17,null,21-Mar-19,"The University of Alabama Birmingham (UAB), Birmingham, Alabama, United States|Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|Mount Sinai Medical Center of Florida, Inc., Miami, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|John Theurer Cancer Center At Hackensack UMC, Hackensack, New Jersey, United States|Rutgers, The State University, New Brunswick, New Jersey, United States|New York University Clinical Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, LLC (SCRI), Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03241173
TNBC,88,24,1,NCT03554109,Ph 2,45,TNBCCPI Combo,CPI Combo,Neo-adj,Breast Only,QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine,TNBC,Not yet recruiting,No Results Available,Triple Negative Breast Cancer (TNBC),Drug: Leucovorin|Drug: 5-Fluorouracil|Drug: Aldoxorubicin HCl|Drug: nab-Paclitaxel|Biological: ETBX-011|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-4000|Biological: GI-6207|Biological: GI-6301|Drug: Avelumab|Biological: ALT-803|Biological: haNK|Drug: Cyclophosphamide|Drug: Doxorubicin HCL|Drug: paclitaxel,Pathological Complete Response Rate|Evaluation of safety as determined by incidence or treatment-emergent adverse events|Evaluate additional measures of efficacy by event-free survival|Overall survival|Locoregional relapse|Distant metastatic rates at 1 year,"NantKwest, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,376,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QUILT-3.057,09/01/18,06/01/20,12/01/21,06/12/18,null,10-Aug-18,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",,https://ClinicalTrials.gov/show/NCT03554109
TNBC,88,25,1,NCT03310957,Ph 2,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer,,Recruiting,No Results Available,Breast Neoplasms,Drug: SGN-LIV1A|Drug: Pembrolizumab,Confirmed objective response rate|Incidence of adverse events|Incidence of laboratory abnormalities|Incidence of dose-limiting toxicities|Duration of response|Disease control rate|Progression-free survival|Overall survival,"Seattle Genetics, Inc.|Merck Sharp & Dohme Corp.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,72,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SGNLVA-002|KEYNOTE 721|2017-002289-35,02/27/18,05/01/20,05/01/22,10/16/17,null,1-Apr-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States|University of California Irvine - Newport, Orange, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|The Whittingham Cancer Center / Norwalk Hospital, Norwalk, Connecticut, United States|Helen F. Graham Cancer Center / Christiana Care Health Systems, Newark, Delaware, United States|AdventHealth Cancer Institute, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Ingalls Cancer Care / Ingalls Memorial Hospital, Harvey, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Saint Luke's Cancer Institute LLC, Kansas City, Missouri, United States|Summit Medical Group, Florham Park, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Weill Cornell Medical College, New York, New York, United States|Hillman Cancer Center / University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Houston Memorial City, Houston, Texas, United States|Texas Oncology - San Antonio Medical Center Northeast, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Gynakologisches Zentrum Bonn Friedensplatz, Bonn, Germany|Klinikum Rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Hospital del Mar, Barcelona, Spain|Institut Catala D'oncologia, L'Hospitalet de Llobregat, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|HM Centro Integral Oncologico Clara Campal, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03310957
TNBC,88,26,2,NCT03829501,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer,,Recruiting,No Results Available,Squamous Cell Carcinoma of Head and Neck|Non-small Cell Lung Cancer|Hepatocellular Carcinoma|Esophageal Cancer|Gastric Cancer|Melanoma|Renal Cell Carcinoma|Pancreatic Cancer|Cervical Cancer|Triple Negative Breast Cancer|Advanced Cancer,Drug: KY1044|Drug: KY1044 and atezolizumab,"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)|Number of dose interruptions, reductions and dose intensity|Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (phase 2)|ORR per RECIST 1.1 (phase 1)|ORR per Immune-Related Response Evaluation Criteria in Solid Tumors (iRECIST) (for phase 1 and phase 2)|PFS per Immune-Related Response Evaluation Criteria in Solid Tumors (iRECIST) (for phase 1 and phase 2)|Survival rate|Best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Incidence and severity of AEs and SAEs (phase 2)|Number of dose interruptions, reductions and dose intensity (phase 2)",Kymab Limited,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,412,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KY1044-CT01,01/28/19,05/01/23,05/01/23,02/04/19,null,19-Feb-19,"Kymab investigational site 1102, New Haven, Connecticut, United States|Kymab investigational site 1104, Sarasota, Florida, United States|Kymab investigational site, New York, New York, United States|Kymab investigational site 1103, Nashville, Tennessee, United States|Kymab investigator site 1101, Houston, Texas, United States|Kymab investigational site 3901, Milan, Italy|Kymab investigational site 3902, Napoli, Italy|Kymab investigational site 8802, Tainan, Taiwan|Kymab investigational site 8801, Taipei, Taiwan|Kymab investigational site 4402, Manchester, United Kingdom|Kymab investigational site 4401, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03829501
TNBC,88,27,1,NCT03170960,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,,Recruiting,No Results Available,Urothelial Carcinoma|Renal Cell Carcinoma|Non-Small Cell Lung Cancer|Castration-resistant Prostate Cancer|Triple Negative Breast Cancer|Ovarian Cancer|Endometrial Cancer|Hepatocellular Carcinoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|Colorectal Cancer|Head and Neck Cancer|Differentiated Thyroid Cancer,Drug: cabozantinib|Drug: atezolizumab,Dose Escalation: MTD/Recommended Dose|Dose Expansion: ORR|Incidence and severity of nonserious AEs and SAEs (Safety),Exelixis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,1000,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XL184-021,09/05/17,03/01/20,12/01/20,05/31/17,null,1-Apr-19,"Exelixis Clinical Site #18, Phoenix, Arizona, United States|Exelixis Clinical Site #1, Duarte, California, United States|Exelixis Clinical Site #20, La Jolla, California, United States|Exelixis Clinical Site #21, Stanford, California, United States|Exelixis Clinical Site #34, Denver, Colorado, United States|Exelixis Clinical Site #16, Jacksonville, Florida, United States|Exelixis Clinical Site #32, Harvey, Illinois, United States|Exelixis Clinical Site #23, Fairway, Kansas, United States|Exelixis Clinical Site #24, New Orleans, Louisiana, United States|Exelixis Clinical Site #10, Boston, Massachusetts, United States|Exelixis Clinical Site #3, Detroit, Michigan, United States|Exelixis Clinical Site #17, Rochester, Minnesota, United States|Exelixis Clinical Site #35, Omaha, Nebraska, United States|Exelixis Clinical Site #38, Camden, New Jersey, United States|Exelixis Clinical Site #27, East Brunswick, New Jersey, United States|Exelixis Clinical Site #31, New Brunswick, New Jersey, United States|Exelixis Clinical Site #37, Bronx, New York, United States|Exelixis Clinical Site #11, New York, New York, United States|Exelixis Clinical Site #6, Oklahoma City, Oklahoma, United States|Exelixis Clinical Site #15, Philadelphia, Pennsylvania, United States|Exelixis Clinical Site #13, Dallas, Texas, United States|Exelixis Clinical Site #26, Dallas, Texas, United States|Exelixis Clinical Site #29, Houston, Texas, United States|Exelixis Clinical Site #33, Lubbock, Texas, United States|Exelixis Clinical Site #2, Salt Lake City, Utah, United States|Exelixis Clinical Site #30, Blacksburg, Virginia, United States|Exelixis Clinical Site #14, Charlottesville, Virginia, United States|Exelixis Clinical Site #8, Villejuif, Cedex, France|Exelixis Clinical Site #7, Paris, France|Exelixis Clinical Site #36, T√ºbingen, Germany|Exelixis Clinical Site #25, Milano, Italy|Exelixis Clinical Site #4, Milano, Italy|Exelixis Clinical Site #12, Nijmegen, Gelderland, Netherlands|Exelixis Clinical Site #28, Barcelona, Spain|Exelixis Clinical Site #9, Barcelona, Spain|Exelixis Clinical Site #22, Madrid, Spain|Exelixis Clinical Site #5, Madrid, Spain|Exelixis Clinical Site #19, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03170960
TNBC,88,28,1,NCT03175666,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy,,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Biological: avelumab|Biological: bevacizumab|Drug: capecitabine|Drug: cisplatin|Drug: cyclophosphamide|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: nab-paclitaxel|Drug: Lovaza|Radiation: Stereotactic Body Radiation Therapy|Biological: ALT-803|Biological: ETBX-011|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-4000|Biological: GI-6207|Biological: GI-6301|Biological: haNK,"Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.|Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|ORR by Immune-related response criteria (irRC )|ORR by RECIST Version 1.1|ORR by irRC|Progression-free survival (PFS) by RECIST Version 1.1|PFS by irRC|Overall survival (OS): time from the date of first treatment to the date of death (any cause)|Duration of response (DR): time from the date of first response (partial response (PR) or complete response (CR)) to the date of disease progression or death (any cause) whichever occurs first|Disease control rate (DCR): confirmed complete response, partial response, or stable disease lasting for at least 2 months|Patient-reported outcomes (PRO) using the Functional Assessment of Cancer Therapy (FACT) Breast Symptom Index (FBSI) questionnaire|Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03","NantKwest, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,79,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QUILT-3.049,12/01/17,01/01/19,03/01/19,06/05/17,null,30-Oct-17,,,https://ClinicalTrials.gov/show/NCT03175666
TNBC,88,29,1,NCT03126110,Ph 2,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",,Recruiting,No Results Available,Advanced Malignancies|Metastatic Cancer,Drug: INCAGN01876|Drug: Nivolumab|Drug: Ipilimumab,"1. Phase 1: Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events (AEs)|Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.|Phase 1: ORR based on RECIST v1.1 and modified RECIST v1.1 (mRECIST v1.1)|Phase 1 & Phase 2: Duration of response based on RECIST v1.1 and mRECIST v1.1|Phase 1 & Phase 2: Duration of disease control based on RECIST v1.1 and mRECIST v1.1|Phase 1 & Phase 2: Progression-free survival based on RECIST v1.1 and mRECIST v1.1|Phase 1 & Phase 2: Overall survival|Phase 2: Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events",Incyte Biosciences International S√†rl|Incyte Corporation,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,285,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCAGN 1876-201,04/13/17,01/01/20,03/01/20,04/24/17,null,10-Dec-18,"The Angeles Clinic and Research Institute, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University - Siteman Cancer Center, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer, New York, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Oklahoma, Sarah Cannon Research Institute, Oklahoma City, Oklahoma, United States|Providance Portland Medical Center, Portland, Oregon, United States|Robert W. Franz Cancer Research Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, United States|BUMC Mary Crowley Cancer Research Centers, Dallas, Texas, United States|MD Anderson, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia|Scientia Clinical Research, Randwick, New South Wales, Australia|Greenslopes Private Hospital, Brisbane, Queensland, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Austin Hospital-Olivia Newton John Cancer Research Institute, Melbourne, Victoria, Australia|Linear Clinical Research, Perth, Western Australia, Australia|CHA Centre Hospitalier de l'Ardenne, Libramont, Chevigny, Belgium|Saint Augustinus Hospital, Antwerpen, Belgium|Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|CHU Brugmann, Bruxelles, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Mi Kryviy Rih Center of Dnipropetrovsk Regional Council, Charleroi, Belgium|Ghent University Hospital, Ghent, Belgium|AZ Groeninge, Kortrijk, Belgium|IRRCS Instituto Clinico Humanitas, Rozzano, Italy|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, Spain|Institut Catala D'Oncologia-Badalona, Barcelona, Spain|Hospital Vall de Hebron, Barcelona, Spain|Hospital Reina Sophia, C√≥rdoba, Spain|University Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario Doce de Octubre, Madrid, Spain|Hospital HM Sanchinarro, Madrid, Spain|University Hospital Virgen de la Victoria, M√°laga, Spain|Clinica Universidad De Navarra (CUN), Pamplona, Spain|University Hospital Marqus de Valdecilla, Santander, Spain",,https://ClinicalTrials.gov/show/NCT03126110
TNBC,88,30,1,NCT03893955,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",,Not yet recruiting,No Results Available,Cancer|Advanced Solid Tumors|Triple-Negative Breast Cancer (TNBC)|Non-small-cell-lung-cancer (NSCLC)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Metastatic Solid Tumors,Drug: ABBV-927|Drug: ABBV-368|Drug: ABBV-181|Drug: Docetaxel,Dose Expansion: Objective Response Rate (ORR)|Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368|Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181|Dose-Expansion Phase: Progression-free Survival (PFS)|Dose-Expansion Phase: Duration of Response (DOR)|Maximum Serum Concentration (Cmax)|Time to Maximum Observed Serum Concentration (Tmax)|Area Under the Serum Concentration Versus Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUCœÑ)|Terminal Phase Elimination Half-life (t1/2),AbbVie,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,150,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M19-037,05/14/19,05/11/23,11/21/23,03/28/19,null,28-Mar-19,"University of Alabama /ID# 210679, Birmingham, Alabama, United States|St Jude Hospital dba St Joseph /ID# 211130, Santa Rosa, California, United States|Yale University /ID# 210678, New Haven, Connecticut, United States|Carolina BioOncology Institute /ID# 210664, Huntersville, North Carolina, United States|Mary Crowley Cancer Research /ID# 210716, Dallas, Texas, United States|Next Oncology /ID# 210717, San Antonio, Texas, United States|Virginia Cancer Specialists /ID# 210671, Fairfax, Virginia, United States|Sheba Medical Center /ID# 211699, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT03893955
TNBC,88,31,1,NCT03891953,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.,,Not yet recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung|Melanoma|Nasopharyngeal Carcinoma|Microsatellite Stable Colorectal Cancer|Triple Negative Breast Cancer",Drug: DKY709|Drug: PDR001,Safety of DKY709 single agent treatment or DKY709 in combination with PDR001.|incidence of Dose Limiting Toxicities (DLTs)|Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.|AUC of DKY709 and PDR001|Cmax of DKY709 and PDR001|Tmax of DKY709 and PDR001|Half-life of DKY709 and PDR001|Concentration vs time profile of DKY709 and PDR001|Progression Free Survival (PFS)|Best Overall Response (BOR)|Duration of Response (DOR)|Time to Progression (TTP),Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,320,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDKY709A12101C,04/18/19,11/28/22,11/28/22,03/27/19,null,8-Apr-19,,,https://ClinicalTrials.gov/show/NCT03891953
TNBC,88,32,1,NCT03821935,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,"Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",,Recruiting,No Results Available,Advanced Solid Tumors Cancer,Drug: ABBV-151|Drug: ABBV-181,Dose Escalation: Recommended Phase 2 Dose (RP2D) ABBV-151 Monotherapy|Dose Escalation: RP2D ABBV-151 + ABBV-181 Combination Therapy|Dose Expansion: Objective Response Rate (ORR)|Dose Expansion: Duration of Response (DOR)|Dose Expansion: Progression-free Survival (PFS)|Maximum Observed Serum Concentration (Cmax)|Time to Maximum Observed Serum Concentration (Tmax)|Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCœÑ)|Terminal-phase Elimination Rate Constant (Œ≤)|Terminal Phase Elimination Half-life (t1/2),AbbVie,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,184,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M19-345,02/21/19,07/14/22,07/14/22,01/30/19,null,8-Mar-19,"Yale University /ID# 208356, New Haven, Connecticut, United States|NEXT Oncology /ID# 208930, San Antonio, Texas, United States|Sheba Medical Center /ID# 209037, Ramat Gan, Israel|National Cancer Center Hospital /ID# 209421, Chuo-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT03821935
TNBC,88,33,1,NCT03829436,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,"TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers",,Recruiting,No Results Available,Hepatocellular Carcinoma|Metastatic Castration Resistant Prostate Cancer|Renal Cell Carcinoma|Non-small Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma of Head and Neck|Triple-Negative Breast Cancer|Urothelial Carcinoma|Cholangiocarcinoma|GastroEsophageal Cancer|Pancreatic Cancer|Sarcoma,Drug: Part 1 TPST-1120|Drug: Part 2a TPST-1120 + nivolumab|Drug: Part 2b TPST-1120 + docetaxel|Drug: Part 2c TPST-1120 + cetuximab|Drug: Part 3 TPST-1120|Drug: Part 4a TPST-1120 + nivolumab|Drug: Part 4b TPST-1120 + docetaxel|Drug: Part 4c TPST-1120 + cetuximab,"Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab, in combination with docetaxel and in combination with cetuximab.|Incidence of treatment-emergent adverse events as assessed by NCI-CTCAE v5.0 of TPST-1120 as a single agent and in combination with nivolumab, in combination with docetaxel and in combination with cetuximab.|Identify the maximum tolerated dose|Assess pharmacokinetics: Area under the curve (AUC)|Assess pharmacokinetics: Maximum serum concentration (Cmax)|Objective response rate",Tempest Therapeutics,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,338,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TPST-1120-001,03/20/19,02/18/22,06/23/24,02/04/19,null,1-Apr-19,"Carolina BioOncology Institute, Huntersville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03829436
TNBC,88,34,1,NCT03549000,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.,,Recruiting,No Results Available,Non-small Cell Lung Cancer (NSCLC)|Triple Negative Breast Cancer (TNBC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Colorectal Cancer Microsatellite Stable (MSS)|Ovarian Cancer|Renal Cell Carcinoma (RCC),Other: NZV930|Other: PDR001|Drug: NIR178,Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178|Overall response rate (ORR)|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)|Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.|Plasma concentration vs. time profiles for NIR178 and derived PK parameters|To assess the immunogenicity of NZV930 and PDR001|Characterize changes in the immune infiltrate in tumors,Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,344,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CNZV930X2101|2018-000153-51,07/18/18,01/24/22,02/14/22,06/07/18,null,11-Apr-19,"Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Sutton, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT03549000
TNBC,88,35,1,NCT03101280,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer,,Recruiting,No Results Available,Gynecologic Neoplasms,Drug: Atezolizumab|Drug: Rucaparib,Percentage of Participants With Adverse Events|Percentage of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]|Recommended Phase II Dose (RP2D) of Rucaparib for the Combination [Part 1]|Number of Dose Modifications due to Adverse Events [Part 2]|Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Percentage of Participants With Objective Response of CR or PR as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (Cancer Antigen 125 [CA125] Response) Considerations|Duration of Response (DOR) as Determined by Investigator Assessment Using RECIST v1.1|DOR as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (CA125 Response) Considerations|Progression-Free Survival (PFS) as Determined by Investigator Assessment Using RECIST v1.1|PFS as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (CA125 Response) Considerations|Overall Survival|Steady State Maximum Plasma Concentration Observed (Cmax) for Rucaparib [Part 1]|Time to Maximum Plasma Concentration (tmax) for Rucaparib [Part 1]|Area Under the Plasma Concentration-Time Curve (AUC) for Rucaparib [Part 1]|Apparent Clearance (CL/F) for Rucaparib [Part 1]|Minimum Plasma Concentration During the Dosing Interval (Cmin) for Rucaparib [Part 2]|Serum Concentration of Atezolizumab [Parts 1 and 2]|Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab,Hoffmann-La Roche,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WO39409|2016-002610-47,04/27/17,12/18/20,12/18/20,04/05/17,null,2-Apr-19,"Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia|Centre Leon Berard, Lyon, France|Centre Hospitalier Lyon Sud; Service d'Oncologie M√©dicale, Pierre Benite, France|Gustave Roussy, Villejuif CEDEX, France|Cl√≠nica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±on, Madrid, Spain|La Paz University Hospital, Madrid, Spain|Clatterbridge Cancer Centre, Bebington, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|University College London Hospitals NHS Foundation Trust - University College Hospital, London, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03101280
TNBC,88,36,1,NCT03742349,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).,,Recruiting,No Results Available,Triple Negative Breast Cancer (TNBC),Biological: spartalizumab|Biological: LAG525|Drug: NIR178|Drug: capmatinib|Biological: MCS110|Biological: canakinumab,"Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety|Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety|Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)|Frequency of dose interuptions|Frequency of dose reductions|Dose intensities|Best overall response (BOR)|Progression free survival (PFS) per RECIST v1.1 and iRECIST|Presence of anti-spartalizumab antibodies|Presence of anti-LAG525 antibodies|Presence of anti-MCS110 antibodies|Presence of anti-canakinumab antibodies|Serum concentration of spartalizumab, LAG525, MCS110, canakinumab|Plasma concentration of NIR178, NJI675, capmatinib|PK parameter (Tmax) of spartalizumab|PK parameter (Cmax) of spartalizumab|PK parameter (AUC) of spartalizumab|PK parameter (Tmax) of LAG525|PK parameter (Cmax) of LAG525|PK parameter (AUC) of LAG525|PK parameter (Tmax) of NIR178|PK parameter (Cmax) of NIR178|PK parameter (AUC) of NIR178|PK parameter (Tmax) of capmatinib|PK parameter (Cmax) of capmatinib|PK parameter (AUC) of capmatinib|PK parameter (Tmax) of MCS110|PK parameter (Cmax) of MCS110|PK parameter (AUC) of MCS110|PK parameter (Tmax) of canakinumab|PK parameter (Cmax) of canakinumab|PK parameter (AUC) of canakinumab|Changes from baseline of PD markers in tumor tissue (TILs, CD8, PD-L1, LAG-3)",Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,220,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CADPT01A12101C|2018-002244-82,01/31/19,10/09/20,10/09/20,11/15/18,null,11-Apr-19,"Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Barcelona, Catalunya, Spain",,https://ClinicalTrials.gov/show/NCT03742349
TNBC,88,37,1,NCT03071757,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",,Recruiting,No Results Available,Advanced Solid Tumors Cancer,Drug: ABBV-368|Drug: ABBV-181,Terminal half-life (t1/2) of ABBV-368|Area under the serum concentration-time curve (AUC) of ABBV-368|Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181|Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181|Time to Cmax (Tmax) of ABBV-368|Terminal phase elimination rate constant (Œ≤) of ABBV-368|Number of Participants With Adverse Events|Maximum observed serum concentration (Cmax) of ABBV-368|Objective Response Rate (ORR)|Clinical benefit rate (CBR)|Duration of Objective Response (DOR)|Progression-Free Survival (PFS),AbbVie,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,170,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M16-074|2016-004205-14,03/21/17,09/17/20,06/25/21,03/07/17,null,5-Mar-19,"Ucsd /Id# 201334, La Jolla, California, United States|UC Davis Comp Cancer Ctr /ID# 201342, Sacramento, California, United States|Stanford University /ID# 206949, Stanford, California, United States|Yale University /ID# 207895, New Haven, Connecticut, United States|Carolina BioOncology Institute /ID# 160786, Huntersville, North Carolina, United States|Greenville Hospital System /ID# 160785, Greenville, South Carolina, United States|UT Southwestern Medical Center /ID# 201934, Dallas, Texas, United States|South Texas Accelerated Research Therapeutics /ID# 160788, San Antonio, Texas, United States|Virginia Cancer Specialists /ID# 160787, Fairfax, Virginia, United States|Institut Curie /ID# 165038, Paris CEDEX 05, Ile-de-France, France|Hopital de la Timone /ID# 165036, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Centre Leon Berard /ID# 165037, Lyon CEDEX 08, Rhone, France|Institut Gustave Roussy /ID# 165035, Villejuif, Val-de-Marne, France|Hospital Duran i Reynals /ID# 205997, L'Hospitalet de Llobregat, Barcelona, Spain|Clinica Universitar de Navarra - Pamplona /ID# 208879, Pamplona, Navarra, Comunidad, Spain|Hospital General Universitario Gregorio Maranon /ID# 205999, Madrid, Spain|Clinica Universidad de Navarra - Madrid /ID# 205996, Madrid, Spain|Hospital Puerta de Hierro /ID# 206973, Madrid, Spain|National Cheng Kung University Hospital /ID# 164002, Tainan City, Tainan, Taiwan|National Taiwan Univ Hosp /ID# 164000, Taipei City, Taipei, Taiwan|Taipei Medical University Hosp /ID# 164001, Taipei City, Taiwan",,https://ClinicalTrials.gov/show/NCT03071757
TNBC,88,38,1,NCT03289962,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,,Recruiting,No Results Available,Melanoma|Non-Small Cell Lung Cancer|Bladder Cancer|Colorectal Cancer|Triple Negative Breast Cancer|Renal Cancer|Head and Neck Cancer|Other Solid Cancers,Drug: RO7198457|Drug: Atezolizumab,"Percentage of Participants with Dose-Limiting Toxicities (DLTs)|MTD/Recommended Phase 2 Dose (RP2D) of RO7198457|Percentage of Participants with Adverse Events (AEs) by Severity According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0|Percentage of Participants with Immune-Mediated Adverse Events (imAEs) by Severity According to NCI CTCAE Version 5.0|Percentage of Participants by Number of Treatment Cycles Received|Dose Intensity of RO7198457|Change from baseline in targeted vital signs|Change from baseline in targeted clinical laboratory test results|Change from baseline in ECGs|Plasma Concentration of (R)-N,N,N-Trimethyl-2,3-Dioleyloxy-1-Propanaminium Chloride (DOTMA)|Plasma Concentration of Ribonucleic Acid (RNA)|Serum Concentration of Atezolizumab|Percentage of Participants with Induction of Antigen-Specific T-Cell Responses in Peripheral Blood|Immune-Related Cytokine Levels|Percentage of Participants with Objective Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1)|Duration of Response (DoR) According to RECIST v1.1|Percentage of Participants with Objective Response of CR or PR According to Immune-Modified RECIST|DoR According to Immune-Modified RECIST|Progression-Free Survival (PFS) According to RECIST v1.1|Overall Survival (OS)|Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab","Genentech, Inc.|Biontech RNA Pharmaceuticals GmbH",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,567,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO39733|2017-001475-23,12/21/17,09/11/20,10/29/20,09/21/17,null,19-Mar-19,"HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States|The Angeles Clinic, Los Angeles, California, United States|UCSF Comprehensive Cancer Ctr, San Francisco, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Yale University Cancer Center, Smilow Cancer Hospital; Medical Oncology, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Can Ins, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States|Columbia University Medical Center; Clinical Research Management Office, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Providence Oncology and Hematology Care Eastside, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Res Inst; TN Onc, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|UZ Gent, Gent, Belgium|CHU Sart-Tilman, Li√®ge, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, Canada|Princess Margaret Cancer Center; Department of Radiation Oncology, Toronto, Ontario, Canada|Universit√§tsklinikum Essen; Innere Klinik und Poliklinik f√ºr Tumorforschung, Essen, Germany|LungenClinic Gro√ühansdorf, Gro√ühansdorf, Germany|Nationales Centrum f√ºr Tumorerkrankungen Heidelberg (NCT); Thoraxklinik Heidelberg, Heidelberg, Germany|Fachklinik f√ºr Lungenerkrankungen, Immenhausen, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|LUMC, Leiden, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Clinica Universitaria de Navarra; Servicio de oncolog√≠a, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Karolinska Hospital; Oncology - Radiumhemmet, Stockholm, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Barts & London School of Med; Medical Oncology, London, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03289962
TNBC,88,39,1,NCT03800836,Ph 1,45,TNBCCPI Combo,CPI Combo,1L,Breast Only,A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: Ipatasertib|Drug: Paclitaxel|Drug: Atezolizumab|Drug: Nab-Paclitaxel,"Cohort 1: Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]), as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST), Version (v) 1.1|Cohort 1: Duration of Confirmed Objective Response, as Determined by the Investigator According to RECIST v1.1|Cohort 1: Progression-Free Survival, as Assessed by Investigator Based on RECIST v1.1|Cohort 1: Percentage of Participants who have an Objective Response (Complete or Partial), or Stable Disease for at least 24 weeks, as Assessed by Investigator Based on RECIST v1.1|Cohort 1: Overall Survival in All Participants|Cohort 1: Plasma Concentration of Ipatasertib|Cohort 1: Plasma Concentration of Ipatasertib's Metabolite (G-037720)|Cohort 1: Presence of Anti-Drug Antibody During Study Treatment|Cohort 1: Plasma Concentration of Atezolizumab|Cohort 1 and Cohort 2: Percentage of Participants with Adverse Events",Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CO40151,02/13/18,05/13/20,05/13/20,01/11/19,null,26-Apr-19,"Pacific Shores Medical Group, Long Beach, California, United States|Northwest Medical Specialties, Tacoma, Washington, United States|St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Institut de Cancerologie de l Ouest, Angers, France|Institut Bergonie, Bordeaux, France|Centre Georges Francois Leclerc, Dijon, France|Institut Curie, Paris, France|Gustave Roussy, Villejuif CEDEX, France|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Direcci√≥n M√©dica, Madrid, Spain|Hospital Universitario Virgen del Roc√≠o, Madrid, Spain|Barts Cancer Institute, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03800836
TNBC,88,40,1,NCT03720431,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast Only,TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer,,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: TTAC-0001 and pembrolizumab combination,Dose limiting toxicities|Adverse events|Immunogenicity|Overall response rate|Disease control rate|Progression free survival|Overall survival,PharmAbcine,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMC_TTAC-0001_05,01/03/19,04/30/20,04/30/20,10/25/18,null,21-Jan-19,"Liverpool Hospital, Liverpool, New South Wales, Australia|Hollywood Private Hospital, Nedlands, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT03720431
TNBC,88,41,1,NCT03849469,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Study of XmAb¬Æ22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors,DUET-4,Not yet recruiting,No Results Available,Melanoma|Cervical Carcinoma|Pancreatic Carcinoma|Triple Negative Breast Cancer|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced or Metastatic Solid Tumors,Biological: XmAb¬Æ22841|Biological: Pembrolizumab (Keytruda¬Æ),Treatment-related adverse events as assessed by CTCAE v4.03,"Xencor, Inc.|ICON plc",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,230,Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XmAb22841-01|DUET-4,06/01/19,09/01/26,03/01/27,02/21/19,null,21-Feb-19,"Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03849469
TNBC,88,42,1,NCT03256344,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases,,Recruiting,No Results Available,Metastatic Triple Negative Breast Cancer|Metastatic Colorectal Cancer,Biological: Talimogene Laherparepvec|Biological: Atezolizumab,Subject's incidence of dose limiting toxicities (DLTs)|Subject's incidence of treatment-emergent adverse events|Number of subject with clinically relevant laboratory abnormalities|Objective response rate (ORR)|Best overall response (BOR)|Duration of response (DOR)|Disease control rate (DCR)|Durable response rate (DRR)|Progression-free survival (PFS)|Overall survival (OS)|Lesion level responses in injected and uninjected tumor lesions,Amgen|Roche-Genentech,All,"18 Years to 99 Years ¬† (Adult, Older Adult)",Phase 1,36,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,20140299,03/19/18,06/24/19,05/13/21,08/22/17,null,13-Dec-18,"Research Site, Los Angeles, California, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, T√ºbingen, Germany|Research Site, Barcelona, Catalu√±a, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland",,https://ClinicalTrials.gov/show/NCT03256344
TNBC,88,43,1,NCT03250832,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,Study of TSR-033 With an Anti-PD-1,,Recruiting,No Results Available,Advanced Solid Tumors|Antibodies|Immunotherapy,Drug: TSR-033|Drug: Anti-PD-1,Number of Participants With Treatment-Emergent Adverse Events as Assessed by CTCAE v4.0|Number of Participants with Solid Tumors With Complete or Partial Response to the Anti-Tumor Activity of TSR-033 in Combination with Anti-PD-1|PK parameter|- Duration of response (DOR) by RECIST v. 1.1|- Disease control rate (DCR) by RECIST v. 1.1|- Progression-free survival (PFS) by RECIST v. 1.1|- Overall survival (OS),"Tesaro, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,260,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4040-01-001,08/01/17,05/01/21,05/01/21,08/16/17,null,3-Aug-18,"Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|START, San Antonio, Texas, United States|Gustave Roussy, Villejuif, Ile-de-France, France",,https://ClinicalTrials.gov/show/NCT03250832
TNBC,88,44,1,NCT03454451,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers,,Recruiting,No Results Available,Non-Small Cell Lung Cancer|Renal Cell Cancer|Colorectal Cancer|Triple Negative Breast Cancer|Cervical Cancer|Ovarian Cancer|Pancreatic Cancer|Endometrial Cancer|Sarcoma|Squamous Cell Carcinoma of the Head and Neck|Bladder Cancer|Metastatic Castration Resistant Prostate Cancer|Non-hodgkin Lymphoma,Drug: CPI-006|Drug: CPI-006 + CPI-444|Drug: CPI-006 + pembrolizumab,"Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with CPI-444 and with pembrolizumab.|Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with CPI-444 and with pembrolizumab.|Identify the MDL(maximum dose level) of single agent CPI-006|Area under the curve (AUC) of CPI-006|Maximum serum concentration (Cmax) of CPI-006|Objective response rate per RECIST v.1.1 criteria of CPI-006 as single agent and in combination with CPI-444 and with pembrolizumab.","Corvus Pharmaceuticals, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,378,Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPI-006-001,04/25/18,03/01/22,12/01/23,03/06/18,null,14-Mar-19,"City Of Hope, Duarte, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|The University of Chicago, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Carolina BioOncology Institute, Huntsville, North Carolina, United States|University of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03454451
TNBC,88,45,1,NCT03667716,Ph 1,45,TNBCCPI Combo,CPI Combo,2L+,Breast + Other,COM701 in Subjects With Advanced Solid Tumors,,Recruiting,No Results Available,Advanced Cancer|Ovarian Cancer|Breast Cancer|Lung Cancer|Endometrial Cancer|Ovarian Neoplasm|Triple Negative Breast Cancer|Lung Neoplasm|Neoplasm Malignant,Drug: COM701|Drug: COM701 with Opdivo (Nivolumab).,Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs).|Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with a PD-1 inhibitor).|Incidence of subjects with Anti-COM701 antibody.|Overall Response Rate as per RECIST v1.1,Compugen Ltd|Bristol-Myers Squibb,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,140,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CPG-01-001,09/06/18,01/01/20,12/01/21,09/12/18,null,27-Feb-19,"University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The University of Tennessee WEST Cancer Center., Memphis, Tennessee, United States|Sarah Cannon Research Institute., Nashville, Tennessee, United States|The START Center for Cancer Care., San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03667716
TNBC,88,46,1,NCT03562637,Ph 3,20,TNBCOther Combo,Other Combo,2L+,Breast Only,Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.,,Recruiting,No Results Available,Triple Negative Breast Cancer,Biological: adagloxad simolenin combined with OBI-821|Biological: Phosphate-buffered saline (PBS),"Measuring the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease free survival (IDFS) in the study population.|Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in TNBC patients at high risk for relapse on Overall Survival (OS).|Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in TNBC patients at high risk for relapse, on Quality of Life (QoL).|Incidence and severity of adverse events (AEs) [Time Frame: AEs will be noted as it occurs, with a timeframe from beginning of randomization to 4 weeks after last dose of study treatment.]|Incidence of a change from baseline in safety parameters related to 12-lead electrocardiogram (ECG) [Time Frame: ECGs will be conducted from time of screening to end of treatment.]","OBI Pharma, Inc",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,668,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OBI-822-011,12/05/18,11/30/25,11/30/25,06/19/18,null,17-Jan-19,"Pinnacle Research Group LLC, Anniston, Alabama, United States|Clearview Cancer Institute, Huntsville, Alabama, United States|Moores UCSD Cancer Center, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, California, United States|Miami Cancer Institute, Miami, Florida, United States|Advanced Research Institute, Inc., New Port Richey, Florida, United States|Summit Cancer Care, PC, Savannah, Georgia, United States|Cotton-O'Neil Clinical Research Center, Hematology and Oncology, Topeka, Kansas, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Henry Ford Medical Center, Detroit, Michigan, United States|CHI Health - St. Francis Medical Center, Grand Island, Nebraska, United States|Austin Cancer Centers, Austin, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Blacktown Hospital, Blacktown, Australia|St Vincent's Hospital Sydney, Darlinghurst, Australia|Gosford Hospital, Gosford, Australia|St John of God Murdoch Hospital, Murdoch, Australia|The First Hospital of Jilin University, Changchun, Jilin, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|Harbin Medical University Cancer Hospital, Harbin, China|Institut Sainte Catherine, Avignon Cedex 9, France|Centre Hospitalier Intercommunal de Cr√©teil, Creteil Cedex, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans Cedex 02, France|Centre Oscar Lambret, Lille Cedex, France|H√¥pital Priv√© du Confluent, Nantes Cedex 2, France|Institut Curie - site de Paris, Paris Cedex 05, France|H√¥pital Saint-Louis, Paris, France|Institut Claudius Regaud - IUCT-O, Toulouse Cedex 09, France|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Luisen Hospital, Duesseldorf, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Ev. Huyssens-Stiftung Kliniken Essen-Mitte, Essen, Germany|Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Kiel, Kiel, Germany|Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Germany|Marien Hospital Witten GmbH, Witten, Germany|The University of Hong Kong, Hong Kong, Hong Kong|UNIMED Medical Institute Comprehensive Centre For Breast Diseases, Hong Kong, Hong Kong|Dong-A University Hospital, Busan, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpitale Pomorskie sp√≥≈Çka z ograniczonƒÖ odpowiedzialno≈õciƒÖ, Gdynia, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna, Lodz, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardyna≈Ça Wyszynskiego SPZOZ w Lublinie, Lublin, Poland|Dolnoslaskie Centrum Onkologii, Wroclaw, Poland|SBIH of Arkhangelsk region ""Arkhangelsk Clinical Oncological Dispensary"", Arkhangelsk, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|SBIH of Moscow city ""Moscow city oncology hospital ‚Ññ62"" of Moscow Healthcare department, Moscow, Russian Federation|BHI of Omsk region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|FSBI ""Clinical Research and Practical Center for specialized medical care (oncology)"", Pesochnyy, Russian Federation|SPb SBIH ""City Clinical Oncological Dispensary"", Saint-Petersburg, Russian Federation|SI ""SRI of Oncology of Tomsk RC of Siberian Branch of RAMS"", Tomsk, Russian Federation|SBHI ""Volgograd Regional Oncology Dispensary #3"", Volzhskiy, Russian Federation|SBIH of Yaroslavl region ""Regional Clinical Oncological Hospital"", Yaroslavl, Russian Federation|Complejo Asistencial de Avila, Avila, Spain|Hospital Quironsalud Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Universitario Ciudad de Jaen, Jaen, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taipei, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|CI Transcarpathian Cl Onc Center Dep of Surgery#1 SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|CHI Kharkiv Regional Clinical Oncological Center, Kharkiv, Ukraine|CI of Kherson Reg Council Kherson Regional Oncologic Dispensary, Kherson, Ukraine|CI Kryvyi Rih Oncological Dispensary of DRC, Kryvyi Rih, Ukraine|Medical Center Verum, Kyiv, Ukraine|Kyiv –°ity Clinical Oncological Center, Kyiv, Ukraine|Treatment-Prevention Institution Volyn Regional Oncological Dispensary, Lutsk, Ukraine|Odesa Regional Oncologic Dispensary, Odesa, Ukraine|CI Zaporizhzhia Regional Clinical Oncological Dispensary of ZRC, Zaporizhzhia, Ukraine",,https://ClinicalTrials.gov/show/NCT03562637
TNBC,88,47,1,NCT03671044,Ph 3,20,TNBCOther Combo,Other Combo,2L+,Breast Only,A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients,,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Drug: Taxotere¬Æ (100 mg/m2),"Proportion of the patients with Objective Response Rate (i.e., CR + PR) as the Best Overall Response Rate (i.e., CR + PR) in the test arm (NDLS) compared to reference arm (Taxotere)|Progression free survival (PFS)|To evaluate the overall survival (OS) of the patients|Incidence of adverse events as assessed by clinical examination, and/or laboratory parameters",Jina Pharmaceuticals Inc.|Intas Pharmaceuticals Limited|Lambda Therapeutic Research Ltd.,Female,"18 Years to 65 Years ¬† (Adult, Older Adult)",Phase 3,657,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0063-17,07/10/18,03/31/22,05/31/22,09/14/18,null,14-Sep-18,"Kailash Cancer Hospital & Research Centre, Vadodara, Gujarat, India",,https://ClinicalTrials.gov/show/NCT03671044
TNBC,88,48,2,NCT03337724,Ph 3,20,TNBCOther Combo,Other Combo,2L+,Breast Only,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",IPATunity130,Recruiting,No Results Available,Breast Cancer,Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo,Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Duration of Response (DOR)|Clinical Benefit Rate (CBR)|Overall Survival (OS)|Global Health Status (GHS)/Health-Related Quality of Life (HRQoL) Score|Time to Deterioration in Pain|Incidence and Severity of Adverse Events (AEs)|Changes in Vital Signs|Changes in Targeted Laboratory Results|Plasma Concentration of Ipatasertib and Its Metabolite (G-037720),Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2|Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CO40016|2017-001548-36,01/06/18,12/22/21,12/22/21,11/09/17,null,11-Apr-19,"UCSD Moores Cancer Center, La Jolla, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Emad Ibrahim, Md, Inc, Redlands, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente - San Francisco (2238 Geary), San Francisco, California, United States|UCSF Comprehensive Cancer Ctr, San Francisco, California, United States|K. Permanente - San Jose, San Jose, California, United States|Kaiser Permanente - San Leandro, San Leandro, California, United States|K. Permanente - Santa Clara, Santa Clara, California, United States|Kaiser Permanente - South San Francisco, South San Francisco, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|K. Permanente - Walnut Creek, Walnut Creek, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Northwestern Center for Clinical Research; Cancer Center, Chicago, Illinois, United States|Rush University Medical Center; Div of Hematology, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mass General/North Shore Cancer, Danvers, Massachusetts, United States|Westchester Medical Center Cancer Institute, Hawthorne, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Mid Ohio Onc Hematology Inc, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|West Clinic, Germantown, Tennessee, United States|Brig Cancer Care, Knoxville, Tennessee, United States|Vanderbilt Breast Center; Vanderbilt Health Pharmacy, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center; Simmons Comprehensive Cancer Center, Simmons Pharmacy, Dallas, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Fundaci√≥n CENIT para la Investigaci√≥n en Neurociencias, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Hosp Provincial D. Centenarios; Oncology Dept, Rosario, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Westmead Hospital; Medical Oncology, Wentworthville, New South Wales, Australia|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Santa Casa de Misericordia de Salvador; Oncologia, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital do C√¢ncer de Londrina, Londrina, PR, Brazil|Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo Andr√©, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Bcca - Cancer Center Southern Interior, Kelowna, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Servicio de Oncolog√≠a Hospital Regional e Concepci√≥n, Concepcion, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Hospital Base de Valdivia; Unidad de Oncolog√≠a M√©dica, Valdivia, Chile|Beijing Hospital, Beijing City, China|Beijing Cancer Hospital, Beijing, China|the First Hospital of Jilin University, Changchun, China|Sun Yat-sen Memorial Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Jiangsu Cancer Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Clinica CIMCA, San Jose, Costa Rica|ICIMED Instituto de Investigaci√≥n en Ciencias M√©dicas, San Jose, Costa Rica|Masaryk≈Øv onkologick√Ω √∫stav; Klinika komplexn√≠ onkologick√© p√©ƒçe, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Institut Sainte Catherine, Avignon, France|CHU Besan√ßon - H√¥pital Jean Minjoz, Besan√ßon Cedex, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Centre Leon Berard; Oncologie Genetique, Lyon, France|ICM; Medecine B3, Montpellier cedex 5, France|Centre Catherine De Sienne, Nantes, France|APHP - Hospital Saint Louis, Paris, France|Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, France|Onkologische Schwerpunktpraxis Kurf√ºrstendamm, Berlin, Germany|Praxis f√ºr Interdisziplin√§re Onkologie und H√§matologie GbR, Freiburg, Germany|Universit√§tsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|Universit√§tsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|Praxis Dr.med. Katja Ziegler-L√∂hr, K√∂ln, Germany|Dres. Andreas K√∂hler und Roswitha Fuchs, Langen, Germany|M√ºhlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik f√ºr Frauenheilkunde und Geburtshilfe, Minden, Germany|Oncologianova GmbH - Gesellschaft f√ºr Innovationen in der Onkologie, Recklinghausen, Germany|Universit√§tsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|Universit√§tsklinikum W√ºrzburg; Frauenklinik, W√ºrzburg, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens, Greece|Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Orszagos Onkologial Intezet; Onkologiai Osztaly X, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Szabolcs-Szatmar-Bereg Megyei; Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Hetenyi Geza County Hospital; Onkologiai Kozpont, Szolnok, Hungary|Zala County Hospital ICU, Zalaegerszeg, Hungary|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unit√† Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|National Hospital Organization Kyushu Cancer Center;Breast Oncology, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Kinki University Hospital, Faculty of Medicine; Surgery, Osaka, Japan|Saitama Cancer Center, Breast Oncology, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|St. Luke's International Hospital, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Showa University Hospital; Breast Surgery, Tokyo, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clinical Hospital; Oncology Department, Bitola, Macedonia, The Former Yugoslav Republic of|PHI University Clinic of Radiotherapy and Oncology; Breast malignancy, Skopje, Macedonia, The Former Yugoslav Republic of|PHI University Clinic of Radiotherapy and Oncology; Malignant diseases of thorax, Skopje, Macedonia, The Former Yugoslav Republic of|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Centro M√©dico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Merida Investigacion Clinica, M√©rida, Yucatan, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Centro Medico Monte Carmelo, Arequipa, Peru|Hospital Daniel Alcides Carrion, Callao, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Cl√≠nica San Gabriel; Unidad de Investigaci√≥n Oncol√≥gica de la Cl√≠nica San Gabriel, Lima, Peru|Hospital Nacional Cayetano Heredia; Ocolog√≠a; Servicio de Hematolog√≠a Oncolog√≠a M√©dica, Lima, Peru|Oncosalud Sac; Oncolog√≠a, Lima, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Cl√≠nica Internacional, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, Peru|Centrum Onkologii, Inst.Im M. Curie-Slodowskiej; Iii Klinika Radioterapii I Chemioterapii, Gliwice, Poland|Klinika Onkologii Klinicznej CO-I Krak√≥w, Krakow, Poland|Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, Poland|Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon, Warszawa, Poland|Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chor√≥b Piersi z Podod. Onko Klinicznej, ≈Å√≥d≈∫, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Nizhny Novgorod Regional Clinical Oncology Center, Nizhny Novgorod, Niznij Novgorod, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|SBIH Kaluga Region Clinical Oncology Dispensary, Kaluga, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Federal State Institution, Moscow Research Oncology Institute n.a. P.A. Hertzen; Oncourology, Moscow, Russian Federation|FSI Rostov research oncological institute of MoH and SD of RF; PAD, Rostov-on-Don, Russian Federation|SBI for HPE ""Ryazan State Medical University n.a. I.P. Pavlov"" of MoH of RF, Ryazan, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Univerzitetni kliniƒçni center Maribor; Oddelek za onkologijo, Maribor, Slovenia|The Oncology Center, Durban, South Africa|Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Hospital Universitario Reina Sofia; Servicio de Oncologia, C√≥rdoba, Cordoba, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coru√±a, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinic Barcelona; Servicio de oncologia, Barcelona, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon, Spain|Hospital de Donostia; Servicio de Oncologia, Guipuzcoa, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario; Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio de Oncologia Medica, Zaragoza, Spain|Changhua Christian Hospital; Dept of Surgery, Changhua, Taiwan|Chi Mei Medical Center Liou Ying Campus, Liuying Township, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey|Ankara Onkoloji Eƒüitim ve Ara≈ütƒ±rma Hastanesi, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Dicle Uni Medical Faculty; Internal Medicine, Diyarbakir, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Okmeydani T and R Hospital; Med Onc, Istanbul, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Oncology, Izmir, Turkey|Sakarya University Medical School; Medical Oncology, Sakarya, Turkey|Municipal Institution Odesa Regional Oncology Dispensary, Odesa, KIEV Governorate, Ukraine|CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients, Kiev, Ukraine|National Cancer Institute MOH of Ukraine, Kiev, Ukraine|Treatment and Prevention Institution Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Velindre Cancer Centre, Cardiff, United Kingdom|University Hospital coventry; Oncology Department, Coventry, United Kingdom|The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit, Glasgow, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Stoke University Hospital, Stoke on Trent, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03337724
TNBC,88,49,1,NCT02574455,Ph 3,20,TNBCOther Combo,Other Combo,2L+,Breast Only,ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer,ASCENT,Recruiting,No Results Available,Breast Cancer,Drug: Sacituzumab govitecan|Drug: Eribulin|Drug: Capecitabine|Drug: Gemcitabine|Drug: Vinorelbine,Progression-Free Survival (PFS):|Overall Survival (OS):|Objective Response Rate|Duration of Response|Time to Onset of response,"Immunomedics, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,488,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMMU-132-05,10/12/17,12/01/19,06/01/20,10/12/15,null,8-Apr-19,"Southern Cancer Center, 29653 Anchor Cross Blvd, Daphne, Alabama, United States|Souther Cancer Center, 3719 Dauphin St., 5 Floor, Mobile, Alabama, United States|Southern Cancer Center, 3 Mobile Infirmary Circle, Mobile, Alabama, United States|Southern Cancer Center, 6701 Airport Blvd., Bldg B, Terace Level, Mobile, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic Hospital, Scottsdale, Arizona, United States|UCLA Jonsson Comprehensive Cancer Center, 1411 S. Garfield Ave Suite 200, Alhambra, California, United States|UCLA Jonsson Comprehensive Cancer Center, 201. S. Buena Vista St Suite 200, Burbank, California, United States|UCLA Jonsson Comprehensive Cancer Center, Laguna Hills, California, United States|UCLA Jonsson Comprehensive Cancer Center, 200 UCLA Medical Plaza, Los Angeles, California, United States|UCLA Jonsson Comprehensive Cancer Center, 625 South Fair Oaks Avenue Suite 320, Pasadena, California, United States|University of California, San Francisco (UCSF) - Innovation, Technology & Alliances, 1600 Divisadero Street, San Francisco, California, United States|UCLA Jonsson Comprehensive Cancer Center, 2020 Santa Monica Boulevard, Santa Monica, California, United States|Rocky Mountain Cancer Centers, 1700 South Potomac Street, Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, 1665 Aurora Court, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, 4715 Arapahoe Ave, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, 2312 N. Nevada Avenue, Suite 400, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, 1800 Williams St., Denver, Colorado, United States|Rocky Mountain Cancer Centers, 4700 E. Hale Parkway, Suite 400, Denver, Colorado, United States|Rocky Mountain Cancer Centers, 499 E Hampden Ave Suite 450, Englewood, Colorado, United States|Rocky Mountain Cancer Centers, 11750 West 2nd Place, Suite 1-100, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, 22 West Dry Creek Circle, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, 10103 Ridge Gate Parkway, Suite G-01, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, 2030 W Mountain View Avenue, Ste. 210, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, 9397 Crown Crest Blvd., Suite 421, Parker, Colorado, United States|Rocky Mountain Cancer Centers, 3676 Parker Blvd., Suite 350, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, 8820 Huron Street, Thornton, Colorado, United States|Yale School Of Medicine, New Haven, Connecticut, United States|Norwalk Hospital, 34 Maple Street, Norwalk, Connecticut, United States|Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Florida Cancer Specialists & Research Institute, 601 E. Altamonte Drive, Altamonte Springs, Florida, United States|Florida Cancer Specialist, Bonita Springs, Florida, United States|Florida Cancer Specialists, Bradenton, Florida, United States|Florida Cancer Specialists & Research Institute, 403 S. King Ave, Brandon, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|Florida Cancer Specialists & Research Institute, 3280 McMullen Booth road, Clearwater, Florida, United States|Sylvester Comprehensive Cancer Center, Coral Gables, Florida, United States|Florida Cancer Specialists & Research Institute, 224 Memorial medical Parway, Daytona Beach, Florida, United States|Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, 6420 W Newberry Road Est Wing, Gainesville, Florida, United States|Florida Cancer Specialists & Research Institute, 100 Highland Avenue, Largo, Florida, United States|Florida Cancer Specialists & Research Institute, 521 N. Lecanto Highway, Lecanto, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|Florida Cancer Specialists & Research Institute, 8763 River Crossing Blvd, New Port Richey, Florida, United States|Florida Cancer Specialists & Research Institute, 1630 SE 18th ST, Ocala, Florida, United States|Florida Cancer Specialists & Research Institute, 765 Image Way, Orange City, Florida, United States|Orlando Regional Medical Center, Orlando, Florida, United States|Florida Cancer Specialists & Research Institute, 70 W Gore Street, Orlando, Florida, United States|Florida Cancer Specialists & Research Institute - 325 Clyde Morris, Ormond Beach, Florida, United States|Sylvester Comprehensive Cancer Center, Plantation, Florida, United States|Florida Cancer Specialists, Port Charlotte, Florida, United States|Florida Cancer Specialists & Research Institute, 1201 Fifth Avenue North, Saint Petersburg, Florida, United States|Florida Cancer Specialists & Research Institute, 560 Jackson St, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists & Research Institute, 7154 Medical Center Drive, Spring Hill, Florida, United States|Florida Cancer Specialists & Research Institute, 3402 W Dr. Martin Luther King Jr Boulevard, Tampa, Florida, United States|Florida Cancer Specialists & Research Institute, 4100 Waterman Way, Tavares, Florida, United States|Florida Cancer Specialists & Research Institute, 1400 US highway 441 N, The Villages, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists & Research Institute - 3730 7th Terrace, Vero Beach, Florida, United States|Florida Cancer Specialists & Research Institute, 1037 State Road 7 Bldg B, Wellington, Florida, United States|Florida Cancer Specialists & Research Institute1309 N Flagler Dr, West Palm Beach, Florida, United States|Florida Cancer Specialists & Research Institute, 2100 Glenwood Drive, Winter Park, Florida, United States|Atlanta Cancer Center - Alpharetta, Alpharetta, Georgia, United States|University Cancer & Blood Center, 3320 Old Jefferson Rd, Athens, Georgia, United States|GCS/Annex, Atlanta, Georgia, United States|Atlanta Cancer Care - Atlanta, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|GCS/Canton, Canton, Georgia, United States|Atlanta Cancer Care - Conyers, Conyers, Georgia, United States|Atlanta Cancer Care - Cumming, Cumming, Georgia, United States|Atlanta Cancer Care - Decatur, Decatur, Georgia, United States|GCS/Stemmer, Decatur, Georgia, United States|Atlanta Cancer Care - Stockbridge, Jonesboro, Georgia, United States|GCS/Macon, Macon, Georgia, United States|GCS/Kennestone, Marietta, Georgia, United States|GCS/Northside, Sandy Springs, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center 5841 S. Maryland Ave, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center at Silver Cross Hospital 1900 Silver Cross Blvd, New Lenox, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Orland Park - UCMC Center for Advanced Care 14290 South LaGrange Rd, Orland Park, Illinois, United States|MidAmerica Division Inc. c/o Menorah Medical Center, Overland Park, Kansas, United States|University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion, Westwood, Kansas, United States|Maryland Oncology Hematology, Bethesda, Maryland, United States|Maryland Oncology Hematology, Brandywine, Maryland, United States|Maryland Oncology Hematology, Clinton, Maryland, United States|Maryland Oncology Hematology, Columbia, Maryland, United States|Maryland Oncology Hematology, Rockville, Maryland, United States|Maryland Oncology Hematology, Silver Spring, Maryland, United States|Maryland Oncology Hematology, Silver Spring, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Mass General - North Shore Cancer Center ( NSCC ), Danvers, Massachusetts, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Minnesota Oncology Hematology P.A., Coon Rapids, Minnesota, United States|Suburban Imaging Northwest, Coon Rapids, Minnesota, United States|Suburban Imaging, Coon Rapids, Minnesota, United States|Mercy Hospital - Unity Campus AHL, Fridley, Minnesota, United States|Minnesota Oncology Hematology P.A., Fridley, Minnesota, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|Abbot Northwestern Hospital, Minneapolis, Minnesota, United States|Virginia G. Piper Cancer Center at HonorHealth, Minneapolis, Minnesota, United States|Mayo Clinic - 200 First Street SW, Rochester, Minnesota, United States|Washington University School of Medicine in St. Louis, Creve Coeur, Missouri, United States|MidAmerica Division Inc. c/o Menorah Medical Center, Independence, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States|Nebraska Cancer Specialists - Midwest Cancer Center - Papillion, Omaha, Nebraska, United States|Nebraska Cancer Specialists - Midwest Cancer Center - Paillion, Omaha, Nebraska, United States|Nebraska Cancer Specialists- Midwest Cancer Center- Papillion, Papillion, Nebraska, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York Oncology Hematology, P.C., Clifton Park, New York, United States|North Shore Hematology Oncology Associates., PC, 235 North Belle Mead Road, East Setauket, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|North Shore Hematology Oncology Associates., PC, 285 Sills Road Building 16, Patchogue, New York, United States|UNC Health Care System, Chapel Hill, North Carolina, United States|The Ohio State University Wexner Medical Center, 460 W 10th Ave, Columbus, Ohio, United States|The Ohio State University Wexner Medical Center, 1145 Olentangy River Road, Columbus, Ohio, United States|Providence Medical Group, Portland, Oregon, United States|UPMC Hillman Cancer Center Mountainview Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|UPMC Hillman Cancer Center UPMC East, Monroeville, Pennsylvania, United States|UPMC Hillman Cancer Center Upper Saint Clair, Pittsburgh, Pennsylvania, United States|Allegheny-Singer Research Institute, 320 East North Avenue, Pittsburgh, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center UPMC Passavant, Pittsburgh, Pennsylvania, United States|Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga, Tennessee, United States|Tennesee Oncology - PLLC, Chattanooga, Tennessee, United States|Tenesse Oncology - PLLC, Cleveland, Tennessee, United States|Tennessee Oncology, LLC, Dickson, Tennessee, United States|Tennessee Ocology, LLC, Franklin, Tennessee, United States|Tennessee Oncology, LLC, Gallatin, Tennessee, United States|West Cancer Center, 7945 Wolf River Blvd, Germantown, Tennessee, United States|Tennessee Oncology, LLC, Hermitage, Tennessee, United States|Tennessee Oncology, LLC, Lebanon, Tennessee, United States|Tennessee Oncology, LLC, Murfreesboro, Tennessee, United States|Sarah Cannon Cancer Institute/Tennessee Oncology, Nashville, Tennessee, United States|Tennessee Oncology, LLC, Nashville, Tennessee, United States|Vanderbilt Breast Cancer Center at One Hundred Oaks 719 Thompson Lane, Suite 25000, Nashville, Tennessee, United States|Tennessee Ocology, LLC, Nashville, Tennessee, United States|Tennessee Oncology, LLC, Nashville, Tennessee, United States|Tenessee Oncology, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic 1301 Medical Center Drive 1903 The Vanderbilt Clinic Nashville, TN 37232, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Tennessee Oncology, LLC, Shelbyville, Tennessee, United States|Center for Cancer and Blood Disorders, Arlington, Texas, United States|Center for Cancer and Blood Disorders, Burleson, Texas, United States|Texas Oncology- Medical City Dallas Building D, Dallas, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, Denton, Texas, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Houston Methodist Hospital - 6565 Fannin St, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Texas Oncology, Plano, Texas, United States|US Oncology, Tyler, Texas, United States|Center for Cancer and Blood Disorders, Weatherford, Texas, United States|Virginia Cancer Specialists, PC, Alexandria, Virginia, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Low Moor, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, P.C., Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Virginia Cancer Specialists, PC, Woodbridge, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States|Swedish Cancer Institute, Edmonds, Washington, United States|Swedish Cancer Institute, Issaquah, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States|Universitair Zlekenhuis Brussel, Brussels, Belgium|Institut Jules Bordet, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Clinique et Maternite Sainte-Elisabeth, Namur, Belgium|Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Jewish General Hospital, 3755 C√¥te-Sainte-Catherine, Montr√©al, Quebec, Canada|Jewish General Hospital, 3755 C√¥te-Sainte-Catherine, Qu√©bec, Quebec, Canada|Centre de Lutte Contre le Cancer - Institut de Cancerologie de l'Ouest - Paul Papin, Angers, France|CHU Besan√ßon - H√¥pital Jean Minjoz, Besan√ßon, France|Institut R√©gional du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Centre Eug√®ne Marquis, Rennes Cedex, France|Florence Lerebours, Saint-Cloud, France|CHU de Nantes - H√¥pital Nord Laennec, Saint-Herblain, France|Institut Claudius Regaud, Toulouse, France|Gustave Roussy, Villejuif, France|H√§matologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany|Praxis f√ºr interdisziplin√§re Onkologie & H√§matologie GbR, Freiburg im Breisgau, Germany|Facharztzentrum Eppendorf, Hamburg, Germany|Institut f√ºr Versorgungsforschung in der Onkologie, Koblenz, Germany|Praxis f√ºr H√§matologie und Internistische Onkologie, Velbert, Germany|Hospital Teresa Herrera, As Xubias, 84, A Coru√±a, Spain|Hospital Quir√≥n Barcelona, Plaza Alfonso Com√≠n 5, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Carrer del Mas Casanovas, 90, Barcelona, Spain|Institut Catala d'Oncologia Hospitalet, Avenida Gran Via 199-203, Hospitalet de Llobregat, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clinco Universaitario, Santiago De Compostela, Spain|Hospital Universitario Virgen del Roc√≠o, Sevilla, Spain|Colchester Hospital University NHS Foundation Trust - Colchester General Hospital, Turner Road, Colchester, ESS, United Kingdom|The Arden Cancer Centre- University Hospital Coventry, Coventry, United Kingdom|County Durham and Darlington NHS Foundation Trust - University Hospital of North Durham, Durham, United Kingdom|The Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom|The County Hospital, Wye Valley NHS Trust, Hereford, United Kingdom|The Royal Free London NHS Foundation Trust - The Royal Free Hospital, Pond Street Oncology & Haematology Clinical Trials Unit Dept. of Academic Oncology, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom|Taunton and Somerset NHS Foundation Trust - Musgrove Park Hospital, Musgrove Park Hospital, Taunton, United Kingdom|The Mid Yorkshire Hospitals NHS Trust - Pinderfields Hospital, Wakefield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02574455
TNBC,88,50,1,NCT03002103,Ph 3,20,TNBCOther Combo,Other Combo,1L,Breast Only,A Trial Evaluating the Efficacy and Safety of EndoTAG¬Æ-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer,,Recruiting,No Results Available,Triple-Negative Breast Cancer,Drug: EndoTAG-1|Drug: Paclitaxel|Drug: Gemcitabine Hydrochloride,"PFS|Overall survival|Clinical benefit rate|Best overall tumor response rate|Duration of response|Quality of life(QLQ-C30,QLQ-BR23)|Post-progression PFS","SynCore Biotechnology Co., Ltd.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,420,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT4005,11/01/16,12/01/21,12/01/22,12/23/16,null,13-Aug-18,"Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|MacKay Memorial Hospital, Taipei branch, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT03002103
TNBC,88,51,1,NCT03674242,Ph 3,20,TNBCOther Combo,Other Combo,1L,Breast Only,Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2),,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: eryaspase (L-asparaginase encapsulated in red blood cells)|Drug: Gemcitabine|Drug: Carboplatin,Objective response rate (ORR),ERYtech Pharma,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2|Phase 3,64,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GRASPA-TNBC-2018-02,12/01/18,04/01/20,04/01/20,09/17/18,null,17-Sep-18,,,https://ClinicalTrials.gov/show/NCT03674242
TNBC,88,52,1,NCT03876886,Ph 3,20,TNBCOther Combo,Other Combo,Adj,Breast Only,The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency,,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Carboplatin,3-year disease-free survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Chinese Academy of Medical Sciences,All,18 Years to 60 Years ¬† (Adult),Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BXu-1839,02/22/19,02/01/24,12/01/24,03/15/19,null,21-Mar-19,"National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03876886
TNBC,88,53,2,NCT03519178,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast + Other,"A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy",,Recruiting,No Results Available,"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer",Drug: PF-06873600|Drug: Endocrine Therapy 1|Drug: Endocrine Therapy 2,"Number of patients with dose limiting toxicities in the Dose Escalation portion|Safety and Tolerability as assessed by adverse event monitoring for patients enrolled in the Dose Escalation, Dose Finding and Dose Expansion Arms|Safety and Tolerability as assessed through monitoring of hematology and blood chemistry laboratory assessments for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Safety and Tolerability as assessed through vital sign monitoring for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Safety and Tolerability as assessed by heart rate corrected QT interval for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Objective Response Rate (ORR) observed in patients in the Dose Expansion Arms|Safety and Tolerability as assessed through monitoring of coagulation laboratory assessments for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Safety and Tolerability as assessed through monitoring of urinalysis laboratory assessments for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Single Dose: Maximal concentration (Cmax) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Plasma concentrations with and without food observed in patients enrolled in one of the single agent Dose Expansion Arms|Single Dose: Time to Maximum Plasma Concentration (Tmax) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point Within the Dose Interval (AUClast) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero Extrapolated to Infinity (AUCinf) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Apparent Oral Plasma Clearance (CL/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Apparent Volume of Distribution (Vz/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Terminal Elimination Half-Life (t1/2) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Steady State Maximal Concentration (Css,max) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Time to Maximum Plasma Concentration at Steady State (Tss,max) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,t) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Steady State Minimum Plasma Concentration (Css,min) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Steady State Apparent Oral Plasma Clearance (CLss/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Apparent Volume of Distribution at Steady State (Vss/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Terminal Elimination Half-Life (t1/2) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Accumulation Ratio (Rac (AUCss,t /AUCsd,t)) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Tumor Response observed in patients in Dose Escalation and Dose Finding portion|Duration of Response (DOR) in patients enrolled in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Progression Free Survival (PFS) observed in patients in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Time to Progression (TTP) observed in patients enrolled in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Overall Survival observed in patients enrolled in the Dose Expansion Arms|Pharmacodynamic (PD) biomarkers (pRb and Ki67) in tumor tissue in patients enrolled in the Dose Escalation and Dose Finding portion and Dose Expansion Arms",Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,220,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C3661001,03/07/18,12/11/21,12/11/21,05/08/18,null,3-Apr-19,"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|UCSF Medical Center, San Francisco, California, United States|University of California -San Francisco, San Francisco, California, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Investigational Pharmacy Services, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03519178
TNBC,88,54,1,NCT02802423,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast Only,"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.",,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: BLEX 404 Oral Liquid,Phase I: Dose-limiting toxicity (DLT) observation|Phase II: Overall response rate (PR + CR)|Phase II: Overall response rate (PR + CR)(at least 1 cycle)|Phase II: Incidence of grade 3/4 hematological toxicity|Quality of Life,"BioLite, Inc.",Female,"20 Years to 70 Years ¬† (Adult, Older Adult)",Phase 1|Phase 2,44,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BLI-1401-2-01,10/30/19,10/30/21,02/28/22,06/16/16,null,12-Apr-19,,,https://ClinicalTrials.gov/show/NCT02802423
TNBC,88,55,1,NCT03012100,Ph 2,20,TNBCOther Combo,Other Combo,Adj,Breast + Other,"Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer",,Recruiting,No Results Available,Bilateral Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma|Unilateral Breast Carcinoma,Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine|Other: Placebo|Biological: Sargramostim,Disease-free survival|Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events 4.0|Overall survival|Vaccine induced folate receptor [FR]alpha-specific T cell responses defined as the proportion of patients with at least a 2-fold increase in the number of cells/plasma concentration|FRalpha levels,Academic and Community Cancer Research United|National Cancer Institute (NCI),Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,280,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RU011501I|NCI-2016-01878|P30CA015083,03/31/17,07/31/21,07/31/23,01/06/17,null,22-Feb-19,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03012100
TNBC,88,56,1,NCT03330847,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast Only,To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.,,Recruiting,No Results Available,Metastatic Triple Negative Breast Cancer,Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.|Drug: AZD6738 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Drug: AZD1775 150 mg BD + olaparib 200 mg BD (21-day cycle).,"Progression-Free Survival (PFS) assessment to evaluate the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy compared to olaparib monotherapy in BRCAm, Non BRCAm HRRm, Non HRRm patient population.|PFS assessment to evaluate the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy compared to olaparib monotherapy in HRRM and in All patient population.|Objective response rate (ORR) assessment to evaluate the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy compared to olaparib monotherapy.|Duration of response (DoR) assessment to evaluate the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy compared to olaparib monotherapy.|Tumour change assessment to evaluate the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy compared to olaparib monotherapy.|Overall survival (OS) assessment to evaluate the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy compared to olaparib monotherapy.|PFS assessment to compare the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy.|ORR assessment to compare the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy.|DoR assessment to compare the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy.|Tumour change assessment to compare the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy.|Overall survival (OS) assessment to compare the efficacy of AZD6738+olaparib and AZD1775+olaparib combination therapy.|Minimum steady-state plasma drug concentration during a dosage interval (Cmin ss).|Number of participants with adverse events (AEs)|Assessment of twelve lead safety electrocardiography (ECG).|Assessment of Eastern Cooperative Oncology Group performance status (ECOG).|Laboratory assessments of urinalysis.|Frequency of tumour HRR mutations|Nature of tumour HRR mutations|To compare the frequency and nature of tumour HRR mutations to germline mutational status|Number of participants with abnormal laboratory assessments of clinical chemistry- AZD6738+olaparib|Number of participants with abnormal laboratory assessments of clinical chemistry- AZD1775+olaparib|Number of participants with abnormal laboratory assessments of clinical chemistry- olaparib monotherapy|Laboratory assessments of Haematology - AZD6738+olaparib|Laboratory assessments of Haematology- AZD1775+olaparib|Laboratory assessments of Haematology - olaparib monotherapy|Assessments of blood pressure- AZD6738+olaparib|Assessments of blood pressure- AZD1775+olaparib|Assessments of blood pressure- olaparib monotherapy|Assessments of pulse- AZD6738+olaparib|Assessments of pulse- AZD1775+olaparib|Assessments of pulse- olaparib monotherapy",AstraZeneca,All,"18 Years to 130 Years ¬† (Adult, Older Adult)",Phase 2,450,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D5336C00001,02/21/18,01/20/21,01/20/21,11/06/17,null,15-Mar-19,"Research Site, Anchorage, Alaska, United States|Research Site, Gilbert, Arizona, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Munster, Indiana, United States|Research Site, Hazard, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Kansas City, Missouri, United States|Research Site, Brick, New Jersey, United States|Research Site, East Setauket, New York, United States|Research Site, Lake Success, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Olympia, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Brasschaat, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Namur, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 8, Czechia|Research Site, Angers Cedex 02, France|Research Site, Besan√ßon Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Caen, France|Research Site, Lille Cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille, France|Research Site, Montpellier Cedex 5, France|Research Site, Nantes, France|Research Site, Paris Cedex 5, France|Research Site, Rennes, France|Research Site, Saint Herblain Cedex, France|Research Site, Tours CEDEX, France|Research Site, Villejuif, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Esslingen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, K√∂ln, Germany|Research Site, Leipzig, Germany|Research Site, M√ºnchen, Germany|Research Site, M√ºnchen, Germany|Research Site, Wiesbaden, Germany|Research Site, Witten, Germany|Research Site, Cork, Ireland|Research Site, Dublin 4, Ireland|Research Site, Galway, Ireland|Research Site, Ancona, Italy|Research Site, Avellino, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Brindisi, Italy|Research Site, Cona, Italy|Research Site, Genova, Italy|Research Site, L' Aquila, Italy|Research Site, Lecco, Italy|Research Site, Macerata, Italy|Research Site, Meldola, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Almelo, Netherlands|Research Site, Breda, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Leidschendam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sittard-geleen, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Dabrowa Gornicza, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Grzepnica, Poland|Research Site, Koscierzyna, Poland|Research Site, Krak√≥w, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, C√°ceres, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Palma de mallorca, Spain|Research Site, San Sebasti√°n(Guip√∫zcoa), Spain|Research Site, Sant Cugat del Valles, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Vigo, Spain|Research Site, Zaragoza, Spain|Research Site, Changhua City, Taiwan|Research Site, Kaohsiung Hsien, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Durham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03330847
TNBC,88,57,1,NCT03150810,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast + Other,"Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",,Recruiting,No Results Available,Locally Advanced or Metastatic Solid Tumors,Drug: BGB-290|Drug: Temozolomide,"Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.|Incidence, nature and severity of adverse events as assessed by CTCAE.|Pharmacokinetic (PK) parameters (Cmax) of BGB-290 and TMZ.|Pharmacokinetic (PK) parameters (Tmax) of BGB-290 and TMZ.|Objective response rate (ORR) as assessed using RECIST.|Duration of response (DOR).|Disease control rate (DCR)|Progression free survival (PFS)|Overall survival (OS)","BeiGene USA, Inc.|Myriad Genetics, Inc.|BeiGene",All,"18 Years to 99 Years ¬† (Adult, Older Adult)",Phase 1|Phase 2,150,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGB-290-103,07/12/17,07/01/20,08/01/20,05/12/17,null,19-Dec-18,"START Midwest, Grand Rapids, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Mount Sinai - PRIME, New York, New York, United States|Montefiore Medical Center PRIME, New York, New York, United States|Sarah Cannon Research Institute (Tennessee Oncology), Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|University of Texas- MD Anderson Cancer Center, Houston, Texas, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Saint Vincent's Hospital, Darlinghurst, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catalia d'oncologia- l'Hospitalet, Barcelona, Spain|START Madrid-Fundaci√≥n Jim√©nez D√≠az, Madrid, Spain|START-Madrid, Madrid, Spain|Hospital Cl√≠nico de Valencia, Valencia, Spain|Sarah Cannon Research Institute UK, London, Greater London, United Kingdom|Sir Bobby Robson Cancer Trials Research Centre, Newcastle, Newcastle Upon Tyne, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Strathclyde, United Kingdom|University College London Hospitals, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03150810
TNBC,88,58,1,NCT03267316,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast + Other,A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors,CANFOUR,Recruiting,No Results Available,Non Small Cell Lung Cancer|Pancreatic Ductal Adenocarcinoma|Triple Negative Breast Cancer|Colorectal Cancer,Biological: CAN04|Drug: Cisplatin|Drug: Gemcitabine|Drug: Nab-paclitaxel,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Maximum concentration (Cmax)|Terminal half-life (t1/2)|Clearance (CL)|Apparent volume of distribution during the terminal phase (VZ)|Area under the curve from time 0 to infinity (AUC0-‚àû)|Anti-drug antibodies (ADA) against CAN04|Preliminary signs of efficacy as assessed by tumor response,Cantargia AB,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CAN04CLIN001|2017-001111-36,09/19/17,12/01/19,03/01/20,08/30/17,null,21-Mar-19,"Landeskrankenhaus Salzburg, Salzburg, Austria|Institut Jules Bordet, Brussels, Belgium|Rigshospitalet, Department of Oncology, Copenhagen, Denmark|Herlev og Gentofte Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Charit√© Universit√§tsmedizin Berlin, Berlin, Germany|Asklepios Klinik Altona, Hamburg, Germany|Netherlands Cancer Institute, Amsterdam, Netherlands|Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, Netherlands|Oslo University Hospital, Radiumhospitalet, Oslo, Norway",,https://ClinicalTrials.gov/show/NCT03267316
TNBC,88,59,1,NCT03875313,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast + Other,Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors,,Recruiting,No Results Available,Solid Tumor|Clear Cell Renal Cell Carcinoma|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer|CRC|RCC|ccRCC,Drug: CB-839|Drug: Talazoparib,Safety and tolerability of CB-839 in combination with talazoparib: Number of participants with treatment related adverse events|Maximum tolerated dose and/ or Recommended Phase 2 Dose|Maximum plasma concentration of CB-839 and talazoparib|Anti-tumor activity of CB-839 in combination with talazoparib,"Calithera Biosciences, Inc",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,92,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CX-839-011,03/01/19,12/01/20,12/01/21,03/14/19,null,14-Mar-19,"South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03875313
TNBC,88,60,1,NCT02978716,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast Only,"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",,"Active, not recruiting",No Results Available,Triple-Negative Breast Neoplasms|Breast Neoplasm|Breast Cancer|Triple-Negative Breast Cancer,Drug: Trilaciclib|Drug: Gemcitabine|Drug: Carboplatin,"Number of Treatment Related Adverse Event, including Abnormal Laboratory Events|Tumor response based on RECIST, Version 1.1|Progression free survival (PFS)|Overall survival (OS)|Hematologic parameters|Pharmacokinetics of Trilaciclib (G1T28), Carboplatin and Gemcitabine: Maximum Plasma Concentration (Cmax)|Pharmacokinetics of Trilaciclib (G1T28), Carboplatin and Gemcitabine: Area under Curve - plasma concentration (AUC)|Pharmacokinetics of Trilaciclib (G1T28), Carboplatin and Gemcitabine: Plasma: terminal half life (T1/2)|Pharmacokinetics of Trilaciclib (G1T28), Carboplatin and Gemcitabine: Plasma - Volume of distribution|Incidence of chemotherapy dose reductions|Incidence of dose interruptions overall","G1 Therapeutics, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,102,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G1T28-04|2016-004466-26,02/07/17,10/01/19,02/01/20,12/01/16,null,25-May-18,"Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Disney Family Cancer Center, Burbank, California, United States|Sharp Clinical Oncology, San Diego, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Memorial UC Health, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Research Institute, LLC., Plantation, Florida, United States|Florida Cancer Specialists - North (FCS North), Saint Petersburg, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Florida Cancer Specialists - East (FCS East), West Palm Beach, Florida, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|The University of Maryland St. Joseph Medical Center, Towson, Maryland, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Levine Cancer Center, Charlotte, North Carolina, United States|Forsyth Memorial Hospital, Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Tennessee Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology-Dallas Presbyterian Hospital, Austin, Texas, United States|Texas Oncology, P.A., Austin, Texas, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center Grandview, El Paso, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology-San Antonio Northeast, San Antonio, Texas, United States|Tyler Hematology-Oncology, PA, Tyler, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Antwerp University Hospital (UZA), Edegem, Belgium|University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria|MHAT for Womens Health - Nadezhda OOD, Sofia, Bulgaria|Special Hospital For Active Treatment In Oncology, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment, Varna, Bulgaria|University Hospital Centre Osijek, Osijek, Croatia|General Hospital Vara≈ædin, Varazdin, Croatia|University Hospital Centre ""Sestre milosrdnice"", Zagreb, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Dr. Trifun Panovski, Bitola, Macedonia, The Former Yugoslav Republic of|University Clinic of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of|Special Hospital for Internal Diseases , Oncomed, Belgrade, Serbia|Clinical Hospital Centre Bezanijska Kosa, Oncology Clinic, Belgrade, Serbia|Center for Oncology and Radiotherapy, Clinical Centre, Kragujevac, Serbia|Clinical Centre Nis, Clinic of Oncology, Nis, Serbia|Oncology Institute of Vojvodina, Clinic for Internal Oncology, Sremska Kamenica, Serbia|Mammacentrum, Sv.Ag√°ty, Bansk√° Bystrica, Slovakia|Cancer Institute VOU, Rastislavova, Ko≈°ice, Slovakia|University Medical Centre Maribor, Maribor, Slovenia",,https://ClinicalTrials.gov/show/NCT02978716
TNBC,88,61,1,NCT03901469,Ph 2,20,TNBCOther Combo,Other Combo,2L+,Breast Only,A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer,TNBC,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: ZEN003694|Drug: Talazoparib,"Part 1 and Part 2: Incidence of of treatment-related adverse events (AE) and treatment-related serious adverse events (SAE)|Part 1: Incidence of dose-limiting toxicities (DLT)|Part 2: Objective response rate (ORR) defined as a complete response (CR), partial response (PR) or stable disease (SD ‚â• 4 cycles) by RECIST 1.1|Part 1 and Part 2: Measure the pharmacokinetic (PK) parameter: AUC of ZEN003694 administered in combination with talazoparib|Part 1 and Part 2: Measure the pharmacokinetic (PK) parameter: Cmax of ZEN003694 administered in combination with talazoparib|Part 1: Measure the pharmacokinetic (PK) parameter: Cmin of ZEN003694 administered in combination with talazoparib|Part 1 and Part 2: Measure the pharmacokinetic (PK) parameter: Tmax of ZEN003694 administered in combination with talazoparib|Part 1 and Part 2: Measure the pharmacokinetic (PK) parameter: t1/2 of ZEN003694 administered in combination with talazoparib|Part 1: Objective response rate (ORR) defined as a complete response (CR), partial response (PR) or stable disease (SD ‚â• 4 cycles) by RECIST 1.1|Part 1 and Part 2: Evaluate median radiographic progression-free survival|Part 1 and Part 2: Evaluate median progression-free survival|Part 1 and Part 2: Evaluate duration of response (DOR)|Part 1 and Part 2: Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) for Overall Duration|Part 1 and Part 2: Change from Baseline in Breast Symptoms Scale as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC-QLQ-BR23)",Zenith Epigenetics|Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,49,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZEN003694-004|2018-003906-26,04/01/19,09/01/20,01/01/21,04/03/19,null,19-Apr-19,"Tennessee Oncology (Sarah Cannon), Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03901469
TNBC,88,62,1,NCT03057600,Ph 2,20,TNBCOther Combo,Other Combo,1L,Breast Only,Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC,,"Active, not recruiting",No Results Available,Triple Negative Breast Cancer|TNBC - Triple-Negative Breast Cancer,Drug: Pac-CB,Objective response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|Duration of response (DOR)|Clinical benefit rate (CBR),"Calithera Biosciences, Inc",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,112,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CX-839-007,05/09/17,06/30/19,05/01/20,02/20/17,null,12-Feb-19,"University of Alabama at Brimingham, Birmingham, Alabama, United States|University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Washington Cancer Institute, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University Cancer and Blood Center, Athens, Georgia, United States|Winship Cancer Institute - Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology, Marietta, Georgia, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint Louis University, Saint Louis, Missouri, United States|JTCC at Hackensack UMC, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Womens Hospital - UPMC, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Charleston, South Carolina, United States|Greenville Health System (GHS) Cancer Institute, Greenville, South Carolina, United States|West Cancer Center, Germantown, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|MD Anderson, Houston, Texas, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03057600
TNBC,88,63,1,NCT03719326,Ph 1,20,TNBCOther Combo,Other Combo,2L+,Breast + Other,A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies,,Recruiting,No Results Available,TNBC - Triple-Negative Breast Cancer|Ovarian Cancer,Drug: AB928|Drug: Pegylated liposomal doxorubicin,Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0|AB928 pharmacokinetic (PK) Concentration: Cmax|AB928 pharmacokinetic (PK) Concentration: Tmax|Clinical activity of combination therapy|AB928 Receptor Occupancy|AB928 Immunophenotyping|AB928 Gene Expression|AB928 Cytokines,"Arcus Biosciences, Inc.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,98,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AB928CSP0002,10/15/18,12/30/20,12/30/21,10/25/18,null,4-Mar-19,"Aurora, CO, Aurora, Colorado, United States|Rockville, MD, Rockville, Maryland, United States|Las Vegas, NV, Las Vegas, Nevada, United States|Huntersville, NC, Huntersville, North Carolina, United States|Eugene, OR, Eugene, Oregon, United States|Austin, TX, Austin, Texas, United States|Dallas, TX, Dallas, Texas, United States|Fort Worth, TX, Fort Worth, Texas, United States|Tyler, TX, Tyler, Texas, United States|Norfolk, VA, Norfolk, Virginia, United States|Spokane, WA, Spokane, Washington, United States|Tacoma, WA, Tacoma, Washington, United States|Camperdown, Australia, Camperdown, New South Wales, Australia|kogarah, Australia, Kogarah, New South Wales, Australia|Sydney, Australia, Sydney, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT03719326
TNBC,88,64,1,NCT03102320,Ph 1,20,TNBCOther Combo,Other Combo,2L+,Breast + Other,Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors,ARCS-Multi,Recruiting,No Results Available,Neoplasms,Drug: Cisplatin|Drug: Gemcitabine|Drug: Anetumab ravtansine (BAY94-9343),Maximum tolerated dose (MTD) of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine in patients with mesothelin-expressing cholangiocarcinoma and pancreatic adenocarcinoma|Objective response (qualitative improvement from baseline) of anetumab ravtansine for monotherapy and combination therapy in mesothelin expressing advanced solid tumors|Durable disease control (lack of progression from baseline) of anetumab ravtansine in indications pancreatic and gastric cancer (co-primary endpoint)|Number of serious and non-serious adverse events (AEs)|Disease control rate (DCR)|Duration of response (DOR)|Durable response rate (DRR)|Progression free survival (PFS)|Durable disease control rate (DDCR) of anetumab ravtansine in indications other than pancreatic and gastric cancer,"Bayer|ImmunoGen, Inc.|MorphoSys AG",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,348,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15834|2016-004002-33,05/26/17,02/28/20,07/28/21,04/05/17,null,19-Apr-19,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford Health Care, Stanford, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|IU Health University Hospital, Indianapolis, Indiana, United States|Ochsner Medical Center - New Orleans, New Orleans, Louisiana, United States|National Cancer Institute, Bethesda, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Farmington Hills, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Blacktown Cancer & Haematology Centre, Blacktown, New South Wales, Australia|Mid North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia|Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Epworth HealthCare, Richmond, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|St John of God Healthcare, Subiaco, Western Australia, Australia|GZA Ziekenhuizen, Wilrijk, Antwerpen, Belgium|H√¥pital Erasme/Erasmus Ziekenhuis, Bruxelles - Brussel, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU de Li√®ge, Liege, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|Hopital Jean Minjoz, Besancon, France|H√¥pital Henri Mondor, Creteil, France|Centre Oscar Lambret - Lille, Lille Cedex, France|Centre L√©on B√©rard, Lyon Cedex, France|Institut Paoli Calmettes, Marseille Cedex 9, France|C.H.U. Timone, Marseille, France|Centre Ren√© Gauducheau, Nantes, France|Centre Antoine Lacassagne, Nice Cedex 2, France|Institut Curie - Ulm - Paris, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|H√¥pital de la Mil√©trie, POITIERS cedex, France|H√¥pital Pontchaillou, Rennes Cedex, France|Centre Eug√®ne Marquis - Rennes Cedex, Rennes Cedex, France|Institue Curie - Centre Ren√© Huguenin, Saint Cloud, France|Institut Gustave Roussy, Villejuif Cedex, France|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-W√ºrttemberg, Germany|Stadt- und Landkreis Kliniken Heilbronn GmbH, Heilbronn, Baden-W√ºrttemberg, Germany|Marienhospital, Stuttgart, Baden-W√ºrttemberg, Germany|Klinikum der Universit√§t M√ºnchen Innenstadt, M√ºnchen, Bayern, Germany|St√§dt. Klinikum M√ºnchen, M√ºnchen, Bayern, Germany|Kliniken Nord und S√ºd, N√ºrnberg, Bayern, Germany|Universit√§tsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Marienhospital Herne Universit√§tsklinik, Herne, Nordrhein-Westfalen, Germany|Universit√§tsklinikum K√∂ln, K√∂ln, Nordrhein-Westfalen, Germany|Kliniken der Stadt K√∂ln - St√§dt. Krankenhaus K√∂ln-Merheim, K√∂ln, Nordrhein-Westfalen, Germany|Universit√§tsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Universit√§tsklinikum Leipzig A√∂R, Leipzig, Sachsen, Germany|SRH Wald-Klinikum Gera gGmbH, Gera, Th√ºringen, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|A.O.U. di Modena - Policlinico, Modena, Emilia-Romagna, Italy|IRCCS Istituto Clinico Humanitas (ICH), Milano, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|A.O.U. Integrata Verona, Verona, Veneto, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei University College of Medicine, Seoul, Korea, Republic of|Nederlands Kanker Instituut, Amsterdam, Netherlands|Maastricht UMC, Maastricht, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|National Cancer Center, Singapore, Singapore|Institut Catal√† d'Oncologia Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Catalunya, Spain|Hospital Universitario Quir√≥n de Madrid, Pozuelo de Alarc√≥n, Madrid, Spain|Ciutat Sanit√†ria i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Cl√≠nic i Provincial de Barcelona, Barcelona, Spain|Hospital Ram√≥n y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital General Universitario Gregorio Mara√±√≥n, Madrid, Spain|Centro Integral Oncol√≥gico Clara Campal, Madrid, Spain|Hospital Virgen de la Victoria, M√°laga, Spain|Kantonsspital Graub√ºnden, Chur, Graub√ºnden, Switzerland|Ospedale Regionale Bellinzona, Bellinzona, Ticino, Switzerland|Leicester Royal Infirmary, Leicester, Leicestershire, United Kingdom|Belfast City Hospital, Belfast, North Ireland, United Kingdom|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Marsden Hospital (London), London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03102320
TNBC,88,65,1,NCT03328494,Ph 1,20,TNBCOther Combo,Other Combo,1L,Breast + Other,Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies,,Recruiting,No Results Available,Advanced Nonhaematologic Malignancies,Drug: BOS172722|Drug: Paclitaxel,Incidence of adverse events (AEs)|Number of participants with a dose-limiting toxicity (DLT)|Part A Monotherapy: Plasma concentration of BOS172722 measured over 24 hours when administered alone|Part A Combination: Plasma concentration of BOS172722 and paclitaxel measured over 24 hours when administered either individually or in combination|Part B Expansion: Plasma concentration of BOS172722 and paclitaxel measured over 24 hours when administered in combination|Objective response rate (ORR)|Duration of response (DOR)|Time to response (TTR)|Time to progression on study,Boston Pharmaceuticals,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,68,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BOS172722-01|2017-001749-29,10/13/17,12/01/20,12/01/20,11/01/17,null,28-Jan-19,"Addenbrooks Hospital, Cambridge, United Kingdom|Edinburgh Cancer Centre - Western General Hospital, Edinburgh, United Kingdom|Royal Marsden, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03328494
TNBC,88,66,1,NCT03499353,Ph 2,18,TNBCOther Mono,Other Mono,Neo-adj,Breast Only,Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer,,Recruiting,No Results Available,Early Breast Cancer,Drug: TALAZOPARIB,"Pathological Complete Response (pCR) by Independent Central Reviewer(ICR)|pCR by Investigator|Residual Cancer Burden(RCB) by Independent reviewer|pCR by independent Reviewer in Breast|Event Free Survival|Overall Survival|Incidence of Adverse Events|Patient Reported Outcome: Deterioration of Global Health Status|Patient Reported Outcome: Nausea and vomiting symptoms|Patient Reported Outcome: global health status/QoL, functioning, and symptoms|Patient Reported Outcome- Antiemetic Log|Patient Reported Outcome: Missed Menstrual Period|Pharmacokenetic assessment of Talazoparib",Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,122,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C3441020|TALAZOPARIB NEOADJ BC,08/27/18,09/01/21,12/01/23,04/17/18,null,16-Apr-19,"Banner Gateway Medical Center, Gilbert, Arizona, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC - HAL, Glendale, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HAL, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States|Arizona Oncology Associates, Tempe, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Highlands Oncology Group, Rogers, Arkansas, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Camarillo, California, United States|UC Irvine Health Cancer Center - Newport, Costa Mesa, California, United States|UC Irvine Health Cancer Center Newport Attn: Kevin Van, Costa Mesa, California, United States|City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States|City of Hope Investigational Drug Services (IDS), Duarte, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Breastlink Medical Group, Inc., Laguna Hills, California, United States|UC Irvine Health, Orange, California, United States|UC Irvine Medical Center, Orange, California, United States|Breastlink Medical Group, Inc, Orange, California, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Emad Ibrahim, MD, INC., Redlands, California, United States|Cancer Research Collaboration, Inc, Santa Ana, California, United States|Stanford Cancer Institute, Stanford, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Stanford Women's Cancer Center, Stanford, California, United States|PMK Medical Group Inc., dba Ventura County Hematology Oncology Specialists, Ventura, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Englewood, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|Innovative Medical Research of South Florida, Inc, Aventura, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Southeastern Regional Medical Center, Newnan, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|University of Illinois Hospital and Health Systems (Investigational Drug Pharmacy), Chicago, Illinois, United States|University of Illinois Hospital and Health Systems (Outpatient Care Center), Chicago, Illinois, United States|University of Illinois Hospital and Health Systems, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Hematology/Oncology Clinic, LLP, Baton Rouge, Louisiana, United States|Baptist Cancer Center, Columbus, Mississippi, United States|Baptist Cancer Center, Grenada, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Baptist Cancer Center, New Albany, Mississippi, United States|Baptist Cancer Center, Oxford, Mississippi, United States|Baptist Cancer Center, Southaven, Mississippi, United States|Baptist Cancer Center, Starkville, Mississippi, United States|Summit Medical Group PA, Florham Park, New Jersey, United States|St. Luke's Hospital - Warren Campus, Phillipsburg, New Jersey, United States|St. Luke's Warren Physician Group, Phillipsburg, New Jersey, United States|University of Toledo Medical Center (Drug Delivery), Toledo, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Tualatin, Oregon, United States|St. Luke's Hematology Oncology Specialists, Allentown, Pennsylvania, United States|St. Luke's Hospital - Allentown Campus, Allentown, Pennsylvania, United States|St. Luke's Hematology Oncology Specialists, Bethlehem, Pennsylvania, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|St. Luke's Hospital - Miners Campus, Coaldale, Pennsylvania, United States|St Luke's Hospital - Anderson Campus, Easton, Pennsylvania, United States|St. Luke's Hospital - Anderson Campus, Easton, Pennsylvania, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|UPMC Hillman Cancer Center Mountainview Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|UPMC Cancer Centers East Oxford Drive, Monroeville, Pennsylvania, United States|Eastern Regional Medical Center, Inc., Philadelphia, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center North Hills at Passavant, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center UPMC Passavant, Pittsburgh, Pennsylvania, United States|St. Luke's Hospital - Quakertown Campus, Quakertown, Pennsylvania, United States|St. Luke's Hospital - Monroe Campus, Stroudsburg, Pennsylvania, United States|UPMC Hillman Cancer Center Uniontown, Uniontown, Pennsylvania, United States|UPMC Hillman Cancer Center Washington, Washington, Pennsylvania, United States|Charleston Hematology Oncology Associates, PA, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Baptist Cancer Center, Bartlett, Tennessee, United States|Baptist Cancer Center, Collierville, Tennessee, United States|Tennessee Cancer Specialists, Harrogate, Tennessee, United States|Tennessee Cancer Specialists, Jefferson City, Tennessee, United States|Brig Center for Cancer Care and Survivorship, Knoxville, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Tennessee Cancer Specialists, Morristown, Tennessee, United States|Tennessee Cancer Specialists, Newport, Tennessee, United States|Texas Oncology - Allen, Allen, Texas, United States|Texas Oncology - Arlington North, Arlington, Texas, United States|Texas Oncology - Arlington South, Arlington, Texas, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology-Austin Central, Austin, Texas, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|U.T. MD Anderson Cancer Center, Investigational Pharmacy Services - Unit 376, Houston, Texas, United States|U.T. MD Anderson Cancer Center, Houston, Texas, United States|US Oncology Investigational Product Center (IPC), Irving, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|Texas Oncology - McKinney, McKinney, Texas, United States|Texas Oncology-New Braunfels, New Braunfels, Texas, United States|Texas Oncology - Round Rock, Round Rock, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States|UW Health University Hospital - Pharmaceutical Research Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03499353
TNBC,88,67,1,NCT03504488,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors,,Recruiting,No Results Available,Solid Tumor|Non Small Cell Lung Cancer|Triple Negative Breast Cancer|Soft Tissue Sarcoma,Biological: CAB-ROR2-ADC,Frequency and severity of Treatment-Emergent Adverse Events (Safety and Tolerability of BA3021)|Dose Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Anti-tumor activity|Pharmacokinetics; Cmax|Pharmacokinetics; AUC|Immunogenicity of BA3021,"BioAtla, LLC",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,120,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BA3021-001,06/27/18,05/13/20,05/13/22,04/20/18,null,12-Mar-19,"University of Colorado, Aurora, Colorado, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03504488
TNBC,88,68,1,NCT03221400,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,PEN-866 in Patients With Advanced Solid Malignancies,,Recruiting,No Results Available,Carcinoma|Sarcoma|Rhabdomyosarcoma|Neoplasms|Small Cell Lung Cancer|Triple Negative Breast Cancer|Adenocarcinoma of the Pancreas|Colorectal Carcinoma|Gastric Adenocarcinoma|Advanced Cancer|Solid Tumor|Solid Carcinoma,Drug: PEN-866,Incidence of Dose-Limiting Toxicities (DLTs)|Incidence of treatment related adverse events|Objective response rate (ORR) of tumors using RECIST 1.1 criteria|Maximum concentration of PEN-866 and its metabolites (Cmax)|Area under the curve (AUC) of PEN-866 and its metabolites|Half-life (t1/2) of PEN-866 and its metabolites|Tumor response using RECIST criteria|Radiographic progression free survival|Overall survival,Tarveda Therapeutics,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,150,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PEN-866-001,08/29/17,12/01/19,06/01/20,07/18/17,null,20-Nov-18,"Sarah Cannon Reasearch Institute at HealthONE, Denver, Colorado, United States|National Institutes of Health / National Cancer Institute, Bethesda, Maryland, United States|Tennessee Oncology, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03221400
TNBC,88,69,1,NCT03576131,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,GEN1029 (HexaBody¬Æ-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors,,Recruiting,No Results Available,Colorectal Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Renal Cell Carcinoma|Gastric Cancer|Pancreatic Cancer|Urothelial Cancer,Biological: GEN1029 (HexaBody¬Æ-DR5/DR5),Dose Limiting Toxicities (DLTs)|Adverse events (AEs),Genmab,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,188,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCT1029-01,05/07/18,12/01/21,03/01/22,07/03/18,null,30-Jan-19,"Yale University, New Haven, Connecticut, United States|UT M.D Anderson Cancer Center, Houston, Texas, United States|Hospital Univeritario Vall d'Hebron, Barcelona, Spain|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom|The Royal Mardsen NHS Foundation Trust, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03576131
TNBC,88,70,1,NCT03917381,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,GEN1046 Safety Trial in Patients With Malignant Solid Tumors,,Not yet recruiting,No Results Available,Solid Tumors|Non-small Cell Lung Cancer|Urothelial Carcinoma|Endometrial Carcinoma|Triple Negative Breast Cancer|Squamous Cell Carcinoma of the Head and Neck|Cervical Cancer,Biological: GEN1046,"Dose limiting toxicity (DLT)|Adverse events|Safety laboratory parameters (hematology, biochemistry, coagulation, endocrines)",Genmab|Biontech AG,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,192,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GCT1046-01,05/01/19,10/01/21,02/01/22,04/17/19,null,17-Apr-19,"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Ramat Gan, Tel HaShomer, Israel|Hospital Universitario Vall dHebron, Barcelona, Spain|Clinica Universidad de Navarra, Pamplona, Spain",,https://ClinicalTrials.gov/show/NCT03917381
TNBC,88,71,1,NCT03692689,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast Only,Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer,,Recruiting,No Results Available,Triple Negative Breast Neoplasms,Biological: SCT200,Objective response rate (ORR)|Adverse events (AEs)|Progress Free Survival ( PFS)|Duration of response (DOR)|Disease control rate (DCR)|Time to Progression (TTP)|Overall survival (OS),Sinocelltech Ltd.,Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",Phase 2,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCT200IITNBC,07/20/18,09/30/19,12/31/19,10/02/18,null,2-Oct-18,"Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China",,https://ClinicalTrials.gov/show/NCT03692689
TNBC,88,72,1,NCT03094169,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,AVID100 in Advanced Epithelial Carcinomas,,Recruiting,No Results Available,"Solid Tumor, Adult|Triple Negative Breast Cancer|Head and Neck Squamous Cell Carcinoma|Non Small Cell Lung Cancer",Drug: AVID100 IV,Phase 1a: Determine safety and tolerability of AVID100|Phase 2a: Evaluation of the preliminary antineoplastic effects of AVID100|PK Profile of Total Antibody,Formation Biologics,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,90,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AVID100-01,02/01/17,09/01/19,06/01/20,03/29/17,null,5-Apr-19,"Yale, New Haven, Connecticut, United States|START Midwest, Grand Rapids, Michigan, United States|The Tisch Cancer Institute-Mt. Sinai, New York, New York, United States|Fox Chase, Philadelphia, Pennsylvania, United States|Texas Oncology Midtown, Austin, Texas, United States|Texas Oncology-Baylor -Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology McAllen, McAllen, Texas, United States|Texas Oncology NE San Antonio, San Antonio, Texas, United States|Texas Oncology Tyler, Tyler, Texas, United States",,https://ClinicalTrials.gov/show/NCT03094169
TNBC,88,73,1,NCT03752723,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast Only,Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899),,Not yet recruiting,No Results Available,Triple Negative Breast Cancer,Drug: GX-I7,"Incidence and nature of DLTs|Incidence, nature and severity of adverse events|Objective response rate (ORR)","Genexine, Inc.|Merck Sharp & Dohme Corp.",Female,"19 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,59,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GX-I7-CA-006,12/01/18,07/01/21,01/01/23,11/26/18,null,26-Nov-18,,,https://ClinicalTrials.gov/show/NCT03752723
TNBC,88,74,1,NCT03634150,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,"Safety and Efficacy of IV Nerofe‚Ñ¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer",,Recruiting,No Results Available,Metastatic Ovarian Cancer|Triple Negative Breast Cancer,"Biological: Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.","The primary safety endpoint will be the Adverse Events (AE) reported during the combined treatment of Nerofe and low Dose doxorubicin , using the CTCAE score.|Assessing Change in tumor size from Baseline to End of study|Assessing Change in Blood markers from Baseline to End of study|Pharmacokinetic Profile|Pharmacodynamics profile",Immune System Key Ltd,Female,"18 Years to 90 Years ¬† (Adult, Older Adult)",Phase 1|Phase 2,24,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ISK-N103,09/06/18,06/01/20,11/01/20,08/16/18,null,19-Oct-18,"Oncologic Institue, Kaplan, Re·∫ñovot, Israel",,https://ClinicalTrials.gov/show/NCT03634150
TNBC,88,75,1,NCT03345485,Ph 2,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,"Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors",,Recruiting,No Results Available,Small-cell Lung Cancer|Soft Tissue Sarcoma|Triple-negative Breast Cancer|Ovarian Cancer|Endometrial Cancer,Drug: Tinostamustine (EDO-S101),Safety: Number of participants with treatment-related adverse events as assessed by CTCAE V4.03|Objective Response Rate (ORR) and SD that persists for at least 4 months in selected solid tumor cohorts|PK: Maximum Plasma Concentration [Cmax]|PK: Time to reach maximum (peak) plasma concentration following drug administration (Tmax)|PK: Area Under the Curve [AUC]|PK: Elimination half-life [t¬Ω]|Response Rate: Progression Free Survival (PFS)|Response Rate: Overall Survival (OS),Mundipharma-EDO GmbH,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,167,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EDO-S101-1002,10/06/17,06/01/20,07/01/20,11/17/17,null,13-Mar-19,"Mayo Clinic Cancer Center, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Georgetown University, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|New York Univesity, New York, New York, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Princess Margaret Cancer Center, Toronto, Ontario, Canada|McGill University, Montr√©al, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03345485
TNBC,88,76,1,NCT03674827,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC,,Recruiting,No Results Available,Non-Small Cell Lung Cancer|Triple-negative Breast Cancer,Biological: PF-06936308,Incidence and grade of treatment-emergent adverse events including DLTs|To evaluate the immune response elicited by VBIR 2 to selected tumor antigens.|To evaluate the antibody response to selected tumor-antigens|Tremelimumab and anti PD-1 (PF-06801591) single dose PK parameter (Cmax)|Tremelimumab and anti PD-1 (PF-06801591) single dose PK parameter (Tmax)|Tremelimumab and anti PD-1 (PF-06801591) single dose PK parameter AUC|Tremelimumab and anti PD-1 (PF-06801591) after multiple doses PK parameter (Ctrough)|the anti drug antibody (ADA) response of tremelimumab and anti PD 1 (PF 06801591) after SC administration with the other components.,Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,97,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C3621001|VBIR-2,11/27/18,11/11/21,11/11/21,09/18/18,null,13-Mar-19,"H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, United States|The University of Kansas Cancer Center (Consenting Only), Westwood, Kansas, United States|Norton Cancer Institute Pharmacy, Louisville, Kentucky, United States|Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States|Norton Hospital, Louisville, Kentucky, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington Medical Center - Translational Research Unit (TRU), Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03674827
TNBC,88,77,1,NCT03538028,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies,,Recruiting,No Results Available,Cervical Cancer|Microsatellite Instability (MSI)-High Endometrial Cancer|Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma (Uveal Melanoma Excluded)|Merkel Cell Carcinoma|Mesothelioma|MSI-high Colorectal Cancer|Non-small Cell Lung Cancer (NSCLC)|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Small Cell Lung Cancer (SCLC)|Renal Cell Carcinoma (RCC)|Triple-negative Breast Cancer|Urothelial Carcinoma|Diffuse Large B-cell Lymphoma,Biological: INCAGN02385,Number of treatment-emergent adverse events (TEAEs)|Cmax of INCAGN02385|Tmax of INCAGN02385|Cmin of INCAGN02385|AUC0-t of INCAGN02385|Objective response rate (ORR) in participants with advanced or metastatic solid tumors|Disease control rate (DCR) in participants with advanced or metastatic solid tumors|Duration of response (DOR) in participants with advanced or metastatic solid tumors|Progression-free survival (PFS) in participants with advanced or metastatic solid tumors|ORR in participants with diffuse large B-cell lymphoma (DLBCL)|DOR in participants with DLBCL|PFS in participants with DLBCL,Incyte Biosciences International S√†rl|Incyte Corporation,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCAGN 2385-101,06/18/18,09/24/20,09/24/20,05/25/18,null,12-Apr-19,"The Angeles Clinic and Research Center, Los Angeles, California, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03538028
TNBC,88,78,1,NCT03386942,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,A Study of MORAb-202 in Participants With Solid Tumors,,Recruiting,No Results Available,Solid Tumors,Drug: MORAb-202,"Part 1: Number of participants with dose-limiting toxicities (DLTs)|Part 1 and Part 2: Number of participants with adverse events (AEs), adverse events of interest (AEIs), and serious adverse events (SAEs)|Number of participants with any clinically significant clinical laboratory test value|Number of participants with any clinically significant vital sign value|Change from Baseline in arterial oxygen saturation|Change from Baseline in body weight|Number of participants with any clinically significant 12-lead electrocardiogram (ECG) value|Change from Baseline in the performance status (PS) score established by the Eastern Cooperative Oncology Group (ECOG)|Change from Baseline in serum anti-drug antibody (ADA) titer|Part 1: Maximum Tolerated Dose (MTD) of MORAb-202|Part 1 and Part 2: Maximum observed serum concentration (Cmax) of MORAb-202|Part 1 and Part 2: Maximum serum concentration of total antibody|Part 1 and Part 2: Plasma concentration of free eribulin|Recommended dose (RD) of MORAb-202 for future studies|Part 1 and Part 2: Best overall response (BOR)|Part 1 and Part 2: Overall response rate (ORR)|Part 1 and Part 2: Disease control rate (DCR)|Part 1 and Part 2: Clinical benefit rate (CBR)|Part 2: Progression-free survival (PFS)|Part 2: Overall Survival (OS)",Eisai Inc.,All,"20 Years and older ¬† (Adult, Older Adult)",Phase 1,55,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MORAb-202-J081-101,11/28/17,09/01/20,09/01/20,12/29/17,null,5-Feb-19,"Eisai Trial Site, Chuo-ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT03386942
TNBC,88,79,1,NCT03654547,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer,,Recruiting,No Results Available,Advanced Solid Tumors|Triple Negative Breast Cancer,Drug: TT-00420,Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT)|Dose Recommended for Dose Expansion (DRDE)|Optimal Biological Dose (OBD)|Number of Participants With Abnormal Laboratory Values|Number of Participants With Adverse Events That Are Related to Treatment|Peak Plasma Concentration (Cmax) of TT-00420|Time at which Cmax was first observed (Tmax) of TT-00420|Half-life (T1/2) of TT-00420|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Overall Survival (OS),"TransThera Biosciences Co., Ltd",All,"18 Years to 75 Years ¬† (Adult, Older Adult)",Phase 1,75,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TT420X2101,01/08/19,03/31/20,09/30/20,08/31/18,null,10-Apr-19,"MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03654547
TNBC,88,80,1,NCT02926690,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast Only,Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer,,Recruiting,No Results Available,Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer,Drug: OTS167PO,MTD,"OncoTherapy Science, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,70,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OTS1070103,05/29/17,12/01/20,12/01/20,10/06/16,null,18-Feb-19,"Norwalk Hospital, Norwalk, Connecticut, United States|Weill Cornell Medicine NewYork-Presbyterian, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02926690
TNBC,88,81,1,NCT03076372,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,A Study Evaluating MM-310 in Patients With Solid Tumors,,Recruiting,No Results Available,Solid Tumors|Urothelial Carcinoma|Gastric Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Ovarian Cancer|Pancreatic Ductal Adenocarcinoma|Prostate Adenocarcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Triple Negative Breast Cancer|Endometrial Carcinoma|Soft Tissue Sarcoma,Drug: MM-310,Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.|Serum levels of analytes that comprise MM-310|Adverse event profile using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Presence of human anti-human antibodies to MM-310|Objective responses based on RECIST v1.1 or other relevant criteria|Disease Control Rate|Progression Free Survival,Merrimack Pharmaceuticals,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,34,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MM-310-01-01-01,02/22/17,06/01/18,12/01/18,03/10/17,null,27-Feb-18,"Honor Health, Scottsdale, Arizona, United States|University California San Francisco, San Francisco, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke University, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03076372
TNBC,88,82,1,NCT03652077,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies,,Recruiting,No Results Available,Cervical Cancer|Gastric Cancer|Stomach Cancer|Gastroesophageal Junction Cancer|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma|Uveal Melanoma|Merkel Cell Carcinoma|Mesothelioma|MSI|Non-small Cell Lung Cancer|NSCLC|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck|Small Cell Lung Cancer|Renal Cell Carcinoma|RCC|Triple-negative Breast Cancer|Urothelial Carcinoma|Mismatch Repair Deficiency,Drug: INCAGN02390,Number of treatment-emergent adverse events|Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only)|Cmax of INCAGN02390|Tmax of INCAGN02390|Cmin of INCAGN02390|AUC0-t of INCAGN02390|Objective response rate|Duration of response|Disease control rate|Progression-free survival|Level of binding of INCAGN02390 to TIM-3|Immunogenicity of INCAGN02390,Incyte Corporation,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,41,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,INCAGN 2390-101,08/29/18,06/01/19,03/01/20,08/29/18,null,12-Apr-19,"The Angeles Clinical and Research Institute, Los Angeles, California, United States|University of Mississippi, Jackson, Mississippi, United States|Carolina BioOncology, Huntsville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT03652077
TNBC,88,83,1,NCT03621982,Ph 1,18,TNBCOther Mono,Other Mono,2L+,Breast + Other,Study of ADCT-301 in Patients With Selected Advanced Solid Tumors,,Recruiting,No Results Available,Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content|Head and Neck Cancer|Non-small Cell Lung Cancer|Gastric Cancer|Esophageal Cancer|Pancreas Cancer|Bladder Cancer|Renal Cell Carcinoma|Melanoma|Triple-negative Breast Cancer|Ovarian Cancer,Drug: ADCT-301,"Assessment of Dose Limiting Toxicities in Determination of the Maximum Tolerated Dose Dose Limiting toxicities as defined per protocol, as related to ADCT-301|Evaluate the preliminary anti-tumor activity of camidanlumab tesirine|Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine total antibody, PBD-conjugated antibody, and unconjugated warhead SG3199 in serum|Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum|Evaluate the immunogenicityof camidanlumab tesirine",ADC Therapeutics S.A.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,50,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ADCT-301-103,11/09/18,03/01/21,07/01/21,08/09/18,null,11-Dec-18,"Stanford Cancer Center, Palo Alto, California, United States|Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03621982
TNBC,88,84,1,NCT02555657,Ph 3,5,TNBCCPI Mono,CPI Mono,2L+,Breast Only,Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),,"Active, not recruiting",No Results Available,Metastatic Triple Negative Breast Cancer,Biological: pembrolizumab|Drug: capecitabine|Drug: eribulin|Drug: gemcitabine|Drug: vinorelbine,Overall Survival (OS)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Duration of Overall Response (DOR),Merck Sharp & Dohme Corp.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3475-119|2015-001020-27|153082|MK-3475-119|KEYNOTE-119,10/13/15,04/11/19,08/30/20,09/21/15,null,24-Jan-19,,,https://ClinicalTrials.gov/show/NCT02555657
TNBC,88,85,1,NCT03145961,Ph 2,5,TNBCCPI Mono,CPI Mono,2L+,Breast Only,A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients,c-TRAK-TN,Recruiting,No Results Available,Triple Negative Breast Cancer,Drug: Pembrolizumab,"Positive ctDNA detection by 12 months|Positive ctDNA detection by 24 months|Absence of detectable ctDNA or disease recurrence 12 months after commencing pembrolizumab|Time to ctDNA detection|Detection of overt metastatic disease at time of first ctDNA detection in patients allocated to pembrolizumab|Lead time between ctDNA detection and disease recurrence in the pembrolizumab treatment and observation groups|Absence of detectable ctDNA or disease recurrence after 12 months in the observation group|Safety and tolerability of pembrolizumab assessed using NCI CTCAE v4.0, and the proportion of patients reporting dose reductions or delays.|Commencement of treatment in patients randomised to receive pembrolizumab","Institute of Cancer Research, United Kingdom|National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK|Merck Sharp & Dohme Corp.",All,"16 Years and older ¬† (Child, Adult, Older Adult)",Phase 2,200,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",ICR-CTSU/2016/10058|2017-000508-92,12/21/17,06/01/21,12/01/22,05/09/17,null,30-Oct-18,"Royal Marsden Hospital, Chelsea, Chelsea, London, United Kingdom|Royal Marsden Hospital, Sutton, Sutton, Surrey, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Guy's Hospital, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College London Hopitals, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Clatterbridge Cancer Centre, Wirral, United Kingdom",,https://ClinicalTrials.gov/show/NCT03145961
TNBC,88,86,1,NCT03855358,Ph 1,5,TNBCCPI Mono,CPI Mono,2L+,Breast Only,An Phase Ib Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC),,Not yet recruiting,No Results Available,Triple Negative Breast Cancer (TNBC),Drug: TQB2450 Injection and Anlotinib Hydrochioride Capsules,Overall Response Rate(ORR)|Complete Response (CR)|Overall Survival (OS)|Duration of Response (DCR),"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",All,"18 Years to 75 Years ¬† (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TQB2450-Ib-07,03/30/19,06/30/20,12/30/20,02/26/19,null,26-Feb-19,,,https://ClinicalTrials.gov/show/NCT03855358
TNBC,88,87,1,NCT03517488,Ph 1,5,TNBCCPI Mono,CPI Mono,2L+,Breast + Other,A Study of XmAb¬Æ20717 in Subjects With Selected Advanced Solid Tumors,DUET-2,Recruiting,No Results Available,Melanoma|Breast Carcinoma|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Renal Cell Carcinoma|Colorectal Carcinoma|Non-small Cell Lung Carcinoma|Gastric or Gastroesophageal Junction Adenocarcinoma|Endometrial Carcinoma|Mesothelioma|Neuroendocrine Carcinoma|Cervical Cancer|Small Cell Lung Carcinoma|Squamous Cell Carcinoma of the Anus,Biological: XmAb20717,Determine the safety and tolerability profile of XmAb20717,"Xencor, Inc.|ICON plc",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,87,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XmAb20717-01|DUET-2,07/10/18,12/01/20,03/01/21,05/07/18,null,5-Apr-19,"Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|UCLA Hematology-Oncology Clinic (Westwood), Los Angeles, California, United States|University of California San Diego Moores Cancer Center, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|University of Chicago Medicine, Chicago, Illinois, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03517488
TNBC,88,88,1,NCT03752398,Ph 1,5,TNBCCPI Mono,CPI Mono,2L+,Breast + Other,A Study of XmAb¬Æ23104 in Subjects With Selected Advanced Solid Tumors (DUET-3),DUET-3,Not yet recruiting,No Results Available,"Melanoma (Excluding Uveal Melanoma)|Cervical Carcinoma|Pancreatic Carcinoma|Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Cancer|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced Solid Tumors",Biological: XmAb¬Æ23104,Treatment-related adverse events as assessed by CTCAE v4.03,"Xencor, Inc.|ICON plc",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,144,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XmAb23104-01|DUET-3,05/01/19,09/01/24,03/01/25,11/26/18,null,26-Nov-18,"Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03752398
HR+/HER2-,74,89,1,NCT03462251,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Ribociclib and Aromatase Inhibitor or Paclitaxel and Bevacizumab for Metastatic Breast Cancer in First Line,RIBBIT,Recruiting,No Results Available,Breast Cancer|Hormone Receptor Positive Tumor|HER 2 Negative Breast Cancer,Combination Product: Ribociclib and aromatase inhibitor|Combination Product: Paclitaxel +/- bevacizumab,Efficacy in terms of PFS|Overall Survival (OS)|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Time To Response (TTR)|Number of participants with Adverse Events|Time to deterioration of ECOG performance status|Tolerability of treatment|corrected QT interval (QTc) time|Health-related quality of life (QoL)|Side effects of treatment|Time spent on treatment,iOMEDICO AG|Novartis Pharmaceuticals,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,160,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IOM-050371,05/24/18,06/30/24,06/30/25,03/12/18,null,6/5/18,"Gemeinschaftspraxis f√ºr H√§matologie und Onkologie, Ravensburg, Baden-Wuerttemberg, Germany",,https://ClinicalTrials.gov/show/NCT03462251
HR+/HER2-,74,90,1,NCT03820830,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer,POLAR,Not yet recruiting,No Results Available,Breast Cancer Recurrent,Drug: Palbociclib 125mg|Drug: Standard endocrine therapy,Duration of invasive disease free survival of all randomized participants.|Number of participants with treatment related adverse events.|Duration of breast cancer free interval of all randomized participants.|Duration of distant recurrence free interval of all randomized participants.|Duration of overall survival of all randomized participants.,International Breast Cancer Study Group|Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,400,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBCSG 59-19|2018-003553-19|BIG 18-02|WI239003,05/01/19,05/01/24,11/01/26,01/29/19,null,1/29/19,"National Institute of Oncology, Budapest, Hungary|Medical University, Debrecen, Hungary|Cro Irccs, Aviano, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|PO Antonio Perrino Brindisi, Brindisi, Italy|Istituto scientifico Romagnolo per lo studio e la cura, Meldola, Italy|Istituto Europeo di Oncologia, Milan, Italy|AOU Maggiore Della Carita, University of Eastern Piedmont, Novara, Italy|Istituti Clinici Scientifici Maugeri, Pavia, Italy|Ospedale S. Stefano, Prato, Italy|Kantonsspital Baden, Baden, Switzerland|Brustzentrum Basel Bethesda Spital, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Centre du Sein Fribourg, Fribourg, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Brust-Zentrum AG Z√ºrich, Z√ºrich, Switzerland|Universit√§tsSpital Z√ºrich, Z√ºrich, Switzerland",,https://ClinicalTrials.gov/show/NCT03820830
HR+/HER2-,74,91,1,NCT03137368,Ph 3,41,HR+/HER2-Other combo,Other combo,2L+,Breast + Other,A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations ÔºàSTEPÔºâ,STEP,Enrolling by invitation,No Results Available,CYP2D6 Polymorphism,Drug: Exemestane Tablets|Other: ovarian function suppression/ablation|Genetic: CYP2D6*10 gene test|Drug: Tamoxifen,Disease free survival (DFS)|Recurrence rate (local or distant)|Overall survival (OS)|Incidence of Treatment-Emergent Adverse Events,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Pfizer",Female,"Child, Adult, Older Adult",Phase 3,300,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CH-BC-059,08/09/18,10/30/23,10/30/23,05/02/17,null,10/31/18,"CancerIHCAMS, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03137368
HR+/HER2-,74,92,1,NCT03447132,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant,SAFIA,Recruiting,No Results Available,Breast Neoplasm Female,Drug: Fulvestrant 500mg|Drug: Palbociclib 125mg|Drug: Goserelin 3.6 MG|Drug: Placebos,pCR according to Le Chevalier's classification|pCR according to Sataloff's classification|radiological response|Rate of breast conservative surgery|Safety /Tolerability of the combination Fulvestrant + Palbociclib|DFS and OS,"International Cancer Research Group, United Arab Emirates|AstraZeneca|Pfizer|Genomic Health¬Æ, Inc.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,400,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ICRG1201,01/01/18,09/01/23,09/01/23,02/27/18,null,11/9/18,"Center Pierre et Marie Curie, Algiers, Algeria|Cancer Center - Blida, Blida, Algeria|CHU - Oran, Oran, Algeria|University of Alexandria, Alexandria, Egypt|National Cancer Institut (NCI), Cairo, Egypt|King Hussein Cancer Center (KHCC) - Amman, Am√°n, Jordan|Hotel Dieu de France, Beyrouth, Lebanon|Hopital Cheikh Khalifa Ibn Zaid, Casablanca, Morocco|Department of Oncology - Institut National d'Oncologie, Rabat, Morocco|King Abdul Aziz Medical City-National Guard Health Affairs (NGHA), Riyadh, Saudi Arabia|Oncology Center- King Fahad Medical City (KFMC), Riyadh, Saudi Arabia|Oncology Center- King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia|Oncologie Medicale de l'Ariana (SOMA), Tunis, Tunisia|Tawam Hospital, Al Ain, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT03447132
HR+/HER2-,74,93,1,NCT03079011,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection,PADA-1,"Active, not recruiting",No Results Available,Metastatic Breast Cancer,Drug: Palbociclib 125mg|Drug: Aromatase Inhibitors|Drug: Fulvestrant Injectable Product,Co-primary :safety until randomization|Co-primary : efficacy from randomization|Overall Survival|quality of life by quality of life questionnaire (QLQ)-C30|other line of therapy,UNICANCER|Pfizer,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,800,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,UC-0140/1615 - UCBG3-05,03/22/17,04/15/22,04/15/24,03/14/17,null,3/4/19,"Centre Leon Berard, Lyon, France|Institut Curie, Paris, France|Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT03079011
HR+/HER2-,74,94,2,NCT03337724,Ph 3,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer",IPATunity130,Recruiting,No Results Available,Breast Cancer,Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo,Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Duration of Response (DOR)|Clinical Benefit Rate (CBR)|Overall Survival (OS)|Global Health Status (GHS)/Health-Related Quality of Life (HRQoL) Score|Time to Deterioration in Pain|Incidence and Severity of Adverse Events (AEs)|Changes in Vital Signs|Changes in Targeted Laboratory Results|Plasma Concentration of Ipatasertib and Its Metabolite (G-037720),Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2|Phase 3,450,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CO40016|2017-001548-36,01/06/18,12/22/21,12/22/21,11/09/17,null,4/11/19,"UCSD Moores Cancer Center, La Jolla, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Emad Ibrahim, Md, Inc, Redlands, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente - San Francisco (2238 Geary), San Francisco, California, United States|UCSF Comprehensive Cancer Ctr, San Francisco, California, United States|K. Permanente - San Jose, San Jose, California, United States|Kaiser Permanente - San Leandro, San Leandro, California, United States|K. Permanente - Santa Clara, Santa Clara, California, United States|Kaiser Permanente - South San Francisco, South San Francisco, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|K. Permanente - Walnut Creek, Walnut Creek, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Northwestern Center for Clinical Research; Cancer Center, Chicago, Illinois, United States|Rush University Medical Center; Div of Hematology, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mass General/North Shore Cancer, Danvers, Massachusetts, United States|Westchester Medical Center Cancer Institute, Hawthorne, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Mid Ohio Onc Hematology Inc, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|West Clinic, Germantown, Tennessee, United States|Brig Cancer Care, Knoxville, Tennessee, United States|Vanderbilt Breast Center; Vanderbilt Health Pharmacy, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center; Simmons Comprehensive Cancer Center, Simmons Pharmacy, Dallas, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Fundaci√≥n CENIT para la Investigaci√≥n en Neurociencias, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Hosp Provincial D. Centenarios; Oncology Dept, Rosario, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Westmead Hospital; Medical Oncology, Wentworthville, New South Wales, Australia|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Santa Casa de Misericordia de Salvador; Oncologia, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital do C√¢ncer de Londrina, Londrina, PR, Brazil|Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo Andr√©, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Bcca - Cancer Center Southern Interior, Kelowna, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Servicio de Oncolog√≠a Hospital Regional e Concepci√≥n, Concepcion, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Hospital Base de Valdivia; Unidad de Oncolog√≠a M√©dica, Valdivia, Chile|Beijing Hospital, Beijing City, China|Beijing Cancer Hospital, Beijing, China|the First Hospital of Jilin University, Changchun, China|Sun Yat-sen Memorial Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Jiangsu Cancer Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Clinica CIMCA, San Jose, Costa Rica|ICIMED Instituto de Investigaci√≥n en Ciencias M√©dicas, San Jose, Costa Rica|Masaryk≈Øv onkologick√Ω √∫stav; Klinika komplexn√≠ onkologick√© p√©ƒçe, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Institut Sainte Catherine, Avignon, France|CHU Besan√ßon - H√¥pital Jean Minjoz, Besan√ßon Cedex, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Centre Leon Berard; Oncologie Genetique, Lyon, France|ICM; Medecine B3, Montpellier cedex 5, France|Centre Catherine De Sienne, Nantes, France|APHP - Hospital Saint Louis, Paris, France|Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, France|Onkologische Schwerpunktpraxis Kurf√ºrstendamm, Berlin, Germany|Praxis f√ºr Interdisziplin√§re Onkologie und H√§matologie GbR, Freiburg, Germany|Universit√§tsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|Universit√§tsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|Praxis Dr.med. Katja Ziegler-L√∂hr, K√∂ln, Germany|Dres. Andreas K√∂hler und Roswitha Fuchs, Langen, Germany|M√ºhlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik f√ºr Frauenheilkunde und Geburtshilfe, Minden, Germany|Oncologianova GmbH - Gesellschaft f√ºr Innovationen in der Onkologie, Recklinghausen, Germany|Universit√§tsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|Universit√§tsklinikum W√ºrzburg; Frauenklinik, W√ºrzburg, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens, Greece|Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Orszagos Onkologial Intezet; Onkologiai Osztaly X, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Szabolcs-Szatmar-Bereg Megyei; Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Hetenyi Geza County Hospital; Onkologiai Kozpont, Szolnok, Hungary|Zala County Hospital ICU, Zalaegerszeg, Hungary|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unit√† Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|National Hospital Organization Kyushu Cancer Center;Breast Oncology, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Kinki University Hospital, Faculty of Medicine; Surgery, Osaka, Japan|Saitama Cancer Center, Breast Oncology, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|St. Luke's International Hospital, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Showa University Hospital; Breast Surgery, Tokyo, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clinical Hospital; Oncology Department, Bitola, Macedonia, The Former Yugoslav Republic of|PHI University Clinic of Radiotherapy and Oncology; Breast malignancy, Skopje, Macedonia, The Former Yugoslav Republic of|PHI University Clinic of Radiotherapy and Oncology; Malignant diseases of thorax, Skopje, Macedonia, The Former Yugoslav Republic of|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Centro M√©dico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Merida Investigacion Clinica, M√©rida, Yucatan, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Centro Medico Monte Carmelo, Arequipa, Peru|Hospital Daniel Alcides Carrion, Callao, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Cl√≠nica San Gabriel; Unidad de Investigaci√≥n Oncol√≥gica de la Cl√≠nica San Gabriel, Lima, Peru|Hospital Nacional Cayetano Heredia; Ocolog√≠a; Servicio de Hematolog√≠a Oncolog√≠a M√©dica, Lima, Peru|Oncosalud Sac; Oncolog√≠a, Lima, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Cl√≠nica Internacional, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, Peru|Centrum Onkologii, Inst.Im M. Curie-Slodowskiej; Iii Klinika Radioterapii I Chemioterapii, Gliwice, Poland|Klinika Onkologii Klinicznej CO-I Krak√≥w, Krakow, Poland|Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, Poland|Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon, Warszawa, Poland|Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chor√≥b Piersi z Podod. Onko Klinicznej, ≈Å√≥d≈∫, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Nizhny Novgorod Regional Clinical Oncology Center, Nizhny Novgorod, Niznij Novgorod, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|SBIH Kaluga Region Clinical Oncology Dispensary, Kaluga, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moscow, Russian Federation|Federal State Institution, Moscow Research Oncology Institute n.a. P.A. Hertzen; Oncourology, Moscow, Russian Federation|FSI Rostov research oncological institute of MoH and SD of RF; PAD, Rostov-on-Don, Russian Federation|SBI for HPE ""Ryazan State Medical University n.a. I.P. Pavlov"" of MoH of RF, Ryazan, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Univerzitetni kliniƒçni center Maribor; Oddelek za onkologijo, Maribor, Slovenia|The Oncology Center, Durban, South Africa|Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Hospital Universitario Reina Sofia; Servicio de Oncologia, C√≥rdoba, Cordoba, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coru√±a, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinic Barcelona; Servicio de oncologia, Barcelona, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon, Spain|Hospital de Donostia; Servicio de Oncologia, Guipuzcoa, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario; Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio de Oncologia Medica, Zaragoza, Spain|Changhua Christian Hospital; Dept of Surgery, Changhua, Taiwan|Chi Mei Medical Center Liou Ying Campus, Liuying Township, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey|Ankara Onkoloji Eƒüitim ve Ara≈ütƒ±rma Hastanesi, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Dicle Uni Medical Faculty; Internal Medicine, Diyarbakir, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Okmeydani T and R Hospital; Med Onc, Istanbul, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Oncology, Izmir, Turkey|Sakarya University Medical School; Medical Oncology, Sakarya, Turkey|Municipal Institution Odesa Regional Oncology Dispensary, Odesa, KIEV Governorate, Ukraine|CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients, Kiev, Ukraine|National Cancer Institute MOH of Ukraine, Kiev, Ukraine|Treatment and Prevention Institution Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Velindre Cancer Centre, Cardiff, United Kingdom|University Hospital coventry; Oncology Department, Coventry, United Kingdom|The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit, Glasgow, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Stoke University Hospital, Stoke on Trent, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03337724
HR+/HER2-,74,95,1,NCT03439046,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole,BioItaLEE,Recruiting,No Results Available,Breast Cancer,Drug: Ribociclib|Drug: Letrozole,Change from baseline ctDNA alterations to progression disease|Change from baseline serum TK1 concentrations to progression disease|The percentage of patients with ctDNA alterations will be provided over time in the subsets|Change from baseline tumor mutational burden (TMB) to progression disease|The percentage of patients with mutations as assessed at baseline across different patient profiles|The percentage of patients with alterations detected through liquid biopsy vs. tissue biopsy|Change from baseline tumor microenvironment parameters to progression disease|Time-to-Progression (TTP)|The number of patients with adverse events as a measure of safety and tolerability|The percentage of patients with best overall response rate CR or PR|The percentage of patients with clinical benefit|The percentage of participants with adverse events as a measure of safety and tolerability,Novartis Pharmaceuticals|Novartis,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,350,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011AIT01,02/02/18,10/31/21,10/31/21,02/20/18,null,8/31/18,"Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Nuoro, NU, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Fano, PU, Italy|Novartis Investigative Site, Faenza, RA, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Salerno, SA, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Negrar, VR, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Perugia, Italy",,https://ClinicalTrials.gov/show/NCT03439046
HR+/HER2-,74,96,1,NCT03155997,Ph 3,41,HR+/HER2-Other combo,Other combo,Neo-adj,Breast Only,Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer,monarchE,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Abemaciclib|Drug: Standard Adjuvant Endocrine Therapy,"Invasive Disease Free Survival (IDFS)|IDFS for Participants with Ki-67 Index ‚â•20%|Distant Relapse-Free Survival (DRFS)|Overall Survival (OS)|Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib|Change from Baseline on the Functional Assessment of Cancer Therapy - Breast (FACT-B)|Change from Baseline on the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)|Change from Baseline on the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)|Change from Baseline on the EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L)",Eli Lilly and Company|NSABP Foundation Inc,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,4580,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16338|I3Y-MC-JPCF|2016-004362-26|NSABP B-58,07/12/17,04/12/21,06/10/27,05/16/17,null,5/3/19,,,
HR+/HER2-,74,97,1,NCT03538171,Ph 3,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer",,Recruiting,No Results Available,Advanced Breast Cancer,Drug: Entinostat|Drug: Placebo|Drug: Exemestane,PFS (The Randomized Double-blinded Part)|OS (both the Open-label and Randomized Double-blinded parts)|Safety and tolerability (both the Open-label and Randomized Double-blinded parts)|ORR (both the Open-label and Randomized Double-blinded parts)|Pharmacokinetics (The Randomized Double-blinded Part)|CBR (both the Open-label and Randomized Double-blinded parts),"EddingPharm Oncology Co., LTD.|Syndax Pharmaceuticals, Inc.",Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",Phase 3,327,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EOC103A3101,05/15/18,02/01/21,08/01/21,05/28/18,null,5/7/19,"Cancer Hospital Chinese Academy Medical Sciences, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03538171
HR+/HER2-,74,98,1,NCT03326674,Ph 3,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC",CONTESSA,Recruiting,No Results Available,Breast Cancer,Drug: Tesetaxel and Capecitabine|Drug: Capecitabine,PFS|OS|ORR|DCR|CNS ORR in patients with CNS metastases at baseline|CNS PFS in patients with CNS metastases at baseline or a history of CNS metastases in the intent-to-treat (ITT) population|CNS OS in patients with CNS metastases at baseline or a history of CNS metastases,"Odonate Therapeutics, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ODO-TE-B301,12/21/17,09/01/20,03/01/23,10/31/17,null,3/28/19,"Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States|Arizona Oncology Associates, P.C. - HOPE, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Carti Cancer Center, Little Rock, Arkansas, United States|Pacific Cancer Medical Center, Anaheim, California, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Compassionate Care Research Group, Fountain Valley, California, United States|California Cancer Associates for Research and Excellence, Fresno, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|UCLA Medical Center, Los Angeles, California, United States|Cancer Care - Torrance Memorial Physician Network, Redondo Beach, California, United States|Sharp Memorial Hospital, San Diego, California, United States|University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|San Luis Obispo Oncology & Hematology Health Center, San Luis Obispo, California, United States|California Cancer Associates for Research and Excellence, San Marcos, California, United States|Cancer Research Collaboration and Breast Link, Santa Ana, California, United States|Stanford Cancer Center / Cancer Clinical Trials, Stanford, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Lakewood, Colorado, United States|Western Connecticut Health Network, Danbury, Connecticut, United States|Hartford Healthcare, Hartford, Connecticut, United States|Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|Orlando Health, Orlando, Florida, United States|University of Miami Sylvester Comprehensive Cancer Center / Sylvester at Plantation, Plantation, Florida, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Florida Cancer Specialists and Research Institute - Panhandle Region, Tallahassee, Florida, United States|Florida Cancer Specialists and Research Institute, West Palm Beach, Florida, United States|University Cancer and Blood Center, Athens, Georgia, United States|Cancer Treatment Centers of America, Newnan, Georgia, United States|University of Chicago Medical Center - Duchossois Center for Advanced Medicine (DCAM), Chicago, Illinois, United States|Orchard Healthcare Research, Skokie, Illinois, United States|American Health Network, Indianapolis, Indiana, United States|Baptist Health Lexington, Lexington, Kentucky, United States|SMHC Cancer Care and Blood Disorders, Biddeford, Maine, United States|University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|GBMC Cancer Center, Baltimore, Maryland, United States|Chevy Chase Health Care Center/ RCCA, Chevy Chase, Maryland, United States|James M. Stockman Cancer Institute, Frederick, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Virginia Piper Cancer Institute, Allina Health, Minneapolis, Minnesota, United States|Forrest General Cancer Center/Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Mercy Cancer Center, Joplin, Missouri, United States|HCA Midwest Health, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital St. Louis, David C. Pratt Cancer Center, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Oncology Hematology West, P.C. dba Nebraska Cancer Specialists, Papillion, Nebraska, United States|New Jersey Hematology Oncology Associates, Brick, New Jersey, United States|Regional Cancer Care Associates, East Brunswick, New Jersey, United States|Valley-Mount Sinai Comprehensive Cancer Care, Paramus, New Jersey, United States|Regional Cancer Care Associates, LLC-Sparta, Sparta, New Jersey, United States|New Mexico Cancer Care Alliance - Southwest Gynecology Oncology, Albuquerque, New Mexico, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York Cancer and Blood Specialists, East Setauket, New York, United States|Hematology Oncology Associates of Central New York, P.C., East Syracuse, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Stephanie Spielman Comprehensive Breast Center, Columbus, Ohio, United States|Mercy Clinic Oncology and Hematology, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Cancer Treatment Centers of America - Philadelphia, Philadelphia, Pennsylvania, United States|Magee-Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States|West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Memorial City, Houston, Texas, United States|Westside Surgical Hospital and Breast Center, Houston, Texas, United States|Oncology Consultants, Houston, Texas, United States|Hope Cancer Center of East Texas, Tyler, Texas, United States|Bon Secours St. Francis, Midlothian, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Overlake Medical Center, Bellevue, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Swedish Cancer Center, Seattle, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Border Medical Oncology, Albury, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Mater Cancer Care Centre, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Breast Cancer Research Centre, Nedlands, Western Australia, Australia|St. John of God Subiaco Hospital, Perth, Western Australia, Australia|Flinders Medical Centre, Bedford Park, Australia|Universit√§tsklinik Onkologie Landeskkrankenhaus, Salzburg, Austria|Facharzt f√ºr Frauenheilkunde und Geburtshilfe Spezialist f√ºr Brustchirurgie und Brustkrebs, Schwaz, Austria|AKH-Frauenheilkunde, Vienna, Austria|Ludwig Boltzmann Institut fur Klinische Onkologie und Photodynamische Therapie, Wien, Austria|AZ Klina AUGUSTIJNSLEI, Antwerp, Belgium|Institut Jules Bordet, Brussels, Belgium|UZA, Edegem, Belgium|UZ Leuven, Leuven, Belgium|CHC-Sant Joseph Oncology-Hematology, Li√®ge, Belgium|The Moncton Hospital, Moncton, New Brunswick, Canada|QEII Health Sciences Centre - Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Hopital Maisonneuve-Rosemont, Montr√©al, Quebec, Canada|Center Hospitalier de Montreal CHUM McPeak Sirois, Montr√©al, Quebec, Canada|CIUSSS de Centre-Ouest-de-l'√éle-de-Montr√©al Jewish General Hospital, Montr√©al, Quebec, Canada|McGill University Health Center, Montr√©al, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre, Sherbrooke, Quebec, Canada|CHU de Quebec-University Laval, Qu√©bec, Canada|NH Hospital a.s. Nemocnice Ho≈ôovice Onkologie, Ho≈ôovice, Czechia|Onkologicka Klinika FN Olomouc, Olomouc, Czechia|Onkologicka Klinika (Vseobecna Fakultni Nemocnici v Praze ), Praha, Czechia|Onkologicka Klinika (Fakultni Nemocnice v Motole), Praha, Czechia|CHRU J. Minjoz Service Oncologie, Besan√ßon, France|Centre Fran√ßois Baclesse Service the Recherche Clinique, Caen, France|Hospices Civils de Lyon Sud Oncologie Medicale, Pierre-Benite, France|Centre Eug√®ne Marquis, Rennes, France|Institut Curie - Hopital Rene Huguenin, Saint-Cloud, France|Clinique Sainte Anne - Strasbourg Oncologie Liberale, Strasbourg, France|Centre Hospitalier Regional et Universitaire de Tours CHRU, Tours, France|Arzt der Studienzentrale Universit√§tsklinikum Erlangen, Erlangen, Berlin, Germany|St. Elisabeth-Krankenhaus GmbH, K√∂ln, NRW, Germany|InVO - Institut f√ºr Versorgungsforschung, Koblenz, Rhineland-Palatinate, Germany|St. Elisabethgruppe GmbH Marien Hospital Witten Brustzentrum, Witten, Rhineland-Palatinate, Germany|Charit√© Universit√§tsmedizin Berlin-Campus Benjamin Franklin Klinik f√ºr H√§matologie, Onkologie und Tumorimmunologie, Berlin, Germany|Helios Klinikum Berlin-Buch, Berlin, Germany|Mammazentrum HH am Krankenhaus Jerusalem, Hamburg, Germany|UKSH, Campus Kiel Klinik f√ºr Gyn√§kologie und Geburtshilfe, Kiel, Germany|Staedtisches Klinikum Lueneburg gGmbH Brustzentrum und gynaekologisches Krebszentrum der Frauenklinik, Lueneburg, Germany|LMU Klinikum der Universit√§t M√ºnchen Breast Cancer, M√ºnchen, Germany|Technische Universit√§t M√ºnchen Klinikum rechts der Isar Klinik und Poliklinik f√ºr Frauenheilkunde, M√ºnchen, Germany|Military Hospital State Health Center, Budapest, Hungary|Orsz√°gos Onkol√≥giai Int√©zet, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Uzsoki utcai k√≥rh√°z, Budapest, Hungary|Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz, Ny√≠regyh√°za, Hungary|University of P√©cs Department of Oncotherapy, P√©cs, Hungary|Ospedale San Raffaele - Medical Oncology Dept., Milano, Italy|Istituto Europeo di Oncologia (IEO), Milano, Italy|Centro Oncologico Modenese, Modena, Italy|S.C. Oncologia/Az. Osp.Ra. S Maria Terni, Terni, Italy|Dong-A University Hospital, Busan, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|St. Vincents Hospital, Suwon, Korea, Republic of|Szpitale Pomorskie Oddzia≈Ç Onkologii i Radioterapii Powstania, Gdynia, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Oddzial Onkologii z Pododdzialem Chemoioterapii, Olsztyn, Poland|Mrukmed, Rzesz√≥w, Poland|Wilmed, Warsaw, Poland|Klinika Nowotwor√≥w Piersi i Chirurgii Rekonstrukcyjnej Centrum Onkologii-Instytut, Warszawa, Poland|Onko-Dent G.L.Slomian, ≈ªory, Poland|State Oncology Clinical Dispansery, Saint Petersburg, Russian Federation|Federal State Budgetary Institution Research Institute of Oncology named after N.N. Petrov of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation|John Hopkins Singapore International Medical Centre, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|National University Hospital, Singapore, Singapore|Onkologikoa, San Sebasti√°n, Gipuzkoa, Spain|Althaia Hospital Sant Joan de Deu, Barcelona, Manresa, Spain|Hospital Teresa Herrera Materno-Infantil (CHUAC), A Coru√±a, Spain|Hospital Quironsalud Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|HU San Pedro de Alcantara, C√°ceres, Spain|Centro Oncol√≥gico de Galicia, La Coru√±a, Spain|Hospital Universitario Ramon y Cajal Servicio de Oncologia, Madrid, Spain|IOB_Hospital Ruber Internacional, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Virgen de la Victoria, M√°laga, Spain|Hospital Universitario Miguel Servet Paseo Isabel la Catolica 1-3 Edificio de Maternidad, Zaragoza, Spain|Changhua Christian Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan|Chulabhorn Hospital, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Buddhachinaraj Hospital, Phitsanulok, Thailand|Dnipropetrovsk City Multifield Clinical Hospital #4, Dnipro, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"", Kharkiv, Ukraine|Kryviy Rih Onkology Dispensary, Kryvyi Rih, Ukraine|National Cancer Institute, Kyiv, Ukraine|Municipal Institution of Lviv Regional Council - Lviv Oncology Regional Treatment Diagnostic Center, Lviv, Ukraine|Podilskiy Regional Center of Oncology, Vinnytsia, Ukraine|Communal Institution ""Zaporizhzhia Regional Clinical Oncological Dispensary"", Zaporizhzhia, Ukraine|Central City Clinical Hospital, City Oncology Center, √özhgorod, Ukraine|Royal Cornwall Hospital Oncology Trials, Sunrise Centre, Truro, Cornwall, United Kingdom|NWCTC, North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Bodelwyddan, Wales, United Kingdom|Hertford County Hospital, Hertford, United Kingdom|Cancer Centre, Guy's Hospital, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03326674
HR+/HER2-,74,99,1,NCT03927456,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,,Not yet recruiting,No Results Available,Advanced Breast Cancer,Drug: SHR6390|Drug: Placebo|Drug: Fulvestrant,Investigator-assessed PFS|Progression-free Survival (PFS) per RECIST 1.1|OS|ORR|DoR|CBR|AEs and SAEs|Ctrough,"Jiangsu HengRui Medicine Co., Ltd.",Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",Phase 3,288,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SHR6390-III-301,05/15/19,06/01/20,04/01/21,04/25/19,null,4/25/19,,,https://ClinicalTrials.gov/show/NCT03927456
HR+/HER2-,74,100,1,NCT02297438,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4],,"Active, not recruiting",No Results Available,Breast Neoplasms,Drug: Palbociclib|Drug: Letrozole|Drug: Placebo,Progression-Free Survival (PFS)|Overall Survival (OS)|Number of Participants With Objective Response|Duration of Response (DR)|Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Week X|FACT-B|Expression/alteration/change of tumor tissue biomarkers|Probability of Participant Survival,Pfizer,Female,"18 Years to 70 Years ¬† (Adult, Older Adult)",Phase 3,339,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A5481027,03/23/15,11/30/19,12/02/22,11/21/14,null,2/6/19,"The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department, Bengbu, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Fujian Medical University Union Hospital/Medical Oncology Department, Fuzhou, Fujian, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center,Sun Yat-Sen University, Guangzhou, Guangdong, China|Guangdong General Hospital/Department of Breast Surgery, Guangzhou, Guangdong, China|Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Harbin Medical University Cancer Hospital/Oncology Department, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Hunan Provincial Tumor Hospital/Breast Internal Medicine Department, Changsha, Hunan, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|The first hospital of jilin university, Changchun, Jilin, China|The First Hospital of China Medical University/Oncology Department, Shenyang, Liaoning, China|Liaoning Province Cancer Hospital, Shenyang, Liaoning, China|Oncology Department, the Second Affiliated Hospital of Third Military Medical University, PLA, Chongqing City, P.R. China, China|Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|West China Hospital, Sichuan University/ Oncology Department, Chengdu, Sichuan, China|Tianjin Cancer Hospital/Breast cancer department, Tianjin, Tianjin, China|The Tumor Hospital of Yunnan Province, Kunming, Yunnan, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|307 Hospital of PLA, Beijing, China|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital/Department of Oncology, Beijing, China|Chinese PLA General Hospital/Oncology, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Department of Clinical Oncology Block R, Hong Kong, Hong Kong|Department of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong Kong|Queen Mary Hospital, HongKong, Hong Kong|Raffles Cancer Centre, Singapore, Singapore|Parkway Cancer Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital / Internal Medicine, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Taipei Medical University Hospital/ Department of Surgery, Taipei, Taiwan|Taipei Veterans General Hospital/Surgery Department, Taipei, Taiwan|Koo Foundation, Sun Yat-Sen Cancer Center, Taipei, Taiwan|Taipei Municipal Wanfang Hospital (Managed by Taipei Medical University ), Taipei, Taiwan|Chula Clinical Research Center (Chula CRC), Patumwan, Bangkok, Thailand|Division of Therapeutic Radiology and Oncology, Department of Radiology, Muang, Chiang MAI, Thailand|Department of Medicine, Faculty of Medicine, Naresuan University, Muang, Phitsanulok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Oncology Unit, Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, Thailand|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Division of Medical Oncology, Department of Medicine,, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT02297438
HR+/HER2-,74,101,1,NCT02941926,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Ribociclib|Drug: Letrozole|Drug: Goserelin|Drug: Leuprolide,The number of participants with adverse events as a measure of safety and tolerability|Time-to-Progression (TTP)|Overall response rate (ORR) for patients with measurable disease|Clinical Benefit Rate (CBR)|Patient Reported Outcome (PRO) using scores from FACT-B questionaire,Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,3253,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011A2404,11/29/16,09/05/19,05/21/21,10/21/16,null,4/8/19,"Alaska Cancer Research & Education Center, Anchorage, Alaska, United States|Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Arizona Oncology Associates, Phoenix, Arizona, United States|Arizona Oncology Associates Arizona Oncology Assoc. (2), Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Pacific Shores Medical Group SC, Long Beach, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|University of California Irvine UC Irvine (11), Orange, California, United States|Ventura County Hematology and Oncology, Oxnard, California, United States|PCR Oncology, Pismo Beach, California, United States|California Pacific Medical Center Onc Dept, San Francisco, California, United States|Centura Health Research Center Centura Health Research Center, Denver, Colorado, United States|Poudre Valley Hospital Poudre Valley Health System, Fort Collins, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States|Watson Clinic Center for Research 1730 Location, Lakeland, Florida, United States|Mid Florida Hematology and Oncology Center, Orange City, Florida, United States|Summit Cancer Care Summit Cancer Care (SC), Savannah, Georgia, United States|John D Archbold Memorial Hospital John D. Archbold Mem Hosp (4), Thomasville, Georgia, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Stroger Cook County Hospital Division of Hematology & Onc, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates Presence Cancer Center, Joliet, Illinois, United States|Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3), Normal, Illinois, United States|Alpha Med Physician Group, LLC, Tinley Park, Illinois, United States|Indiana University Health Goshen Center for Cancer SC, Goshen, Indiana, United States|Northwest Oncology, Munster, Indiana, United States|June E. Nylan Cancer Center, Sioux City, Iowa, United States|University of Kansas Cancer Center University of Kansas Med Ctr 9, Kansas City, Kansas, United States|Sarah Cannon at Overland Park Regional Medical Center, Overland Park, Kansas, United States|John Ochsner Heart and Vascular Institute Clinical Trials, New Orleans, Louisiana, United States|Mercy Oncology / Hematology Center SC, Portand, Maine, United States|Greater Baltimore Medical Center Cancer Center Greater Baltimore Medical Ctr, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A. Columbia, Rockville, Maryland, United States|Kaiser Permanente, Rockville, Maryland, United States|Medical Faculty Assc Inc Medical Faculty Assc., Inc. (2, Washington DC, Maryland, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Las Vegas, Nevada, United States|Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|The Valley Hospital / Luckow Pavillion, Paramus, New Jersey, United States|Somerset Hematology Oncology Associates Somerset Hematolgy Onc -MI, Somerset, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|Oncology Speciialists of Charlotte, Charlotte, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|The Christ Hospital Cancer Center Research Program Linder Research Center, Cincinnati, Ohio, United States|University Hospitals of Cleveland Seidman Cancer Center Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cleveland Clinic (5), Cleveland, Ohio, United States|Dayton Physicians, Kettering, Ohio, United States|Oklahoma Cancer Specialists and Research Institute SC-2, Tulsa, Oklahoma, United States|Oregon Health and Science University SC-5, Portland, Oregon, United States|McLeod Center for Cancer Treatment and Research, Florence, South Carolina, United States|Carolina Blood and Cancer Care of South Carolina, Rock Hill, South Carolina, United States|Oncology Consultants Oncology Consultants, Houston, Texas, United States|Millennium Oncology Millennium Oncology - FL, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Cancer Therapy & Research Center UT Health Science Center, San Antonio, Texas, United States|Hope Cancer Center of East Texas, Tyler, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|PeaceHealth St Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Medical Centre of Everett, Everett, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Valley Medical Center Research Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center-Oncology SC, Seattle, Washington, United States|Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, United States|Columbia St Mary s Hospital of Milwaukee St. Mary's Hospital Ozaukee, Milwaukee, Wisconsin, United States|Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3), Cheyenne, Wyoming, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel De Tucuman, Tucuman, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Sint Niklaas, Vlaams Brabant, Belgium|Novartis Investigative Site, Antwerp, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Luxembourg, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Sofia, Sofia-Grad, Bulgaria|Novartis Investigative Site, Gabrovo, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Kingston, Ontario, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, North York, Ontario, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Sault Ste Marie, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Laval, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Prague 8, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Ceske Budejovice, Czechia|Novartis Investigative Site, Pardubice, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha 4, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Oulu, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Dijon Cedex, Cote D Or, France|Novartis Investigative Site, Limoges cedex, Haute Vienne, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Tours Cedex 9, Indre Et Loire, France|Novartis Investigative Site, Reims Cedex, Marne, France|Novartis Investigative Site, Albi, France|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Bobigny Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Colmar Cedex, France|Novartis Investigative Site, Corbeil Essonnes, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Le Mans Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Mont de Marsan cedex, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Nantes Cedex, France|Novartis Investigative Site, Neuilly sur Seine, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Plerin Sur Mer, France|Novartis Investigative Site, P√©rigueux C√©dex, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulon La Seyne Sur Mer, France|Novartis Investigative Site, Troyes, France|Novartis Investigative Site, Vandoeuvre-les-Nancy cedex, France|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Tamil Nadu, Chennai, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Admedabad, Gujarat, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Alessandria, AL, Italy|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, L'Aquila, AQ, Italy|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Asti, AT, Italy|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Treviglio, BG, Italy|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Monserrato, CA, Italy|Novartis Investigative Site, Cuneo, CN, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Grosseto, GR, Italy|Novartis Investigative Site, Lecco, LC, Italy|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Lucca, LU, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Taormina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Nuoro, NU, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Fano, PU, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Salerno, SA, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Savona, SV, Italy|Novartis Investigative Site, Trento, TN, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Saronno, Va, Italy|Novartis Investigative Site, Mirano, VE, Italy|Novartis Investigative Site, Negrar, VR, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Viterbo, VT, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Tanjong Bungah, Penang, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Putrajaya, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Selangor, Malaysia|Novartis Investigative Site, Monterrey, Nuevo Le√≥n, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Venray, CE, Netherlands|Novartis Investigative Site, Apeldoorn, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Beverwijk, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Bosch, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Goes, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Hilversum, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Roermond, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Zutphen, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Gralum, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, Taguig City, Metro Manila, Philippines|Novartis Investigative Site, Las Pinas, Philippines|Novartis Investigative Site, San Juan City, Philippines|Novartis Investigative Site, Zory, Slaskie, Poland|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Bytom, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Guimaraes, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Leningrad Region, Russia, Russian Federation|Novartis Investigative Site, Kazan, Tatarstan Republic, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Kaluga, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Moscow Rerion,Balashiha, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Rostov-na-Donu, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Dammam, Saudi Arabia|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Makkah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Banska Bystrica, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Maribor, Slovenia|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Huelva, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Jaen, Andaluc√≠a, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Jerez, Cadiz, Spain|Novartis Investigative Site, Toledo, Castilla La Mancha, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Lleida, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Girona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalu√±a, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Las Palmas De Gran Canarias, Las Palmas De Gran Canaria, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Vigo, Pontevedra, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Reus, Tarragona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Burgos, Spain|Novartis Investigative Site, Granollers, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Gothenburg, Sweden|Novartis Investigative Site, Orebro, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Peterborough, Cambridgeshire, United Kingdom|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Maidstone, Kent, United Kingdom|Novartis Investigative Site, Blackburn, Lancashire, United Kingdom|Novartis Investigative Site, York, North Yorkshire, United Kingdom|Novartis Investigative Site, Aberdeen, Scotland, United Kingdom|Novartis Investigative Site, Ipswich, Suffolk, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, East Sussex, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom|Novartis Investigative Site, Preston, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Stoke-on-Trent, United Kingdom",,https://ClinicalTrials.gov/show/NCT02941926
HR+/HER2-,74,102,1,NCT02600923,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate,,"Active, not recruiting",No Results Available,Advanced Breast Cancer Female,Drug: Palbociclib|Drug: Letrozole,Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment|Objective Response (OR),Pfizer,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,131,Industry,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A5481053,04/15/16,05/31/19,05/31/19,11/09/15,null,3/26/19,"Instituto de Oncologia de Rosario, Rosario, Santa FE, Argentina|Sanatorio Guemes, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Hospital Britanico de Buenos Aires, Caba, Argentina|Instituto Medico Especializado Alexander Fleming, Caba, Argentina|Instituto de Cardiologia y Cirugia Cardiovascular, Santa Fe, Argentina|ISIS Centro Especializado, Santa Fe, Argentina|Hospital Da Cidade De Passo Fundo, Passo Fundo, RIO Grande DO SUL, Brazil|Hospital Sao Lucas da PUCRS / Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RIO Grande DO SUL, Brazil|Oncologia Rede D'Or S.A., Rio de Janeiro, Brazil|IDOR - Instituto D'Or em Pesquisa e Ensino, Rio de Janeiro, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Sao Paulo, Brazil|Cl√≠nica de Pesquisa e Centro de Estudos em Oncologia Ginecol√≥gica e Mam√°ria Ltda, S√£o Paulo, Brazil|Instituto de Cancerologia S.A., Medellin, Antioquia, Colombia|Oncomedica S.A., Monteria, Cordoba, Colombia|Administradora Country, Bogota, Distrito Capital, Colombia|Oncology Center, Bogota, Distrito Capital, Colombia|Imagenes Diagnosticas, Pereira, Risaralda, Colombia|ONCOLOGOS DEL OCCIDENTE S.A.S Sede Pereira Clinica de Alta Tecnologia Maraya, Pereira, Risaralda, Colombia|Fucam A.C., Coyoacan, D.f., Mexico|Instituto Nacional de Cancerologia, Tlalpan, D.f., Mexico|Hospital Maria Auxiliadora, Guadalajara, Jalisco, Mexico|Clinica de Especialidades Medicas Intepro, ONCE Oncologia Especializada, Zapopan, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico",,https://ClinicalTrials.gov/show/NCT02600923
HR+/HER2-,74,103,1,NCT02763566,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer,MONARCH plus,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Abemaciclib|Drug: Anastrozole|Drug: Letrozole|Drug: Placebo|Drug: Fulvestrant,"Progression Free Survival (PFS)|Overall Survival (OS)|Proportion of Participants with Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]|Duration of Response (DoR)|Proportion of Participants who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]|Proportion of Participants with Best Overall Response of CR, PR, or SD with Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]|Change from Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)|Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, its Metabolites, NSAI, and Fulvestrant",Eli Lilly and Company,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,463,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15530|I3Y-CR-JPBQ,12/05/16,03/29/19,11/27/19,05/05/16,null,4/17/19,"Hospital de Caridade Ijui, Ijui, Rio Grande Do Sul, Brazil|Instituto do C√¢ncer - Hospital M√£e de Deus Center/AESC, Porto Alegre, Rio Grande Do Sul, Brazil|Funda√ß√£o PIO XII, Barretos, Sao Paulo, Brazil|Hospital de Base Fac de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, Sao Paulo, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, Brazil|Clin. Pesq.e Centro Estudos Oncologia Ginecol√≥gica e Mam√°ria, S√£o Paulo, Brazil|Afflilated Hospital of Bengbu Medical College, Bengbu, Anhui, China|The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China|Fujian Provincial Cancer hospital, Fuzhou, Fujian, China|Fujian Province Hospital, Fuzhou, Fujian, China|Affiliated Cancer Hospital of Guangxi Medical University, Nan Ning, Guang XI, China|Guangdong Province People's Hospital, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Harbin Medical University Caner Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Wu Han Tongji Hospital, Wuhan City, Hubei, China|Wuhan Union (Xiehe) Hospital, Wuhan, Hubei, China|Hu Bei Cancer Hospital, Wuhan, Hubei, China|Hunan Province Tumor Hospital, Changsha, Hunan, China|Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China|Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China|Jiangsu Province Cancer Hospital, Nanjing, Jiangsu, China|Dalian Med. Univ. No 2 Affiliate Hospital, Dalian, Liao Ning, China|Liaoning Cander Hospital&Institute, Shenyang, Liaoning, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The First Affiliated Hospital with Nanjing Medical Universit, Nanjing, Nanjing, China|First Affiliated Hospital of Medical College, Xi'an Jiaotong, Xi'an, Shaanxi, China|Zhejiang Cancer Hospital, Hang Zhou, Zhejiang, China|Second Affiliate Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China|Beijing Tumor Hospital, Beijing, China|Shanghai Tumor Hospital, Shanghai, China|Shanghai First People's Hospital, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China|Dr. B. L. Kapur Memorial Hospital, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute (GCRI), Ahmedabad, Gujarat, India|M S Ramaiah Medical College Hospital, Bangalore, Karnataka, India|Healthcare Global Enterprises Limited (HCG), Bangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Christian Medical College and Hospital, Vellore, Tamil Nadu, India|Medica Superspecialty Hospital, Kolkata, West Bengal, India|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Eastleigh Breast Care Center, Pretoria, Gauteng, South Africa|Sandton Oncology Centre, Johannesburg, South Africa",,https://ClinicalTrials.gov/show/NCT02763566
HR+/HER2-,74,104,1,NCT03176238,Ph 3,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",EVEREXES,"Active, not recruiting",No Results Available,Post Menopausal Breast Cancer,Drug: everolimus|Drug: exemestane,Incidence of treatment emergent adverse events (Safety and tolerability)|Objective Response Rate|Progression Free Survival rate|Clinical Benefit Rate|Changes from baseline in ECOG performance status,Novartis Pharmaceuticals|Novartis,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,236,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRAD001JIC06,03/29/13,01/07/19,01/07/19,06/05/17,null,1/15/19,"Novartis Investigative Site, Garran, Australian Capital Territory, Australia|Novartis Investigative Site, Caringbah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, St Albans, Victoria, Australia|Novartis Investigative Site, Karamsad, Gujarat, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Cuttack, Orissa, India|Novartis Investigative Site, Bandung, Indonesia|Novartis Investigative Site, Jakarta, Indonesia|Novartis Investigative Site, Jogyakarta, Indonesia|Novartis Investigative Site, Semarang, Indonesia|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Seoul, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho-gu, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Kuala Lumpur, MYS, Malaysia|Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Casablanca, Morocco|Novartis Investigative Site, Rabat, Morocco|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, New Taipei City, TWN, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ariana, Tunisia|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Gaziantep, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kartal, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, Ho Chi Minh, Vietnam",,https://ClinicalTrials.gov/show/NCT03176238
HR+/HER2-,74,105,1,NCT03096847,Ph 3,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer,,"Active, not recruiting",No Results Available,Advanced Metastatic Breast Cancer,Drug: ribociclib|Drug: letrozole|Drug: goserelin,"Clinical Benefit Rate (CBR) in women and men with hormone receptor positiv, HER-2 negative breast cancer treated with ribocilib and letrozole|CBR|Progression free surviival (PFS) for different populations at month 12 and 18 months|Overall Survival (OS)|Overall response rate (ORR)|Patient reported Quality of Life (QoL) via EORTC QLQ-C30|Patient reported Quality of Life (QoL) via EORTC BR-23",Novartis Pharmaceuticals|Novartis,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,504,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011XDE01|2016-002556-24,01/03/10,12/11/18,02/06/20,03/30/17,null,4/16/19,"Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Langen, Hessen, Germany|Novartis Investigative Site, Recklinghausen, North Rhine-westphalia, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Boeblingen, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Dessau-Rosslau, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Fuerstenwalde, Germany|Novartis Investigative Site, Fuerth, Germany|Novartis Investigative Site, Georgsmarienhuette, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Goslar, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Hildesheim, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Kulmbach, Germany|Novartis Investigative Site, Landshut, Germany|Novartis Investigative Site, Leer, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Moenchengladbach, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Neuruppin, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Passau, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Rotenburg, Germany|Novartis Investigative Site, Saarbruecken, Germany|Novartis Investigative Site, Schweinfurt, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Suhl, Germany|Novartis Investigative Site, Torgau, Germany|Novartis Investigative Site, Trier, Germany|Novartis Investigative Site, Troisdorf, Germany|Novartis Investigative Site, T√ºbingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Voelklingen, Germany|Novartis Investigative Site, Weinheim, Germany|Novartis Investigative Site, Wetzlar, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Wuerzburg, Germany",,https://ClinicalTrials.gov/show/NCT03096847
HR+/HER2-,74,106,1,NCT02437318,Ph 3,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,SOLAR-1,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Fulvestrant|Drug: Alpelisib|Drug: Alpelisib placebo,Progression-free survival (PFS) for patients with PIK3CA mutant status|Overall survival (OS) for patients with PI3KCA mutant status|Overall response rate (ORR)|Time to definitive deterioration of Eastern Cooperative Oncology Group (ECOG) performance status|Safety and tolerability of alpelisib in combination with fulvestrant|Time to 10% deterioration in the global health status/Quality of Life (QOL) scale score of the EORTC QLQ-C30|Plasma concentration-time profile of alpelisib given in combinatio with fulvestrant and appropriate pharmacokinetics (PK) parameters|PFS based on radiology assessments and using RECIST 1.1 criteria|Clinical benefit rate (CBR)|Change in the global health status/(QOL) scale score of the EORTC QLQ-C30|Summary statistics of fulvestrant and alpelisib plasma concentrations|PFS for patients with PIK3CA non-mutant status|OS for patients with PIK3CA non-mutant status,Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,572,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CBYL719C2301|2015-000340-42,07/23/15,06/12/18,09/16/20,05/07/15,null,4/29/19,"Ironwood Cancer and Research Centers Chandler 2, Chandler, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|City of Hope National Medical Center, Duarte, California, United States|Compassionate Care Research Group Inc CCCMG, Fountain Valley, California, United States|St. Helena Martin ONeil Cancer Center, Napa Valley SC, Helena, California, United States|Scripps Clinic SC, La Jolla, California, United States|University of California San Diego - Moores Cancer Center Onc Dept., La Jolla, California, United States|University of Calif Irvine Medical Center Uni of California, Irvine, Orange, California, United States|Kaiser Permanente - California Southern, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists - North SC, Saint Petersburg, Florida, United States|Cancer Treatment Centers of Americas, Newnan, Georgia, United States|Rush University Medical Center Rush Uni Medical Center, Chicago, Illinois, United States|North Shore University Health System NorthShore University, Evanston, Illinois, United States|Edward Cancer Center SC, Naperville, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Fort Wayne Medical Oncology/Hematology, Inc. Dept.of Fort Wayne Med Onc/Hem, Fort Wayne, Indiana, United States|St. Francis Health Comprehensive Cancer Center SC, Topeka, Kansas, United States|Hematology and Oncology Clinic SC, Baton Rouge, Louisiana, United States|Mercy Medical Center SC-2, Baltimore, Maryland, United States|Massachusetts General Hospital Updated Regulatory, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Detroit Clinical Research Center, Owosso, Michigan, United States|Metro Health Cancer Center, Wyoming, Michigan, United States|St. Luke's Cancer Institute SC, Kansas City, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Rutgers Cancer Institute of New Jersey SC-2, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Oncology & Hematology Care,Inc SC, Cincinnati, Ohio, United States|University Hospitals of Cleveland Seidman Cancer Center SC, Cleveland, Ohio, United States|Good Samaritan Regional Medical Center Good Samaritan Reg Med Ctr, Corvallis, Oregon, United States|Andrew & Patel Associates,, Camp Hill, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Charleston Hematology Oncology Association PA, Charleston, South Carolina, United States|Greenville Health System SC-2, Greenville, South Carolina, United States|Avera Cancer SC, Sioux Falls, South Dakota, United States|Tennessee Oncology SC-3, Nashville, Tennessee, United States|Texas Oncology PA Dallas Presbyterian Hospital SC-1, Dallas, Texas, United States|Texas Oncology P A Forth Worth -- 12th Avenue, Dallas, Texas, United States|El Paso, Texas Oncology, El Paso, Texas, United States|Center for Cancer and Blood Disorders SC-2, Fort Worth, Texas, United States|Texas Oncology Houston Memorial City SC, Houston, Texas, United States|Baylor College of Medicine SC, Houston, Texas, United States|Methodist Richardson Cancer Center SC, Richardson, Texas, United States|Cancer Therapy & Research Center UT Health Science Center InstituteForDrugDevelopment(4), San Antonio, Texas, United States|US Oncology P A, Tyler, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Specialists SC, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Vista Oncology Inc. PS, Olympia, Washington, United States|MultiCare Health System Institute for Research & Innovation SC, Tacoma, Washington, United States|Wenatchee Valley Medical Center SC-2, Wenatchee, Washington, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Wahroonga, New South Wales, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Elizabeth Vale, South Australia, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Jette, Brussel, Belgium|Novartis Investigative Site, Sint Niklaas, Vlaams Brabant, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Libramont, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Salvador, Bahia, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Lajeado, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Jose Do Rico Preto, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Vina del Mar, Chile|Novartis Investigative Site, Brno Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, Czech Republic, Czechia|Novartis Investigative Site, Praha 4, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Prague 8, Czechia|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Angers cedex 02, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint-Herblain C√©dex, France|Novartis Investigative Site, Sarcelles, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Recklinghausen, North Rhine-westphalia, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Amberg, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Friedrichshafen, Germany|Novartis Investigative Site, Fulda, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Memmingen, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Vijayawada, Andhra Pradesh, India|Novartis Investigative Site, Indore, Madhya Pradesh, India|Novartis Investigative Site, Nagpur - Maharashtra, Maharashtra, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Chieti, CH, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pontedera, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Rionero in Vulture, PZ, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Savona, SV, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Negrar, VR, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Kagoshima-city, Kagoshima, Japan|Novartis Investigative Site, Isehara, Kanagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Minato ku, Tokyo, Japan|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Monterrey, N.L., Monterrey, Mexico|Novartis Investigative Site, Morelos, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Venray, CE, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Terneuzen, Netherlands|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, Surquillo, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Loures, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Floresti, Cluj, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Jerez, Cadiz, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalu√±a, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Gavle, Sweden|Novartis Investigative Site, Joenkoeping, Sweden|Novartis Investigative Site, Karlstad, Sweden|Novartis Investigative Site, Oerebro, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Al Ain Abu Dhabi, United Arab Emirates|Novartis Investigative Site, Reading, Berkshire, United Kingdom|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02437318
HR+/HER2-,74,107,1,NCT02482753,Ph 3,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer,,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Chidamide|Drug: exemestane|Drug: placebo,"progression-free survival (PFS), double-blinded period|pharmacokinetic profiles of Chidamide, open-label period|pharmacokinetic profiles of exemestane, open-label period|acetylation level of histone H3, open-label period|overall survival, double-blinded period|duration of response (DOR), double-blinded period|objective response rate (ORR), open-label period and double-blinded period|clinical benefit rate (CBR), open-label period and double-blinded period|PFS, open-label period","Chipscreen Biosciences, Ltd.",Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",Phase 3,365,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CDM301,07/01/15,03/01/18,07/01/19,06/26/15,null,1/31/19,"The 307th Hospital of Chinese people's Liberation Army, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT02482753
HR+/HER2-,74,108,1,NCT03822468,Ph 2,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer",PMR,Not yet recruiting,No Results Available,Breast Cancer,Drug: Ribociclib|Drug: Letrozole or Anastrozole|Drug: Goserelin,Overall Response Rate (ORR)|Œî QTcF at Cycle 1 Day 15 (at 2h post-dose) (Key Secondary Endpoint)|Progression-free survival (PFS)|Clinical benefit rate (CBR)|Time to response (TTR)|Duration of response (DOR)|Pharmacokinetics (PK) of ribociclib: Cmax|Pharmacokinetics (PK) of ribociclib: Tmax|Pharmacokinetics (PK) of ribociclib: AUC0 - 24h,Novartis Pharmaceuticals|Novartis,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,350,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011A2207|2018-004234-15,06/03/19,02/02/26,02/02/26,01/30/19,null,4/10/19,,,https://ClinicalTrials.gov/show/NCT03822468
HR+/HER2-,74,109,1,NCT03609047,Ph 2,41,HR+/HER2-Other combo,Other combo,Neo-adj,Breast Only,Adjuvant Palbociclib in Elderly Patients With Breast Cancer,Appalaches,Not yet recruiting,No Results Available,Breast Cancer Stage II|Breast Cancer Stage III,Drug: Palbociclib|Drug: Docetaxel / cyclophosphamide|Drug: doxorubicin/cyclophosphamide|Drug: epirubicin/cyclophosphamide|Drug: paclitaxel,distant recurrence-free interval (D-RFI) rate|Breast cancer specific survival|Overall survival|Incidence of permanent treatment discontinuation,European Organisation for Research and Treatment of Cancer - EORTC|Pfizer,All,70 Years and older ¬† (Older Adult),Phase 2,366,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EORTC 1745-ETF-BCG,05/07/19,05/07/24,05/07/31,08/01/18,null,3/13/19,,,https://ClinicalTrials.gov/show/NCT03609047
HR+/HER2-,74,110,1,NCT03839823,Ph 2,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer,RIGHT Choice,Recruiting,No Results Available,Breast Cancer,Combination Product: Docetaxel / Capecitabine|Combination Product: Capecitabine / Vinorelbine|Combination Product: Paclitaxel / Gemcitabine|Drug: Ribociclib|Drug: Letrozole OR Anastrozole|Drug: Goserelin,"Progression Free Survival|Time to treatment failure|Overall response rate (ORR)|Clinical benefit rate|Time to response|Overall survival|Frequency/severity of adverse events, lab abnormalities.|Change from baseline in the global health status/QOL scale score by using FACT-B questionnaire",Novartis Pharmaceuticals|Novartis,Female,18 Years to 59 Years ¬† (Adult),Phase 2,222,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011A3201C,02/25/19,10/31/22,10/31/22,02/15/19,null,5/10/19,"Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03839823
HR+/HER2-,74,111,1,NCT03584009,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy",,Recruiting,No Results Available,Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer,Drug: Venetoclax|Drug: Fulvestrant,"Clinical benefit defined as Complete Response (CR), Partial Response (PR) or Sudden Death (SD) lasting >= 24 weeks|Progression Free Survival (PFS)|Objective Response (OR)|Duration of Response (DOR)|Overall Survival (OS)|Percentage of participants with adverse events|Plasma concentration of Venetoxclax and fulvestrant|Mean changes from baseline scores in functional disease/treatment-related symptoms and global health status health-related quality of life (GHS/HRQoL) by cycle|Change in baseline pain score as assessed by the pain scale of EORTC QLQ-C30|Baseline BCL-2 protein levels as measured by International Council for Harmonisation (IHC) correlating with clinical response measures",Hoffmann-La Roche,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WO40181|2017-005118-74,09/06/18,03/03/22,03/03/22,07/12/18,null,4/16/19,"Mayo Clinic Hospital, Phoenix, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|UC San Deigo Moores Cancer Center, La Jolla, California, United States|Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States|St. Joseph Health Medical Group - Annadel Medical Group, Santa Rosa, California, United States|Sylvester Comprehensive Cancer Center - Deerfield Beach; Sylvester Cancer Center, Deerfield Beach, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Kaiser Permanente - Moanalua Medical Center, Honolulu, Hawaii, United States|Ashland-Bellefonte Cancer Center, Ashland, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Mass General/North Shore Cancer, Danvers, Massachusetts, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Nebraska Hematology Onco, PC, Lincoln, Nebraska, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Cleveland Clinic, Cleveland, Ohio, United States|Sanford Health System, Sioux Falls, South Dakota, United States|The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Millennium Oncology, Houston, Texas, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research, North Sydney, New South Wales, Australia|Mater Misericordiae Limited, South Brisbane, Queensland, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Southlake Regional Health Center, Newmarket, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|CHUS - H√¥pital Fleurimont, Sherbrooke, Quebec, Canada|Centre L√©on B√©rard, Lyon, France|H√¥pital Saint-Louis, Paris, France|Institut Claudius R√©gaud, Toulouse, France|H√§mato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg, Aschaffenburg, Germany|Universit√§tsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Klinikum Frankfurt H√∂chst GmbH, Frankfurt, Germany|Facharztzentrum Eppendorf, Studien GbR, Hamburg, Germany|Rotkreuzklinikum M√ºnchen; Frauenklinik, Muenchen, Germany|Onkologie Ravensburg, Ravensburg, Germany|Klinikum S√ºdstadt Rostock, Rostock, Germany|Royal United Hospital Bath NHS Trust, Bath, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Barts Health NHS Trust - St Bartholomew's Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03584009
HR+/HER2-,74,112,2,NCT03519178,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast + Other,"A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy",,Recruiting,No Results Available,"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer",Drug: PF-06873600|Drug: Endocrine Therapy 1|Drug: Endocrine Therapy 2,"Number of patients with dose limiting toxicities in the Dose Escalation portion|Safety and Tolerability as assessed by adverse event monitoring for patients enrolled in the Dose Escalation, Dose Finding and Dose Expansion Arms|Safety and Tolerability as assessed through monitoring of hematology and blood chemistry laboratory assessments for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Safety and Tolerability as assessed through vital sign monitoring for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Safety and Tolerability as assessed by heart rate corrected QT interval for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Objective Response Rate (ORR) observed in patients in the Dose Expansion Arms|Safety and Tolerability as assessed through monitoring of coagulation laboratory assessments for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Safety and Tolerability as assessed through monitoring of urinalysis laboratory assessments for patients enrolled in the Dose Escalation, Dose Finding Portion and the Dose Expansion Arms|Single Dose: Maximal concentration (Cmax) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Plasma concentrations with and without food observed in patients enrolled in one of the single agent Dose Expansion Arms|Single Dose: Time to Maximum Plasma Concentration (Tmax) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point Within the Dose Interval (AUClast) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero Extrapolated to Infinity (AUCinf) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Apparent Oral Plasma Clearance (CL/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Apparent Volume of Distribution (Vz/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Single Dose: Terminal Elimination Half-Life (t1/2) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Steady State Maximal Concentration (Css,max) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Time to Maximum Plasma Concentration at Steady State (Tss,max) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,t) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Steady State Minimum Plasma Concentration (Css,min) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Steady State Apparent Oral Plasma Clearance (CLss/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Apparent Volume of Distribution at Steady State (Vss/F) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Terminal Elimination Half-Life (t1/2) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Multiple Dose: Accumulation Ratio (Rac (AUCss,t /AUCsd,t)) in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Tumor Response observed in patients in Dose Escalation and Dose Finding portion|Duration of Response (DOR) in patients enrolled in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Progression Free Survival (PFS) observed in patients in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Time to Progression (TTP) observed in patients enrolled in the Dose Escalation and Dose Finding portion and Dose Expansion Arms|Overall Survival observed in patients enrolled in the Dose Expansion Arms|Pharmacodynamic (PD) biomarkers (pRb and Ki67) in tumor tissue in patients enrolled in the Dose Escalation and Dose Finding portion and Dose Expansion Arms",Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,220,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C3661001,03/07/18,12/11/21,12/11/21,05/08/18,null,5/6/19,"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|UCSF Medical Center, San Francisco, California, United States|University of California -San Francisco, San Francisco, California, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Investigational Pharmacy Services, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03519178
HR+/HER2-,74,113,1,NCT03858972,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC",CONTESSA 2,Recruiting,No Results Available,Breast Cancer,Drug: Tesetaxel|Drug: Capecitabine,ORR|DoR|PFS|DCR|OS|CNS ORR in patients with CNS metastases at baseline|CNS DoR in patients with CNS metastases at baseline|CNS PFS in patients with CNS metastases at baseline or a history of CNS metastases and in the intent-to-treat (ITT) population|CNS OS in patients with CNS metastases at baseline or a history of CNS metastases,"Odonate Therapeutics, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,125,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ODO-TE-B201,02/05/19,03/01/21,03/01/22,03/01/19,null,3/28/19,"New York Cancer and Blood Specialists, East Setauket, New York, United States",,https://ClinicalTrials.gov/show/NCT03858972
HR+/HER2-,74,114,1,NCT03147287,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,Palbociclib After CDK and Endocrine Therapy (PACE),,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Palbociclib|Drug: Fulvestrant|Drug: Avelumab,Progression Free Survival|Overall Response Rate|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability),Dana-Farber Cancer Institute|Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,220,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-101,08/09/17,12/31/20,12/31/24,05/10/17,null,2/7/19,"Northwestern University, Chicago, Illinois, United States|The University of Kansas Cancer Center - North, Kansas City, Kansas, United States|The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber at St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|DF/BWCC at Milford Regional Medical Center, Milford, Massachusetts, United States|Berkshire Hematology Oncology Services, Pittsfield, Massachusetts, United States|DF/BWCC in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States|The University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Dana-Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Baylor University, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03147287
HR+/HER2-,74,115,1,NCT03659136,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,The XENERA‚Ñ¢-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread,,Recruiting,No Results Available,Breast Neoplasms,Drug: Xentuzumab|Drug: Placebo|Drug: Everolimus|Drug: Exemestane,"Progression free survival (PFS) as assessed by central review|Overall survival (OS) defined as the time from randomisation until death from any cause|Disease control (DC)|Duration of DC is defined as the time from randomisation until the earliest of disease progression or death, among patients with DC|Objective response (OR) Defined as a best overall response of complete response (CR) or partial response (PR)|Time to pain progression or intensification of pain palliation",Boehringer Ingelheim,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1280-0022|2017-003131-11,11/28/18,12/14/20,01/12/22,09/06/18,null,5/15/19,"Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Southeastern Regional Medical Center, Newnan, Georgia, United States|Advocate Medical Group Oncology, Niles, Illinois, United States|Cancer Treatment Centers of America, Zion, Illinois, United States|Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|HCA Midwest Division, Kansas City, Missouri, United States|Hematology Oncology Associates of Rockland, Nyack, New York, United States|Oncology Specialists of Charlotte, PA, Charlotte, North Carolina, United States|Southwestern Regional Medical Center, Tulsa, Oklahoma, United States|Cancer Treatment Centers of America at Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Peninsula Haematology & Oncology, Frankston, Victoria, Australia|Brussels - UNIV UZ Brussel, Brussel, Belgium|Brussels - UNIV Saint-Luc, Bruxelles, Belgium|Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|McGill University Health Centre (MUHC), Montreal, Quebec, Canada|CHU de Quebec-Universite Laval Research Centre, Quebec, Canada|CLI Bordeaux Nord Aquitaine, Bordeaux, France|HOP Victor Hugo, Le Mans, France|INS Paoli-Calmettes, Marseille, France|INS Curie, Paris, France|HOP Europ√©en G. Pompidou, Paris, France|HOP Lyon Sud, Pierre Benite, France|Universit√§tsklinikum Erlangen, Erlangen, Germany|Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany|Vincentius-Diakonissen-Kliniken gAG, Karlsruhe, Germany|St. Elisabeth-Krankenhaus, K√∂ln, Germany|Universit√§tsklinikum T√ºbingen, T√ºbingen, Germany|University General Hospital of Heraklion, Heraklion, Greece|University Hospital of Larisa, Oncology Clinic, Larisa, Greece|Metropolitan Hospital, Oncology Clinic, Neo Faliro, Athens, Greece|Euromedica Kyanous Stavros General Hospital, Thessaloniki, Greece|Azienda Ospedaliera Sant'Andrea-Universit√† di Roma La Sapienza, Roma, Italy|Hospital de Braga - Centro Cl√≠nico Acad√©mico (2CA), Braga, Portugal|Hospital Beatriz √Çngelo, Loures, Portugal|USLM, EPE - Hospital Pedro Hispano, Matosinhos, Portugal|H. Santo Ant√≥nio - Centro Hospitalar do Porto, Porto, Portugal|Hospital Teresa Herrera, A Coru√±a, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Cl√≠nic de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Mara√±√≥n, Madrid, Spain|Hospital Ram√≥n y Cajal, Madrid, Spain|Hospital Cl√≠nico San Carlos, Madrid, Spain|Hospital Regional Universitario de M√°laga, M√°laga, Spain|Hospital Cl√≠nico de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT03659136
HR+/HER2-,74,116,1,NCT02964507,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer,,Recruiting,No Results Available,Neoplasms,Drug: GSK525762|Drug: Placebo|Drug: Fulvestrant,"Phase I: Number of subjects with adverse events (AE) and serious adverse events (SAE), for the determination of recommended Phase II dose of GSK525762|Phase I: Number of subjects with dose limiting toxicities (DLT)|Phase I: Number of subjects with dose reductions or delays, for the determination of recommended Phase II dose of GSK525762|Phase I: Overall response rate (ORR)|Phase I: Plasma concentration of GSK525762, for the determination of recommended Phase II dose of GSK525762|Phase I: Plasma concentration of fulvestrant, for the determination of recommended Phase II dose of GSK525762|Phase II: Progression free survival (PFS)|Phase I: Number of subjects with AEs or SAEs, as a measure of safety and tolerability|Phase I: Number of subjects with dose reductions or delays, as a measure of safety and tolerability|Phase I: Number of subjects withdrawn due to toxicity|Phase I: Number of subjects with abnormality in hematology parameters|Phase I: Number of subjects with abnormality in clinical chemistry parameters|Phase I: Number of subjects with abnormality in urinalysis parameters|Phase I: Number of subjects with abnormality in systolic and diastolic blood pressure|Phase I: Number of subjects with abnormality in pulse rate|Phase I: Number of subjects with abnormality in respiratory rate|Phase I: Number of subjects with abnormality in electrocardiogram (ECG)|Phase I: Number of subjects with abnormality in any cardiotoxicity parameters|Phase I: Number of subjects with abnormality in gastrointestinal parameters|Phase I: Disease control rate (DCR)|Phase I: Duration of response|Phase I: PFS|Phase I: Plasma concentration of GSK525762 and its metabolites, as a measure of drug exposure|Phase I: Plasma concentration of fulvestrant, as a measure of drug exposure|Phase II: Overall Survival (OS)|Phase II: ORR|Phase II: DCR|Phase II: Plasma concentration of GSK525762 and its metabolites, as a measure of drug exposure|Phase II: Plasma concentration of fulvestrant, as a measure of drug exposure",GlaxoSmithKline,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,294,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201973,02/02/17,04/23/20,06/01/20,11/16/16,null,10/17/18,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Tamarac, Florida, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, White Plains, New York, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Camperdown, New South Wales, Australia|GSK Investigational Site, Port Macquarie, New South Wales, Australia|GSK Investigational Site, Bedford Park, South Australia, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Bordeaux Cedex, France|GSK Investigational Site, Saint-Herblain cedex, France|GSK Investigational Site, Saint-Herblain, France|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, A Coruna, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Lerida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Northwood, Middlesex, United Kingdom|GSK Investigational Site, Nottingham, Nottinghamshire, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02964507
HR+/HER2-,74,117,1,NCT03056755,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments",BYLieve,Recruiting,No Results Available,Breast Cancer,Drug: alpelisib|Drug: fulvestrant|Drug: letrozole|Drug: Goserelin|Drug: Leuprolide,The percentage of patients who are alive without disease progression|Progression free survival (PFS) for each cohort|Progression free survival (PFS) on next line treatment PFS2) for each cohort|Percentage of participants Overall response rate (ORR) for each cohort|Percentage of participants with clinical benefit rate (CBR) for each cohort|Duration of response (DOR)|Percentable of overall suvivial (OS) for each cohort,Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,336,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CBYL719X2402,08/14/17,04/10/20,09/30/20,02/17/17,null,5/1/19,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic (Arizona), Phoenix, Arizona, United States|Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C, Anaheim, California, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|University of Calif Irvine Medical Center, Orange, California, United States|Kaiser Permanente Southern California, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Cancer Research Collaboration, Inc, Santa Ana, California, United States|Yale University Yale Cancer Center, New Haven, Connecticut, United States|Florida Hospital Cancer Center, Orlando, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Louisville Hospital/James Brown Cancer Ctr. SC, Louisville, Kentucky, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Neuroendocrine Unit, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Josephine Ford Cancer Institute, Detroit, Michigan, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Memorial Sloane Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland Seidman Cancer Center, Cleveland, Ohio, United States|UT Health San Antonio, San Antonio, Texas, United States|Northwest Medical Specialists, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Troisdorf, Germany|Novartis Investigative Site, T√ºbingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Mexico D F, Distrito Federal, Mexico|Novartis Investigative Site, Jalisco, Mexico|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03056755
HR+/HER2-,74,118,1,NCT03078751,Ph 2,41,HR+/HER2-Other combo,Other combo,Neo-adj,Breast Only,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer,EarLEE-1,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Ribociclib|Drug: Adjuvant endocrine therapy,Preliminary safety and tolerability of the ribociclib + ET in patients that were randomized to ribociclib + ET prior to the early closure of enrollment.,Novartis Pharmaceuticals|Novartis,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,52,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CLEE011G2301|2014-001795-53,06/20/17,03/25/20,03/25/20,03/13/17,null,7/25/18,"Alabama Oncology, LLC, Birmingham, Alabama, United States|Oncology Specialties P.C., Huntsville, Alabama, United States|Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Arizona Oncology Associates PC- HAL, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Kaiser Permanente Medical Group Kaiser Hawaii -, Anaheim, California, United States|CBCC Global Research, Bakersfield, California, United States|City of Hope National Medical Center, Duarte, California, United States|Jude Medical Center, Fullerton, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Southern California Oncology Research Alliance (SCORA), Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|Ventura County Hematology and Oncology, Oxnard, California, United States|Tenet Health System Desert Inc, Palm Springs, California, United States|TRIO - Torrance Health Association, Redondo Beach, California, United States|Sutter Institute for Medical Research Suite 410, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California San Francisco Drug Shipment, San Francisco, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Cancer Research Collaboration, Santa Ana, California, United States|Santa Barbara Hematolgy Oncology Medical Group, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation Onc Dept, Santa Maria, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|St Josephs Medical Associates Oncology Dept., Stockton, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Kaiser Permanente - Denver, Denver, Colorado, United States|Rocky Mountain Cancer Centers Regulatory, Denver, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut, United States|Lynn Cancer Institute SC, Boca Raton, Florida, United States|Holy Cross Hospital - Ft. Lauderdale, Fort Lauderdale, Florida, United States|Florida Cancer Specialists (South Region), Fort Myers, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|21st Century Oncology, Jacksonville, Florida, United States|Southern Baptist Hospital of Florida, Inc, Jacksonville, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Florida Cancer Specialists - North Florida Cancer Specialist N, Saint Petersburg, Florida, United States|Florida Cancer Specialists- East Region, West Palm Beach, Florida, United States|Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States|Northside Hospital Central Research Dept., Atlanta, Georgia, United States|Columbus Regional, Columbus, Georgia, United States|Cancer Treatment Centers of Americas, Newnan, Georgia, United States|Summit Cancer Care, PC, Savannah, Georgia, United States|John D. Archbold Memorial Hospital Main, Thomasville, Georgia, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Cancer Treatment Centers of America, Zion, Illinois, United States|Fort Wayne Medical Oncology/Hematology, Inc. Jefferson Blvd, Fort Wayne, Indiana, United States|IU Health Arnett Cancer Center, Lafayette, Indiana, United States|Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Div., Leawood, Kansas, United States|St. Francis Health Comprehensive Cancer Center, Topeka, Kansas, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Saint Joseph Hematology Oncology, Lexington, Kentucky, United States|Oncology Associates of West Kentucky, Paducah, Kentucky, United States|Metairie Oncologists, LLC, Metairie, Louisiana, United States|Maryland Oncology Hematology P A, Silver Spring, Maryland, United States|Mass General Hospital SC, Boston, Massachusetts, United States|Baystate Medical Associates, Springfield, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Freeman Cancer Institute, Joplin, Missouri, United States|Mercy Cancer Center, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Kalispell Regional Med Ctr Suite 2100, Kalispell, Montana, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada (8), Las Vegas, Nevada, United States|Saint Barnabas Medical Center 2nd Floor East Wing, Livingston, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|St. Peter's University Hospital, New Brunswick, New Jersey, United States|Southern Oncology Hematology Association, Vineland, New Jersey, United States|Montefiore Medical Center SC-5, Bronx, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|Pro Health Care Associates, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medicine Breast Center, New York, New York, United States|Columbia University Medical Center Oncology, New York, New York, United States|Nyack Hospital, Nyack, New York, United States|Rochester General Hospital / Lipson Cancer Center, Rochester, New York, United States|The Presbyterian Hospital, Charlotte, North Carolina, United States|Trinity Medical Group, Minot, North Dakota, United States|The Christ Hospital Cancer Center Research Program Linder Research Center, Cincinnati, Ohio, United States|Mid Ohio Oncology/Hematology, Columbus, Ohio, United States|Bend Memorial Clinic Bend Mem. Clinic, Bend, Oregon, United States|Compass Oncology, OR, Portland, Oregon, United States|Kent County Hosptial, Warwick, Rhode Island, United States|UT Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|SCRI - Tennessee Oncology, Nashville, Tennessee, United States|Harrington Cancer Center, Amarillo, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology P A Central Austin CancerCenter(2), Dallas, Texas, United States|Texas Oncology P A Texas Oncology - Houston, Dallas, Texas, United States|UT Southwestern Clinical Trials Office UT Southwestern Medical Center, Dallas, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|The Methodist Hospital Research Institute The Methodist Hospital, Houston, Texas, United States|University of Texas MD Anderson Cancer Center Dep. of Investigational Cancer, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|Cancer Care Network of South Texas, San Antonio, Texas, United States|Texas Oncology PA - Tyler, Tyler, Texas, United States|Northern Utah Cancer Associates Northern Utah Associates, Ogden, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Fairfax Northern Virginia Hem/Onc, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|Providence Regional Medical Center, Everett, Washington, United States|Virginia Mason Medical Center-Oncology, Seattle, Washington, United States|Univeristy of Washington, Seattle, Washington, United States|Multicare Institute for Research and Innovation, Tacoma, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Medical College of Wisconsin, Inc., Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03078751
HR+/HER2-,74,119,1,NCT03312738,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor",BOLERO-5,Recruiting,No Results Available,Advanced Breast Cancer,Drug: Everolimus|Drug: Exemestane|Drug: Everolimus Placebo,Progression-free Survival (PFS)|Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC).|Overall survival|Overall response rate (ORR)|Clinical benefit rate (CBR)|Time to response|Duration of Response DOR|ECOG,Novartis Pharmaceuticals|Novartis,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,160,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRAD001Y2202,09/21/17,12/03/19,09/03/21,10/18/17,null,1/15/19,"Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Chongqing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Qingdao, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Wuhan, China",,https://ClinicalTrials.gov/show/NCT03312738
HR+/HER2-,74,120,1,NCT02983071,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,"G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",,Recruiting,No Results Available,"Carcinoma, Ductal, Breast|Breast Cancer|Breast Neoplasm",Drug: G1T38|Drug: Fulvestrant,"Dose Limiting Toxicity|Recommended Phase 2 dose|Recommended Phase 2 dose interval|Number of Treatment Related Adverse Event, including Abnormal Laboratory Events|Tumor response based on RECIST, Version 1.1|Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Maximum Plasma Concentration (Cmax)|Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Area under Curve - plasma concentration (AUC)|Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Plasma: terminal half life (T1/2)|Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Plasma - Volume of distribution|Progression free survival (PFS)|Overall survival (OS)","G1 Therapeutics, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,102,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G1T38-02|2016-001485-29,01/01/17,12/01/19,12/01/20,12/06/16,null,12/17/18,"MHAT for Womens Health - Nadezhda OOD, Sofia, Bulgaria|Comac Medical, Sofia, Bulgaria|Special Hospital For Active Treatment In Oncology, Sofia, Bulgaria|ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia|The Institute of Oncology, Chisinau, Moldova, Republic of|Cambridge University, Cambridge, United Kingdom|University College London Hospital (UCLH), London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|The Christie NHS Foundation, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02983071
HR+/HER2-,74,121,1,NCT03291886,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer,,"Active, not recruiting",No Results Available,Advanced or Recurrent Breast Cancer,Drug: Entinostat|Drug: Entinostat(Placebo)|Drug: Exemestane,Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)|Overall survival (OS)|Antitumor effect,"Kyowa Hakko Kirin Co., Ltd",Female,"20 Years and older ¬† (Adult, Older Adult)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2375-002,09/22/17,12/01/19,11/01/21,09/25/17,null,2/11/19,"Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan|Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan|Gunma Cancer Center, Ota, Gunma, Japan|Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|The Hospital of Hyogo College of Medicine, Nishinomiya, Hyogo, Japan|Tsukuba University Hospital, Tsukuba, Ibaraki, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Nahanishi Clinic, Naha, Okinawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Bunkyo, Tokyo, Japan|National Cancer Center Hospital, Chuo, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto, Tokyo, Japan|Toranomon Hospital, Minato, Tokyo, Japan|Showa University Hospital, Shinagawa, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu Cancer Center, Fukuoka, Japan|Sagara Hospital, Kagoshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka National Hospital, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT03291886
HR+/HER2-,74,122,1,NCT03671330,Ph 2,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.",,Recruiting,No Results Available,Breast Cancer,Drug: Ribociclib Placebo|Drug: Ribociclib|Drug: NSAI: Letrozole or Anastrazole|Drug: Letrozole|Drug: Goserelin,Progressive free survival (PFS) based on local assessment by RECIST 1.1 guideline|Pharmaconinetic (PK) parameter: Cmax|PK parameter: Tmax|PK parameter: AUC024h|Overall Survival (OS)|Overall response rate (ORR)|Clinical Benefit Rate (CBR)|Time To Response (TTR)|Duration of Response (DoR)|Time to deterioration of ECOG performance status from baseline,Novartis Pharmaceuticals|Novartis,Female,18 Years to 60 Years ¬† (Adult),Phase 2,315,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLEE011A2206,08/29/18,08/30/19,10/17/22,09/14/18,null,4/25/19,"Novartis Investigative Site, Hefei, Anhui, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shijiazhuang, Hebei, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Shengyang, Liaoning, China|Novartis Investigative Site, Xian, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Kunming, Yunnan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Fuzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03671330
HR+/HER2-,74,123,1,NCT03703466,Ph 2,41,HR+/HER2-Other combo,Other combo,1L,Breast Only,A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer,,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Abemaciclib,Percentage of Participants with Severe Diarrhea (‚â• Grade 3)|Percentage of Participants with Prolonged Grade 2 Diarrhea|Percentage of Participants with Dose Reductions Due to Diarrhea|Percentage of Participants with Dose Interruptions Due to Diarrhea|Percentage of Participants who Discontinue Treatment due to Diarrhea|Percentage of Participants Utilizing Antidiarrheals|Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib|PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567|PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726,Eli Lilly and Company,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17041|I3Y-MC-JPCP|2018-001853-28,11/28/18,07/20/19,02/20/21,10/12/18,null,5/3/19,"Mater Private Hospital, North Sydney, New South Wales, Australia|St Vincent's Hospital, Sydney, New South Wales, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|Russian Oncological Research Center, Moscow, Russian Federation|Volgograd regional clinical oncology dispensary, Volgograd, Russian Federation|Hospital Quir√≥n Salud Barcelona-Instituto Oncol√≥gico Baselga, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Akdeniz University Medical Faculty, Antalya, Turkey|Trakya University Faculty of Medicine, Edirne, Turkey|Medical Park Izmir Hospital, Izmir, Turkey|Inonu University Medical Faculty, Malatya, Turkey|Commu Instit ""Krivorizhskiy oncology dispensary"" Dnip reg Co, Kriviy Rig, Ukraine|Central Municipal Clinical Hospital, Uzhhorod, Ukraine|Podilskyi Regional Center of Oncology, Vinnytsia, Ukraine",,https://ClinicalTrials.gov/show/NCT03703466
HR+/HER2-,74,124,1,NCT03481998,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,,Recruiting,No Results Available,Advanced Breast Cancer,Drug: SHR6390|Drug: Letrozole or anastrozole or Fulvestrant,Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1|Area under the plasma concentration versus time curve (AUC) of SHR6390|Peak Plasma Concentration (Cmax) of SHR6390|The time of SHR6390 to reach the maximum concentration (Tmax)|Half-time (t1/2) of SHR6390|Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Progression-free Survival (PFS) per RECIST 1.1|Disease Control Rate (DCR) per RECIST 1.1|Number of Participants With adverse events (AEs) and serious adverse events (SAEs),"Jiangsu HengRui Medicine Co., Ltd.",Female,"18 Years to 75 Years ¬† (Adult, Older Adult)",Phase 1|Phase 2,146,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHR6390-Ib/II-201,03/27/18,06/30/19,06/30/21,03/29/18,null,3/26/19,"Ha'erbin Tumor Hospital, Ha'erbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China",,https://ClinicalTrials.gov/show/NCT03481998
HR+/HER2-,74,125,1,NCT03241810,Ph 2,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer,SHERBOC,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Seribantumab|Drug: Fulvestrant|Drug: Placebo,Progression Free Survival|Overall Survival|Objective Response Rate|Time to Progression|Rate of treatment-emergent adverse events reported with the combinations of seribantumab plus fulvestrant versus fulvestrant alone|Pharmacokinetic (PK) profile of seribantumab when given in combination with fulvestrant and of fulvestrant when given in combination with serbantumab.,Merrimack Pharmaceuticals,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,80,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MM-121-02-02-10|2017-000565-76,08/15/17,04/01/19,09/01/20,08/08/17,null,9/18/18,"Ironwood Cancer and Research Centers- Chandler, Chandler, Arizona, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Stanford University, Palo Alto, California, United States|Saint Helena Hospital, Saint Helena, California, United States|Stamford Hospital, Stamford, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|James M Stockman Cancer Institute, Frederick, Maryland, United States|Holy Cross Hospital Health Center, Silver Spring, Maryland, United States|Lahey Clinical Medical Center, Burlington, Massachusetts, United States|University of Mississippi, Jackson, Mississippi, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|University of Utah Health Care - Huntsman Cancer Institute, Salt Lake City, Utah, United States|LKH - Universit√§tsklinikum Graz, Graz, Austria|Universitaetsklinik fuer Gynaekologie und Geburtshilfe, Innsbruck, Austria|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Medizinische Universit√§t Wien, Vienna, Austria|Medizinische Universit√§t Wien, Wien, Austria|Clinique Saint-Pierre, Ottignies, Brabant Wallon, Belgium|Centre Hospitalier de l'Ardenne - Clinique du Sein, Libramont, Luxembourg, Belgium|Universitaire Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium|Universitair Ziekenhuis Antwerpen, Antwerp, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|CHU UCL NAMUR - Sainte Elisabeth, Namur, Belgium|University of Calgary, Calgary, Alberta, Canada|British Columbia Cancer Agency, Kelowna, British Columbia, Canada|McGill University - Jewish General Hospital, Montreal, Canada|Centre Hospitalier Affilie Universitaire de Quebec, Quebec, Canada|Universit√§tsklinikum Erlangen, Erlangen, Bayern, Germany|Medizinisches Zentrum Bonn Friedensplatz, Bonn, Germany|Centrum fuer Haematologie und Onkologie Bethanien, Frankfurt, Germany|Gyn√§kologisch-Onkologische Praxis Hannover, Hannover, Germany|Rotkreuzklinikum M√ºnchen-Frauenklinik, Munich, Germany|Klinikum Rechts der Isar der Technischen Universit√§t M√ºnchen, M√ºnchen, Germany|Onkologie Rheinsieg, Troisdorf, Germany|Universit√§tsklinikum Ulm, Ulm, Germany|Hospital Universitari General de Catalunya, Sant Cugat Del Vall√®s, Barcelona, Spain|Hospital Teresa Herrera, A Coru√±a, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Gerona, Spain|Complejo Hospitalario de Ja√©n, Ja√©n, Spain|Complejo Hospitalario Universitario La Coru√±a, La Coru√±a, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Mara√±√≥n, Madrid, Spain|Hospital Universitario Ram√≥n Y Cajal, Madrid, Spain|Hospital Cl√≠nico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, M√°laga, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|De La Cruz Merino, Luis, Sevilla, Spain|Hospital Cl√≠nico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT03241810
HR+/HER2-,74,126,1,NCT03685591,Ph 1,41,HR+/HER2-Other combo,Other combo,2L+,Breast + Other,PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors,,Recruiting,No Results Available,Hormone Receptor Positive Advanced Breast Cancer|Metastatic Breast Cancer|Human Epidermal Receptor 2 Negative Advanced Breast Cancer|Castration Resistant Prostate Cancer,Drug: PF-06952229|Drug: Palbociclib|Drug: Letrozole|Drug: Enzalutamide,Percentage of patients with dose limiting toxicities to determine maximum tolerated dose/recommended Phase 2 dose|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)|Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities|Number of Participants With Clinically Significant Change From Baseline in Vital Signs|Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings|Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax) as a single agent in Part 1 and in combination in Part 2|Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)|Pharmacokinetic Parameters: Area Under the Curve (AUC)|Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)|Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)|Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)|Evaluate preliminary anti-tumor activity of PF-06952229|Objective Response Rate (ORR)|Duration of Response (DOR)|Progression free survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)|Time to Response (TTR),Pfizer,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C3881001,10/04/18,12/01/21,10/06/23,09/26/18,null,5/15/19,"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Dept of Medicine -Hematology/Oncology,Santa Monica, Santa Monica, California, United States|Tennessee Oncology,PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03685591
HR+/HER2-,74,127,1,NCT03840200,Ph 1,41,HR+/HER2-Other combo,Other combo,2L+,Breast + Other,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.",,Not yet recruiting,No Results Available,Breast Cancer|Prostate Cancer|Ovarian Cancer,"Drug: Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib|Drug: Part 1, Dose level 2b and dose level 3: Ipatasertib|Drug: Part 1, Dose Level 1 and Dose Level 2b: Rucaparib|Drug: Part 1, Dose Level 2a and Dose Level 3: Rucaparib","Percentage of Participants with Adverse Events|Percentage of Participants with Dose-Limiting Toxicities (DLTs) that Determine the Maximum-Tolerated Dose (MTD) of the Ipatasertib and Rucaparib Combination|Percentage of Participants with Prostate-Specific Antigen (PSA) Response|Percentage of Participants with Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1)|Duration of Objective Response in Participants with Measurable Disease at Baseline, as Assessed by Investigator Based on RECIST v1.1|Radiographic Progression Free Survival, as Assessed by Prostate Cancer Working Group 3 Criteria|Overall Survival in All Participants|Plasma Concentration of Ipatasertib|Plasma Concentration of Ipatasertib's Metabolite, G-037720|Plasma Concentration of Rucaparib",Hoffmann-La Roche,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,54,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO40933,04/30/19,09/24/21,09/24/21,02/15/19,null,4/5/19,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Macquarie University Hospital; Macquarie Medical Imaging, Macquarie University, New South Wales, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori; S. C. Oncologia Medica 2, Milano, Lombardia, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, Umbria, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center - Neurology, Seoul, Korea, Republic of|Cl√≠nica Universidad de Navarra, Pamplona, Navarra, Spain|Vall d¬¥Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain",,https://ClinicalTrials.gov/show/NCT03840200
HR+/HER2-,74,128,1,NCT03134638,Ph 1,41,HR+/HER2-Other combo,Other combo,2L+,Breast + Other,A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,,Recruiting,No Results Available,Advanced Solid Tumors|Ovarian Cancer|Breast Cancer,Drug: SY-1365|Drug: Carboplatin|Drug: Fulvestrant,"First-cycle dose-limiting toxicities (DLTs)|Maximum tolerated dose (MTD)|Safety and tolerability of SY-1365 as a single agent and in combination with either carboplatin or fulvestrant|Evaluate the antitumor activity of SY-1365 in patients with ovarian cancer, breast cancer, and advanced solid tumors|Peak plasma concentration (Cmax)|Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-last)|Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-INF)|Terminal elimination half-life (t1/2)|Time of maximum observed plasma concentration (tmax)|Evaluate the PD effects of SY-1365 by measuring the CDK7 occupancy after SY-1365 administration in PBMCs and tumor tissue",Syros Pharmaceuticals,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,137,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SY-1365-101,05/12/17,06/01/20,06/01/22,05/01/17,null,1/8/19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Scottsdale Healthcare Hospitals, Scottsdale, Arizona, United States|Palo Alto Medical Foundation Group, San Francisco, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Tennessee Oncology, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03134638
HR+/HER2-,74,129,1,NCT03099174,Ph 1,41,HR+/HER2-Other combo,Other combo,2L+,Breast Only,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,,Recruiting,No Results Available,Neoplasms|Breast Neoplasms,Drug: Xentuzumab|Drug: Abemaciclib|Drug: Letrozole|Drug: Anastrozole|Drug: Fulvestrant,"Cohorts A, B,C & D - Maximum Tolerated Dose (MTD)|Cohorts A, B,C & D - Number of patients with dose limiting toxicities (DLT) in the Maximum Tolerated Dose (MTD) evaluation period|Cohorts E & F: objective response (OR), defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1.|Cohorts D1 & D2 - Progression-free survival (PFS) rate|Cohorts E, F, D1 & D2: Disease control (DC) defined as best overall response of complete response (CR) or partial response (PR) or confirmed stable disease (SD) where best overall response is defined according to RECIST version 1.1|Cohorts E, F, D1 & D2: Time to objective response defined as the time from first treatment administration until first documented complete response (CR) or partial response (PR).|Cohorts E, F, D1 & D2: Duration of objective response defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response|Cohorts E, F, D1 & D2: Duration of disease control is defined as the time from first treatment administration until the earliest of disease progression or death, among patients with disease control|Cohorts E, F, D1 & D2: Progression-free survival (PFS)|Cohorts D1 & D2: Objective response (OR) defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1",Boehringer Ingelheim,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,148,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1280.18|2016-003142-85,05/04/17,04/10/20,11/08/21,04/04/17,null,5/15/19,"University of California Los Angeles, Santa Monica, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|INS Paoli-Calmettes, Marseille, France|INS Curie, Paris, France|Aichi Cancer Center Hospital, Aichi, Nagoya, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, Japan|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Cl√≠nic de Barcelona, Barcelona, Spain|Cl√≠nica Universidad de Navarra - Madrid, Madrid, Spain|Hospital Ram√≥n y Cajal, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Quir√≥nsalud Madrid, Pozuelo de Alarc√≥n, Spain",,https://ClinicalTrials.gov/show/NCT03099174
HR+/HER2-,74,130,1,NCT03734029,Ph 3,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04],,Recruiting,No Results Available,Breast Cancer,Drug: Trastuzumab deruxtecan (DS-8201a)|Drug: Capecitabine|Drug: Eribulin|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Nab-paclitaxel,"Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR)|PFS based on Investigator Assessment|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DoR), based on BICR and Investigator assessment","Daiichi Sankyo, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,540,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DS8201-A-U303|2018-003069-33|184223,12/27/18,01/01/22,01/01/22,11/07/18,null,5/9/19,"Ironwood Cancer & Research Centers - Chandler II, Chandler, Arizona, United States|Eastern Connecticut Hematology/Oncology Assoc., Norwich, Connecticut, United States|Touro Infirmary, New Orleans, Louisiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|St Francis Hospital, Greenville, South Carolina, United States|BloomTrials Clinical Research, LLC, Dallas, Texas, United States|University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics, Houston, Texas, United States|Clinique Victor Hugo - Centre Jean Bernard, Le Mans Cedex 02, Sarthe, France|Aichi Cancer Center Hospital, Nagoya, Aichi-Ken, Japan|NHO Kyushu Cancer Center, Fukuoka-shi, Fukuoka-Ken, Japan|Fukushima Medical University Hospital, Fukushima, Fukushima-Ken, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima-shi, Hiroshima-Ken, Japan|NHO Hokkaido Cancer Center, Sapporo-shi, Hokkaido, Japan|Hakuaikai Sagara Hospital, Kagoshima, Kagoshima-Ken, Japan|Tokai University Hospital, Isehara, Kanagawa-Ken, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo-To, Japan|Toranomon Hospital, Minato-Ku, Tokyo-To, Japan|Showa University Hospital, Shinagawa-Ku, Tokyo-To, Japan",,https://ClinicalTrials.gov/show/NCT03734029
HR+/HER2-,74,131,1,NCT03901339,Ph 3,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02),,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Sacituzumab Govitecan|Drug: Eribulin|Drug: Capecitabine|Drug: Gemcitabine|Drug: Vinorelbine,Progression-free survival (PFS)|Objective (overall) response rate (ORR)|Overall Survival (OS)|Duration of Response (DoR),"Immunomedics, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,400,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IMMU-132-09,05/01/19,11/01/21,05/01/23,04/03/19,null,4/30/19,"Highlands Oncology Group, Fayetteville, Arkansas, United States",,https://ClinicalTrials.gov/show/NCT03901339
HR+/HER2-,74,132,1,NCT03778931,Ph 3,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer,EMERALD,Recruiting,No Results Available,Breast Cancer,Drug: Elacestrant|Drug: Standard of Care,Progression Free Survival (PFS) in the ESR1-mut subjects|PFS in all (ESR1-mut and ESR1-WT) subjects|Objective Survival (OS) in ESR1-mut subjects|OS in all (ESR1-mut and ESR1-WT) subjects,"Radius Pharmaceuticals, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,466,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RAD1901-308,11/20/18,08/01/21,08/01/22,12/18/18,null,5/15/19,"Adventist Health Glendale, Glendale, California, United States|TMPN Cancer Care, Redondo Beach, California, United States|Piedmont Cancer Institute, P.C. - Oncology, Atlanta, Georgia, United States|Suburban Hematology-Oncology Associates, PC - Lawrenceville, Lawrenceville, Georgia, United States|Joliet Oncology-Hematology Associates Ltd., Joliet, Illinois, United States|Presence Medical Group Hematology Oncology, Skokie, Illinois, United States|Healthcare Research Network II, Tinley Park, Illinois, United States|American Health Network of Indiana LLC, Avon, Indiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|Mercy Hospital St. Louis - Oncology, Saint Louis, Missouri, United States|New Mexico Oncology Hematology Consultants - Oncology, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|White Plains Hospital Center for Cancer Care - Oncology, White Plains, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Toledo Clinic Cancer Center - Toledo, Toledo, Ohio, United States|Pinnacle Health Cancer Institute, Harrisburg, Pennsylvania, United States|Brig Center For Cancer Care And Survivorship, Knoxville, Tennessee, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03778931
HR+/HER2-,74,133,1,NCT03658213,Ph 3,24,HR+/HER2-Other mono,Other mono,Neo-adj,Breast Only,To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.,LARES,Not yet recruiting,No Results Available,Breast Cancer,Drug: ZOLADEX 10.8 mg|Drug: ZOLADEX 3.6mg,Effective inhibition rate of serum estradiol(E2)|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change in Alanine aminotransferase(U/L)|Change in Aspartate aminotransaminase(U/L)|Change in Albumin(g/L)|Change in Alkaline phosphatase(U/L)|Change in Calcium(mmol/L)|Change in Creatinine(ŒºmoI/L)|Change in High density lipoprotein cholesterol(mmol/L)|Change in Inorganic phosphate(mmol/L)|Change in Low density lipoprotein cholesterol(mmol/L)|Change in Plasma glucose(mmol/L)|Change in Potassium(mmol/L)|Change in Lactate dehydrogenase(U/L)|Change in Triglyceride(mmol/L)|Change in Sodium(mmol/L)|Change in Total bilirubin(Œºmol/L)|Change in Total cholesterol(mmol/L)|Change in Absolute neutrophil count(/L)|Change in Haematocrit(vol%)|Change in Haemoglobin(g/L)|Change in Mean cell volume(fl)|Change in Platelet count(/L)|Change in White blood cell count (total)(/L)|Change in Systolic Blood Pressure(mmHg)|Change in Diastolic blood pressure(mmHg)|Change in Heart rate(bpm)|To evaluate the estradiol (E2) suppression by assessment of area under the curve (AUC) of E2 serum concentration.|Observed maximum Goserelin plasma concentration (Cmax)|Time to maximum Goserelin plasma concentration (tmax)|Area under the Goserelin plasma concentration-time curve from time zero to time of the last measurable concentration (AUCt)|Area under the Goserelin plasma concentration-time curve from time zero to 4 weeks (AUC (0-4 weeks))|Area under the Goserelin plasma concentration-time curve from time zero to 8 weeks (AUC (0-8 weeks))|Area under the Goserelin plasma concentration-time curve from time zero to 12 weeks (AUC (0-12 weeks))|Trough concentration (Ctrough)|The rate of participants who had menstruation.|E2 serum concentrations|FSH serum concentrations,AstraZeneca,Female,18 Years to 59 Years ¬† (Adult),Phase 3,168,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8666C00004,04/30/19,12/31/20,12/31/20,09/05/18,null,12/3/18,"The 307th hospital of Chinese People's Liberation Army, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03658213
HR+/HER2-,74,134,1,NCT03315364,Ph 3,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy,OPTIMAL,Recruiting,No Results Available,Recurrent or Metastatic Breast Cancer,Drug: Oral paclitaxel|Drug: Paclitaxel injection,[Phase II] Objective Response Rate (ORR)|[Phase III] Progression Free Survival (PFS)|[Phase II] Progression Free Survival (PFS)|[Phase III] Objective Response Rate (ORR)|[Phase II&III] Overall Survival(OS)|[Phase II&III] Time to Treatment Failure(TTF)|[Phase II&III] Disease Control Rate(DCR)|[Phase II&III] Quality of life(QoL)|Incidence of Treatment-Emergent Adverse Events [Safety],"Daehwa Pharmaceutical Co., Ltd.",All,"19 Years and older ¬† (Adult, Older Adult)",Phase 2|Phase 3,476,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,107CS-5,12/18/17,01/31/19,03/31/22,10/20/17,null,6/5/18,"Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Wonju Severance Christian Hospital, W≈ènju, Gangwon-do, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Cha University Cha Bundang Medical Center, Seongnam, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Yonsei University Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03315364
HR+/HER2-,74,135,1,NCT03878823,Ph 2,24,HR+/HER2-Other mono,Other mono,2L+,Breast + Other,Safety and Pharmacokinetics of ODM-209,STESIDES,Recruiting,No Results Available,Prostate Cancer Metastatic|Advanced Breast Cancer|Castration-resistant Prostate Cancer|Metastatic Breast Cancer,Drug: ODM-209,Maximum tolerated dose (MTD),"Orion Corporation, Orion Pharma",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,256,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3125001,04/17/19,01/01/23,01/01/23,03/18/19,null,5/17/19,"Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Institut Gustave Roussy, Villejuif, France",,https://ClinicalTrials.gov/show/NCT03878823
HR+/HER2-,74,136,1,NCT03422679,Ph 2,24,HR+/HER2-Other mono,Other mono,2L+,Breast + Other,Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies,,Recruiting,No Results Available,"Breast Cancer|Colorectal Cancer|Cholangiocellular Carcinoma|Sarcoma|Desmoid Tumour|Adenoid Cystic Carcinoma|Non-hodgkin Lymphoma|Glomus Tumor, Malignant",Drug: CB-103,Part A: Dose limiting toxicity (DLT)|Part B: antitumour efficacy|Part A and B: incidence of all adverse events and serious adverse events (safety and tolerability)|Part A and B: pharmacokinetic - Cmax|Part A and B: pharmacokinetic - tmax|Part A and B: pharmacokinetic - AUC|Part A and B: pharmacokinetic - t1/2|Part A: preliminary antitumour efficacy,Cellestia Biotech AG,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,165,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CB103-C-101,12/05/17,06/30/21,06/30/21,02/06/18,null,2/21/19,"Academic Medical Center, Amsterdam, Netherlands|Maastricht UMC, Maastricht, Netherlands|UMC Utrecht Cancer Center, Utrecht, Netherlands|Instituto Oncol√≥gico Baselga. IOB, Barcelona, Spain|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain|Hospital Ram√≥n y Cajal, Madrid, Spain|Oncology Institute of Southern Switzerland, Bellinzona, Switzerland",,https://ClinicalTrials.gov/show/NCT03422679
HR+/HER2-,74,137,1,NCT03284957,Ph 2,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: SAR439859|Drug: palbociclib,"Part A : To determine the RD of SAR439859|Part C : To determine the RD of SAR439859 in combination with palbociclib|Part B : to evaluate the ORR of SAR439859|Part D : to evaluate the ORR of SAR439859 administered in combination with palbociclib|Adverse Events|ORR|Time to First Response (TTR)|Clinical Benefit Rate (CBR)|Duration of response|tlag of SAR439859 after single dose (Part A, B, C, D)|tmax of SAR439859 after single dose (Part A, B, C, D)|Cmax of SAR439859 after single dose (Part A, B, C, D)|AUC0-24 of SAR439859 after single dose (Part A, B, C, D)|tmax of SAR439859 after repeated dose administration (Part A, B, C, D)|Cmax of SAR439859 after repeated dose administration (Part A, B, C, D)|AUC0-24 of SAR439859 after repeated dose administration (Part A, B,C, D)|Ctrough of SAR439859 during repeated dose administration (Part A, B, C, D)|tmax of palbociclib after single dose (Part C, D)|Cmax of palbociclib after single dose (Part C, D)|AUC0-24 of palbociclib after single dose (Part C, D)|tmax of palbociclib after repeated dose administration (Part C, D)|Cmax of palbociclib after repeated dose administration (Part C, D)|AUC0-24 of palbociclib after repeated dose administration (Part C, D)|Urine excretion of SAR439859 (Part B)|Cytochrome P450 3A (CYP3A) enzyme induction and inhibition (Part B)|ER occupancy at 18FES-PET imaging (Part A)|Non-progression rate at 6 months|Observation of tumor changes by FES PET and FDG PET scans",Sanofi,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,156,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED14856|2017-000690-36|U1111-1189-4896,09/20/17,01/08/21,01/08/21,09/15/17,null,5/6/19,"Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400002, Boston, Massachusetts, United States|Investigational Site Number 8400102, Boston, Massachusetts, United States|Investigational Site Number 8400003, New York, New York, United States|Investigational Site Number 8400008, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400009, Charleston, South Carolina, United States|Investigational Site Number 8400004, Dallas, Texas, United States|Investigational Site Number 8400007, Round Rock, Texas, United States|Investigational Site Number 8400001, Seattle, Washington, United States|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560002, Wilrijk, Belgium|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030003, Praha 4, Czechia|Investigational Site Number 2500002, Bordeaux Cedex, France|Investigational Site Number 2500005, Lille, France|Investigational Site Number 2500003, Lyon, France|Investigational Site Number 2500001, Saint-Herblain, France|Investigational Site Number 2500004, Villejuif Cedex, France|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800003, Milano, Italy|Investigational Site Number 3800002, Negrar, Italy|Investigational Site Number 6160001, Warsaw, Poland|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 7240007, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 8260002, Cardiff, United Kingdom|Investigational Site Number 8260001, Glasgow, United Kingdom|Investigational Site Number 8260003, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03284957
HR+/HER2-,74,138,1,NCT03575065,Ph 2,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China,,Recruiting,No Results Available,HER2-negative Breast Cancer,Drug: BGB-290,"Objective response rate|Progression-free survival of response|Progression-free duration of response|Disease control rate|Best overall response|Clinical benefit rate|Overall survival|Incidence of treatment-emergent adverse events, graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events, version 4.03 (Common Toxicity Criteria Version 4.03) or higher|Timing of treatment-emergent adverse events, graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events, version 4.03 (Common Toxicity Criteria Version 4.03) or higher|Severity of treatment-emergent adverse events, graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events, version 4.03 (Common Toxicity Criteria Version 4.03) or higher",BeiGene,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,75,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGB-290-201,05/23/18,10/01/20,12/01/20,07/02/18,null,7/2/18,"Harbin Cancer Hospital, Harbin, Heilongjiang, China",,https://ClinicalTrials.gov/show/NCT03575065
HR+/HER2-,74,139,1,NCT03773133,Ph 2,24,HR+/HER2-Other mono,Other mono,2L+,Breast + Other,"Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)",SSTR2+,Not yet recruiting,No Results Available,Small Cell Lung Cancer and Breast Cancer,Drug: Satoreotide tetraxetan|Drug: Satoreotide trizoxetan,"Maximum administered cumulative activity (MTCA) - phase I|Objective response rate (ORR) over the two treatment cycles - phase II|Maximum observed plasma drug concentration of 177Lu-OPS201 (Cmax) - phase I|Time to maximum observed drug concentration of 177Lu-OPS201 (tmax) - phase I|Maximal uptake (%) of 177Lu-OPS201 - phase I|Area under the plasma concentration time curve (AUC) of 177Lu-OPS201 at the target lesions, discernible organs and blood - phase I|Elimination half life (t1/2) of radioactivity concentrations in blood - phase I|Highest absorbed dose to the target lesions (Gy/GBq) - phase I|Specific absorbed dose per organ (Gy/GBq) - phase I|Total plasma clearance (CL) - phase I|Apparent volume of distribution (Vd) - phase I|Cumulative amount (of unchanged drug) excreted into the urine (Ae) - phase I|Renal clearance - phase I|Mean change in tumour volume - phase II|Best overall response - phase I|Overall survival (OS)|Quantitative changes in tumour|Durable response rate (DRR) - phase II|Progression free survival (PFS) - phase II",Ipsen,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,172,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,D-FR-01072-002|2017-005173-39,03/01/19,06/04/20,11/24/23,12/12/18,null,3/28/19,"MD Anderson Cancer Center, Houston, Texas, United States|Medical University of Innsbruck, Innsbruck, Austria|University Hospital (UZ) Leuven, Leuven, Belgium|CHU de Marseille - H√¥pital la Timone, Marseille, France|CHU de Bordeaux - H√¥pital Haut L√©v√™que, Pessac, France|Universitaetsklinikum Essen, Essen, Germany|University Hospital Basel, Basel, Switzerland|Royal Marsden Hospital - Surrey, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03773133
HR+/HER2-,74,140,1,NCT03250676,Ph 2,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",,Recruiting,No Results Available,"Breast Neoplasms|Breast Cancer|Estrogen-receptor Positive Breast Cancer|Cancer, Breast|Breast Cancer Female|Breast Adenocarcinoma|Estrogen Receptor Positive Tumor|ER Positive",Drug: H3B-6545,Number of Participants with Dose-limiting Toxicities (DLTs)|Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Area under the Plasma Concentration-time Curve from Time 0 Through the Last Measurable Point (AUC0-t) of H3B-6545|Mean Maximum Observed Plasma Concentration (Cmax) of H3B-6545|Time of Maximum Observed Plasma Concentration (tmax) of H3B-6545|Duration of Response (DoR)|Disease Control Rate (DCR)|Progression-free survival (PFS)|Overall Survival (OS),H3 Biomedicine Inc.|Eisai Inc.,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,110,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,H3B-6545-A001-101,08/17/17,04/01/19,12/01/19,08/16/17,null,1/30/19,"Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Tennessee Oncology, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03250676
HR+/HER2-,74,141,1,NCT03616587,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer,,Recruiting,No Results Available,ER+ HER2- Advanced Breast Cancer,Drug: AZD9833|Drug: AZD9833 with palbociclib,"The number of subjects with dose-limiting toxicity, as defined in the protocol.|The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.|Objective Response Rate|Duration of Response|Clinical benefit rate at 24 weeks|Percentage Change in Tumour Size|Progression Free Survival|Maximum Observed Plasma Concentration (Cmax) of AZD9833 alone or in combination with Palbociclib|Time to observed Cmax (Tmax) for AZD9833 alone or in combination with Palbociclib|Area under the plasma concentration-time curve (AUC) for AZD9833 alone or in combination with Palbociclib|Renal clearance (CLR) for AZD9833",AstraZeneca,Female,"18 Years to 130 Years ¬† (Adult, Older Adult)",Phase 1,168,Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,D8530C00001|2018-000667-92|138396,10/11/18,11/30/21,11/30/21,08/06/18,null,4/29/19,"Research Site, Aurora, Colorado, United States|Research Site, Sarasota, Florida, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, New York, New York, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Cambridge, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03616587
HR+/HER2-,74,142,1,NCT03332797,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: GDC-9545|Drug: Palbociclib|Drug: LHRH agonist,Percentage of Participants with Adverse Events|Maximum Tolerated Dose (MTD) of GDC-9545 When Used as a Single Agent|Maximum Observed Plasma Concentration (Cmax) of GDC-9545 Administered as a Single Agent|Maximum Observed Plasma Concentration (Cmax) of GDC-9545 Administered in Combination|Objective Response|Clinical Benefit Rate Assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v 1.1)|Duration of Response (DOR)|Maximum Observed Plasma Concentration (Cmax) of Palbociclib|Maximum Observed Plasma Concentration (Cmax) of LHRH,"Genentech, Inc.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,150,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO39932|2017-002083-41,11/27/17,07/31/21,07/31/21,11/06/17,null,4/8/19,"University of Colorado, Aurora, Colorado, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Vanderbilt University Medical Center; Vanderbilt University, Nashville, Tennessee, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia|National Cancer Center; Medical Oncology, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|ICO L'Hospitalet; Servicio de oncologia medica, L Hospitalet De Llobregat, Barcelona, Spain|Onkologikoa; Ensayos Clinicos, Donostia, Guipuzcoa, Spain|Hospital Quiron Barcelona; Servicio de Oncologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|MD Anderson Cancer Center Madrid - Espa√±a; Servicio de Farmacia, Madrid, Spain|Hospital Universitario Ram√≥n y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario HM Sanchinarro; South Texas Accelerated Research Therapeutics, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Barts Health NHS Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust; Oncology, London, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03332797
HR+/HER2-,74,143,1,NCT03916744,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,"A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer",,Recruiting,No Results Available,Breast Cancer,Drug: GDC-9545|Procedure: Surgery,"Change from Baseline in Tumor Cell Proliferation Measured by Ki67 Expression Between Pre- and Post-Treatment Tumor Biopsy Samples|Number of Participants with at Least One Adverse Event and by Severity, Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)|Change from Baseline in Pulse Rate|Change from Baseline in Systolic Blood Pressure|Change from Baseline in Diastolic Blood Pressure|Change from Baseline in Body Temperature|Change from Baseline in Prothrombin Time (PT)|Change from Baseline in Activated Partial Thromboplastin Time (aPTT)|Change from Baseline in International Normalized Ratio (INR)|Plasma Concentration of GDC-9545 at Steady State","Genentech, Inc.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,45,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,GO40987|2018-003798-85,05/15/19,10/30/20,12/31/20,04/16/19,null,4/26/19,"University of Colorado, Aurora, Colorado, United States|University of Colorado Health Lone Tree Medical Center, Lone Tree, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Peter MacCallum Cancer Centre-Box Hill, East Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital; Investigational Drugs, Pharmacy Department, Murdoch, Western Australia, Australia|Centre Oscar Lambret, Lille, France|Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer, Rennes, France|Centre Rene Gauducheau, Saint Herblain, France|HOPITAL RENE HUGUENIN- Institut Curie, Saint-Cloud, France|Institut Claudius R√©gaud, Toulouse, France|Universit√§tsklinikum ""Carl Gustav Carus""; Frauenheilkunde und Geburtshilfe, Dresden, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universit√§tsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|Klinikum rechts der Isar der Technischen Universit√§t M√ºnchen, Munchen, Germany|Hospital Sant Joan Despi- Moises Broggi; Servicio de Oncologia, Sant Joan Desp√≠, Barcelona, Spain|Onkologikoa - Instituto Oncol√≥gico de Donostia, San Sebastian, Guipuzcoa, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Ruber Internacional;Servicio de Oncologia, Madrid, Spain|HM Sanchinarro - CIOCC, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Clatterbridge Cancer Centre Liverpool, Liverpool, United Kingdom|Barts Health NHS Trust; William Harvey Heart Centre, QMUL School of Medicine & Dentistry, London, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT03916744
HR+/HER2-,74,144,1,NCT03850873,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics,,Not yet recruiting,No Results Available,Advanced Breast Cancer,Drug: TQB3616,DLT|MTD|Cmax|Tmax|t1/2|AUC,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TQB3616-I-0001,03/01/19,09/30/20,09/30/21,02/22/19,null,2/22/19,,,https://ClinicalTrials.gov/show/NCT03850873
HR+/HER2-,74,145,1,NCT03088527,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,"Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer",,Recruiting,No Results Available,Hormone Receptor Positive Malignant Neoplasm of Breast,Drug: RAD140,Incidence rate of dose-limiting toxicities (DLTs) RAD140 treatment|Number of adverse events related to study treatment|Number participants with dose interruptions and dose adjustments|Maximum plasma concentration (Cmax)|Time to maximum plasma concentration (Tmax)|Area under the plasma concentration versus time curve (AUC)|Tumor response,"Radius Pharmaceuticals, Inc.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RAD140-01-001,10/23/17,07/01/20,12/01/20,03/23/17,null,10/16/18,"Yale Cancer Center, New Haven, Connecticut, United States|Cancer Center Protocol Office, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03088527
HR+/HER2-,74,146,1,NCT03560531,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,A Study of ZN-c5 in Subjects With Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: ZN-c5|Drug: Palbociclib,Determine a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) for ZN-c5 as a monotherapy|Determine a maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) for ZN-c5 when administered in combination with palbociclib|Safety and tolerability of ZN-c5 as a monotherapy as measured by number of treatment-emergent adverse events|Safety and tolerability of ZN-c5 in combination with palbociclib as measured by number of treatment-emergent adverse events,Zeno Alpha Inc.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,85,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZN-c5-001,12/08/18,06/01/20,12/01/20,06/18/18,null,2/15/19,"Site 3, Tucson, Arizona, United States|Site 5, Los Angeles, California, United States|Site 2, New York, New York, United States|Site 4, Nashville, Tennessee, United States|Site 1, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03560531
HR+/HER2-,74,147,1,NCT03471663,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: D-0502|Drug: palbociclib,Incidence of AEs meeting protocol defined dose-limiting toxicities (DLTs) criteria|Maximum observed serum concentration (Cmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Time of maximum observed concentration (Tmax)|Objective response rate (ORR)|Progression free survival (PFS),InventisBio Inc.,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,57,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IBIO-301,03/18/18,04/01/20,10/01/20,03/20/18,null,6/25/18,"Local Institution, Aurora, Colorado, United States|Local Institution, Nashville, Tennessee, United States|Local Institution, Dallas, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Tyler, Texas, United States|Local Institution, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT03471663
HR+/HER2-,74,148,1,NCT03455270,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,"G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer",,Recruiting,No Results Available,"Carcinoma, Ductal, Breast|Breast Cancer Female|Breast Neoplasm|Breast Cancer",Drug: G1T48,"Dose Limiting Toxicity|Recommended Phase 2 dose|Number of Treatment Related Adverse Event, including Abnormal Laboratory Events|Tumor response based on RECIST, Version 1.1|Effect of food on bioavailability of G1T48|Pharmacokinetics of G1T48 and metabolites: Maximum Plasma Concentration (Cmax)|Pharmacokinetics of G1T48 and metabolites: Area under Curve - plasma concentration (AUC)|Pharmacokinetics of G1T48 and metabolites: Plasma: terminal half life (T1/2)|Pharmacokinetics of G1T48 and metabolites: Plasma - Volume of distribution","G1 Therapeutics, Inc.",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,96,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,G1T48-01|2017-004502-17,05/09/18,03/01/20,05/01/22,03/06/18,null,12/17/18,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Institut Jules Bordet, Brussels, Belgium|UZ Leuven, Leuven, Belgium|VU University Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT03455270
HR+/HER2-,74,149,1,NCT03816839,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Evaluation of Orally Administered SAR439859 in Japanese Postmenopausal Patients With Advanced Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: SAR439859,Investigational medicinal product (IMP)-related dose limiting toxicities (DLTs)|Safety: Adverse Events (AEs)|Assessment of Pharmacokinetic parameter of SAR439859: tlag|Assessment of Pharmacokinetic parameter of SAR439859: tmax|Assessment of Pharmacokinetic parameter of SAR439859: Cmax|Assessment of Pharmacokinetic parameter of SAR439859: AUC0-24|Assessment of Pharmacokinetic parameter of SAR439859: Ctrough|Assessment of antitumor activity: Objective response rate (ORR)|Assessment of antitumor activity: Clinical benefit rate (CBR)|Assessment of antitumor activity: Duration of response|Assessment of antitumor activity: Non-progression rate,Sanofi,Female,"20 Years and older ¬† (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TED15954|U1111-1217-2758,03/25/19,01/01/20,06/01/20,01/25/19,null,5/6/19,"Investigational Site Number 3920002, Chuo-Ku, Japan|Investigational Site Number 3920001, Kashiwa-Shi, Japan|Investigational Site Number 3920003, Nagoya-Shi, Japan",,https://ClinicalTrials.gov/show/NCT03816839
HR+/HER2-,74,150,1,NCT03201913,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,,Recruiting,No Results Available,Metastatic ER+ Breast Cancer,Drug: TTC-352,MTD|Best response to treatment|PFS|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum Plasma Concentration (Cmax)|Half life|Area Under the Curve (AUC),"TTC Oncology, LLC",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,36,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TTC-352-101,12/11/17,12/31/19,04/30/20,06/28/17,null,8/15/18,"HonorHealth Research Institute, Scottsdale, Arizona, United States|HealthPartners Institute, Regions Cancer Care Center, Saint Paul, Minnesota, United States|Sanford Health, Sioux Falls, South Dakota, United States|University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03201913
HR+/HER2-,74,151,1,NCT03552718,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast + Other,QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.,,Recruiting,No Results Available,Colorectal Cancer|Breast Cancer|Head and Neck Squamous Cell Carcinoma|Melanoma|Non Small Cell Lung Cancer|Pancreatic Cancer|Liver Cancer,Biological: YE-NEO-001,Incidence of treatment-emergent adverse events|Recommended Phase 2 Dose|Recurrence rate|Disease-free survival (DFS)|Overall survival (OS)|Progression-free survival (PFS),"NantBioScience, Inc.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,16,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QUILT-2.025,08/10/18,12/30/19,12/30/20,06/12/18,null,4/11/19,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",,https://ClinicalTrials.gov/show/NCT03552718
HR+/HER2-,74,152,1,NCT03596658,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast Only,SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer,,Not yet recruiting,No Results Available,ER+ HER2- Advanced Breast Cancer,Drug: SHR9549,Dose Limited Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|overall response rate (ORR)|progression free survival (PFS)|Incidence of Treatment-Emergent Adverse Events,"Jiangsu HengRui Medicine Co., Ltd.",Female,"18 Years to 70 Years ¬† (Adult, Older Adult)",Phase 1,44,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHR9549-I-101,07/01/18,12/01/19,03/01/20,07/24/18,null,7/24/18,,,https://ClinicalTrials.gov/show/NCT03596658
HR+/HER2-,74,153,1,NCT03583125,Ph 1,24,HR+/HER2-Other mono,Other mono,2L+,Breast + Other,Study of EOC317 in Chinese Patients With Advanced Solid Tumors,,Recruiting,No Results Available,Solid Tumor,Drug: EOC317,DLT|ORR|DCR|DOR|PFS|Cmax|Tmax|AUC 0-inf|T1/2,"EddingPharm Oncology Co., LTD.",All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,140,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EOC317X1101,05/29/18,05/29/19,11/29/20,07/11/18,null,5/17/19,"Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT03583125
HR+/HER2-,74,154,1,NCT03725059,Ph 3,6,HR+/HER2-CPI combo,CPI combo,Neo-adj,Breast Only,"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)",,Recruiting,No Results Available,Breast Cancer,Biological: Pembrolizumab (K)|Drug: Placebo (P)|Drug: Paclitaxel (X)|Drug: Doxorubicin hydrochloride (A)|Drug: Epirubicin (E)|Drug: Cyclophosphamide (C)|Drug: Endocrine therapy|Radiation: Radiation therapy|Procedure: Surgery,"Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0|Event-Free Survival (EFS)|Overall Survival (OS)|pCR Rate Using the Definition of ypT0ypN0|pCR Rate Using the Definition of ypT0/Tis|pCR Rate Using the Definitions of ypT0/Tis ypN0, ypT0/Tis, and ypT0 ypN0 in Participants With a Combined Positive Score [CPS] ‚â•1|EFS in Participants With a CPS ‚â•1|OS in Participants With a CPS ‚â•1|Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Experiencing a Serious Adverse Event (SAE)|Number of Participants Experiencing an Immune-related AE (irAE)|Number of Study Treatment Discontinuation Due to AEs|Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire Core 30 (QLQ-C30) Score|Change from Baseline in EORTC Breast Cancer-Specific QoL Questionnaire (QLQ-BR23) Score",Merck Sharp & Dohme Corp.,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 3,1140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3475-756|2017-004869-27|MK-3475-756|194604,12/27/18,01/24/31,01/24/31,10/30/18,null,5/10/19,"Southern Cancer Center, PC ( Site 8003), Daphne, Alabama, United States|Cancer Treatment Centers of America at Western Regional Medical Center ( Site 0001), Goodyear, Arizona, United States|Arizona Oncology Associates PC- HOPE ( Site 8008), Tucson, Arizona, United States|University of Colorado Cancer Center ( Site 0008), Aurora, Colorado, United States|Southeastern Regional Medical Center, Inc. ( Site 0075), Newnan, Georgia, United States|Orchard Healthcare Research Inc. ( Site 0020), Skokie, Illinois, United States|Midwestern Regional Medical Center, Inc. ( Site 0077), Zion, Illinois, United States|Goshen Center for Cancer Care ( Site 0021), Goshen, Indiana, United States|MercyOne Waterloo Cancer Center ( Site 0016), Waterloo, Iowa, United States|James Graham Brown Cancer Center ( Site 0022), Louisville, Kentucky, United States|Maryland Oncology Hematology, P.A. ( Site 8007), Bethesda, Maryland, United States|St. Vincent Frontier Cancer Center ( Site 0033), Billings, Montana, United States|Nebraska Cancer Specialists ( Site 0039), Omaha, Nebraska, United States|Holy Name Medical Center ( Site 0041), Teaneck, New Jersey, United States|CTCA Southwestern ( Site 0074), Tulsa, Oklahoma, United States|Northwest Cancer Specialists, P.C. ( Site 8000), Portland, Oregon, United States|Fox Chase Cancer Center ( Site 0078), Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0076), Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000), Nashville, Tennessee, United States|Texas Oncology-Austin Central ( Site 8004), Austin, Texas, United States|Texas Oncology-Dallas Presbyterian Hospital ( Site 8002), Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8009), Dallas, Texas, United States|Texas Oncology- Plano East ( Site 8010), Plano, Texas, United States|Texas Oncology-Tyler ( Site 8006), Tyler, Texas, United States|Bon Secours St. Francis Medical Center Oncology Research ( Site 0064), Midlothian, Virginia, United States|Virginia Oncology Associates ( Site 8001), Norfolk, Virginia, United States|Kadlec Clinic Hematology and Oncology ( Site 0070), Kennewick, Washington, United States|Medical Oncology Associates (Summit Cancer Centers) ( Site 0066), Spokane, Washington, United States|Royal North Shore Hospital ( Site 2100), Sydney, New South Wales, Australia|Westmead Hospital ( Site 2101), Sydney, New South Wales, Australia|Frankston Hospital ( Site 2103), Frankston, Victoria, Australia|Peter MacCallum Cancer Centre ( Site 2102), Melbourne, Victoria, Australia|Mater Misericordiae Ltd Mater Cancer Care Centre ( Site 2106), South Brisbane, Australia|Institut Jules Bordet ( Site 0710), Brussels, Belgium|Cliniques Universitaires Saint-Luc ( Site 0701), Brussels, Belgium|AZ Maria Middelares Gent ( Site 0700), Gent, Belgium|Jessa Ziekenhuis Campus Virga Jesse ( Site 0704), Hasselt, Belgium|AZ Groeninge ( Site 0705), Kortrijk, Belgium|UZ Leuven ( Site 0702), Leuven, Belgium|Clinique Saint Joseph ( Site 0707), Liege, Belgium|CHU UCL Namur Site de Godinne ( Site 0706), Yvoir, Belgium|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0207), Itajai, SC, Brazil|Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 0204), Sao Paulo, Brazil|Princess Margaret Cancer Centre ( Site 0112), Toronto, Ontario, Canada|CISSS de la Monteregie-Centre ( Site 0108), Greenfield Park, Quebec, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0114), Montreal, Quebec, Canada|Jewish General Hospital ( Site 0103), Montreal, Quebec, Canada|CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0101), Quebec, Canada|Centro Medico Imbanaco de Cali S.A ( Site 0406), Cali, Valle Del Cauca, Colombia|Oncomedica S.A. ( Site 0401), Monteria, Colombia|Institut Sainte Catherine ( Site 0916), Avignon, France|Centre Jean Perrin ( Site 0909), Clermont Ferrand Cedex, France|Centre Georges Francois Leclerc ( Site 0920), Dijon, France|Clinique Victor Hugo ( Site 0906), Le Mans, France|Centre Oscar Lambret ( Site 0911), Lille, France|CHR-METZ-THIONVILLE - Hopital de Mercy ( Site 0919), Metz, France|Centre de Cancerologie du Grand Montpellier ( Site 0925), Montpellier, France|Institut Curie ( Site 0900), Paris, France|Hopital Tenon ( Site 0914), Paris, France|Institut Curie - Centre Rene Huguenin ( Site 0917), Saint-Cloud, France|Institut Claudius Regaud IUCT Oncopole ( Site 0903), Toulouse, France|Institut Gustave Roussy ( Site 0926), Villejuif, France|Orszagos Onkologiai Intezet ( Site 2908), Budapest, Hungary|Uzsoki Utcai Korhaz ( Site 2902), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 2907), Debrecen, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 2904), Miskolc, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 2905), Pecs, Hungary|Soroka Medical Center ( Site 1701), Beer Sheva, Israel|Rambam Medical Center ( Site 1705), Haifa, Israel|Shaare Zedek Medical Center ( Site 1708), Jerusalem, Israel|Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1700), Jerusalem, Israel|Rabin Medical Center ( Site 1702), Petah Tikva, Israel|Chaim Sheba Medical Center. ( Site 1707), Ramat Gan, Israel|Kaplan Medical Center ( Site 1703), Rehovot, Israel|Sourasky Medical Center ( Site 1706), Tel Aviv, Israel|Aichi Cancer Center Hospital ( Site 2601), Nagoya, Aichi, Japan|National Cancer Center Hospital East ( Site 2613), Kashiwa, Chiba, Japan|National Hospital Organization Hokkaido Cancer Center ( Site 2607), Sapporo, Hokkaido, Japan|Hyogo College of Medicine Hospital ( Site 2600), Nishinomiya, Hyogo, Japan|Kitasato University Hospital ( Site 2616), Sagamihara, Kanagawa, Japan|Saitama Medical University International Medical Center ( Site 2606), Hidaka, Saitama, Japan|Shizuoka Cancer Center Hospital and Research Institute ( Site 2611), Sunto-gun, Shizuoka, Japan|Chiba Cancer Center ( Site 2605), Chiba, Japan|Fukushima Medical University Hospital ( Site 2610), Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2603), Hiroshima, Japan|Kumamoto University Hospital ( Site 2602), Kumamoto, Japan|National Hospital Organization Osaka National Hospital ( Site 2614), Osaka, Japan|The Cancer Institute Hospital of JFCR ( Site 2604), Tokyo, Japan|Showa University Hospital ( Site 2615), Tokyo, Japan|National Cancer Center ( Site 2204), Goyang-si, Korea, Republic of|Seoul National University Hospital ( Site 2200), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2201), Seoul, Korea, Republic of|Asan Medical Center ( Site 2202), Seoul, Korea, Republic of|Samsung Medical Center ( Site 2203), Seoul, Korea, Republic of|Capital & Coast District Health Board - Wellington Hospital ( Site 2301), Wellington, Newtown, New Zealand|Canterbury Regional Cancer & Blood Services ( Site 2303), Christchurch, New Zealand|Tauranga Hospital ( Site 2302), Tauranga, New Zealand|Mazowiecki Szpital Specjalistyczny im. dr Jozefa Psarskiego ( Site 1814), Ostroleka, Mazowieckie, Poland|Mazowiecki Szpital Onkologiczny ( Site 1803), Wieliszew, Mazowieckie, Poland|Centrum Onkologii Instytut im. Marii Sk≈Çodowskiej Curie ( Site 1801), Gliwice, Slaskie, Poland|Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1810), Bielsko-Biala, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1800), Bydgoszcz, Poland|Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu ( Site 1807), Bytom, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej Curie ( Site 1899), Warszawa, Poland|Hospital Geral de Santo Antonio ( Site 2503), Porto, Portugal|Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 2502), Porto, Portugal|Arkhangelsk Clinical Oncological Dispensary ( Site 1901), Arkhangelsk, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1903), Kazan, Russian Federation|N.N. Blokhin NMRCO ( Site 1908), Moscow, Russian Federation|Central Clinical Hospital with outpatient Clinic ( Site 1907), Moscow, Russian Federation|Medical Rehabilitation Center ( Site 1912), Moscow, Russian Federation|Ryazan Regional Clinical Oncology Dispensary ( Site 1910), Ryazan, Russian Federation|Railway Hospital of OJSC ( Site 1913), Saint Petersburg, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1900), Saint Petersburg, Russian Federation|Tomsk Scientific Research Institute of Oncology ( Site 1905), Tomsk, Russian Federation|Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1909), Ufa, Russian Federation|Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 1363), Hospitalet de Llobregat, Barcelona, Spain|Hospital Quiron de Madrid ( Site 1351), Pozuelo de Alarcon, Madrid, Spain|Hospital Teresa Herrera - Chuac ( Site 1358), A Coruna, Spain|Instituto Oncologico Baselga.Hospital Quiron. ( Site 1352), Barcelona, Spain|Hospital Vall D Hebron ( Site 1357), Barcelona, Spain|Hospital Clinic I Provincial de Barcelona ( Site 1353), Barcelona, Spain|Complejo Hospitalario de Jaen ( Site 1364), Jaen, Spain|Hospital General Universitario Gregorio Maranon ( Site 1367), Madrid, Spain|Hospital Clinico San Carlos ( Site 1354), Madrid, Spain|Hospital Universitario 12 de Octubre ( Site 1356), Madrid, Spain|Hospital Universitario Virgen del Rocio ( Site 1360), Sevilla, Spain|Hospital Clinico Universitario de Valencia ( Site 1355), Valencia, Spain|Hospital General Arnau de Vilanova de Valencia ( Site 1369), Valencia, Spain|China Medical University Hospital ( Site 2401), Taichung, Taiwan|National Cheng Kung University Hospital ( Site 2400), Tainan, Taiwan|National Taiwan University Hospital ( Site 2404), Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 2403), Taipei, Taiwan|Linkou Chang Gung Memorial Hospital ( Site 2402), Taoyuan, Taiwan|MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2700), Kryviy Rih, Dnipropetrovsk Region, Ukraine|MI KhRC Kherson Regional Oncology Dispensary ( Site 2713), Antonivka Village, Ukraine|Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 2702), Dnipropetrovsk, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 2707), Ivano-Frankivsk, Ukraine|National Cancer Institute of the MoH of Ukraine ( Site 2719), Kyiv, Ukraine|Kyiv City Clinical Oncology Centre ( Site 2716), Kyiv, Ukraine|MI Odesa Regional Clinical Hospital ( Site 2701), Odesa, Ukraine|MI Odessa Regional Oncological Centre ( Site 2714), Odesa, Ukraine|Nottingham University Hospitals NHS Trust ( Site 1504), Nottingham, Nottinghamshire, United Kingdom|University Hospitals Bristol NHS Foundation Trust ( Site 1503), Bristol, United Kingdom|Guy's Hospital ( Site 1501), London, United Kingdom|Royal Cornwall Hospital ( Site 1502), Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT03725059
HR+/HER2-,74,155,2,NCT03829501,Ph 2,6,HR+/HER2-CPI combo,CPI combo,2L+,Breast + Other,Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer,,Recruiting,No Results Available,Squamous Cell Carcinoma of Head and Neck|Non-small Cell Lung Cancer|Hepatocellular Carcinoma|Esophageal Cancer|Gastric Cancer|Melanoma|Renal Cell Carcinoma|Pancreatic Cancer|Cervical Cancer|Triple Negative Breast Cancer|Advanced Cancer,Drug: KY1044|Drug: KY1044 and atezolizumab,"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)|Number of dose interruptions, reductions and dose intensity|Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (phase 2)|ORR per RECIST 1.1 (phase 1)|ORR per Immune-Related Response Evaluation Criteria in Solid Tumors (iRECIST) (for phase 1 and phase 2)|PFS per Immune-Related Response Evaluation Criteria in Solid Tumors (iRECIST) (for phase 1 and phase 2)|Survival rate|Best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Incidence and severity of AEs and SAEs (phase 2)|Number of dose interruptions, reductions and dose intensity (phase 2)",Kymab Limited,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,412,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KY1044-CT01,01/28/19,05/01/23,05/01/23,02/04/19,null,2/19/19,"Kymab investigational site 1102, New Haven, Connecticut, United States|Kymab investigational site 1104, Sarasota, Florida, United States|Kymab investigational site, New York, New York, United States|Kymab investigational site 1103, Nashville, Tennessee, United States|Kymab investigator site 1101, Houston, Texas, United States|Kymab investigational site 3901, Milan, Italy|Kymab investigational site 3902, Napoli, Italy|Kymab investigational site 8802, Tainan, Taiwan|Kymab investigational site 8801, Taipei, Taiwan|Kymab investigational site 4402, Manchester, United Kingdom|Kymab investigational site 4401, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03829501
HR+/HER2-,74,156,1,NCT03879174,Ph 2,6,HR+/HER2-CPI combo,CPI combo,1L,Breast Only,Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation,Pembro,Not yet recruiting,No Results Available,Breast Cancer Female,Drug: Pembrolizumab + Tamoxifen,Progression Free Survival|Overall Response Rate (ORR)|Overall Survival,Mediclinic Middle East,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 2,25,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AN.MCME.CR.12|MISP # 55574,08/01/19,08/01/22,08/01/22,03/18/19,null,3/18/19,"Mediclinic City Hospital, Dubai, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT03879174
HR+/HER2-,74,157,1,NCT03280563,Ph 2,6,HR+/HER2-CPI combo,CPI combo,2L+,Breast Only,A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,MORPHEUS,Recruiting,No Results Available,Breast Neoplasms,"Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Drug: Bevacizumab|Drug: Enitinostat|Drug: Exemestane|Drug: Fulvestrant|Drug: Ipatasertib|Drug: Tamoxifen",Percentage of Participants with Objective Response during Stage 1 According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1|Progression-Free Survival during Stage 1 According to RECIST v1.1|Percentage of Participants with Clinical Benefit during Stage 1 According to RECIST v1.1|Overall Survival during Stage 1|Percentage of Participants Alive at 18 Months during Stage 1|Duration of Response during Stage 1 According to RECIST v1.1|Percentage of Participants with Adverse Events (AEs) during Stage 1|Percentage of Participants with AEs during Stage 2|Atezolizumab Serum Concentration during Stage 1|Entinostat Serum and Plasma Concentration during Stage 1|Fulvestrant Plasma Concentration during Stage 1|Ipatasertib Plasma Concentration during Stage 1|Atezolizumab Serum Concentration during Stage 2|Bevacizumab Serum Concentration during Stage 2|Exemestane Plasma Concentration during Stage 2|Fulvestrant Plasma Concentration during Stage 2|Tamoxifen Plasma Concentration during Stage 2|Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab during Stage 1|Percentage of Participants with ADAs to Atezolizumab during Stage 2|Percentage of Participants with ADAs to Bevacizumab during Stage 2,Hoffmann-La Roche,Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,111,Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CO39611|2017-000335-14,09/30/17,02/19/21,10/05/22,09/12/17,null,4/18/19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCSF Helen Diller Family CCC, San Francisco, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Wellness Oncology and Hematology - Main Office, West Hills, California, United States|Yale University School Of Medicine; Yale Cancer Center, Trumbull, Connecticut, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Providence Cancer Center, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Univ of Pittsburgh Sch of Med; Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Houston Methodist Hospital; Department of Pharmacy, Houston, Texas, United States|Northwest Medical Specialties, PLLC; Research Department, Tacoma, Washington, United States|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center; Pharmacy, Tel Aviv, Israel|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|University of Ulsan College of Medicine - Asan Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03280563
HR+/HER2-,74,158,1,NCT03328026,Ph 2,6,HR+/HER2-CPI combo,CPI combo,2L+,Breast Only,Combination Study of SV-BR-1-GM in Combination With Pembrolizumab,,Recruiting,No Results Available,Breast Cancer Female|Breast Neoplasm Female,Biological: SV-BR-1-GM|Biological: Pembrolizumab|Drug: Low dose cyclophosphamide|Biological: Interferon Inoculation,Evaluate the Safety of SV-BR-1-GM (Adverse Events) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors) [Safety]|Evaluate the Safety of SV-BR-1-GM (Laboratory Parameters) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors) [Safety]|Evaluate the tumor response to SV-BR-1-GM (ORR) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD L1/2+ tumors)|Evaluate the tumor response to SV-BR-1-GM (Non-progression) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD L1/2+ tumors)|Evaluate the tumor response to SV-BR-1-GM (Durability of response) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD L1/2+ tumors)|Evaluate the immune responses elicited by SV-BR-1-GM (DTH) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors)|Evaluate the immune responses elicited by SV-BR-1-GM (T cell responses) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors)|Evaluate the immune responses elicited by SV-BR-1-GM (other immunological tests) when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors)|Evaluate patient characteristics (HLA type) that may be predictive of responses to SV-BR-1-GM when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors)|Evaluate tumor characteristics that may be predictive of responses to SV-BR-1-GM when administered in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors)|Evaluate Quality of Life (QOL) in patients administered SV-BR-1-GM in combination with ipilimumab (for patients with PD-L1/2- tumors) or pembrolizumab (for patients with PD-L1/2+ tumors),"BriaCell Therapeutics Corporation|Cancer Insight, LLC",Female,"18 Years and older ¬† (Adult, Older Adult)",Phase 1|Phase 2,40,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BRI-ROL-001,03/16/18,12/31/20,12/31/20,11/01/17,null,2/1/19,"St. Joseph Heritage Healthcare, Santa Rosa, California, United States|University of Miami/Sylvester at Plantation, Plantation, Florida, United States|Cancer Center of Kansas (CCK), Wichita, Kansas, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Providence Regional Medical Center, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT03328026
HR+/HER2-,74,159,1,NCT03600090,Ph 1,6,HR+/HER2-CPI combo,CPI combo,2L+,Breast Only,Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer,,Recruiting,No Results Available,"Solid Tumor, Adult",Biological: EOC202|Drug: Paclitaxel,DLT|PFS|Cmax|Tmax|AUC 0-inf|T1/2,"EddingPharm Oncology Co., LTD.",Female,"18 Years to 70 Years ¬† (Adult, Older Adult)",Phase 1,18,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EOC202A1101,10/16/18,08/31/19,09/30/20,07/25/18,null,5/9/19,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03600090
HR+/HER2-,74,160,1,NCT03572361,Ph 2,3,HR+/HER2-CPI mono,CPI mono,Neo-adj,Breast Only,Open Label Immunotherapy Trial for Breast Cancer,V3-MOMMO,Recruiting,No Results Available,Breast Cancer,Biological: V3-MOMMO,Effect on tumor size|Effect on level of serum tumor markers compared to baseline,Immunitor LLC,Female,"18 Years to 65 Years ¬† (Adult, Older Adult)",Phase 2,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,V3-MOMMO-01,07/01/18,11/30/19,12/31/19,06/28/18,null,7/4/18,"Immunitor LLC, Ulaanbaatar, Mongolia",,https://ClinicalTrials.gov/show/NCT03572361
HR+/HER2-,74,161,1,NCT03514121,Ph 1,3,HR+/HER2-CPI mono,CPI mono,2L+,Breast + Other,FPA150 in Patients With Advanced Solid Tumors,FPA150-001,Recruiting,No Results Available,Breast Cancer|Ovarian Cancer|Endometrial Cancer|Advanced Solid Tumors,Biological: FPA150|Biological: Pembrolizumab,"For Phase 1a dose escalation, to determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of FPA150|For Phase 1a dose escalation, dose exploration and combination safety lead-in the number of participants with adverse events as assessed by the latest version of CTCAE|For Phase 1b, number of participants with adverse events as assessed by the latest version of CTCAE at the maximum tolerated dose (MTD) and/or recommended dose (RD) of FPA150|Area under serum concentration-time curve of FPA150 in day*¬µg/mL|Maximum serum concentration of FPA150 in ¬µg/mL|Trough serum concentration of FPA150 in ¬µg/mL|Clearance of FPA150 in mL/day/kg|Terminal Half-Life of FPA150 in day|Volume of distribution (mL/kg) of FPA150|Incidence of treatment emergent anti-FPA150 antibody response (levels in serum)|Pharmacodynamic profile of FPA150","Five Prime Therapeutics, Inc.",All,"18 Years to 99 Years ¬† (Adult, Older Adult)",Early Phase 1,278,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FPA150-001,03/27/18,01/01/23,01/01/24,05/02/18,null,4/4/19,"Honor Health, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03514121
HR+/HER2-,74,162,1,NCT03329950,Ph 1,3,HR+/HER2-CPI mono,CPI mono,2L+,Breast + Other,A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies,,Recruiting,No Results Available,Melanoma|Non-small Cell Lung Cancer|Breast Cancer|Gastric Cancer|Renal Cell Carcinoma|Ovarian Cancer|Cholangiocarcinoma|Bladder Urothelial Carcinoma|Pancreatic Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Hepatic Cancer|Head and Neck Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Other Solid Tumors|Diffuse Large B-cell Lymphoma (DLBCL)|Mantle Cell Lymphoma|Indolent B-cell Lymphomas|Non-Hodgkin Lymphoma,Drug: CDX-1140|Drug: CDX-301,Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0,Celldex Therapeutics,All,"18 Years and older ¬† (Adult, Older Adult)",Phase 1,180,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDX1140-01,12/01/17,07/01/20,12/01/20,11/06/17,null,2/15/19,"HonorHealth Research Insititute, Scottsdale, Arizona, United States|Northside Hospital, Inc., Atlanta, Georgia, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Gabrail Cancer Center Research LLC, Canton, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03329950
HER2+,46,163,1,NCT03561740,Ph 3,22,HER2+Other Combo,Other Combo,Adj,Breast Only,A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients,,Recruiting,No Results Available,Breast Cancer,Drug: capecitabine,Invasive disease-free survival (IDFS)|Invasive disease-free survival including second non-breast cancers|Disease-free survival|Overall survival|Breast cancer specific survival|Distant recurrence-free interval,Sun Yat-sen University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,794,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCBCG-006,07/25/18,06/15/23,12/31/28,06/19/18,null,26-Jul-18,"Shusen Wang, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03561740
HER2+,46,164,1,NCT03863223,Ph 3,22,HER2+Other Combo,Other Combo,1L,Breast Only,A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer,,Not yet recruiting,No Results Available,Metastatic Breast Cancer,"Drug: Pyrotinib, Trastuzumab, Docetaxel|Drug: Placebo, Trastuzumab, Docetaxel",PFS|AEs+SAEs|OS|ORR|DoR|CBR,"Jiangsu HengRui Medicine Co., Ltd.",Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,590,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HR-BLTN-III-MBC-C,03/30/19,07/30/22,07/30/24,03/05/19,null,11-Mar-19,"Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03863223
HER2+,46,165,1,NCT02947685,Ph 3,22,HER2+Other Combo,Other Combo,2L+,Breast Only,"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer",,Recruiting,No Results Available,HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer,Drug: palbociclib|Drug: trastuzumab|Drug: pertuzumab|Drug: letrozole|Drug: Anastrozole|Drug: Exemestane|Drug: Fulvestrant,Progression-free survival (PFS) as assessed by Investigator|Overall Survival (OS)|3 and 5 year survival probabilities|Objective Response Rate (OR: CR or PRR)|Duration of Response (DOR)|Clinical Benefit Rate (CBR: CR or PR or SD ≥ 24 weeks|Safety: Type incidence and severity (as graded by NCI CTCAE v 4.0)|Patient Reported Outcomes,"Alliance Foundation Trials, LLC.|Pfizer|German Breast Group|Fondazione Michelangelo|PrECOG, LLC.|Breast Cancer Trials, Australia and New Zealand|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|Syneos Health|SOLTI Breast Cancer Research Group|UNICANCER",All,"18 Years and older   (Adult, Older Adult)",Phase 3,496,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AFT-38,06/21/17,10/31/20,08/31/24,10/28/16,null,19-Jun-18,"Mayo Clinic, AZ, Phoenix, Arizona, United States|UCSF, San Francisco, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Baycare Healthcare (Morton Plant Mease), Clearwater, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Mount Sinai Medical Center - FL, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Chicago, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|St. Elizabeth Healthcare /Edgewood, Edgewood, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|EMMC Cancer Care, Brewer, Maine, United States|New England Cancer Specialists, Scarborough, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|University of Maryland (St. Joseph's Medical Center, Towson, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|Michigan Cancer Research Consortium (St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|West Michigan Cancer Center, Grand Rapids, Michigan, United States|Metro-Minnesota NCI Community Oncology Research Program, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, MN, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|The Valley Hospital, Okonite Research Center, Paramus, New Jersey, United States|St. Joseph's Regional Medical Center, Paterson, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|First Health of the Carolinas Cancer Center, Pinehurst, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Legacy Good Samaritan Hospital, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC (University of Pittsburgh Medical Center), Pittsburgh, Pennsylvania, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Multicare Institute for Research and Innovation, Puyallup, Washington, United States",,https://ClinicalTrials.gov/show/NCT02947685
HER2+,46,166,1,NCT03433313,Ph 3,22,HER2+Other Combo,Other Combo,Neo-adj,Breast Only,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: EG12014|Drug: Herceptin,Determination of pathologic complete response (pCR) at time of surgery|pCR at the time of surgery|Event-free survival (EFS) up to end of study (EOS)|Overall response (OR) prior to surgery|Overall survival (OS) up to End of Study (EOS)|Incidence of AEs|Evaluation of Immunogenicity of EG12014 and Herceptin|Measure serum trastuzumab concentration,"EirGenix, Inc.",Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EGC002|2017-003973-33,10/16/18,08/05/20,10/13/21,02/14/18,null,3-May-19,"Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Aultman Hospital, Cancer Center, Canton, Ohio, United States|Brest Regional Oncology Center, Brest, Belarus|Gomel Regional Clinical Oncology Center, Gomel, Belarus|N.N. Aleksandrov Republican Research Oncology and Medical Radiology Center, Lesnoy, Belarus|Minsk City Clinical Oncology Center, Minsk, Belarus|Mogilev Regional Oncology Center, Mogilev, Belarus|Vitebsk Regional Clinical Oncology Center, Vitebsk, Belarus|Medical Research Limited Society, Temuco, Chile|Clinic Vina del Mar Hospital, Viña Del Mar, Chile|Ophthalmological Foundation of Santander -FOSCAL, Floridablanca, Colombia|Clinic Life Foundation, Medellín, Colombia|Rodrigo Botero SAS, Medellín, Colombia|University Hospital San Vicente de Paul, Medellín, Colombia|JSC Saint Nikolozi Surgery and Oncological Centre, Kutaisi, Georgia|LTD Acad. F. Todua Medical Center - LTD Research Institute of Clinical Medicine, Tbilisi, Georgia|LTD Cancer Research Centre, Tbilisi, Georgia|LTD Health House, Tbilisi, Georgia|LTD Institute of Clinical Oncology, Tbilisi, Georgia|LTD S.Khechinashvili University Hospital, Tbilisi, Georgia|Metro Mas Hospital, Jaipur, Rajasthan, India|Cytecare Cancer Hospitals, Bengaluru, India|Aster Medcity, Kochi, India|King George's Medical University, Department of Endocrine surgery, Shatabdi Phase II, Lucknow, India|Tata Memorial Centre, Mumbai, India|HCG NCHRI Cancer Centre, Nagpur, India|Noble Hospital Pvt Ltd, Pune, India|Christian Medical College, Department of Medical Oncology, Vellore, India|Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam, India|Keimyung University - Dongsan Medical Center, Daegu, Korea, Republic of|Catholic University of Korea St. Vincent's Hospital, Gyeonggi-do, Korea, Republic of|Arkhangelsk Clinical Oncology Center, Arkhangel'sk, Russian Federation|Chelyabinsk Regional Clinical Oncology and Nuclear Medicine Center, Chelyabinsk, Russian Federation|Evimed, LLC, Chelyabinsk, Russian Federation|Sverdlovsk Regional Oncology Center, Ekaterinburg, Russian Federation|Ivanovo Regional Oncology Center, Ivanovo, Russian Federation|Republican Clinical Oncology Center, Kazan, Russian Federation|Krasnoyarsk A.I. Kryzhanovsky Regional Oncology Center, Krasnoyarsk, Russian Federation|Kursk Regional Clinical Oncology Center, Kursk, Russian Federation|Moscow City Oncology Hospital #62, Moscow, Russian Federation|N.N. Blokhin National Medical Oncology Research Center, Moscow, Russian Federation|National Medical Research Center for Radiology, Moscow, Russian Federation|Siberian District Medical Center, Novosibirsk, Russian Federation|Clinical Oncology Center, Omsk, Russian Federation|Pyatigorsk Interdistrict Oncology Center, Pyatigorsk, Russian Federation|Rostov Oncology Research Institute, Rostov-on-Don, Russian Federation|Regional Clinical Oncology Center, Ryazan', Russian Federation|AV Medical Group, Saint Petersburg, Russian Federation|Clinic ""Mart"", Saint Petersburg, Russian Federation|I.I. Mechnikov North-Western State Medical University, Saint Petersburg, Russian Federation|Leningrad Regional Oncology Center, Saint Petersburg, Russian Federation|N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russian Federation|Oncology Center of Moskovskiy District, Saint Petersburg, Russian Federation|Private Medical Institution ""EVROMEDSERVIS"", Department of Oncology, Saint Petersburg, Russian Federation|St. Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncology), Saint Petersburg, Russian Federation|Samara Regional Clinical Oncology Center, Samara, Russian Federation|Republican Oncology Center, Saransk, Russian Federation|Oncology Center #2, Sochi, Russian Federation|Regional Clinical Oncology Center, Veliky Novgorod, Russian Federation|Volgograd Regional Clinical Oncology Center, Volgograd, Russian Federation|GVI Oncology, Cape Gate Oncology Centre, Cape Town, South Africa|The Oncology Centre, Durban, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|Little Company of Mary Medical Center, Department of Oncology, Pretoria, South Africa|University of Pretoria, Department of Medical Oncology, Pretoria, South Africa|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan|Chernihiv Regional Oncology Center, Chernihiv, Ukraine|Chernivtsi Regional Clinical Oncology Center, Chernivtsi, Ukraine|Clinical Oncology Center, Dnipro, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Department of Chemotherapy, Dnipro, Ukraine|Prikarpattia Clinical Oncology Center, Ivano-Frankivsk, Ukraine|Communal Non-profit enterprise ""Regional Center of Oncology"", Kharkiv, Ukraine|State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences, Department of Clinical Oncology and Hematology, Kharkiv, Ukraine|Khmelnytskyi Regional Oncology Center, Khmelnytskyi, Ukraine|Kryvyi Rih Oncology Center, Department of Chemotherapy, Kryvyi Rih, Ukraine|Kyiv Regional Oncology Center, Department of Mastology, Kyiv, Ukraine|Medical Center ""Verum"", Kyiv, Ukraine|Medical Center of First Private Clinic, Kyiv, Ukraine|National Institute of Cancer, Department of Minimally Invasive and Endoscopic Surgery, Interventional Radiology, Kyiv, Ukraine|Volyn Regional Oncology Center, Department of Chemotherapy, Luts'k, Ukraine|Public Institution under Lviv Regional Council: Lviv Regional Treatment and Diagnostics Oncology Center, Department of Chemotherapy, Lviv, Ukraine|Odesa Regional Clinical Hospital, Center for Mastology, Department of Thoracic Surgery, Odesa, Ukraine|Odesa Regional Oncology Center, Odesa, Ukraine|Ternopil Regional Clinical Oncology Center, Department of Chemotherapy, Ternopil', Ukraine|Central City Clinical Hospital, Department of Oncology and Radiology, Uzhhorod, Ukraine|Zakarpattia Regional Clinical Oncology Center, Department of Chemotherapy, Uzhhorod, Ukraine|Health Clinic, LLC, Vinnytsia, Ukraine|Podillia Regional Oncology Center, Vinnytsia, Ukraine",,https://ClinicalTrials.gov/show/NCT03433313
HER2+,46,167,1,NCT02492711,Ph 3,22,HER2+Other Combo,Other Combo,2L+,Breast Only,Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,,Recruiting,No Results Available,HER-2 Positive Breast Cancer|Metastatic Neoplasm,Biological: Margetuximab|Biological: Trastuzumab|Drug: Capecitabine|Drug: Eribulin|Drug: Gemcitabine|Drug: Vinorelbine,"Progression-free survival (PFS) as determined by independent radiological review.|Overall survival (OS) defined as the number of days from randomization to the date of death (from any cause).|Infusion rate sub-study Grade 3 plus safety|To evaluate progression-free survival (PFS), as assessed by study investigators.|To evaluate the objective response rate (ORR) as determined by independent radiological review.|Infusion rate sub-study all safety",MacroGenics,All,"18 Years and older   (Adult, Older Adult)",Phase 3,530,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP-MGAH22-04,08/24/15,03/01/20,03/01/21,07/09/15,null,25-Mar-19,"Southern Cancer Center, Mobile, Alabama, United States|Ironwood Cancer & Research Center, Chandler, Arizona, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Western Regional Medical Center, Inc., Goodyear, Arizona, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|East Valley Hematology And Oncology, Burbank, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Comprehensive Hematology Oncology Center, Los Angeles, California, United States|UCLA Hematology Oncology Santa Monica, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|Stanford University Medical Center, Stanford, California, United States|Kaiser Permenente Medical Center, Vallejo, California, United States|Poudre Valley Health Care, Inc., Fort Collins, Colorado, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Florida Cancer Specialists, New Port Richey, Florida, United States|Orlndo Health Cancer Center, Orlando, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Hem-Onc Associates, Port Saint Lucie, Florida, United States|Palm Beach Cancer Center, West Palm Beach, Florida, United States|Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States|Gwinnett Medical Center - Center for Cancer Care, Lawrenceville, Georgia, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|CTCA - Southeastern Regional Medical Center, Newnan, Georgia, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Hematology Oncology North Shore, Skokie, Illinois, United States|Presence Medical Group Hematology Oncology, Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|CTCA - Midwestern Regional Medical Center, Zion, Illinois, United States|Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States|Physicians Clinic of Iowa, Cedar Rapids, Iowa, United States|Flaget Cancer Center, Bardstown, Kentucky, United States|ARH Cancer Clinic, Hazard, Kentucky, United States|St. Joseph's Hospital, Lexington, Kentucky, United States|Jewish Medical Center Northeast, Louisville, Kentucky, United States|Touro Infirmary Hospital, New Orleans, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|AAMC Oncology and Hematology, Annapolis, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|FRHS - James M. Stockman Cancer Institute, Frederick, Maryland, United States|Tufts-NEMC Cancer Center, Boston, Massachusetts, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Forrest General Hospital, Hattiesburg, Mississippi, United States|Saint Luke's Cancer Specialists, Kansas City, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Dartmouth-Hitchcock - Norris C, Lebanon, New Hampshire, United States|New Jersey Hematology Oncology Associates, Brick, New Jersey, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Barnabas Medical Center - The Cancer Center, Livingston, New Jersey, United States|New Mexico Cancer Care Alliance (NMCCA), Albuquerque, New Mexico, United States|Queens Hospital Center, Jamaica, New York, United States|ProHEALTH CARE Associates, LLP, Lake Success, New York, United States|New York University Clinical Cancer Center, New York, New York, United States|Weill Cornell Breast Center, New York, New York, United States|ECU - Leo W. Jenkins Cancer Center, Greenville, North Carolina, United States|Wake Forest University Baptist Medical Center (WFUBMC), Winston-Salem, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Mercy Physicians Of Oklahoma, Oklahoma City, Oklahoma, United States|CTCA - Southwestern Regional Medical Center, Inc., Tulsa, Oklahoma, United States|Pinnacle Health Cancer Institute, Harrisburg, Pennsylvania, United States|Monongahela Valley Hospital, Monongahela, Pennsylvania, United States|CTCA - Eastern Regional Medical Center, Inc., Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Tennessee Cancer Specialists, PLLC - Dowell Springs, Knoxville, Tennessee, United States|The Sarah Cannon Research Institute, Nashville, Tennessee, United States|Arlington Cancer Center, Arlington, Texas, United States|Austin Cancer Center, Austin, Texas, United States|St. Joseph Health Cancer Center, Bryan, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|East Texas Medical Center Cancer Institute, Tyler, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States|Swedish Cancer Institute/ Swedish Health Services, Seattle, Washington, United States|University of Washington/ Seattle Cancer Care Alliance, Seattle, Washington, United States|Cancer Care Northwest, PS, Spokane, Washington, United States|Medizinische Universität Innsbruck, Innsbruck, Tirol, Austria|Landeskrankenhaus Rankweil, Rankweil, Vorarlberg, Austria|UZ Antwerpen, Edegem, Antwerpen, Belgium|GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium|Clinique Saint-Pierre Ottignies, Ottignies, Brabant Wallon, Belgium|UZ Brussel - Campus Jette, Brussels, Brussels Capital Region, Belgium|Cliniques universitaires Saint-Luc, Brussels, Brussels Capital Region, Belgium|INDC Entité Jolimontoise - CH de Jolimont-Lobbes, Haine-Saint-Paul, Hainaut, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Limburg, Belgium|CHR Verviers East Belgium, Verviers, Liège, Belgium|AZ Nikolaas - Campus Sint-Niklaas Moerland, Sint-Niklaas, Oost-Vlaanderen, Belgium|AZ Sint-Jan Brugge - Oostende - Campus Sint-Jan, Brugge, West-Vlaanderen, Belgium|AZ Groeninge - Campus Loofstraat, Kortrijk, West-Vlaanderen, Belgium|AZ Damiaan, Oostende, West-Vlaanderen, Belgium|Chc - Clinique Saint-Joseph, Liège, Belgium|Clinique Sainte Elisabeth, Namur, Belgium|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|The Atlantic Clinical Cancer Research Unit (ACCRU), Halifax, Nova Scotia, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Fakultni nemocnice Brno, Brno, Brno-město, Czechia|Masarykuv onkologicky ustav, Brno, Brno-město, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Aarhus Universitetshospital, Aarhus C, Central Jutland, Denmark|Regionshospitalet Herning (Herning Centralsygehus), Herning, Central Jutland, Denmark|Vejle Sygehus, Vejle, South Denmark, Denmark|Næstved Sygehus, Aarhus N, Zeeland, Denmark|Tampere University Hospital, Tampere, Etelä-Suomen Lääni, Finland|Helsinki University Central Hospital (HUCH) - Meilahden Sair, Helsinki, Länsi-Suomen Lääni, Finland|Center de Lutte Contre le Cancer (CLCC), Nice, Alpes-Martitimes, France|Hôpital Privé Clairval, Marseille, Bouches-du-Rhône, France|Center de Lutte Contre le Cancer (CLCC), Caen cedex 05, Calvados, France|Centre Georges-François Lecler, Dijon, Côte-d'Or, France|Centre de Lutte Contre le Cancer (CLCC) - Institut de Cancer, St Herblain, Loire-Atlantique, France|Centre Jean Perrin, Clermont-Ferrand, Puy-de-Dôme, France|Centre Léon Bérard, Lyon Cedex 08, Rhône-Alpes, France|Institut Curie, Paris, Île-de-France, France|Institut Curie - Hôpital René Huguenin, Saint-Cloud, Île-de-France, France|Universitaetsklinikum Tuebingen, Tuebingen, Baden-Württemberg, Germany|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Interdisziplinäres Onkologisches Zentrum München, München, Bayern, Germany|Städtisches Krankenhaus München - Neuperlach, München, Bayern, Germany|Praxis für Frauenheilkunde Anita, München, Bayern, Germany|Marien Hospital Düsseldorf, Düsseldorf, Nordhein-Westfalen, Germany|Universitaetsklinikum Essen - Klinik fuer Frauenheilkunde, Essen, Nordrhein-Westfalen, Germany|Marien Hospital, Witten, Nordrhein-Westfalen, Germany|Medizinische Fakultät Carl Gustav Carus, Dresden, Sachsen, Germany|Campus Charité Mitte (CCM), Berlin, Germany|Katholisches Marienkrankenhaus gGmbH - Frauenklinik, Hamburg, Germany|Universtatsklinikum Heidelberg Nationales, Heidelberg, Germany|Soroka Medical Center [Oncology], Beersheba, HaDarom, Israel|The Edith Wolfson Medical Center, Holon, HaMerkaz, Israel|Meir Medical Center, Kfar Saba, HaMerkaz, Israel|Rabin Medical Center - Beilinson Hospital, Petaẖ Tiqwa, HaMerkaz, Israel|The Chaim Sheba Medical Center - Insititute of Oncology, Ramat Gan, HaMerkaz, Israel|Kaplan Medical Center, Rehovot, HaMerkaz, Israel|Galilee Medical Center, Nahariya, HaZafon, Israel|Hadassah Medical Organisation, Hadassah Medical Center, Ein-Karem, Jerusalem, Yerushalayim, Israel|Clalit Health Services - Lin Medical Center, Haifa, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|PO Garibaldi-Nesima, ARNAS Garibaldi, Catania, Cantania, Italy|Irccs Irst, Meldola, Forli, Italy|Istituto di Candiolo, IRCCS, Candiolo, Torino, Italy|Azienda Ospedaliero Universitaria Senese Universita degli St, Siena, Toscana, Italy|Ospedale Umberto I, AOU Ospedali Riuniti Umberto I - GM.Lanc, Ancona, Italy|AO G.Rummo, Benevento, Italy|ASST Papa Giovanni XXIII - Oncologia-Bergamo, Bergamo, Italy|PO di Cremona, ASST di Cremona - Patologia Mammaria e Breast Unit - Cremona, Cremona, Italy|Arcispedale S.Anna, AOU di Ferrara, Ferrara, Italy|E.O. Ospedali Galliera, Genova, Italy|PO A.Manzoni di Lecco, ASST Lecco - Oncologia Medica - Lecco, Lecco, Italy|Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milano, Italy|Istituto Europeo di Oncologia Via Ripamonti, Milano, Italy|AOU Policlinico di Modena, Modena, Italy|Fondazione Pascale, IRCCS Istituto Nazionale dei Tumori, Napoli, Italy|AOU di Parma, Parma, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|IRCSS Fodazione Salvatore Maugeri, Pavia, Italy|SO S.Chiara, AOU Pisana, Pisa, Italy|Nuovo ospedale di Prato, Prato, Italy|PU Campus Bio-medico di Roma, Roma, Italy|AO S.Andrea, Università degli Studi di Roma La Sapienza, Roma, Italy|Ospedale Belcolle Viterbo, Viterbo, Italy|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Asan Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Maastricht University Medical Centre, Maastricht, Limburg, Netherlands|Stichting Zuyderland Medisch Centrum, Sittard, Limburg, Netherlands|Elizabeth Tweesteden Ziekenhuis, Tilburg, Noord-Brabant, Netherlands|Haga Ziekenhuis, loc. Leyenburg, Haag, Zuid-Holland, Netherlands|MAGODENT Sp. z o.o., Warszawa, Mazowieckie, Poland|Mazowiecki Szpital Onkologiczny, Wieliszew, Mazowieckie, Poland|Centro Clínico Champalimaud/Fundação Champalimaud, Lisbon, Lisboa, Portugal|H. Santa Maria - Centro Hospitalar Lisboa Norte, Lisboa, Portugal|Instituto Português Oncologia Francisco Gentil do Porto, Porto, Portugal|Fundacion de Investigacion de Diego, San Juan, Puerto Rico|H.U.V. del Rocío, Sevilla, Andalucía, Spain|Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Catalunya, Spain|H.C.U. Valencia, Valencia, Comunidad, Spain|H. Madrid Norte Sanchinarro, PAU de Sanchinarro, Madrid, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|H.U. Sant Joan de Reus, Reus, Tarragona, Spain|H.G.U. Alicante, Alicante, Spain|H. Quirón Barcelona, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|H. San Pedro de Alcántara, Cáceres, Spain|ICO-Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain|H.U. Arnau de Vilanova, Lleida, Spain|M.D. Anderson Cancer Center Madrid, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitari I Politecnic La Fe, Valencia, Spain|Hospital Ntra. Sra. de Sonsoles, Ávila, Spain|Guys and St Thomas Hospital, London, City Of London, United Kingdom|Castle Hill Hospital (Hull), Hull, East Riding Of Yorkshire, United Kingdom|Kent Oncology Centre, Maidstone Hospital, Maidstone, Kent, United Kingdom|Royal Preston Hospital, Fulwood, Lancashire, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, Nottinghamshire, United Kingdom|Blackpool Victoria Hospital, Blackpool, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom",,https://ClinicalTrials.gov/show/NCT02492711
HER2+,46,168,1,NCT01572038,Ph 3,22,HER2+Other Combo,Other Combo,1L,Breast Only,A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer,,"Active, not recruiting",No Results Available,Breast Neoplasms,Drug: Docetaxel|Drug: Nab-paclitaxel|Drug: Paclitaxel|Drug: Pertuzumab|Drug: Trastuzumab,"Percentage of Participants With AEs Leading to Study Treatment Interruption and Discontinuation|Percentage of Participants who Died, Reported by Cause of Death|Percentage of Participants with Congestive Heart Failure (CHF)|Percentage of Participants with Adverse Events (AEs) and Serious AEs (SAEs)|Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study|Time to Onset of the First Episode of CHF|Progression-Free Survival (PFS) as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1|Overall Survival|Percentage of Participants with Objective Response (Complete Response [CR] or Partial Response [PR]) Based on Best Confirmed Overall Response as Assessed by Investigator Based on RECIST v1.1|Percentage of Response with Clinical Benefit Response (CR, PR or Stable Disease [SD; for At Least 6 months] Based on Best Confirmed Overall Response as Assessed by Investigator Based on RECIST v.1.1|Duration of Response as Assessed by Investigator Based on RECIST v1.1|Time to Response Among Participants with Best Response of PR or CR as Assessed by Investigator Based on RECIST v1.1|Functional Assessment of Cancer Therapy - Breast (FACT-B) Subscale Scores for Female Participants Only",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,1436,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO28047|2011-005334-20,06/01/12,09/28/19,09/28/19,04/05/12,null,8-Apr-19,"CPMC; Service d'Oncologie Médicale, Algiers, Algeria|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Instituto de Oncología de Rosario, Rosario, Argentina|Canberra Hospital; Medical Oncology, Canberra, Australian Capital Territory, Australia|Royal Prince Alfred Hospital; Medical Oncology, Camperdown, New South Wales, Australia|HOCA Chermside, Chermside, Queensland, Australia|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Queen Elizabeth Hospital, Woodville, South Australia, Australia|Austin and Repatriation Medical Centre; Cancer Services, Melbourne, Victoria, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie, Graz, Austria|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|A.Ö. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gaströnter. & Onkologie, Steyr, Austria|Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie, Wien, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|UZ Brussel, Brussel, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Gent, Gent, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU Sart-Tilman, Liège, Belgium|Oncologistas Associados, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Hospital das Clinicas - FMUSP Ribeirao Preto, Ribeirao Preto, SP, Brazil|Hospital Sirio Libanes; Centro de Oncologia, Sao Paulo, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Lion'S Gate Hospital, North Vancouver, British Columbia, Canada|Bcca - Vancouver Island Cancer Centre; Oncology, Victoria, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|CSSS champlain - Charles-Le Moyne, Greenfield Park, Quebec, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|Southwest Hospital , Third Military Medical University, Chongqing, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Heilongjiang Provincial Tumor Hospital, Harbin, China|Jiangsu Cancer Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Cancer Hospital, Tianjin, China|The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital), Xi'an, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China|Hospital Solca Portoviejo; Oncologia, Portoviejo, Ecuador|Hospital Solca Quito; Oncologia, Quito, Ecuador|Manial Specialized Hospital; Oncology, Cairo, Egypt|El Mokatam HIO Hospital, Cairo, Egypt|Nci; Oncology Dept, Cairo, Egypt|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, Estonia|Helsinki University Central Hospital; Oncology Clinics, Helsinki, Finland|Satakunta Central Hospital; Oncology, Pori, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Clinique Du Docteur Calabet; Cromg, Agen, France|Clinique De L Europe; Radiotherapie Chimiotherapie, Amiens, France|ICO Paul Papin; Oncologie Medicale., Angers, France|Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie, Bordeaux, France|Centre Hospitalier Fleyriat; Oncologie/Hematologie, Bourg En Bresse, France|Chi De Creteil; Radiotherapie Oncologie, Creteil, France|Centre Leonard De Vinci;Chimiotherapie, Dechy, France|Fondation Clement Drevon; Oncology, Dijon, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Clinique Sainte Marguerite; Oncologie Medicale, Hyeres, France|Polyclinique de Blois; Chimiotherapie Ambulatoire, La Chaussee St Victor, France|Clinique Victor Hugo, LeMans, France|Centre Hartmann, Levallois Perret, France|Polyclinique Du Bois; Centre Bourgogne, Lille, France|Clinique Chenieux; Oncology, Limoges, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Centre Azureen De Cancerologie; Cons externes, Mougins, France|Polyclinique Du Languedoc; Chimiotherapie, Narbonne, France|Hopital Cochin; Unite Fonctionnelle D Oncologie, Paris, France|Hopital Hotel Dieu; Oncologie Medicale, Paris, France|Hia Du Val De Grace; Radiotherapie Oncologie, Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis; Service Onco Thoracique, Paris, France|Hopital Des Diaconesses; Oncologie, Paris, France|Centre Catalan D' Oncologie, Perpignan, France|Polyclinique De Courlancy; Centre Radiotherapie Oncologie, Reims, France|Centre Eugene Marquis; Unite Huguenin, Rennes, France|Centre Rene Huguenin; ONCOLOGIE GENETIQUE, Saint Cloud, France|Chp Saint Gregoire; Cancerologie Radiotherapie, Saint Gregoire, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Institut D Oncologie Medical, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Hopital Prive Drome Ardeche; Hopital De Jour, Valence, France|Clinique Radio Des Dentellieres; Chimiotherapie Radiotherapie, Valenciennes, France|Klinikum am Bruderwald; Frauenklinik, Bamberg, Germany|Gynaekologicum Bremen; Prof. Dr. Willibald Schröder, Bremen, Germany|Klinikum Bremerhaven Reinkenheide; Frauenklinik, Bremerhaven, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Essen, Germany|Klinikum Esslingen; Klinik für Frauenheilkunde und Geburtshilfe, Esslingen, Germany|AGAPLESION Markus-Krankenhaus, Frankfurt, Germany|SRH Wald-Klinikum Gera; Klinik für Frauenheilkunde und Geburtshilfe, Gera, Germany|Universitätsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|St.-Vincenz-Krankenhaus; Frauenklinik, Limburg, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany|Brustzentrum Rhein-Ruhr Servicegesellschaft mbH, Mönchengladbach, Germany|Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde, München, Germany|Ruppiner Kliniken, Klinik fuer Gynaekologie und Geburtshilfe, Neuruppin, Germany|Med. Versorgungszentrum GbR - Praxis Pihusch, Rosenheim, Germany|Agaplesion Diakonieklinikum Rotenburg, Rotenburg/Wümme, Germany|Praxis Dr. Wagner, Saarbruecken, Germany|Onkologische Schwerpunktpraxis, Soest, Germany|Kreiskrankenhaus Torgau; Abt.Gynäkologie und Geburtshilfe, Torgau, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, Germany|Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece|Hippokratio Hospital; 2Nd Internal Medicine, Athina, Greece|University General Hospital of Heraklion, Crete, Greece|University Hospital of Larissa; Oncology, Larissa, Greece|University Hospital of Patras Medical Oncology, Patras, Greece|Metropolitan Hospital; 2Nd Oncology Clinic, Piraeus, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Queen Elizabeth Hospital; Clinical Oncology, Hong Kong, Hong Kong|Szent Margit Hospital; Dept. of Oncology, Budapest, Hungary|Fovarosi Szent Laszlo Korhaz-Rendelointezet; Onkologiai Osztaly X, Budapest, Hungary|Orszagos Onkologial Intezet; Onkologiai Osztaly X, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Medical Center; Oncology, Haifa, Israel|Wolfson Hospital; Oncology, Holon, Israel|Shaare Zedek Medical Center; Oncology Dept, Jerusalem, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Nahariya Hospital; Oncology, Nahariya, Israel|Rabin Medical Center; Oncology Dept, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Kaplan Medical Center; Oncology Inst., Rehovot, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Assuta Medical Centre; Oncology, Tel Aviv, Israel|Assaf Harofeh; Oncology, Zerifin, Israel|Azienda Ospedaliera San Giuseppe Moscati, Avellino, Campania, Italy|Az. Osp. Ospedale Civile; U.O. Di Oncologia Medica Ed Ematologia, Piacenza, Emilia-Romagna, Italy|Azienda USL di Ravenna; Unità Operativa di Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia, Udine, Friuli-Venezia Giulia, Italy|Ospedale Belcolle Di Viterbo; Oncologia, Viterbo, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; S.C. Oncologia Medica, Genova, Liguria, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Ospedale Mater Salutis; Dept of Oncology, Legnago, Lombardia, Italy|Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Irccs Policlinico S. Matteo - Uni Pavia; Clinica Medica I Div. Med. Int. Onc. Medica E Gastroent., Pavia, Lombardia, Italy|Ospedali Riuniti Di Ancona; Oncology, Ancona, Marche, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, Italy|Ospedale Maggiore Della Carita; Oncologia Medica, Novara, Piemonte, Italy|Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica, Ponderano (BI), Piemonte, Italy|Fondazione Del Piemonte; Medical Oncology, Torino, Piemonte, Italy|Ospedale Civile SS Annunziata; oncologia medica, Sassari, Sardegna, Italy|Ospedale S. Vincenzo; Oncologia Medica, Taormina, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Arcispedale S.Anna; Oncologia Medica, Cona (Ferrara), Veneto, Italy|American University of Beirut - Medical Center, Beirut, Lebanon|Hotel Dieu de France; Oncology, Beirut, Lebanon|Hospital of Lithuanian University of Health. Sciences Kaunas Clinics, Kaunas, Lithuania|Uni Oncology Inst. ; Chemo - Radiation Dept, Vilnius, Lithuania|Centro Estatal de Oncología de Campeche, Campeche, Mexico|Iem-Fucam, D.f., Mexico|Medica Sur Centro Oncologico Integral, D.f., Mexico|Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Centro Medico Nacional Siglo Xxi - Imss; Hospital de Oncologia, Mexico City, Mexico|Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán, Mexico City, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, Mexico|Cancerologia de Queretaro; Oncologia, Queretaro, Queretaro, Mexico|Institut National D'oncologie Sidi Mohammed Ben Abdellah; Anatomopathologie, Rabat, Morocco|Medisch Centrum Alkmaar, Alkmaar, Netherlands|Gelre Ziekenhuis Apeldoorn, Lokatie Lukas; Afdeling Interne Geneeskunde, Apeldoorn, Netherlands|Rijnstate Ziekenhuis; Inwendige Geneeskunde, Arnhem, Netherlands|Wilhelmina Ziekenhuis; Inwendige Geneeskunde, Assen, Netherlands|Albert Schweitzer Ziekenhuis; Inwendige Geneeskunde, Dordrecht, Netherlands|Catharina ZKHS; Inwendige Geneeskunde Afd., Eindhoven, Netherlands|Martini Ziekenhuis; Dept of Internal Medicine, Groningen, Netherlands|Diaconessenhuis Leiden, Leiden, Netherlands|Mc Haaglanden, Locatie Antoniushove; Interne Geneeskunde, Leidschendam, Netherlands|Ikazia Ziekenhuis; Interne Oncologie, Rotterdam, Netherlands|Twee Steden Ziekenhuis - Locatie Tilburg; Interne Geneesekunde, Tilburg, Netherlands|Vie Curie, Venlo, Netherlands|Shifa International Hospital; Department of Oncology, Islamabad, Pakistan|Shaukat Khanum Memorial Cancer Hospital; Department of Oncology, Lahore, Pakistan|Hameed Latif Hospital; Department of Oncology, Lahore, Pakistan|Instituto;Oncologico Miraflores, Lima, Peru|Hospital Nacional LNS dela Policia Nacional del Perú. Unidad Onco; Deapartamento de Oncología, Lima, Peru|Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, Poland|Świętokrzyskie Centrum Onkologii; Dział Chemioterapii, Kielce, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Krakow, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii; Poradnia Chemioterapii, Lodz, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon, Warszawa, Poland|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|Hospital do Espirito Santo; Servico de Oncologia Medica, Evora, Portugal|Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Hospital de Sao Joao; Servico de Oncologia, Porto, Portugal|King Faisal Specialist Hospital & Research Centre; Oncology, Riyadh, Saudi Arabia|King Abdul Aziz Medical City, King Fahd National Guard; Oncology, Riyadh, Saudi Arabia|Institute for Onc/Rad Serbia, Belgrade, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Hospital Virgen de los Lirios; Servicio de Oncologia, Alcoy, Alicante, Spain|Hospital General de Elda; Servicio de Oncologia, Elda, Alicante, Spain|Hospital de Cabueñes; Servicio de Oncologia, Gijon, Asturias, Spain|Complejo Hospitalario de Althaia; Servicio de Oncologia, Manresa, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital de Jerez de la Frontera; Servicio de Oncologia, Jerez de La Frontera, Cadiz, Spain|Hospital de Barbastro; Servicio de Oncologia, Barbastro, Huesca, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Complejo Hospitalario San Millan - San Pedro; Servicio de Oncologia, Logroño, LA Rioja, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, LAS Palmas, Spain|Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia, Las Palmas de Gran Canaria, LAS Palmas, Spain|Fundacion Hospital de Alcorcon; Servicio de Oncologia, Alcorcon, Madrid, Spain|Hospital Severo Ochoa; Servicio de Oncologia, Leganes, Madrid, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Universitari Sant Joan de Reus; Servicio de Oncologia, Reus, Tarragona, Spain|Complejo Hospitalario Nuestra Señora de la Candelaria; Servicio de Oncologia, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Sagunto; Servicio de Oncologia, Sagunto, Valencia, Spain|Hospital Lluis Alcanys; Servicio de Oncologia, Xativa, Valencia, Spain|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Quiron Barcelona; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain|Complejo Asistencial Universitario De Burgos; Servicio de Oncologia, Burgos, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia, Girona, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, Spain|Hospital General Universitario de Guadalajara; Servicio de Oncologia, Guadalajara, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Fundacion Jimenez Diaz; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia, Murcia, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Complejo Hospitalario de Orense; Servicio de Oncologia, Orense, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clinico Universitario de Valladolid; Servicio de Oncologia, Valladolid, Spain|Hospital de Rio Hortega; Servicio de Oncologia, Valladolid, Spain|Complejo Hospitalario Zamora- H. Virgen de la Concha; Servicio Oncologia, Zamora, Spain|Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia, Zaragoza, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Gävle Sjukhus; Onkologiska Kliniken, Gävle, Sweden|Sahlgrenska Universitetssjukhuset; Jubileumskliniken, Göteborg, Sweden|Centralsjukhuset Karlstad, Onkologkliniken, Karlstad, Sweden|Skånes University Hospital, Skånes Department of Onclology, Lund, Sweden|Länssjukhuset Sundsvall, Onkologkliniken, Sundsvall, Sweden|Centrallasarettet Växjö, Onkologkliniken, Vaxjo, Sweden|Västmanlands sjukhus Västerås, Onkologkliniken, Västerås, Sweden|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, İ̇zmi̇r, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, Turkey|Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department, Erzurum, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, Ankara, Turkey|Karadeniz Tecnical University Medical Faculty; Oncology Department, Trabzon, Turkey|Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU; Chair of Oncology and Medical Radiology, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center; Chemotherapy Department, Kiev, Ukraine|State Oncology Regional Treatment-Diagnostic Center; Chemotherapy Department, Lviv, Ukraine|Zaporozhye Regional Oncology Hospital; Dept of Oncology, Zaporozhye, Ukraine|Tawam Hospital, Al Ain, United Arab Emirates|Royal United Hospital; Oncology Department, Bath, United Kingdom|City Hospital NHS Trust, Birmingham, United Kingdom|Bradford Royal Infirmary; Dept of Medical Oncology C/O Ward15, Bradford, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital; Dept of Oncology, Cambridge, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|Walsgrave Hospital, Coventry, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Hairmyres Hospital; Oncology Dept, East Kilbride, United Kingdom|Eastbourne District Hospital; Department of Pharmacy, Eastbourne, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Diana Princess of Wales Hosp., Grimsby, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Leeds Teaching Hosp NHS Trust;St James's Institute of Onc, Leeds, United Kingdom|Huddersfield Royal Infirmary - Pharmacy department, Lindley, United Kingdom|Barts and the London NHS Trust., London, United Kingdom|Royal Free Hospital; Dept of Oncology, London, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Macclesfield District General Hospital, Macclesfield, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|James Cook Uni Hospital, Middlesborough, United Kingdom|Freeman Hospital; Northern Centre For Cancer Care, New Castle Upon Tyne, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Derriford Hospital; Plymouth Oncology Centre, Plymouth, United Kingdom|Musgrove Park Hospital, Somerset, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Wishaw General Hospital, Wishaw, United Kingdom|Grupo Oncológico Cooperativo Uruguayo; Hospital de Clínicas - Dpto. de Oncología, Montevideo, Uruguay|Hospital Central De Las FF.AA.; Servicio De Oncologia, Montevideo, Uruguay|Hospital Pereira Rossell; Oncology Department, Montevideo, Uruguay|Instituto Oncológico Luis Razetti, Caracas, Venezuela|Centro Integral de Oncología, Caracas, Venezuela|Centro Médico Docente La Trinidad; Servicio de Gastroenterología, Caracas, Venezuela",,https://ClinicalTrials.gov/show/NCT01572038
HER2+,46,169,1,NCT03588091,Ph 3,22,HER2+Other Combo,Other Combo,Neo-adj,Breast Only,Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer,,Recruiting,No Results Available,HER2-positive Breast Cancer,Drug: Pyrotinib|Drug: Placebo Oral Tablet|Drug: Trastuzumab|Drug: Docetaxel,Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by independent review committee(IRC)|Percentage of Participants With Pathological Complete Response (pCR) at the Time of Surgery evaluated by sites|Event-free survival(EFS)|Disease-free Survival (DFS)|Distance Disease-free Survival (DDFS)|Objective Response Rate (ORR) during neoadjuvant period,"Jiangsu HengRui Medicine Co., Ltd.",Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,294,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HR-BLTN-III-NeoBC,07/01/18,09/01/19,06/01/22,07/17/18,null,19-Jul-18,"Fudan University Shanghai Cancer Center, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03588091
HER2+,46,170,1,NCT03493854,Ph 3,22,HER2+Other Combo,Other Combo,Neo-adj,Breast Only,"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",,"Active, not recruiting",No Results Available,Early Breast Cancer,Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Docetaxel|Drug: Paclitaxel|Drug: Pertuzumab IV|Drug: FDC of Pertuzumab and Trastuzumab SC|Drug: Trastuzumab IV|Drug: Trastuzumab SC|Procedure: Surgery|Radiation: Post-operative Radiotherapy|Drug: Hormone Therapy,"Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7|Ctrough of Trastuzumab During Cycle 7|Percentage of Participants with Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment|Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Invasive Disease-Free Survival (iDFS; Excluding Second Primary Non-Breast Cancer [SPNBC]) Criteria|Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to iDFS (Including SPNBC) Criteria|Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Event-Free Survival (EFS; Excluding SPNBC) Criteria|Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to EFS (Including SPNBC) Criteria|Kaplan-Meier Estimate of the Percentage of Participants Who Are Event-Free According to Distant Recurrence-Free Interval (DRFI) Criteria|Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival|Percentage of Participants With Adverse Events (Including Serious Adverse Events), Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4 (NCI CTCAE v4)|Percentage of Participants With a Primary Cardiac Event|Percentage of Participants With a Secondary Cardiac Event",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WO40324|2017-004897-32,06/14/18,06/27/19,04/04/24,04/11/18,null,12-Apr-19,"Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|CBCC Global Research Inc., at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Hematology Oncology Clinic, Baton Rouge, Louisiana, United States|Maryland Oncology Hematology, Rockville, Maryland, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Westchester Medical Center Cancer Institute, Hawthorne, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Texas Tech University HSC, El Paso, Texas, United States|Northwest Medical Specialties, Lakewood, Washington, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|COIBA, Provincia De Buenos Aires, Argentina|Institut Jules Bordet, Brussels, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Clinique Ste-Elisabeth, Namur, Belgium|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|CHUS (Centre Hospitalier Universitaire de Sherbrooke), Sherbrooke, Quebec, Canada|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Multiscan s.r.o., Pardubice, Czechia|ICO Paul Papin; Oncologie Medicale., Angers, France|Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Institut Bergonie; Oncologie, Bordeaux, France|Centre Léon Bérard, Lyon, France|Institut Curie; Oncologie Medicale, Paris, France|Hôpital Saint-Louis: Service Pharmacie - essaie Clinique, Paris, France|ICO - Site René Gauducheau, Saint Herblain, France|Klinikum Augsburg; Frauenklinik, Augsburg, Germany|Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie, Bad Nauheim, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|St. Johannes-Hospital, Dortmund, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Evangelische Kliniken Gelsenkirchen GmbH; Brustzentrum, Gelsenkirchen, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, Germany|gSUND Gynäkologie Kompetenzzentrum Stralsund; Frauenheilkunde & Geburtshilfe, Stralsund, Germany|Debreceni Egyetem, Debrecen, Hungary|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Università degli Studi Federico II; Clinica di Oncologia Medica, Napoli, Campania, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Uni Degli Studi Di Genova ; Clinica Di Medicina Interna Ad Indirizzo Oncologico, Genova, Liguria, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gifu University Hospital, Gifu, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|Sagara Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Medical University International Medical Center, Saitama, Japan|St. Luke's International Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center - Oncology, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Centro Médico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|Iem-Fucam, D.f., Mexico|Bialostockie Centrum Onkologii im. Marii Sklodowskiej - Curie, Bialystok, Poland|Centrum Onkologii, Inst.Im M. Curie-Slodowskiej; Iii Klinika Radioterapii I Chemioterapii, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, Poland|Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wroclaw, Poland|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|Omsk Region Clinical Oncology Dispensary; 1St Sergical Department, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital de Cruces; Servicio de Oncología Médica, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|China Medical University Hospital; Surgery, Taichung, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Dept of Surgery, Taoyuan, Taiwan|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Songklanagarind Hospital; Department of Surgery, Songkla, Thailand|Municipal Noncommercial Institution Regional Center of Oncology, Kharkiv, Kharkiv Governorate, Ukraine|CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|National Cancer Institute MOH of Ukraine, Kiev, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|Brighton and Sussex Univ Hosp, Brighton, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|St Georges University Hospitals NHS Foundation Trust, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom",,https://ClinicalTrials.gov/show/NCT03493854
HER2+,46,171,1,NCT03080805,Ph 3,22,HER2+Other Combo,Other Combo,1L,Breast Only,Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer,,Recruiting,No Results Available,HER2 Positive Metastatic Breast Cancer,Drug: Pyrotinib Plus Capecitabine|Drug: Lapatinib Plus Capecitabine,Progression Free Survival(PFS)|Safety: AE|Overall Survival (OS)|Objective Response Rate (ORR)|Time to Progression (TTP)|Duration of Response (DOR)|Clinical Benefit rate (CBR),"Jiangsu HengRui Medicine Co., Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,240,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HR-BLTN-Ⅲ-MBC,05/03/17,06/01/19,12/01/19,03/15/17,null,20-Dec-17,"Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT03080805
HER2+,46,172,1,NCT02973737,Ph 3,22,HER2+Other Combo,Other Combo,2L+,Breast Only,A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer,,"Active, not recruiting",No Results Available,HER2 Positive Metastatic Breast Cancer,Drug: pyrotinib|Drug: placebo|Drug: Capecitabine,Progression Free Survival (PFS)|Objective Response Rate (ORR)|Safety(adverse Events [AEs] and Serious Adverse Events [SAEs])|Duration of Response (DOR)|Clinical Benefit rate (CBR)|Overall Survival (OS),"Jiangsu HengRui Medicine Co., Ltd.",Female,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,350,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HR-BLTN-Ⅲ-MBC-A,07/01/16,12/01/18,12/01/19,11/25/16,null,20-Dec-17,"307 Hospital Affiliated to Academy Military Medical Science, Beijing, China",,https://ClinicalTrials.gov/show/NCT02973737
HER2+,46,173,1,NCT02896855,Ph 3,22,HER2+Other Combo,Other Combo,1L,Breast Only,A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC),,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Docetaxel|Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab,"Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Percentage of Participants With Symptomatic Left Ventricular Systolic Dysfunction, as Determined Using Echocardiography (ECHO) or Multiple-gated Acquisition (MUGA) Scan|Percentage of Participants With Asymptomatic Left Ventricular Ejection Fraction, as Determined Using ECHO or MUGA Scan|LVEF as Determined Using ECHO or MUGA Scan|Overall Survival|Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1|Duration of Objective Response as Determined by the Investigator Using RECIST v1.1|Percentage of Participants With Adverse Events",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,243,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",YO29296,09/13/16,06/27/18,09/24/20,09/12/16,null,30-Jan-19,"CHINESE ACADEMY OF MEDICAL SCIENCE; CANCER INST. & HOSPITAL; Medical ward, Beijing, China|Beijing Cancer Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|the First Hospital of Jilin University, Changchun, China|Changzhou First People's Hospital, Changzhou, China|West China Hospital, Sichuan University, Chengdu, China|Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, China|Guangdong General Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu province hospital; surgery on galactophore, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|First Hospital of China Medical University, Shenyang, China|Liaoning cancer Hospital & Institute, Shenyang, China",,https://ClinicalTrials.gov/show/NCT02896855
HER2+,46,174,1,NCT03085368,Ph 3,22,HER2+Other Combo,Other Combo,1L,Breast Only,A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin,,Recruiting,No Results Available,HER2-positive Breast Cancer,Drug: lapatinib/herceptin,DFS|OS,"Peking Union Medical College Hospital|EddingPharm Oncology Co., LTD.",Female,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,482,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,lapatinib,03/01/17,05/01/18,03/01/21,03/21/17,null,28-Jul-17,"PUMCH, Beijing, China",,https://ClinicalTrials.gov/show/NCT03085368
HER2+,46,175,1,NCT02586025,Ph 3,22,HER2+Other Combo,Other Combo,Neo-adj,Breast Only,Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel,,"Active, not recruiting",Has Results,Breast Cancer,Drug: FEC Chemotherapy|Procedure: Surgery|Drug: Docetaxel|Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab,"Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)|Percentage of Participants With tpCR as Assessed by the Local Pathologist|Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the American Joint Committee on Cancer Staging System as Assessed by the IRC|Percentage of Participants With bpCR as Assessed by the Local Pathologist|Percentage of Participants With Complete Response, Partial Response, Stable Disease, or Progressive Disease During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1|Percentage of Participants With an Objective Response (Complete or Partial Response) During Cycles 1-4, According to RECIST Version 1.1|Kaplan-Meier Estimate of the Percentage of Participants With 3 Years of Event-Free Survival|Kaplan-Meier Estimate of the Percentage of Participants With 3 Years of Disease-Free Survival|Kaplan-Meier Estimate of the Percentage of Participants With 3 Years of Overall Survival|Percentage of Participants With At Least One Adverse Event During the Neoadjuvant Treatment Period|Percentage of Participants With At Least One Adverse Event During the Adjuvant Treatment Period|Percentage of Participants With At Least One Adverse Event During the Treatment-Free Follow-Up Period|Percentage of Participants Who Experienced a Primary Cardiac Event|Percentage of Participants Who Experienced a Secondary Cardiac Event|Maximum Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,329,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",YO28762,03/14/16,10/23/17,04/30/22,10/26/15,01/03/19,12-Mar-19,"The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|Jilin Cancer Hospital, Changchun, China|the First Hospital of Jilin University, Changchun, China|Fujian Medical University Union Hospital, Fujian, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|The 1st Affiliated Hospital of Nanchang Unversity, Nanchang, China|Jiangsu Province Hospital, Nanjing, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Henan Cancer Hospital, Zhengzhou, China|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Taipei Medical University -Shuang Ho Hospital, New Taipei City, Taiwan|China Medical University Hospital; Surgery, Taichung, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Wanfang Hospital, Taipei, Taiwan|Bhumibol Adulyadej Hospital; Medicine, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen University; Surgery, Khon Kaen, Thailand|Songklanagarind Hospital; Department of Surgery, Songkla, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02586025/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02586025/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02586025
HER2+,46,176,1,NCT03910712,Ph 2,22,HER2+Other Combo,Other Combo,1L,Breast Only,Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC,,Not yet recruiting,No Results Available,Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor,Drug: Pyrotinib|Drug: Trastuzumab|Drug: Aromatase inhibitor,Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Overall Response Rate (ORR)|Duration of Response (DoR)|Time to Response (TTR)|Clinical Benefit Response (CBR)|Adverse events (AEs)|Quality of Life (QoL) by FACT-B|Quality of Life (QoL) by EQ-5D,Peking Union Medical College Hospital,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,250,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BREAST-Pyrotinib,06/01/19,06/01/22,12/01/23,04/10/19,null,10-Apr-19,,,https://ClinicalTrials.gov/show/NCT03910712
HER2+,46,177,1,NCT03161353,Ph 2,22,HER2+Other Combo,Other Combo,Neo-adj,Breast Only,Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.,,Recruiting,No Results Available,Breast Cancer,Drug: Perjeta|Drug: Herceptin|Drug: Docetaxel|Drug: Carboplatin|Drug: Letrozole|Drug: Tamoxifen,Evaluate the rate of pCR|3-year iDFS rate|pCR rates in the breast and axilla (ypTO/isN0)|pCR rates in the breast (ypT0/is)|RCB score (residual cancer burden)|pCR rates in the breast and axilla|Rate of breast conserving surgery|18F-FDG PET/CT response rate (18F-FDG: 18F-fluorodeoxyglucose)|Optimal 18F-FDG PET/CT cut-off for pCR|Other 18FDG PET quantification parameters|MRI response rate|Health-related quality of life|3-year iDFS (cohort A).|3-year DDFS (cohort A; cohort B) (DDFS:Distant disease-free survival)|3-year DFS (cohort A; cohort B) (DFS:Disease-free survival)|OS (cohort A; cohort B; cohort C) (OS: overall survival)|PFS (cohort C) (PFS: Progression-free survival),MedSIR,All,"18 Years and older   (Adult, Older Adult)",Phase 2,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MedOPP096,06/26/17,10/01/21,10/01/22,05/19/17,null,11-Mar-19,"Institute Jules Bordet, Bruxelles, Belgium|CLCC d'Auvergne. Centre Jean Perrin., Clermont-Ferrand, France|Institute de Cancerologie de Laurraine, Nancy, France|Groupe Hospitalier Diaconesses, Paris, France|Hopital Tenon, Paris, France|Hospital Georges Pompidou, Paris, France|Centre Paul Strauss, Strasbourg, France|Institut Claudius Régaud, Toulouse, France|Kliniken Essen Mitte, Essen, Germany|Klinikum der Med. Fakultät Halle, Halle, Germany|National center for tumor disease NCT, Heidelberg, Germany|Städtisches Klinikum ""St. Georg"" Leipzig, Leipzig, Germany|Hämatologisch-Onkologische Schwerpunktpraxis, Munchen, Germany|Clinical of Nuclear Medicine Technical University Munich, Munich, Germany|Ospedale Maggiore Bologna, Bologna, Italy|Ospedale Antonio Perrino, Brindisi, Italy|Istituto Ospedalieri di Cremona, Cremona, Italy|Ospedale Mantova, Mantova, Italy|Istituto Europeo di Oncologia, Milan, Italy|Ospedale San Gerardo, Monza, Italy|Ospedale Guglielmo de Saliceto, Piacenza, Italy|Hospital Senhora da Oliveira, Guimarães, Portugal|Hospital Beatriz Angelo, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|Hospital Fernando Fonseca, Lisboa, Portugal|Centro Hospitalar Sao Joao, Oporto, Portugal|Hospital do Santo Antonio, Oporto, Portugal|Centro Hospitalaer de Tras-os-Montes e Alto Douro, Vila Real, Portugal|ICO Badalona, Badalona, Barcelona, Spain|ICO l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Provincial de Castellón, Castello, Castelló, Spain|Hospital de Jaén, Jaen, Jaén, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Málaga, Spain|Hospital San Joan de Reus, Reus, Tarragona, Spain|Hospital Universitario A Coruña, A Coruna, Spain|Hospital Vall Hebrón, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Reina Sofía, Cordoba, Spain|ICO Girona, Girona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital La Paz, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|CHUS Santiago de Compostela, Santiago de Compostela, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínic Universitari de Valencia, Valencia, Spain|Hospital Dr Peset, Valencia, Spain|Hospital General Universitari de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miquel Servet, Zaragoza, Spain|Barts Cancer Institute, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",,https://ClinicalTrials.gov/show/NCT03161353
HER2+,46,178,1,NCT03674112,Ph 2,22,HER2+Other Combo,Other Combo,Adj,Breast Only,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,,Recruiting,No Results Available,HER2-Positive Early Breast Cancer,Drug: Pertuzumab and Trastuzumab FDC SC|Drug: Pertuzumab IV|Drug: Trastuzumab IV,"Percentage of Participants Who Indicated They Preferred the Pertuzumab and Trastuzumab Fixed-Dose Combination Subcutaneous (FDC SC) Administration as Assessed in Question 1 of the Patient Preference Questionnaire|Participant-Assessed Satisfaction with Pertuzumab and Trastuzumab FDC SC, Based on Responses to Question 1 of the Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC)|Participant-Assessed Satisfaction with Pertuzumab and Trastuzumab IV, Based on Responses to Question 1 of the Therapy Administration Satisfaction Questionnaire - Intravenous (TASQ-IV)|Percentage of Participants Who Select Pertuzumab and Trastuzumab FDC SC for the Study Treatment Continuation Period|Healthcare Professional (HCP) Perception of Time/Resource Use and Convenience of Each Study Regimen, Based on HCP Responses to the Healthcare Professional Questionnaire (HCPQ) - Treatment Room, by Individual Question|Healthcare Professional (HCP) Perception of Time/Resource Use and Convenience of Each Study Regimen, Based on HCP Responses to the HCPQ - Drug Preparation Room, by Individual Question|Change From Baseline Over Time in Health-Related Quality of Life (HRQoL) as Assessed by the Global Health Status/QoL Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Physical Functioning Scale Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30)|Change From Baseline Over Time in the Role Functioning Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Emotional Functioning Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Cognitive Functioning Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Social Functioning Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Fatigue Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Nausea and Vomiting Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Pain Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Dyspnoea Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Insomnia Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Appetite Loss Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Constipation Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Diarrhoea Scale Score of the EORTC QLQ-C30|Change From Baseline Over Time in the Financial Difficulties Scale Score of the EORTC QLQ-C30|Percentage of Participants with at Least One Adverse Event|Percentage of Participants with at Least One Grade ≥3 Adverse Event, Severity Assessed According to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0)|Percentage of Participants with Heart Failure|Percentage of Participants with Left Ventricular Ejection Fraction (LVEF) Decreases of At Least 10 Percentage Points From Baseline and to Below 50%|Percentage of Participants who Withdraw Prematurely from Study Treatment|Percentage of Participants with an Adverse Event of Abnormal Targeted Vital Signs|Percentage of Participants with an Adverse Event of Abnormal Physical Examination Findings|Percentage of Participants with an Adverse Event of Abnormal Targeted Clinical Laboratory Test Results|Kaplan-Meier Estimate of the Percentage of Participants in Invasive Disease-Free Survival|Kaplan-Meier Estimate of the Percentage of Participants in Invasive Disease-Free Survival Including Second Primary Non-Breast Cancer|Kaplan-Meier Estimate of the Percentage of Participants in Distant Disease-Free Survival|Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,140,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MO40628|2018-002153-30,12/19/18,03/31/20,10/04/22,09/17/18,null,25-Apr-19,"Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center - Lakewood (West), Lakewood, Colorado, United States|Northside Hospital, Atlanta, Georgia, United States|University of Chicago Medical Center; Cancer Research Center, Chicago, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center, Sioux City, Iowa, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Univ of Michigan Medical Ctr, Ann Arbor, Michigan, United States|St. John'S Mercy Medical Center; David C. Pratt Cancer Center, Saint Louis, Missouri, United States|USOR - Compass Oncology - East, Portland, Oregon, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Memorial City, Houston, Texas, United States|USOR - Texas Oncology - San Antonio Northeast, San Antonio, Texas, United States|Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler, Texas, United States|Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg, Virginia, United States|Inst. Alexander Fleming; Oncology Dept, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|ICTR Curitiba, Curitiba, PA, Brazil|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, Brazil|Instituto do Radium de Campinas Ltda, Campinas, SP, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, SP, Brazil|Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia, Sao Paulo, SP, Brazil|Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas, Recoleta, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Hospital Hermanos Ameijeiras, La Habana, Cuba|Instituto Nacional de Oncología y Radiología (INOR), La Habana, Cuba|KYS Sadesairaala; Syopatautien poliklinikka, Kuopio, Finland|VAASAN KESKUSSAIRAALA; Onkologian poliklinikka, Vaasa, Finland|Princess Margaret Hospital, Oncology; Department of Oncology, Hong Kong, Hong Kong|Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong|King Hussein Cancer Center, Amman, Jordan|Bellevue Medical Center, El-Ment, Lebanon|Hammoud Hospital, Saida, Lebanon|Consultorio Privado (José Luis González Trujillo), Leon, Guanajuato, Mexico|Centro Médico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Cuidados oncologicos, Querétaro, Queretaro, Mexico|Centro Oncológico de Panamá, Panama, Panama|Centro Hemato Oncologico Panama, Panama, Panama|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|National Center for Cancer Care and Research, Doha, Qatar|King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia|King Khaled Uni Hospital; Oncology, Riyadh, Saudi Arabia|Institute of Oncology and Radiology of Serbia, Belgrade, Serbia|Clinical Centre Nis, Clinic for Oncology, Nis, Serbia|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Sodersjukhuset; Onkologkliniken, Stockholm, Sweden|Västmanlands sjukhus Västerås, Onkologkliniken, Västerås, Sweden",,https://ClinicalTrials.gov/show/NCT03674112
HER2+,46,179,1,NCT03379428,Ph 2,22,HER2+Other Combo,Other Combo,2L+,Breast Only,Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer,,Recruiting,No Results Available,Breast Neoplasms|Malignant Neoplasm of Breast,Drug: Trastuzumab|Drug: Ibrutinib 560 mg|Drug: Ibrutinib 840 mg|Drug: Ibrutinib 420 mg,Phase I: Maximum Tolerated Dose|Phase II: Clinical Benefit Rate|Objective Response Rate|Median Overall Survival|Median Progression-free Survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of ibrutinib plus trastuzumab.|Pharmacokinetic Analysis for Ibrutinib (Phase I only)- Cmax|Pharmacokinetic Analysis for Ibrutinib (Phase I only)- Area under Curve,US Oncology Research|AbbVie|Pharmacyclics LLC.,Female,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,51,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14059|14-05914-059,11/29/17,12/01/19,12/01/21,12/20/17,null,21-Mar-19,"10 sites incl TX, WA, VA, and NV, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03379428
HER2+,46,180,1,NCT02682693,Ph 2,22,HER2+Other Combo,Other Combo,Neo-adj,Breast Only,Denosumab as an add-on Neoadjuvant Treatment (GeparX),,"Active, not recruiting",No Results Available,Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III,Drug: Denosumab|Drug: nab-Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab,pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC.|pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks|To test for interaction of denosumab treatment with RANK expression.|To assess the pCR rates per arm for both randomizations separately for TNBC and HR-/HER2+ tumors.,German Breast Group|Amgen|Celgene Corporation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,780,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GBG 88,02/13/17,10/01/19,12/01/19,02/15/16,null,1-Apr-19,"Charité Campus Mitte, Berlin, Germany",,https://ClinicalTrials.gov/show/NCT02682693
HER2+,46,181,1,NCT03319459,Ph 1,22,HER2+Other Combo,Other Combo,2L+,Breast + Other,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,,Recruiting,No Results Available,HER2 Positive Gastric Cancer|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|EGFR Positive Solid Tumor|Advanced Solid Tumors|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer,Drug: FATE-NK100|Drug: Cetuximab|Drug: Trastuzumab,Incidence of dose-limiting toxicity (DLT)|Objective-response rate (ORR)|FATE-NK100 persistence,Fate Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,100,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NK-101,01/18/18,10/01/21,10/01/22,10/24/17,null,4-Apr-19,"UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota, Minneapolis, Minnesota, United States|The Ohio State University James Cancer Hospital, Columbus, Ohio, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT03319459
HER2+,46,182,1,NCT03429101,Ph 1,22,HER2+Other Combo,Other Combo,2L+,Breast Only,A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer,,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Poziotinib|Drug: T-DM1,Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression-free Survival (PFS),"Spectrum Pharmaceuticals, Inc",Female,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SPI-POZ-101,04/04/18,01/15/21,06/15/21,02/12/18,null,6-Feb-19,"Pacific Cancer Medical Center, Inc., Anaheim, California, United States",,https://ClinicalTrials.gov/show/NCT03429101
HER2+,46,183,1,NCT03767335,Ph 1,22,HER2+Other Combo,Other Combo,2L+,Breast Only,MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer,,Recruiting,No Results Available,Advanced or Metastatic Breast Cancer,Drug: MEN1611|Drug: Trastuzumab|Drug: Fulvestrant,Maximum Tolerated Dose (MTD) and Recommended Phase 2 dose (RP2D)|Treatment emergent adverse events (TEAEs)|Progression Free Survival|Overall Survival,Menarini Group,Female,"18 Years and older   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEN1611-01|2017-004631-36,07/19/18,07/31/20,07/31/20,12/06/18,null,16-Jan-19,"Cliniques Universitaires Saint-Luc, Brussels, Belgium|Institut Jules Bordet, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Centre Georges François Leclerc, Dijon, France|Institut Régional du Cancer de Montpellier, Montferrier Sur Lez, France|ICO - Site René Gauducheau, Saint-Herblain, France|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|START Madrid Fundacion Jimenez Diaz, Madrid, Spain|Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Sarah Cannon Research Institute UK, London, United Kingdom|The Christie, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT03767335
HER2+,46,184,1,NCT03308201,Ph 1,22,HER2+Other Combo,Other Combo,2L+,Breast Only,Study Evaluating Hemay022 in Combination With Exemestane In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: Hemay022|Drug: exemestane,Number of participants with adverse events|Objective response rate (complete response rate + partial response rate) according to RECIST v1.1|Clinical benefit rate defined as percentage of patients with stable disease (SD) ≥ 6 months/partial response (PR)/complete response (CR). according to RECIST v1.1|Progression Free Survival defined as the proportion of patients alive and without progression (according to RECIST v1.1 criteria)|Observed maximum concentration of Hemay022 and exemestane|Time of maximum concentration of Hemay022 and exemestane|Area under the plasma concentration versus time curve of Hemay022 and exemestane|Trough Plasma Concentrations of Hemay022 and exemestane,"Tianjin Hemay Pharmaceutical Co.,Ltd",Female,"18 Years and older   (Adult, Older Adult)",Phase 1,48,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HM022BC1C01,10/16/17,03/01/19,07/01/19,10/12/17,null,19-Jun-18,"Beijing Cancer Hospital, Beijing, China",,https://ClinicalTrials.gov/show/NCT03308201
HER2+,46,185,1,NCT03523585,Ph 3,19,HER2+Other Mono,Other Mono,2L+,Breast Only,DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02],,Recruiting,No Results Available,Breast Cancer,Drug: Trastuzumab deruxtecan|Drug: Capecitabine|Drug: Lapatinib|Drug: Trastuzumab,Progression-free survival (PFS) based on blinded independent central review (BICR)|Overall survival (OS)|Objective response rate (ORR) based on BICR and investigator assessment|Duration of response (DoR) based on BICR and investigator's assessment|Clinical benefit rate (CBR) based on BICR and investigator assessment|Progression-free survival (PFS) based on investigator's assessment,"Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,600,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DS8201-A-U301|2018-000221-31|184017,08/01/18,02/01/22,02/01/22,05/14/18,null,3-May-19,"Ironwood Cancer Research Centers, Chandler, Arizona, United States|UCLA Hematology Oncology - Main Site, Los Angeles, California, United States|Pacific Cancer Care, Monterey, California, United States|Cancer Research Collaboration, Santa Ana, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|Community Hospital, Munster, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Cornell-Beshore Cancer Institute, Joplin, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States|The Ohio State University, Columbus, Ohio, United States|Dayton Physicians, LLC, Kettering, Ohio, United States|Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Community Cancer Trials of Utah, Ogden, Utah, United States|MultiCare Health System Institute for Research and Innovation, Tacoma, Washington, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peninsula and South Eastern Haematology & Oncology Group, Frankston, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sunshine Hospital, Saint Albans, Victoria, Australia|AZ Maria Middelares, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHU UCL Namur site de Sainte Elisabeth, Namur, Belgium|Fakultni nemocnice v Motole, Prague 5, Czechia|Nemocnice Na Bulovce, Praha, Czechia|Hôpital Nord - CHU Marseille, Marseille cedex 20, Bouches-du-Rhône, France|Centre François Baclesse, Caen Cedex 05, Calvados, France|CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie, Plérin, Cotes d'Armor, France|CHU Besançon - Hôpital Jean Minjoz, Besançon, Doubs, France|Hôpital Privé d'Antony, Antony, Hauts De Seine, France|Centre René Huguenin, Saint-Cloud, Hauts De Seine, France|Institut Régional du Cancer de Montpellier, Montpellier, Herault, France|Centre Oscar Lambret, Lille cedex, Nord, France|Institut Curie - site de Paris, Paris Cedex 05, Paris, France|Centre Hospitalier de la côte Basque, Bayonne Cedex, Pyrenees Atlantiques, France|Centre Hospitalier Lyon Sud, Pierre Benite cedex, Rhone, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans Cedex 02, Sarthe, France|Institut Sainte Catherine, Avignon Cedex 9, Vaculuse, France|Institut Gustave Roussy, Villejuif cedex, Val De Marne, France|Institut Régional du Cancer de Montpellier, Montpellier, France|Institut Curie - site de Paris, Paris, France|Hopital Tenon, Paris, France|251 General Air Force Hospital, Athens, Greece|General Hospital of Athens ""Alexandra"", Athens, Greece|General Oncology Hospital of Kifissia "" Agioi Anargyroi"", Athens, Greece|Euromedica General Clinic Thessaloniki, Thessaloníki, Greece|Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte, Messina, Italy|Ospedale San Raffaele, Milano, Italy|Fukushima Medical University Hospital, Fukushima-shi, Fukushima-Ken, Japan|National Cancer Center Hospital, Chuo Ku, Tokyo-To, Japan|NHO Shikoku Cancer Center, Ehime, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|NHO Hokkaido Cancer Center, Hokkaido, Japan|Hyōgo College of Medicine Hospital, Hyōgo, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kyoto University Hospital, Kyoto, Japan|Tohoku University Hospital, Miyagi, Japan|Aichi Cancer Center Hospital, Nagoya, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|NHO Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Toranomon Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Infanta Cristina, Badajoz, Spain|Hospital Quironsalud Barcelona, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncologia IVO, Valencia, Spain|Derriford Hospital, Plymouth, Devon, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Grampian Region, United Kingdom|University College London Hospitals, London, Greater London, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03523585
HER2+,46,186,1,NCT03529110,Ph 3,19,HER2+Other Mono,Other Mono,2L+,Breast Only,"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]",,Recruiting,No Results Available,Breast Cancer,Drug: Trastuzumab deruxtecan (DS-8201a)|Drug: Ado-trastuzumab emtansine (T-DM1),Progression-free survival (PFS) based on blinded independent central review (BICR)|Overall survival (OS)|Objective response rate (ORR) based on BICR and investigator's assessment|Duration of response (DoR) based on BICR and investigator's assessment|Clinical benefit rate (CBR)|Progression-free survival (PFS) based on investigator's assessment,"Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DS8201-A-U302|2018-000222-61|183976,07/20/18,02/01/22,02/01/22,05/18/18,null,10-May-19,"UCLA Hematology Oncology, Los Angeles, California, United States|Pacific Cancer Care, Monterey, California, United States|Cancer Research Collaboration, Santa Ana, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Mercy Medical Center, Baltimore, Maryland, United States|Research Medical Center, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Seidman Cancer Center, Cleveland, Ohio, United States|Dayton Physicians, LLC, Kettering, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Chattanooga, Tennessee, United States|Tennessee Oncology- St Thomas Location, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|The University of Texas Health Science Center at Tyler, Tyler, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|MultiCare Health System Institute for Research and Innovation, Auburn, Washington, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peninsula and South Eastern Haematology & Oncology Group, Frankston, Victoria, Australia|Peter MacCallum Cancer, Melbourne, Victoria, Australia|St John of God Subiaco Hospital, Subiaco, Western Australia, Australia|Institut Jules-Bordet, Bruxelles, Belgium|AZ Sint-Lucas - Campus Sint-Lucas, Gent, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|CHU UCL Namur site de Sainte Elisabeth, Namur, Belgium|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Centre Paul Strauss, Strasbourg Cedex, Bas Rhin, France|Hôpital Nord - CHU Marseille, Marseille Cedex 20, Bouches-du-Rhone, France|Centre François Baclesse, Caen Cedex 05, Calvados, France|CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie, Plérin, Cotes d'Armor, France|CHRU Jean Minjoz, Besançon, Doubs, France|ICM Val d'Aurelle, Montpellier, Herault, France|CRLCC Eugene Marquis, Rennes cedex, Ille Et Vilaine, France|Institut de cancérologie de l'ouest, site René Gauducheau, Saint-Herblain, Loire Atlantique, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, Rhone, France|Clinique Victor Hugo - Centre Jean Bernard, LeMans Cedex 02, Sarthe, France|Institut Sainte Catherine, Avignon Cedex 9, Vaculuse, France|Hôpital d'Instruction des Armees Begin*, Saint-Mandé, Val De Marne, France|Institut Gustave Roussy, Villejuif cedex, Val De Marne, France|Institut Curie - site de Paris, Paris, France|Hopital Tenon, Paris, France|Queen Mary Hospital, Hong Kong, Hong Kong|Chinese University of Hong Kong, Shatin, Hong Kong|Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte, Messina, Italy|Ospedale San Raffaele, Milano, Italy|Aichi Cancer Center Hospital, Aichi, Japan|NHO Shikoku Cancer Center, Ehime, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|NHO Hokkaido Cancer Center, Hokkaido, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|Niigata Cancer Center, Niigata, Japan|Okayama University Hospital, Okayama, Japan|NHO Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Satiama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Showa University Hospital, Tokyo, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Universitario Virgen Macarena, Sevilla, Sevill, Spain|Hospital Infanta Cristina, Badajoz, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|IOB-Institute of Oncology, Barcelona, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Koo Foundation, Sun Yat-Sen Cancer Center, Taipei, Taiwan|Aberdeen Royal Infirmary, Aberdeen, Grampian Region, United Kingdom|University College London Hospitals, London, Greater London, United Kingdom|Guy's Hospital, London, Greater London, United Kingdom|Western General Hospital, Edinburgh, Lothian Region, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, Nottinghamshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT03529110
HER2+,46,187,1,NCT02771795,Ph 3,19,HER2+Other Mono,Other Mono,Neo-adj,Breast Only,A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC,,"Active, not recruiting",No Results Available,Breast Neoplasms,Drug: Herceptin (trastuzumab)|Drug: SB3 (proposed trastuzumab biosimilar),The incidence of congestive heart failure and LVEF decrease,"Samsung Bioepis Co., Ltd.",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,367,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SB3-G31-BC-E,04/01/16,12/01/21,12/01/21,05/13/16,null,4-Apr-19,"Complex Oncological Center - Vratsa, EOOD, Vratsa, Bulgaria|ONKOCENTRUM Medicon Services s.r.o., Praha, Czechia|CHU Besançon - Hôpital Jean Minjoz, Besançon, France|Centre Hospitalier de Belfort-Montbeliard, Montbéliard, France|Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie w Bialymstoku, Bialystok, Poland|Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii I Radioterapii, Gdansk, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej, Olsztyn, Poland|Samodzielny Publiczny ZOZ Opolskiego Centrum Onkologii w Opolu im. T. Koszarowskiego, Opole, Poland|Wielkopolskie Centrum Onkologii, im Marii Sklodowskiej-Curie, Poznań, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland|Magodent Sp. Z o.o., Warszawa, Poland|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"" Baia Mare, Baia Mare, Romania|SC Centrul Medical Unirea SRL-Policlinica Baneasa, Specialitatea Oncologie Medicala, Bucuresti, Romania|Spitalul Clinic Filantropia, Compartimentul Oncologie Ginecologica, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Cluj Napoca, Cluj-Napoca, Romania|Spitalul Municipal Ploiesti, Sectia Oncologie Medicala, Ploiesti, Romania|S.C Oncomed S.R.L, Timisoara, Romania|Spitalul Clinic Municipal de Urgenta Timisoara, Timisoara, Romania|SBHI of Moscow City ""Moscow City Oncology Hospital №62"" of Moscow Healthcare Department, Istra, Krasnogorsk District, Russian Federation|S.I. Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Medical Research Center n.a. P.A Gertsen"" of Ministry of healthcare of RF/3, Moscow, Russian Federation|SBI of Ryazan region ""Regional Clinical Oncological Dispensary"", Ryazan, Russian Federation|Non-state Healthcare Institution ""Roadway Clinical Hospital of OJSC Russian Railways"", Saint Petersburg, Russian Federation|Saint-Petersburg SBHI ""City Clinical Oncology Dispensary"", Saint Petersburg, Russian Federation|SBHI ""Leningrad Regional Oncology Dispensary"", Saint-Petersburg, Russian Federation|FSI ""Scientific and Research Institution of Oncology n.a. N.N.Petrov"" of Ministry of Healthcare and SD of RF, Saint-Petersburg, Russian Federation|SBHI ""Saint-Petersburg Scientific and Practical Center of Specialized Methods of Medical Help (oncological), Saint-Petersburg, Russian Federation|SHBI of Yaroslavl Region ""Regional Clinical Oncology Hospital"", Yaroslavl, Russian Federation|BHI of Omsk Region ""Clinical Oncology Dispensary"", Оmsk, Russian Federation|Communal Institution Cherkasy Regional Oncological Dispensary of Cherkasy Regional Council, Cherkasy, Ukraine|Communal Institution Dnipropetrovsk City Multifield Clinical Hospital No.4 of Dnipropetrovsk Regional Council, Dnipropetrovsk, Ukraine|Communal Non-commercial Enterprise Regional Center of Oncology, Kharkiv, Ukraine|Communal Institution of Kherson Regional Council Kherson Regional Oncological Dispensary, Kherson, Ukraine|Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Regional Communal Institution Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|Uzhgorod Central City Clinical Hospital City Oncological Center, Uzhgorod, Ukraine|Vinnytsia Regional Clinical Oncological Dispensary, Vinnytsia, Ukraine|Communal Institution Zaporizhzhia Regional Clinical Oncological Dispensary of Zaporizhzhia Regional Council, Zaporizhzhia, Ukraine",,https://ClinicalTrials.gov/show/NCT02771795
HER2+,46,188,1,NCT03556358,Ph 3,19,HER2+Other Mono,Other Mono,Neo-adj,Breast Only,"Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer",,Recruiting,No Results Available,Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer,Biological: TX05 (trastuzumab)|Biological: Herceptin®|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide,Pathologic complete response (pCR)|Objective response rate (ORR),"Tanvex BioPharma USA, Inc.",Female,"18 Years and older   (Adult, Older Adult)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",TX05-03,06/28/18,02/01/20,03/01/20,06/14/18,null,15-Apr-19,"Tanvex Investigational Site, Lesnoy, Minsk Region, Belarus|Tanvex Investigational Site, Babruysk, Mogilev Region, Belarus|Tanvex Investigational Site, Gomel, Belarus|Tanvex Investigational Site, Grodno, Belarus|Tanvex Investigational Site, Minsk, Belarus|Tanvex Investigational Site, Mogilev, Belarus|Tanvex Investigational Site, Vitebsk, Belarus|Tanvex Investigational Site, Temuco, Chile|Tanvex Investigational Site, Viña Del Mar, Chile|Tanvex Investigational Site, Batumi, Georgia|Tanvex Investigational Site, Batumi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Tbilisi, Georgia|Tanvex Investigational Site, Budapest, Hungary|Tanvex Investigational Site, Debrecen, Hungary|Tanvex Investigational Site, Győr, Hungary|Tanvex Investigational Site, Miskolc, Hungary|Tanvex Investigational Site, Pécs, Hungary|Tanvex Investigational Site, Nashik, Maharashtra, India|Tanvex Investigational Site, Nashik, Maharashtra, India|Tanvex Investigational Site, Pune, Maharashtra, India|Tanvex Investigational Site, Pune, Maharashtra, India|Tanvex Investigational Site, Pune, Maharashtra, India|Tanvex Investigational Site, Bīkaner, Rajasthan, India|Tanvex Investigational Site, Madurai, Tamil Nadu, India|Tanvex Investigational Site, Zapopan, Jalisco, Mexico|Tanvex Investigational Site, Ciudad de Mexico, Mexico|Tanvex Investigational Site, Trujillo, La Libertad, Peru|Tanvex Investigational Site, Chiclayo, Lambayeque, Peru|Tanvex Investigational Site, San Borja, Lima, Peru|Tanvex Investigational Site, Arequipa, Peru|Tanvex Investigational Site, Lima, Peru|Tanvex Investigational Site, Lima, Peru|Tanvex Investigational Site, Lima, Peru|Tanvex Investigational Site, Lima, Peru|Tanvex Investigational Site, Santo Tomas, Batangas, Philippines|Tanvex Investigational Site, Cebu City, Cebu, Philippines|Tanvex Investigational Site, Quezon City, Manila, Philippines|Tanvex Investigational Site, Manila, Metro Manila, Philippines|Tanvex Investigational Site, Makati City, National Capital Reg, Philippines|Tanvex Investigational Site, Quezon City, National Capital Reg, Philippines|Tanvex Investigational Site, Quezon City, NCR, Philippines|Tanvex Investigational Site, Bacolod City, Negros Occidental, Philippines|Tanvex Investigational Site, Davao City, Philippines|Tanvex Investigational Site, Manila, Philippines|Tanvex Investigational Site, Łódź, Poland|Tanvex Investigational Site, Krasnodar, Krasnodar Region, Russian Federation|Tanvex Investigational Site, Sochi, Krasnodar Region, Russian Federation|Tanvex Investigational Site, Omsk, Omsk Region, Russian Federation|Tanvex Investigational Site, Ufa, Republic Of Bashkortostan, Russian Federation|Tanvex Investigational Site, Pushkin, Saint Petersburg, Russian Federation|Tanvex Investigational Site, Novosibirsk, Siberia, Russian Federation|Tanvex Investigational Site, Pyatigorsk, Stavropol Region, Russian Federation|Tanvex Investigational Site, Tomsk, Tomsk Region, Russian Federation|Tanvex Investigational Site, Arkhangel'sk, Russian Federation|Tanvex Investigational Site, Belgorod, Russian Federation|Tanvex Investigational Site, Ivanovo, Russian Federation|Tanvex Investigational Site, Izhevsk, Russian Federation|Tanvex Investigational Site, Kaluga, Russian Federation|Tanvex Investigational Site, Krasnoyarsk, Russian Federation|Tanvex Investigational Site, Kursk, Russian Federation|Tanvex Investigational Site, Moscow, Russian Federation|Tanvex Investigational Site, Moscow, Russian Federation|Tanvex Investigational Site, Moscow, Russian Federation|Tanvex Investigational Site, Omsk, Russian Federation|Tanvex Investigational Site, Rostov-Na-Donu, Russian Federation|Tanvex Investigational Site, Saint Petersburg, Russian Federation|Tanvex Investigational Site, Saint Petersburg, Russian Federation|Tanvex Investigational Site, Saint Petersburg, Russian Federation|Tanvex Investigational Site, Saint Petersburg, Russian Federation|Tanvex Investigational Site, Saint Petersburg, Russian Federation|Tanvex Investigational Site, Saint-Petersburg, Russian Federation|Tanvex Investigational Site, Saransk, Russian Federation|Tanvex Investigational Site, St. Petersburg, Russian Federation|Tanvex Investigational Site, Tomsk, Russian Federation|Tanvex Investigational Site, Yaroslavl, Russian Federation|Tanvex Investigational Site, Chernihiv, Ukraine|Tanvex Investigational Site, Dnipro, Ukraine|Tanvex Investigational Site, Kherson, Ukraine|Tanvex Investigational Site, Kiev, Ukraine|Tanvex Investigational Site, Kiev, Ukraine|Tanvex Investigational Site, Kryvyi Rih, Ukraine|Tanvex Investigational Site, Odesa, Ukraine|Tanvex Investigational Site, Sumy, Ukraine|Tanvex Investigational Site, Vinnitsya, Ukraine|Tanvex Investigational Site, Zaporizhzhia, Ukraine",,https://ClinicalTrials.gov/show/NCT03556358
HER2+,46,189,1,NCT01810393,Ph 3,19,HER2+Other Mono,Other Mono,1L,Breast Only,A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years,,"Active, not recruiting",No Results Available,Breast Cancer,Drug: Trastuzumab,Percentage of Participants With Preference for Either SC or IV Route of Administration According to Participant Preference Questionnaire (PPQ) Score|Percentage of Participants With Adverse Events|Percentage of Health Care Professionals With Preference for Either SC or IV Administration According to Health Care Professional Questionnaire (HCPQ) Score,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,114,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML28589|2012-003442-32,06/11/13,08/10/19,08/10/19,03/13/13,null,6-Mar-19,"Clinique Du Docteur Calabet; Cromg, Agen, France|Clinique De L Europe; Radiotherapie Chimiotherapie, Amiens, France|ICO Paul Papin; Oncologie Medicale., Angers, France|HOP Prive Arras Les Bonnettes; Chimiotherapie, Arras, France|Ch D Auxerre; Oncologie, Auxerre, France|Institut Sainte-Catherine; Oncologie, Avignon, France|Centre Hospitalier de La Cote Basque; Oncologie, Bayonne, France|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Hospitalier Fleyriat; Oncologie/Hematologie, Bourg En Bresse, France|Hopital Morvan, Brest, France|Clinique Pasteur Lanroze; Chimiotherapie Radiotherapie, Brest, France|Centre Francois Baclesse; Oncologie, Caen, France|Ch De Chambery; Hematologie Oncologie, Chambery, France|Centre Jean Perrin; Oncologie, Clermont Ferrand, France|Pole Sante Republique;Oncologie Hematologie, Clermont Ferrand, France|Chi De Creteil; Radiotherapie Oncologie, Creteil, France|Centre Leonard De Vinci;Chimiotherapie, Dechy, France|Fondation Clement Drevon; Oncology, Dijon, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|CHD Les Oudairies, La Roche Sur Yon, France|Ch Louis Pasteur; Oncologie, Le Coudray, France|Clinique des Ormeaux; Oncologie, Le Havre, France|Clinique Victor Hugo; Radiotherapie, Le Mans, France|Polyclinique Du Bois; Oncologie, Lille, France|Centre Oscar Lambret; Unite de Recherche Clinique, Lille, France|Ch Bretagne Sud Site Scorff; Oncologie Medicale, Lorient, France|Centre Leon Berard, Lyon, France|Clinique De La Sauvegarde; Chimiotherapie, Lyon, France|Hopital Prive Jean Mermoz, Lyon, France|Institut Paoli Calmettes; Oncologie Medicale, Marseille, France|Hopital de Mercy ;ONCOLOGIE MEDICALE, Melz, France|Hopital Belle Isle; Oncologie Hematologie, Metz, France|Clinique Clementville; Hopital De Jour, Montpellier, France|Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE, Nancy, France|Centre Catherine de Sienne; Chimiotherapie, Nantes, France|Polyclinique Du Languedoc; Chimiotherapie, Narbonne, France|Clinique Henry Hartmann; Oncologie, Neuilly Sur Seine, France|Centre Antoine Lacassagne, Nice, France|Clinique Valdegour, Nimes, France|HOPITAL DE LA SOURCE; Service de Cardiologie, Point Jaune, Orleans, France|APHP - Hopital de la Pitie Salpetriere, Paris, France|Groupe Hospitalier Diaconesses, Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis; Oncologie Medicale, Paris, France|HOPITAL TENON; Cancerologie Medicale, Paris, France|Polyclinique Francheville; MED CHIMIOTHERAPIE RADIOTHERAPIE, Perigueux, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Hospitalier Universitaire de Poitiers, Poitiers cedex, France|CH d'Annecy, Pringy, France|Chi De Cornouaille; Oncologie Hospitalisation, Quimper, France|Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, France|Institut du Cancer Coulancy Reims, Reims, France|Centre Eugene Marquis; Bureau D Etudes Cliniques, Rennes, France|Centre Henri Becquerel; Oncologie Medicale, Rouen, France|Chp Saint Gregoire; Cancerologie Radiotherapie, Saint Gregoire, France|Centre Rene Gauducheau, Saint Herblain, France|Polyclinique de la Cote Basque Sud; Oncologie, Saint Jean de Luz, France|Clinique Mutualiste L Estuaire, Saint Nazaire, France|CH de Saint Quentin, Saint Quentin, France|Hopital Prive Nord Parisien; Soins De Suite - Oncologie, Sarcelles, France|CMCO De La Cote D Opale; Auberge De Jour, St Martin Boulogne, France|Institut de Cancérologie de Loire, St-Priest-En-Jarez, France|Clinique Ste Anne, Strasbourg, France|Clinique Chir De L Orangerie; Chimiotherapie, Strasbourg, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Hopital de Hautepierre, Strasbourg, France|Hopital Sainte Musse; Oncologie Hematologie, Toulon, France|Hôpital Rangueil - CHU de Toulouse, Toulouse, France|Clinique Pasteur; Oncologie Medicale, Toulouse, France",,https://ClinicalTrials.gov/show/NCT01810393
HER2+,46,190,1,NCT03262935,Ph 3,19,HER2+Other Mono,Other Mono,2L+,Breast Only,SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer,,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: (vic-)trastuzumab duocarmazine|Drug: Physician's choice,Progression Free Survival|Overall Survival|Objective Response Rate|Investigator assessed Progression Free Survival|Patient reported outcomes for health related quality of life,Synthon Biopharmaceuticals BV,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,345,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SYD985.002,11/30/17,05/01/19,05/01/21,08/25/17,null,16-May-19,"Southern Cancer Center, Mobile, Alabama, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Moores UCSD Cancer Center, San Diego, California, United States|Woodlands Medical Specialists, Pensacola, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina, United States|Toledo Clinic Cancer Center, Toledo, Ohio, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Magee-Womens Hospital of UPMS, Pittsburgh, Pennsylvania, United States|Texas Oncology PA (Texas Oncology-Dallas Presbyterian Hospital), Dallas, Texas, United States|Texas Oncology- Baylor Charles A. Sammor, Dallas, Texas, United States|Texas Oncology - Denton South, Denton, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Texas Oncology-San Antonio Northeast, San Antonio, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Institut Jules Bordet, Brussel, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|University Hospital Antwerp, Edegem, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven - campus Gasthuisberg, Leuven, Belgium|CHU Liege, Liege, Belgium|Cross Cancer Institute, Edmonton, Canada|McGill University Health Centre, Montreal, Canada|The Ottawa Hospital Cancer Center, Ottawa, Canada|Sealand University Hospital, Naestved, Denmark|Odense University Hospita, Odense, Denmark|Sønderborg sygehus, Sønderborg, Denmark|Institut de Cancerologie de l'ouest, Angers, France|Institut Bergonie, Bordeaux, France|Centre Georges francois leclerc, Dijon, France|Oscar Lambret, Lille, France|CHR Metz-Thionville, Metz, France|Hopital Saint Louis, Paris, France|Centre Henri Becquere, Rouen, France|Centre Paul Strauss, Strasbourg, France|IRCCS Istituto Oncologico, Bari, Italy|Policlinico S.Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Garibaldi- Nesima, Catania, Italy|Azienda Ospedaliero - Universitaria Careggi, Firenze, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|University Hospital of Modena, Modena, Italy|Ospedale San Gerardo-Asst Monza, Monza, Italy|Istituto Oncologico Veneto Irccs, Padova, Italy|Nuovo Ospedale Santo Stefano, Prato, Italy|Istituto Nazionale dei Tumori Regina Elena, Roma, Italy|Azienda Ospedaliera Sant'Andrea, Roma, Italy|Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy|Radboud University Medical Center, Nijmegen, Gelderland, Netherlands|VU Medical Center, Amsterdam, Noord-Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands|National University Cancer Institute, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Quironsalud, Barcelona, Spain|Hospital Universitari Vall d'Hebron Vall d' Hebron Institute of Oncology (VHIO), Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Institut Catala D'oncologia, Barcelona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|IOB del Hospital Ruber Internacional, Madrid, Spain|Hospital HM Universitario Sanchinarro, Madrid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Gävle Sjukhus Onkologkliniken, Gävle, Sweden|Sahlgrenska University Hospital, Göteborg, Sweden|Karolina University Hospital, Stockholm, Sweden|Akademiska Hospital, Uppsala, Sweden|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom|Velindre Cancer Centre VCC, Cardiff, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|SCRI UK, London, United Kingdom|The Christie NHS Foundation, Manchester, United Kingdom|Oxford University NHS hospital, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03262935
HER2+,46,191,1,NCT03084939,Ph 3,19,HER2+Other Mono,Other Mono,1L,Breast Only,Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer,,"Active, not recruiting",No Results Available,Breast Cancer,Biological: Trastuzumab Emtansine|Drug: Lapatinib|Drug: Capecitabine,Progression-free survival (PFS)|Objective Response Rate (ORR)|Duration of Response (DOR)|Overall Survival (OS)|Number of Participants with Adverse Events|Serum Concentration of Trastuzumab Emtansine Conjugate|Plasma Concentration of N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine (DM1)|Serum Concentration of Total Trastuzumab|Percentage of Participants with Anti-therapeutic Antibodies (ATA) to Trastuzumab Emtansine|Patient-reported Outcome: Percentage of Participants with Clinically Significant Deterioration|Patient-reported Outcome: Time to Clinically Significant Deterioration,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,351,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO29919,04/24/17,04/30/19,10/05/19,03/21/17,null,27-Feb-19,"Beijing Hospital, Beijing City, China|The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA), Beijing, China|Beijing Cancer Hospital, Beijing, China|Jilin Cancer Hospital, Changchun, China|the First Hospital of Jilin University, Changchun, China|Changzhou First People's Hospital, Changzhou, China|West China Hospital, Sichuan University, Chengdu, China|Fujian Medical University Union Hospital, Fujian, China|Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou City, China|The Second Affiliated Hospital of Zhejiang University College, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Tianjin Cancer Hospital, Tianjin, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China",,https://ClinicalTrials.gov/show/NCT03084939
HER2+,46,192,1,NCT03013504,Ph 3,19,HER2+Other Mono,Other Mono,Neo-adj,Breast Only,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients",,"Active, not recruiting",No Results Available,HER2 Positive Breast Cancer,Drug: HD201|Drug: Herceptin|Drug: Docetaxel|Drug: Epirubicin|Drug: Cyclophosphamide,"total pathological complete response rate (tpCR)|total breast pathological complete response rate (bpCR)|Overall response rate (ORR)|Overall Survival (OS)|Event-free Survival (EFS)|Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)|Cardiac dysfunction|Immunogenecity|Clearance (Pharmacokinetic)|Area under the curve (AUC, Pharmacokinetic)|Plasma half life (Pharmacokinetic)",Prestige Biopharma Pte Ltd,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,500,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TROIKA,01/01/18,04/01/19,04/01/20,01/06/17,null,18-Feb-19,"Minsk Clinical Oncological Dispensary, Minsk, Belarus|Complex Oncology Center, Plovdiv, Bulgaria|East Tallinn Central Hospital, Tallinn, Estonia|Centre René Huguenin (Institut Curie), Saint-Cloud, France|S. Khechinashvili University Hospital, Tbilisi, Georgia|National Institute of Oncology, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Modena Hospital, Modena, Italy|Beacon International Specialist Centre, Kuala Lumpur, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Szpital Specjalistyczny Brzeziny, Brzeziny, Poland|LLC ""Vitamed"", Moscow, Russian Federation|Hospital Universitario Virgen Macarena, Sevilla, Spain|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|GI ""V. T. Zaycev Institute General and Urgent Surgery of NAMS of Ukraine "", Kharkiv, Ukraine",,https://ClinicalTrials.gov/show/NCT03013504
HER2+,46,193,1,NCT03684863,Ph 2,19,HER2+Other Mono,Other Mono,Adj,Breast Only,Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy,,Not yet recruiting,No Results Available,HER2-positive Breast Cancer,Drug: Capecitabine,disease free survival(DFS)|overall survival(OS)|medicine safety,Shandong Cancer Hospital and Institute,Female,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ShandongCHI-06,10/01/18,12/01/23,12/01/25,09/26/18,null,26-Sep-18,,,https://ClinicalTrials.gov/show/NCT03684863
HER2+,46,194,1,NCT03602079,Ph 2,19,HER2+Other Mono,Other Mono,2L+,Breast + Other,Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene,,Recruiting,No Results Available,HER2-positive Breast Cancer|HER2 Gene Mutation|HER-2 Gene Amplification|HER2 Positive Gastric Cancer|Salivary Gland Cancer|Salivary Gland Tumor|Salivary Gland Carcinoma|Salivary Gland Neoplasms|Lung Cancer|Colo-rectal Cancer|Rare Diseases|Solid Tumor|Recurrent Gastric Cancer|Recurrent Colon Cancer|Recurrent Breast Cancer|Head and Neck Cancer|Head and Neck Carcinoma|Bladder Cancer|Cervical Cancer|Liver Cancer|Bile Duct Cancer|Urologic Cancer|Pancreatic Cancer|Prostate Cancer|Recurrent Prostate Cancer|Rectal Cancer|Recurrent Ovarian Carcinoma|Recurrent Renal Cell Cancer|Rectal Cancer Stage II|Rectal Cancer Stage I|Rectal Cancer Stage III|Skin Cancer|Mouth Cancer|Lip Cancer Stage I|Tongue Cancer|Breast Neoplasm Malignant Primary|Larynx Cancer|Tonsil Cancer|Palate Cancer|Mucoepidermoid Carcinoma|Primary Peritoneal Carcinoma|Mucinous Adenocarcinoma Gastric|Mucinous Breast Cancer Recurrent|Cholangiocarcinoma,Drug: A166,Phase I: Maximum Tolerated Dose|Phase II: Percentage of patients with an Objective Response Rate (ORR) [Complete Response (CR) + Partial Response (PR)]|Phase I: Number of patients with Dose Limiting Toxicities|Phase I: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.|Phase I: Number of participants who developed measurable anti-drug antibodies|Phase II: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.|Phase II: Duration of response (DOR) in patients who responded as determined by RECIST|Phase II: Number of participants who developed measurable anti-drug antibodies|Phase II: Progression Free Survival (PFS)|Phase II: Overall Survival (OS)|Phase I and II: Phase I and II Maximum observed serum or plasma concentration (Cmax).|Phase I and II: Clearance (CL).|Phase I and II: Area under the serum or plasma concentration time curve from 0 to infinity (AUC[0-∞]).|Phase I and II: Terminal phase elimination half life (t½).|Phase I and II: Volume of distribution at terminal phase (Vz).|Phase I and II: Volume of distribution at steady state (Vss).,Klus Pharma Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,82,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KlusPharma,07/16/18,10/01/20,05/01/21,07/26/18,null,13-Mar-19,"Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States|Beth Israel Deaconess Medical Center Cancer Center, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Clinical Research Alliance, Inc., Lake Success, New York, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Cancer Institute, Portland, Oregon, United States|Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States|Virginia Cancer Specialist, Fairfax, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03602079
HER2+,46,195,1,NCT03248492,Ph 2,19,HER2+Other Mono,Other Mono,2L+,Breast Only,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01],,"Active, not recruiting",No Results Available,Breast Cancer,Drug: DS-8201a,Objective response rate (ORR) per imaging assessment|Duration of response|Best percent change in the sum of the longest diameters (SLD) of measurable tumors|Disease control rate (DCR)|Clinical benefit rate (CBR)|Progression-free survival|Overall survival (OS)|ORR assessed by the investigator based on RECIST version 1.1|Maximum plasma/serum concentration (Cmax)|Time to Cmax (Tmax)|Area under the concentration-time curve (AUC) from dosing until the last quantifiable concentration (AUClast)|AUC from the time of dosing until day 21 (AUC0-21d),"Daiichi Sankyo, Inc.|Daiichi Sankyo Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,230,Industry,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DS8201-A-U201|2016-004986-18|JapicCTI-173693(en),08/25/17,02/01/20,02/01/20,08/14/17,null,12-Feb-19,"Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Arizona Oncology Associates, Tucson, Arizona, United States|The Regents of the University of California, Los Angeles, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Sansum Clinic, Santa Barbara, California, United States|Innovative Clinical Research Institute, LLC, Whittier, California, United States|Sylvester Comprehensive Cancer Center - Deerfield Beach, Boca Raton, Florida, United States|Specialist Global Research, Hialeah, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Straub Medical Center, Honolulu, Hawaii, United States|University of Hawaii, Honolulu, Hawaii, United States|Norton Healthcare, Louisville, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists, East Setauket, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Aultman Hospital Cancer Center, Canton, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|St Francis Hospital, Greenville, South Carolina, United States|Accurate Clinical Research, Baytown, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology - Memorial City, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Texas Oncology, P.A. - Longview, Tyler, Texas, United States|The University of Texas Health Science Center at Tyler, Tyler, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Providence Regional Medical Center - Everett, Everett, Washington, United States|Imeldaziekenhuis, Bonheiden, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|UZ Leuven, Leuven, Belgium|CHU Sart Tilman, Liège, Belgium|AZ Sint-Maarten, Mechelen, Belgium|Institut Sainte Catherine, Avignon, France|CHU Besançon - Hôpital Jean Minjoz, Besançon, France|Centre Georges François Leclerc, Dijon, France|CHU Bordeaux - Hôpital Saint André, Gironde, France|CH de la Rochelle - Hopital St Louis, La Rochelle, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Hôpital Nord - CHU Marseille, Marseille, France|Institut Régional du Cancer de Montpellier, Montpellier, France|Centre Catherine de Sienne, Nantes, France|Hôpital Saint-Louis - Paris, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|CRLCC Eugene Marquis, Rennes, France|Hôpital d'Instruction des Armees Begin, Saint-Mandé, France|Centre Paul Strauss, Strasbourg, France|Institut Gustave Roussy, Villejuif, France|Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), Monza, Italy|Ospedale degli Infermi, Rimini, Italy|NHO Shikoku Cancer Center, Matsuyama, Ehime-Ken, Japan|Toranomon Hospital, Minato-Ku, Tokyo-To, Japan|Aichi Cancer Center Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Hakuaikai Sagara Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|St. Luke's International Hospital, Tokyo, Japan|Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Infanta Cristina, Badajoz, Spain|Hospital Universitari Quiron Dexeus, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals, Barcelona, Spain|Hospital Quiron Barcelona, Barcelona, Spain|MD Anderson Cancer Centre, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Derriford Hospital, Plymouth, Devon, United Kingdom|Queen Mary University of London, London, Greater London, United Kingdom|University College London Hospitals, London, Greater London, United Kingdom|Western General Hospital, Edinburgh, Lothian Region, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, Nottinghamshire, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT03248492
HER2+,46,196,1,NCT03500380,Ph 2,19,HER2+Other Mono,Other Mono,2L+,Breast Only,A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer,,Recruiting,No Results Available,Breast Neoplasms|Breast Diseases|Capecitabine|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma,Drug: RC48-ADC|Drug: Lapatinib|Drug: Capecitabine,Progression-free Survival (PFS) as Assessed by an IRC|Progression-free Survival (PFS) as Assessed by Investigator|Objective Response Rate （ORR）|Duration of Objective Response (DOR)|Clinical Benefit Rate （CBR）|Time to Treatment Failure|Overall Survival,RemeGen,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,228,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC48-C006,04/24/18,12/01/19,12/01/20,04/17/18,null,16-May-19,"Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|The First Hospital of China Medical University, Shengyang, Liaoning, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|Peking Union Medical College Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|The First Hospital of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha, China|Affiliated Hospital of Chengde Medical University, Chengde, China|Sichuan Cancer Hospital, Chengdu, China|West China Hospital, Chengdu, China|The Second Hospital of Dalian Medical University, Dalian, China|Fujian Cancer Hospital, Fuzhou, China|Sun Yat-Sen Memorial Hospital, Guangzhou, China|The Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou, China|Guizhou Cancer Hospital, Guiyang, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Anhui Cancer Hospital, Hefei, China|Anhui Province Hospital, Hefei, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|Qilu Hospital of Shandong University, Jinan, China|Shandong Cancer Hospital, Jinan, China|Linyi Cancer Hospital, Linyi, China|The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China|Jiangxi Cancer Hospital, Nanchang, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China|Yunnan Cancer Hospital, Nanning, China|Hospital of Qingdao University, Qingdao, China|Fudan University Shanghai Cancer Center, Shanghai, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Hubei Cancer Hospital, Wuhan, China|Wuhan Union Hospital, Wuhan, China|The First Affiliated Hospital of the Fourth Military University of P.L.A., Xi'an, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China|Xuzhou Central Hospital, Xuzhou, China|Yantai Yuhuangding Hospital, Yantai, China|Henan Cancer Hospital, Zhengzhou, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China",,https://ClinicalTrials.gov/show/NCT03500380
HER2+,46,197,1,NCT03944499,Ph 1,19,HER2+Other Mono,Other Mono,2L+,Breast + Other,"Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Local Advanced or Metastatic, HER2 Positive Breast Cancer.",,Not yet recruiting,No Results Available,Solid Tumor|Breast Cancer,Drug: FS-1502,Dose limiting toxicity (DLT) within 28 days of first single dose of FS-1502.|Overall response rate (ORR) by measurement of target lesions|Incidence Rate and type of treatment emergent adverse event (Safety)|Number of Participants with serious adverse events and adverse reactions that leading to treatment permanent discontinuation of FS1502.|Incidence of deaths and causes within 30 days after the last dose.|Progression free survival (PFS)|Overall survival (OS)|1-year overall survival (OS) rate|Duration of response (DoR)|Clinical benefit response (CBR)|Area under the plasma concentration versus time curve (AUC)|Peak Plasma Concentration (Cmax)|Time to maximum concentration (tmax)|Elimination half life (T1/2)|Clearance (Cl)|Anti-FS-1502 antibody,"Shanghai Fosun Pharmaceutical Development Co, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,92,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FS-CY1502-Ph1-01,05/01/19,01/01/25,06/01/25,05/09/19,null,13-May-19,,,https://ClinicalTrials.gov/show/NCT03944499
HER2+,46,198,1,NCT03451162,Ph 1,19,HER2+Other Mono,Other Mono,2L+,Breast Only,"Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",,Recruiting,No Results Available,Breast Cancer,Drug: DHES0815A,Percentage of Participants with Adverse Events (AEs) and Serious AEs|Percentage of Participants with DLT|MTD of DHES0815A|Recommended Phase 2 Dose (RP2D) of DHES0815A|Concentration of DHES0815A|Area Under the Concentration-Time Curve (AUC) of DHES0815A|Maximum Observed blood Concentration (Cmax) of DHES0815A|Minimum Observed blood Concentration (Cmin) of DHES0815A|Clearance of DHES0815A|Volume of Distribution at Steady State (Vss) of DHES0815A|Percentage of Participants with Objective Response Assessed According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Duration of Response (DoR) Assessed According to RECIST v1.1|Percentage of Participants with Anti-Drug Antibody (ADA) to DHES0815A,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,55,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GO39869,04/17/18,01/01/22,01/01/22,03/01/18,null,1-May-19,"Yale Cancer Center, New Haven, Connecticut, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Columbia Univ Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Asan Medical Center - Oncology, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03451162
HER2+,46,199,1,NCT03284723,Ph 1,19,HER2+Other Mono,Other Mono,2L+,Breast + Other,PF-06804103 Dose Escalation in HER2 Positive Solid Tumors,,Recruiting,No Results Available,"Breast Neoplasms|Stomach Neoplasms|Esophagogastric Junction Neoplasm|Carcinoma, Non-small-cell Lung",Drug: PF-06804103,Number of participants with Dose-Limiting Toxicities (DLTs)|Maximum Observed Concentration (Cmax)|Time to reach maximum observed concentration (Tmax)|Incidence and titers of anti-drug antibodies|Incidence and titers of neutralizing antibodies|Number of participant with objective response|Number of patients with progression free survival|HER2 expression level in patients with documented anti-tumor activity|Area under the curve from time zero to end of dosing interval (AUCtau)|Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast),Pfizer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,95,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C0541001|2017-002538-22,11/01/17,09/14/21,09/14/21,09/15/17,null,6-May-19,"Banner- University Medical Center Tucson Campus LLC, Tucson, Arizona, United States|The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States|Banner-University Medical Center Tucson, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|(IRB#17-001086) Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States|UCLA Hematology/Oncology, Los Angeles, California, United States|Santa Monica - UCLA Medical Center and Orthopaedic Hospital, Santa Monica, California, United States|UCLA Dept of Medicine - Hematology/Oncology, Santa Monica, Santa Monica, California, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Istituto Europeo di Oncologia, Milano, MI, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario HM Sanchinarro, Madrid, Spain",,https://ClinicalTrials.gov/show/NCT03284723
HER2+,46,200,1,NCT03330561,Ph 1,19,HER2+Other Mono,Other Mono,2L+,Breast + Other,PRS-343 in HER2-Positive Solid Tumors,,Recruiting,No Results Available,HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Bladder Cancer|HER2-positive Solid Tumor,Drug: PRS-343,Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Time to maximum dose concentration (Tmax)|Terminal half life (t1/2)|Tumor responses as defined by the Response Evaluation in Solid Tumors (RECIST) v.1.1|Duration of response|Disease control rate,"Pieris Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,78,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRS-343-PCS_04_16,09/28/17,04/01/20,09/01/20,11/06/17,null,25-Apr-19,"University of Arizona Cancer Center, Tucson, Arizona, United States|University of California Los Angeles (UCLA), Santa Monica, California, United States|Georgetown University, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|NEXT Oncology, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03330561
HER2+,46,201,1,NCT03619681,Ph 1,19,HER2+Other Mono,Other Mono,2L+,Breast + Other,Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer,,Recruiting,No Results Available,Breast Cancer|Gastric Cancer,Drug: KN026,"The proportion of patients experiencing dose limiting toxicities.|Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest.|Percentage of participants who experience laboratory abnormalities and/or adverse events as defined by CTCAE that are related to treatment|Maximum observed serum concentration (Cmax) of KN026.|Time of Maximum observed serum concentration (Tmax) of KN026.|Adjusted geometric means of area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) for KN026.|Serum Half-life (T-HALF) of KN026.|Serum clearance (CL) of KN026.|Volume of distribution at steady state (VSS) of KN026.|Frequency and titer of anti-KN026 antibody.|The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria.|Progression free survival according to RECIST 1.1 criteria.","Jiangsu Alphamab Biopharmaceuticals Co., Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,20,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,KN026-CHN-001,09/17/18,09/30/19,08/30/20,08/08/18,null,2-Nov-18,"Fudan University Shanghai Cancer Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03619681
HER2+,46,202,1,NCT03281824,Ph 1,19,HER2+Other Mono,Other Mono,2L+,Breast Only,"Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients",,Enrolling by invitation,No Results Available,HER2-positive Breast Cancer,Biological: ALT-P7 (HM2-MMAE),DLT test|Incidence of Treatment-Emergent Adverse Events|Pharmacokinetics test|Immunogenicity test|Efficacy test,"Alteogen, Inc.",Female,"19 Years and older   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,ALT-P7,01/11/18,12/31/18,03/31/19,09/13/17,null,10-Jul-18,"Alteogen, Daejeon, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03281824
HER2+,46,203,1,NCT03368196,Ph 1,19,HER2+Other Mono,Other Mono,2L+,Breast + Other,DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein,,"Active, not recruiting",No Results Available,"Adenocarcinoma, Gastric|Neoplasm, Breast",Drug: DS-8201a,Number of participants with treatment-related adverse events (AEs)|Area under the drug concentration time curve at the last observation (AUClast)|Area under the drug concentration time curve in 21 days (AUC0-21)|Maximum concentration (Cmax)|Time to maximum concentration (Tmax)|Minimum concentration (Ctrough)|Number of participants with anti-drug antibodies against DS-8201a|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS)|Best change from baseline in the size of target lesions,"Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company|Daiichi Sankyo, Inc.",All,"20 Years and older   (Adult, Older Adult)",Phase 1,12,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DS8201-A-A103,04/02/18,09/14/18,04/01/20,12/11/17,null,19-Mar-19,"National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03368196
HER2+,46,204,1,NCT03595592,Ph 3,5,HER2+CPI Combo,CPI Combo,Neo-adj,Breast Only,Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer,,Recruiting,No Results Available,Invasive Breast Cancer,Drug: Trastuzumab|Drug: Pertuzumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Atezolizumab|Procedure: Surgery,Event Free Survival (EFS)|Pathological complete response (pCR)|Clinical objective response|Distant Event Free Survival (DEFS)|Overall Survival (OS)|Number of participants with adverse events as a measure of safety and tolerability,Fondazione Michelangelo|Hoffmann-La Roche,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,650,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,FM-17-B01|2017-000981-31,09/07/18,12/15/26,06/15/27,07/23/18,null,15-Feb-19,"A.O. Ospedale Civile di Legnano, Legnano, MI, Italy|Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|Presidio Ospedaliero Di Summa-Perrino, Brindisi, Italy|Dipartimento di Oncologia Medica AUSL della Romagna, Faenza, Italy|IST San Martino, Genova, Italy|Istituto Scientifico Romagnolo per lo studio e la cura dei tumori, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|Ospedale San Raffaele, Milano, Italy|AO Universitaria Policlinico di Modena, Modena, Italy|Ospedale Sacro Cuore - Don Calabria, Negrar, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Azienda Ospedaliero Universitaria Pisana Ospedale S. Chiara, Pisa, Italy|Arcispedale Santa Maria Nuova - A.O. Reggio Emilia, Reggio Emilia, Italy|Ospedale Infermi AUSL della Romagna, Rimini, Italy|Istituto Nazionale Tumori - Regina Elena, Roma, Italy|Ospedale Santa Maria della Misericordia, Udine, Italy",,https://ClinicalTrials.gov/show/NCT03595592
HER2+,46,205,1,NCT03199885,Ph 3,5,HER2+CPI Combo,CPI Combo,1L,Breast Only,"Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer",,Recruiting,No Results Available,Breast Adenocarcinoma|HER2/Neu Positive|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7,Drug: Atezolizumab|Drug: Paclitaxel|Biological: Pertuzumab|Other: Placebo|Other: Quality-of-Life Assessment|Biological: Trastuzumab,"Progression free survival|Overall survival|Overall objective response|Duration of objective response|Cumulative incidence of brain metastases|Frequency of adverse events, including late immune-related toxicities",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 3,600,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NCI-2017-01119|NRG-BR004|U10CA180868,03/12/19,12/31/20,12/31/20,06/27/17,null,17-May-19,"Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States|Louisiana Hematology Oncology Associates LLC, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Our Lady of the Lake Physicians Group - Medical Oncology, Baton Rouge, Louisiana, United States|Woman's Hospital, Baton Rouge, Louisiana, United States|Northshore Oncology Associates-Covington, Covington, Louisiana, United States|Oncology Center of The South Incorporated, Houma, Louisiana, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho, New Mexico, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03199885
HER2+,46,206,1,NCT03726879,Ph 3,5,HER2+CPI Combo,CPI Combo,1L,Breast Only,A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer,,Recruiting,No Results Available,Breast Cancer,Drug: Atezolizumab|Drug: Placebo|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Trastuzumab|Drug: Pertuzumab,"Percentage of Participants with Pathological Complete Response (pCR)|Percentage of Participants with pCR Based on Hormone Receptor Status|Percentage of Participants with pCR Based on PD-L1 Status|Event-Free Survival (EFS)|Disease-Free Survival (DFS)|Overall Survival (OS)|Mean Changes From Baseline in Function (Role, Physical)|Mean Changes From Baseline in Global Health Status|Percentage of Participants With Adverse Events|Maximum Serum Concentration (Cmax) of Atezolizumab|Minimum Serum Concentration (Cmin) of Atezolizumab|Trough Concentration (Ctrough) for Pertuzumab and Trastuzumab in Serum|Percentage of Participants with Treatment-Emergent Anti-Drug Antibodies (ADAs) to Atezolizumab|Percentage of Participants with Treatment-Emergent Anti-Drug Antibodies (ADAs) to Trastuzumab|Percentage of Participants with Treatment-Emergent Anti-Drug Antibodies (ADAs) to Pertuzumab",Hoffmann-La Roche|Chugai Pharmaceutical,All,"18 Years and older   (Adult, Older Adult)",Phase 3,224,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",BO40747,01/11/19,09/23/20,02/08/23,11/01/18,null,1-May-19,"Yale Cancer Center, New Haven, Connecticut, United States|Mercy Medical Center, Baltimore, Maryland, United States|HCA Midwest Division, Kansas City, Missouri, United States|New York University Medical Center PRIME; NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Ctr, Portland, Oregon, United States|Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt, Nashville, Tennessee, United States|Cancer Therapy and Research Center CTRC at UTHSCSA, San Antonio, Texas, United States|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|CHU de Québec - Hôpital du Saint-Sacrement, Quebec City, Quebec, Canada|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Multiscan s.r.o., Pardubice, Czechia|Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt am Main, Germany|Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Germany|Sankt Elisabeth Krankenhaus; Gynaekology, Leipzig, Germany|Rotkreuzklinikum München; Frauenklinik, Muenchen, Germany|Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe, Münster, Germany|Universitätsfrauenklinik Ulm; Abteilung Gynäkologie, Ulm, Germany|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, Italy|Arcispedale S.Anna; Oncologia Medica, Cona (Ferrara), Veneto, Italy|National Hospital Organization Shikoku Cancer Center, Ehime, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Hyogo Cancer Center, Hyogo, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Saitama Medical University International Medical Center, Saitama, Japan|Toranomon Hospital, Tokyo, Japan|Showa University Hospital, Tokyo, Japan|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Centre; Oncology, Seoul, Korea, Republic of|FSBI National Medical Research Radiological Center; A. TSYB MEDICAL RADIOLOGICAL RESEARCH CENTER, Obninsk, Kaluga, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|City Clinical Oncology Hospital, Moscow, Russian Federation|Petrov Research Inst. of Oncology, St Petersburg, Russian Federation|Tomsk National Research Medical Center RAS; Research Intitute of Oncology, Tomsk, Russian Federation|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Virgen de La Arrixaca; Servicio De Oncologia, El Palmar, Murcia, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Complejo Asistencial Universitario De Burgos; Servicio de Oncologia, Burgos, Spain|Hospital Clinico de Granada; Servicio de Oncologia, Granada, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|CLINICA UNIVERSIDAD DE NAVARRA MADRID; Servicio de Oncología, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|China Medical University Hospital; Surgery, Taichung, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei, Taiwan|Chang Gung Medical Foundation - Linkou; Dept of Surgery, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT03726879
HER2+,46,207,1,NCT03841110,Ph 1,5,HER2+CPI Combo,CPI Combo,2L+,Breast + Other,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,,Recruiting,No Results Available,Advanced Solid Tumors|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma,Drug: FT500|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine,The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.|Objective-response rate (ORR)|Duration of FT500 persistence,Fate Therapeutics,All,"18 Years and older   (Adult, Older Adult)",Phase 1,64,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,FT500-101,02/15/19,03/01/22,06/01/22,02/15/19,null,14-May-19,"UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03841110
HER2+,46,208,1,NCT03650348,Ph 1,5,HER2+CPI Combo,CPI Combo,2L+,Breast + Other,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,,Recruiting,No Results Available,HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Bladder Cancer|HER2-positive Solid Tumor,Drug: PRS-343 in Combination with Atezolizumab,"Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab|Overall response rate (ORR) per RECIST v1.1|Duration of response (DOR) per RECIST v1.1|Rate of complete response (CR) per RECIST v1.1|Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, and changes in clinical laboratory parameters|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Time to maximum dose concentration (Tmax)|Terminal half life (t1/2)|Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs])","Pieris Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1,70,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRS-343-PCS_08_18,08/21/18,04/01/20,08/01/20,08/28/18,null,10-May-19,"USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|UCLA Health, Santa Monica, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03650348